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Abstract 
Elizabeth Margaret Mary Fylan Gwynn 
Medicines Management after Hospital Discharge: Patients’ Personal and 
Professional Networks 
Keywords: Patient safety; medicines management; hospital discharge; social 
network analysis; medications; care transitions; human factors. 
 
Improving the safety of medicines management when people leave hospital is 
an international priority. There is evidence that poor co-ordination of medicines 
between providers can cause preventable harm to patients, yet there is 
insufficient evidence of the structure and function of the medicines management 
system that patients experience. This research used a mixed-methods social 
network analysis to determine the structure, content and function of that system 
as experienced by patients. Patients’ networks comprised a range of loosely 
connected healthcare professionals in different organisations and informal, 
personal contacts. Networks performed multiple functions, including health 
condition management, and orienting patients concerning their medicines. 
Some patients experienced safety incidents as a function of their networks. 
Staff discharging patients from hospital were also observed. Contributory 
factors that were found to risk the safety of patients’ discharge with medicines 
included active failures, individual factors and local working conditions. System 
defences involving staff and patients were also observed. The study identified 
how patients often co-ordinated a system that lacked personalisation and there 
is a need to provide more consistent support for patients’ self-management of 
medicines after they leave hospital. This could be achieved through 
interventions that include patients’ informal contacts in supporting their 
medicines use, enhancing their resilience to preventable harm, and developing 
and testing the role of a ‘medicines key worker’ in safely managing the transfer 
of care. The role of GP practices in co-ordinating the involvement of multiple 
professionals in patient polypharmacy needs to be further explored.  
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people with heart failure. 
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Chapter 1 – Introduction 
1 Background 
Maintaining patient safety when healthcare is transferred between providers is 
recognised as an international priority. People, especially those with 
complicated healthcare needs such as multiple morbidities, are at risk during 
care transfers because care is delivered by different providers who may not 
effectively co-ordinate and because patients may not receive the information, 
help and support they need. Within the UK NHS, for example, people receive 
healthcare from different organisations at different times according to their 
needs. Their care may be provided by a hospital when they need emergency 
treatment or the care of specialist clinicians, and when they leave hospital, care 
is usually transferred from an acute NHS trust to an NHS primary care team 
(usually the GP-led team). Discharge information about their treatment and 
recommendations for future care should be communicated to the patient and to 
the primary care team managing their ongoing healthcare needs. This 
information includes their current medicines list, which may have been changed 
by the hospital team, along with any recommendations for how their medicines 
should be managed. Patients are at risk during this transfer because discharge 
medicines information can be poorly managed or inaccurate and patients may 
have new or changed medicines that they do not understand or feel confident 
about using. 
A range of healthcare professionals (HCPs) perform roles supporting 
discharged patients' medicines use, including GPs, nurses, community 
pharmacists and administrative teams. Patients may also have follow-up out-
patient treatment provided by the hospital and additional appointments with 
specialist healthcare providers managing any other chronic conditions.  
This thesis aims to explore and appraise patients’ experiences of the healthcare 
they receive specifically relating to their medicines from the point of hospital 
discharge, examining the structure and function of the medicines management 
system. In doing so, it will also identify the risks to patient safety in the system 
and how they impact on patients.  
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This work employs novel methods through the application of Social Network 
Analysis to explore how patients experience the system of medicines 
management and its contribution to patient safety and the effective use of 
medicines. Specifically it addresses the following objectives: 
• To determine the structure of the discharge medicines management 
system from patients’ perspectives; 
• To understand how patients’ medicines are optimised from the point of 
hospital discharge; 
• To examine how safe the discharge medicines management system is 
for patients. 
The following sections will explore the underpinning theories, research 
approaches and policies relevant to this thesis. To begin, the topic of patient 
safety is discussed and its rise in prominence across international and UK 
healthcare. 
1.1 Patient safety 
This section provides a concise background to the concept of patient safety 
both internationally and in the UK, initially considering the various definitions of 
patient safety in the literature. 
Patient safety is the reduction in preventable harm in healthcare;1,2 a series of 
processes to reduce error and mitigate risk;3,4 an attribute of a system of care; 
4–6 and a healthcare discipline.6  Any outcome of harm which has arisen from 
the care provided is generally known as an ‘adverse event’,1 which is an injury 
caused by the care provided rather than by the patient’s health condition. These 
can be caused by failure to provide suitable care (omission) or by care that 
causes harm (commission).1 
In the early 1990s in the USA, the Harvard Medical Practice Study (HMPS) 
aimed to estimate the incidence of adverse events experienced by patients in 
hospital.7,8 The first large-scale epidemiology of patient safety, its team 
reviewed over 30,000 case notes from 51 hospitals. The first published paper 
from the study calculated a 3.7% incidence of adverse events due to diagnostic 
errors and negligence; the second reported that drug complications were the 
most common type of harm caused to patients in hospital (19%), followed by 
wound infections (14%). Since then, patient safety has been a growing 
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international priority in healthcare systems. Influenced by the findings of the 
HMPS, the landmark USA report To Err is Human: Building a safer healthcare 
system established the high level of death in the USA attributable to 
preventable harm in healthcare and how the fragmented healthcare system was 
a contributing factor to unsafe care.9 The report laid bare the level of harm 
caused to patients; indeed, deaths due to error were thought to outstrip those 
attributable to diseases such as breast cancer and AIDS.  
Since then, patient safety has become a priority for many governments and 
health services, leading to the establishment of different national bodies and 
organisations to lead research and policy initiatives, including the USA Agency 
for Healthcare Research and Quality (established in 1999), the Danish Society 
for Patient Safety (2001), the Canadian Patient Safety Institute (2003), and the 
Australian Commission on Safety and Quality in Healthcare (2006). Globally, 
the World Health Organization (WHO) made reducing patient harm a priority, 
launching its Patient Safety Programme in 2004. The WHO Patient Safety 
vision is that ‘every patient receives safe healthcare every time, everywhere’.10 
To achieve this, it co-ordinates a range of international programmes and policy 
initiatives including research initiatives, safety event classification frameworks 
and a range of guidance on solutions for specific risks, including communication 
during patient handovers,11 and assuring medication accuracy at transitions of 
care.12 
In the UK, the publication fifteen years ago of An Organisation with a Memory 
highlighted the number of preventable safety incidents that regularly occurred.13 
It detailed how approximately 10,000 patients each year experienced serious 
adverse reactions from medicines (which are harmful unintended effects 
experienced by a patient as a result of taking a medicine) and recommended a 
range of changes, including unifying reporting systems, changing and opening 
up organisational cultures and adopting a ‘systems’ way of thinking – one that 
looks at the system that processes and people operate within – rather than 
solely focusing on the individual when an error has occurred. This Department 
of Health publication also eventually led to the formation of the National Patient 
Safety Agency (NPSA); the publically funded, arms-length organisation that 
developed a UK definition of a patient-safety incident:  
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“Any unintended or unexpected incident which could have or did lead to harm 
for one or more patients receiving NHS care.”14(p9) 
This definition has since been adopted by NHS England as the NPSA was 
decommissioned in 2012 following a House of Commons Select Committee 
report in 2009. The UK government’s response to An Organisation with a 
Memory was the 2001 report Building a safer NHS for patients: implementing an 
organisation with a memory, announced the establishment of the NPSA and 
plans for a new incident reporting and learning system, eventually leading to the 
establishment of the National Reporting and Learning System (NRLS) in 2003 
to record and analyse patient safety-related events and compile a central 
database of patient safety incident reports. The Department for Health 
published further reports, notably Building a Safer NHS for Patients: Improving 
Medication Safety,15 exploring the causes and frequency of medication errors 
and recommending action for the NPSA to take forward, including national 
standards of prescribing, dispensing and administering medicines.  
Despite a continued focus on patient safety, progress has been slow. Indeed, 
work published in the last five years suggests that adverse events in hospitals 
continue to be greatly underestimated;16 and that harm to patients is still 
common.17 In the UK, the 2013 Francis Report documented the extremely poor 
standards of care experienced by some patients in Mid-Staffordshire NHS 
Foundation Trust.18 The UK Prime Minister issued an official apology describing 
what had occurred as “a national failure of the regulatory and supervisory 
system, which should have secured the quality and safety of patient care”.18(p12) 
This official enquiry led to the Berwick Report into patient safety commissioned 
by the government, which clearly stated that individual staff members are rarely 
to blame for safety problems, rather the cause is usually the “systems, 
procedures, conditions, environment and constraints” faced by staff.19(p4) It 
recommended enhancing patient power and involvement at all levels of 
healthcare, sufficient current and future staffing, better patient safety training 
and a commitment to organisational learning. The Keogh Review, published in 
the same year, explored the quality of care provided by NHS trusts and 
foundation trusts with persistently high mortality rates.20 The review developed a 
set of eight ambitions for the NHS, including: better uses of data to reduce 
preventable deaths; involving patients and the public as equal partners;   
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integration of trusts into the new Academic Health Science Networks; adequate 
staffing levels; and a happy, engaged, motivated and valued workforce. 
Currently patient safety is firmly embedded in commissioning and governance 
structures.21,22 Indeed, protecting patients from harm is now a specific NHS 
responsibility;23 the most recent outcome framework for the NHS details key 
indicators around treating people in safe environments and protecting people 
from preventable harm.24 Nested safety indicators to assess performance use 
reported patient safety incidents, incidents causing severe harm or death, 
hospital deaths caused by problems with care, and specifically the incidence of 
medication errors. The use of negative outcomes such as mortality rates is 
useful, however, as Reason argues, “safety is a term more defined by its 
absence than its presence,” and measures of the “positive face of safety”,25(p267) 
such as the ability of the system to resist hazards might be better, more 
proactive indicators. 
I have discussed how successive healthcare policy drives have advocated a 
systems way of thinking about patient safety in healthcare. The next section will 
focus on systems and specifically human factors. 
1.1.1 Systems approaches to patient safety 
This section discusses systems approaches to patient safety and how the 
human factors approach has been applied to exploring risks to patients in the 
healthcare system, understanding risk causation, and developing defences 
against errors. It begins with an overview of the science of human factors. 
Human Factors 
In 2000, the International Ergonomics Association adopted the following 
definition of human factors, which was seen as interchangeable with 
ergonomics:  
“Ergonomics (or human factors) is the scientific discipline concerned with the 
understanding of interactions among humans and other elements of a system, 
and the profession that applies theory, principles, data, and other methods to 
design in order to optimize human well-being and overall system 
performance.”26 
According to the Human Factors and Ergonomics Society, a focus on Human
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 Factors arose during the second world war resulting from the work of 
specialists studying staffed systems. Their work focussed on systems 
performance, action control, workspace arrangements and skills requirements.27 
The results of their work resulted in, inter alia, safety improvements. Taking on 
board perspectives primarily from disciplines such as psychology and 
engineering, human factors is a multidisciplinary approach to explore how 
people and systems interact, for example, poor equipment design can lead to 
poor human use of equipment which may increase risk. Similarly, organisational 
factors, such as staffing levels, can place pressure on staff and influence the 
decisions they make within the workplace, leading to inappropriate and 
sometimes hazardous workarounds.  
The WHO defines human factors slightly differently as: “the study of all the 
factors that make it easier to do the work in the right way”.28 As a definition it 
does not explicitly recognise that there may be multiple perspectives on what 
the right way is to perform a task and that an organisation’s policies and 
procedures may be perceived by staff as the right way but in fact may contribute 
towards risk.  
More recently, Russ et al. argued that the science of human factors is primarily 
concerned with promoting efficiency, safety and effectiveness by improving 
systems to enhance their design for human use.29 A central assumption in 
human factors is that people interact with systems in a complex and variable 
way. By accepting this, organisations can explore how systems and working 
conditions interact with human behaviour to create risk and take steps to 
mitigate those risks. Within the healthcare system, for example, factors combine 
to influence patient safety at organisational, immediate environment, team, 
individual and task levels, which in turn interact with external environmental 
factors and patient characteristics to create safety risks.1,30  
This theoretical concept was described in James Reason’s 1990 work on the 
breakdown of complex systems, in which he also explained that the individual 
actions of people – or the people themselves – are often the subject of scrutiny 
after incidents occur, yet they are rarely the direct cause. Instead it is the 
systems within which people operate that give rise to the conditions that allow 
safety incidents and major disasters to occur, especially in high risk industries   
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such as aeronautics and the travel industry.31 Whilst this work focussed on 
major high-profile system breakdowns outside healthcare, later work shifted the 
focus to healthcare and adverse events in clinical practice, highlighting the two 
approaches to human fallibility: the person approach and the systems 
approach.32 The person approach concentrates on and blames the actions of 
individuals, whilst the system approach recognises people’s fallibility, the role of 
systems in organisational failure, that errors are inevitable, and that reliable 
organisations have well-constructed systems that avoid or can tolerate errors. 
The person approach is considered flawed because the person is judged to be 
separate to the system in which they operate, rather than an integral part of it. 
Reason outlined how systems have defences, barriers and safeguards that 
protect people from harm. If holes in those defences simultaneously align then 
this allows hazards to impact on people. In his ‘Swiss Cheese’ model (see 
Figure 1) he outlined how holes arise through ‘active failures’: slips and lapses; 
fumbles; procedural violations; and mistakes.  
 
Figure 1: Reason's 2000 'Swiss Cheese' model of hazard trajectory.32 Reproduced with kind 
permission. 
Lapses, for example, are errors associated with forgetting to perform actions, 
slips and fumbles are errors that occur when a person performs an action but it 
is not the one they intended to perform. Mistakes are described as actions that 
are performed as intended but they are incorrectly planned. Violations are 
deliberate deviations from procedures, although sometimes a deviation may be 
unknowingly committed. ‘Local conditions’ such as the routine business of a 
ward are influenced by ‘latent conditions’ – those aspects of the system that 
create the conditions where it is easier for active failures to occur, such as 
staffing policies or inadequate training. Reason explains that latent conditions 
can exist in systems for long periods of time whilst essentially ‘lying dormant’   
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until holes in defences align to allow a hazard to become a loss.32 The central 
premise remains as the model has evolved, that latent conditions are not 
definitive causes but are essential for causal agents to have an impact.25 
Whilst the human factors paradigm has been widely acknowledged as useful in 
developing organisational resilience in healthcare, patients have probably yet to 
recognise it or indeed understand it, and human factors does not focus on the 
roles patients play in healthcare systems. Patients are well positioned to make a 
strong contribution to understanding the cause of preventable harm and to 
building a more resilient healthcare system;33,34 yet they are often characterised 
as passive recipients of care, as well as passive victims when things go wrong, 
rather than experts in their own health, well positioned to build resilience into 
the healthcare system by creating strategies to avoid error or mitigate its 
effects.35 Indeed approaches to safety have underplayed the involvement of 
patients in setting safety agendas and engaging in safety initiatives.36,37  
This section has focussed on the theory underlying a systems approach to 
patient safety in healthcare, and criticised it for its lack of focus on the role of 
the patient within healthcare systems. The following section will explore the 
issues that create risk for patients in the healthcare system when their care is 
transferred between clinicians and organisations. It will also discuss the 
inherent problems which may occur when patients are not a fully integrated part 
of the healthcare system and errors and discrepancies are considered at patient 
and system levels separately.38,39 
1.1.2 Patient safety at transfers of care 
A transfer of care is “the movement of patients between health care 
practitioners, settings, and home as their condition and care needs 
change”.40(p3) ‘Gaps’ in the continuity of care can be experienced by patients 
when their care is transferred and gaps are “most readily seen when they are 
aligned with organisational and institutional boundaries that mark changes in 
responsibility or authority, different roles of professionals, or formal divisions of 
labour”.41(p792) 
Transfers of care can take several forms. Care can be transferred within the 
same organisation where responsibility transfers between staff members, for 
example during a shift change or the transfer of a patient between wards or   
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departments. Care transfers also occur between organisations – from hospital 
to a nursing home, for example, or to a primary care team. When care transfers 
back to the GP-led team the patient will probably be returning to their home or 
to the home of a relative of friend and so there is usually no continuous direct 
observation of their condition by a HCP. 
Hand-offs (which are communications that transfer responsibility for care) are 
complicated, poorly standardised, single- or multi-organisation events in patient 
care in which the responsibility for the patient is transferred either between 
individuals or organisations.42,43 Handovers in care (or transfers of care from 
one clinician to another) are recognised as parts of the healthcare system 
where the risk of error is heightened.44 Handovers also represent opportunities 
for corrective action, updating and correcting the patient’s current list of 
medicines, and patient involvement, such as giving patients information about 
current medicines and who is now responsible for their care.11,45  
In the USA, both 30-day re-admission rates after leaving hospital and the rate of 
adverse events after discharge are high (20%).46,47 Specifically after discharge 
from hospital, patients have been found to experience adverse drug events;48–51 
and experience dissatisfaction with the care they receive.52 Patients can also 
experience disorientation after their care is transferred: research has found that 
people, especially older people, experience anxiety and struggle to access 
information about their health and treatment.53 
Concern about the safety of care transfers has led to a focus on what is referred 
to as ‘transitional care’, which is the care a patient receives when they move 
between care providers. Eric Coleman and Chad Boult, on behalf of the 
American Geriatrics Society define transitional care as:  
“A set of actions designed to ensure the coordination and continuity of health 
care as patients transfer between different locations or different levels of care 
within the same location. Representative locations include (but are not limited 
to) hospitals, sub-acute and post-acute nursing facilities, the patient's home, 
primary and specialty care offices, and long-term care facilities. Transitional 
care is based on a comprehensive plan of care and the availability of health 
care practitioners who are well-trained in chronic care and have current 
information about the patient's goals, preferences, and clinical status. It includes   
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logistical arrangements, education of the patient and family, and coordination 
among the health professionals involved in the transition. Transitional care, 
which encompasses both the sending and the receiving aspects of the transfer, 
is essential for persons with complex care needs.” 54(p556) 
A review of evidence into care-transfer interventions initiated by hospitals, 
specifically hospital discharge, indicated that bridging interventions to avoid 
adverse outcomes (which are those that include components delivered in-
hospital and after discharge) have embraced different strategies including 
patient engagement, use of dedicated staff and better co-ordinated 
communication with other care providers. Those interventions using dedicated 
staff working with patients before and after discharge reduced re-admissions 
and visits to emergency care.55 In the USA, a range of initiatives have 
attempted to improve patients’ experiences of hospital discharge. For example, 
Project RED (Re-engineered Discharge) comprises a multi-disciplinary team 
intervention delivering an eleven-component discharge package, including:  
• Making appointments for tests and  follow-up of test results;  
• Organising post-discharge services and equipment;  
• Identifying correct medicines and organising for the patient to receive 
them; 
• Resolving discrepancies between the discharge plan and national 
guidance; 
• Teaching the patient about the discharge plan and their diagnosis;  
• Communication of the discharge plan to primary care;  
• A follow-up phone call.56 
Evaluation indicated that the programme was successful in reducing 
readmission, increasing attendance at follow-up appointments and reducing 
costs.56,57 Again in the USA, Coleman et al. developed the Care Transitions 
Intervention, which is a patient-led self-managed programme focussing on 
medicines self-management; a patient-centred health record; primary care 
follow-up; and increased knowledge of ‘red-flags’ that indicate health 
deterioration. Part of the intervention is a Care Transitions Measure which is 15-
item survey instrument assessing preparation for care transitions.58 Qualitative  
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research employed in developing the measure indicated that there were four 
transition content domains which patients considered important:  
• Information transfer; 
• Preparation for what to expect next;  
• Support for self-management; and  
• Encouragement to assert preferences.58 
In general, however, care transfer interventions have been found to lack 
economic justification and to lack a focus on contextual factors that may impact 
on patients’ ability to access health services, such as the availability of primary 
care once they have left hospital.55 These contextual factors may also include 
the level of informal support at home. 
This section has outlined the major issues in patient safety, and specifically how 
patient safety is threatened during the gaps in care that arise when patient care 
is transferred, especially when they are discharged from hospital. The following 
section will begin by discussing a particular system in healthcare, medicines 
management, and the risks to patient safety that are created by that system, 
despite its intended purpose to reduce risk. 
1.2 Medicines management 
This section discusses medicines management, and the models that exist to 
describe it. The definition of medicines management has evolved over time. 
Early definitions described it as a composite system involving processes and 
behaviours that ultimately result in specific ways of using medicines.59  As such, 
medicines management is the system that ultimately influences patients’ 
experiences with their medicines. Indeed, when effective, the system can 
achieve an improved patient experience and better health outcomes;59,60 
increased value in medicines expenditure; and reduce hospital admissions.60 
The Medicines and Healthcare products Regulatory Agency definition, cited by 
the Nursing and Midwifery Council, tied patient safety and patient benefit firmly 
into medicines management: 
“The clinical, cost-effective and safe use of medicines to ensure patients get the 
maximum benefit from the medicines they need, while at the same time 
minimising potential harm.”61(p4)  
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More recently, The King’s Fund offered a definition that linked medicines 
management to safety with an additional focus on value for money and an 
enhanced use of medicines by patients, thereby introducing the idea that 
patients themselves have a role in managing their medicines: 
“Medicines management supports better and more cost-effective prescribing in 
primary care, as well as helping patients to manage medications better. Good 
medicines management can help to reduce the likelihood of medication errors 
and hence patient harm.”60(p10) 
However, relatively simple definitions of medicines management, such as the 
ones above, do not communicate the complicated, multi-professional, dynamic 
system that comprises different types of patients interacting with different 
healthcare professionals – doctors, pharmacists, health visitors, nurses – 
working across different sites and settings who adopt varying roles in supplying, 
monitoring and reviewing medicines. The healthcare professionals involved 
work for different organisations and belong to different professional groups with 
diverse proprietary processes, procedures, discourses and professional 
jurisdictions, norms and prejudices. Within this complicated environment 
patients who receive multiple medicines, who are often chronically ill and have 
multiple co-morbidities, will often self-manage their day-to-day medicines. As 
such, it is a complex system – one in which there are many interrelated 
components that impact on each other but cannot be explored in isolation;62 and 
one that varies in different care settings – for example in the community and in 
hospitals – and for different medicines.  
1.2.1 Medicines management models 
As discussed, systems of medicines management are complex and so to better 
understand how they operate in different settings and to impose some 
standardisation, a number of models have been developed to describe and map 
their processes. 
Avery et al. adopted a systems approach to explore medicines management but 
with a focus on the primary care system to identify the risks in the system that 
can produce adverse events.63 Stages in this model were prescribing, 
dispensing, monitoring and review, and patient education and compliance. 
Systems failures included deficiencies in computerised warning systems,  
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inadequate inter-organisation communication, poor therapeutic knowledge 
dissemination, poor systems for repeat prescribing, organisation and training of 
staff and deficiencies in HCP-patient communication. They listed possible 
proximal causes of an adverse event including lack of medicines knowledge, 
slips and memory lapses. Figure 2 is the Avery et al. adaptation of Reason’s 
‘swiss cheese’ model describing risks in medicines management using the 
scenario of a patient request for a repeat prescription of a previously used 
medicines which is contra-indicated – it demonstrates how a specific risk in the 
system can penetrate multiple layers or barriers designed to prevent it.63 
Building on this model, there is an opportunity to enhance the role the patient 
plays as a system barrier to create more resilience in the system. For example, 
enhanced patient knowledge of their medicines – those that are current and 
discontinued – may avoid the repeat prescription request and patients creating 
their own checklists of medicines may reduce the risk of them ordering a 
discontinued medicine. 
 
Figure 2: Avery et al. adaptation of Reason's 'swiss cheese' model to illustrate risk in medicines 
management.63 Reproduced with kind permission. 
Deeper integration of the pharmacist into the patient pathway, for example 
through discussing new medicines with the patient, would act as an earlier 
system barrier through increasing their understanding of and confidence in their 
medicines. There has been a growing acknowledgement that patients can play 
a meaningful role in their own safety if sensitively empowered to do so, despite 
both patient and clinician reservations about patient involvement in patient 
safety.34 Patient vigilance, for example, can increase HCP compliance with 
safety measures in clinical settings, such as hand hygiene;64 in medicines 
reconciliation following hospital discharge;65 and in identifying problems with  
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medicines in primary care.66 Furthermore, Furniss et al. recently explored how 
patients develop resilience strategies, such as developing cues to take 
medicines, such as alarms, to reduce the risk of unintentional non-adherence.67  
The Swedish Lund Integrated Medicines Management Model for care transfers 
is a team-based approach that included clinical pharmacists performing 
medicines reconciliation and review functions to reduce medicines reconciliation 
errors and readmissions to hospital due to medicines errors.68 Rather than 
being a universal medicines management model, it is an intervention to improve 
the medicines management of elderly people in hospital. It ends at discharge 
with medicines reconciliation and a discharge medicines report. The report, 
which details medicines changes and organises the medicines list by time of 
day, was found to reduce medication errors after discharge and the need for 
medical care caused by medication errors.69,70 
Stowasser et al. mapped a universal medicines management pathway that is 
both independent of the care setting and the type of medicine.71 The patient is 
involved at the different, largely interdependent stages, as shown in Figure 3 
The patient (‘consumer’) is described as the focus of the pathway and interacts 
with its many stages. It is supported by three background processes: medicines 
procurement, reporting and quality and safety audit to monitor safety, and 
communication, which they describe as a vital process to keep patients 
informed about their treatment and to ensure information between healthcare 
providers is transferred accurately. The model is comprehensive yet, despite its 
central positioning of the patient, its focus falls on professional processes rather 
than on the patients themselves and as such it does not specify the patient-
centred care now recommended.72   
For example, keeping patients informed about their treatment falls short of 
current recommendations to give patients the opportunity to make informed 
decisions about their care. It also fails to communicate the range of 
professionals who are involved in the different stages and the multi-professional 
nature of many of the stages, for example in monitoring medicines, which may 
be done by doctors, pharmacists, nurses or a combination of all three. In Figure 
4 I have developed Stowasser’s model, drawing on current patient-centred 
approaches that take into account the patient’s own preferences.72  
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Figure 3: Medicines management model from Stowasser et al. 71 
 
  
CONSUMER 
• Medicines 
procurement 
 
• Reporting and audit 
 
• Communication 
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Figure 4: A patient-focussed adaptation of Stowasser et al.’s 2004 medicines management model. 
 
1.2.2 Medicines optimisation 
Medicines management has developed over time and organisations have 
attempted to offer definitions and articulate its role in the safety and quality of   
•Sites: hospital; GP practice; home; telephone.
•Clinicians: GP; hospital doctor; nurse; pharmacist
Patient and prescriber discuss 
treatment options, their benefits and 
risks and the patient decides the best 
treatment.
•Sites: hospital; GP practice; home; telephone.
•Clincians: GP; hospital doctor; nurse; pharmacist
•Timing: patient preference
Information about the treatment is 
given to the patient according to 
patient preference.
•Across organisational boundaries
•Medium: Electronic / paper
Information about the treatment is 
communicated to other healthcare 
providers and actioned.
•Site hospital; community pharmacy.
•Clincians: nurse; community pharmacist
•Timing: patient preference
Patient receives medicines and their 
orientation about their medicines 
commences depending on their 
preferences.
•Medium: patient preference e.g.  paper vs webPatient is given information about 
where to get help with their 
medicines.
•Sites: hospital; GP practice; home; telephone.
•Clincians: GP; hospital doctor; nurse; pharmacists
Medicines are monitored and 
adjusted if necessary in agreement 
with the patient.
•Sites: hospital; GP practice; community pharmacy
•Clinicians: GP; hospital doctor; community 
pharmacists
Medicines are reviewed by a clinician 
and the patient.
•Medium: patient preference
Information about any changes is 
discussed by the patient and HCP.
•Across organsiational boundaries
•Medium: electronic / paper
Information about changes is given 
to others in the healthcare team and 
actioned.
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care. However, medicines management has not been truly patient-centred – it 
has not focussed on patients as individuals nor taken into account their own 
preferences when defining care and role in its safety. In recognition of this, the 
term medicines optimisation has emerged in recent years as a patient-centred 
approach to medicines management, designed to achieve the best possible 
outcomes from medicines through their safe and effective use.72 It is a multi-
professional approach that involves patients in decisions about their treatment, 
but also one that encourages reporting of patient safety incidents concerning 
medicines, by both HCPs and by patients. Indeed, there is a growing 
recognition that the patient’s role in reporting patient safety incidents is an 
“untapped resource”.33(p698)  
In 2013 the Royal Pharmaceutical Society (RPS) issued best-practice guidance 
for medicines optimisation based on four key principles, which are shown in 
Figure 5.73 It combines professional efficacy in the choice and safety of 
medicines with a focus on understanding the patient experience. 
 
Figure 5: The RPS's four principles of medicines optimisation.73 Reproduced with kind permission. 
Medicines optimisation is an important underpinning policy and model of 
practice to the research described here because it combines the interrelated 
concepts of medicines safety, patient-centred care and medicines management 
systems. In this thesis, the concept of medicines optimisation has been used as   
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a foundation to explore patients’ experiences with and roles in managing their 
medicines. 
1.2.3 Preventable harm and risks in safe medicines management 
Medicines management systems, which deliver and support people’s use of 
medicines, are subject to risk. This section explores the epidemiology of 
medicines errors, some of the risks faced by patients in their use of medicines 
and the policies implemented to address those risks. 
The Health and Social Care Information Centre (HSCIC) reported that in excess 
of 1000 million NHS prescriptions items were dispensed in the community in 
England in 2014 at a cost of £8.9 billion;74 and the number of items dispensed 
has increased year-on-year and by over 50% since 2004. Patients increasingly 
manage polypharmacy (the concurrent use of several medicines); and 
organisations operating within the medicines management system must 
manage the clinical and administrative components that supply medicines to 
patients, monitor and review their use. Patients can consult different clinicians 
working within different healthcare organisations for different co-morbidities who 
may prescribe medicines concurrently. Within this complex system there are 
many opportunities for preventable harm to occur. 
The WHO positioned medicines safety as an essential component of patient 
safety and recognised morbidity and mortality as a result of medicines errors as 
a major healthcare problem.75 The NPSA calculated that preventable harm from 
medicines in England may cost in excess of £750 million each year.14 At the 
time, the NPSA also believed that the incidence of medication error in primary 
care was under-reported because the volumes of reported incidents are low in 
relation to the proportion of medicines prescribed. This is a view that is still held 
today by policymakers,72 supported by data from NRLS indicating that 
medication incident reports submitted by primary care organisations have 
continued to be comparatively low since reporting began in 2005.76  
Reflecting the definition of a patient safety incident in section 1.1, medication 
error has been defined as “a failure in the treatment process that leads to, or 
has the potential to lead to, harm to the patient”.77(p601) The range of errors 
patients experience include inappropriate or ineffective prescribing (prescribing 
error), errors on the prescription (prescription error), errors made during  
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dispensing the drug such as providing the wrong label (dispensing error), and 
during monitoring, for example not adjusting medication when necessary.78 
Administration errors involve giving or taking the wrong medicines dose, or 
using the wrong administration route, or an incorrect frequency or duration. 
Responsibility for administering medicines usually transfers from clinical staff to 
the patient, a member of their family or a carer after discharge from hospital, so 
errors can be made which may be harder to detect and address. Errors are also 
made during the use of medicines and if that is in the patient’s home then they 
are harder to detect and address – partly due to patient characteristics, such as 
personality (for example their attitudes towards medicines), and social factors 
(such as others who may influence them). Medicines errors have been 
classified as knowledge-based errors, rule-based errors, action-based errors 
(slips) and memory-based errors (lapses);78 and as slips and lapses, 
knowledge- and rule-based mistakes, and violations (routine, optimising and 
necessary).79 
Amongst the patient safety incidents that patients may experience during their 
care, experiencing medication error is relatively common. For example in the 
UK hospital setting, adverse drug events affected 7–10% of in-patients;80,81 
Sandars and Esmail estimated that prescribing and prescription errors occur in 
up to 11% of prescriptions;82 and harm from medicines is thought to contribute 
to between 2.5–6.5% of hospital admissions.83,84 A recent review of reports to 
NRLS assessed that over half a million medication incident reports from primary 
and secondary care over five years from 2005–2010 comprised 10% of reported 
patient safety incidents and 16% of those resulted in patient harm.76 Reporting 
levels from the acute/hospital sector far outweighed those from primary care, 
which is probably explained by  underreporting of incidents by the primary care 
sector.14 Not all medication errors result in significant harm to patients; many 
may cause mild harm, which may also influence the rates at which they are 
reported. Indeed, degrees of harm from patient safety incidents are classified 
into five categories – from mild to death – by the WHO, as presented in Table 
1.85 
A further risk to well optimised medicines is poor patient adherence: intentional 
and unintentional non-adherence is estimated to affect 30-50% of patients in   
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primary care.86 In their review Garfield et al. suggested that focusing on 
improving adherence – along with safety and effectiveness of medicines – had 
the most potential for improving the system to maximise the benefit to 
patients.86 Recent policy suggests that to do this patients should be involved in 
decisions about their medicines, that communication with patients must be 
effective, and that patients’ perceptions of their need for medicines, and their 
knowledge and concerns about their medicines should be regularly reviewed.87 
Table 1: Degrees of harm caused by patient safety incidents from The WHO, 2010.85  
None Patient outcome is not symptomatic or no symptoms detected and no treatment is 
required.  
Mild Patient outcome is symptomatic, symptoms are mild, loss of function or harm is minimal 
or intermediate but short term, and no or minimal intervention (e.g. extra observation, 
investigation, review or minor treatment) is required.  
Moderate Patient outcome is symptomatic, requiring intervention (e.g. additional operative 
procedure; additional therapeutic treatment), an increased length of stay, or causing 
permanent or long term harm or loss of function.  
Severe Patient outcome is symptomatic, requiring life-saving intervention or major 
surgical/medical intervention, shortening life expectancy or causing major permanent or 
long term harm or loss of function. 
Death On balance of probabilities, death was caused or brought forward in the short term by the 
incident. 
 
Various UK policy initiatives and guidance have aimed to improve medication 
safety as a means of enhancing patient safety overall.14,15,88 Most recently, the 
NICE guidelines for medicines optimisation made recommendations for 
reducing medicines-related patient safety incidents in three key areas:  
• Improving reporting systems with the aim of learning from medicines-
related patient safety incidents. Recommendations within this area 
included HCPs explaining to patients how to identify and report incidents. 
• Medicines reconciliation – which is the process of identifying a complete 
and accurate list of a patient’s medicines through comparing lists, 
resolving discrepancies and changes. Recommendations by NICE 
included conducting medicines reconciliation in primary care for patients 
discharged from hospital as soon as possible. It also stated that there 
should be clear lines of responsibility for conducting medicines 
reconciliation, and that it should be carried out by a trained healthcare 
professional. Furthermore that patients, family members and carers 
should be involved where appropriate, although no guidance is given 
about when this might be appropriate.  
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• Medicines review – a structured medicines review with a clear purpose 
should be implemented for defined groups of patients (those on multiple 
medicines; those with chronic and long-term conditions; and older 
people). The review should be carried out by a pharmacist or another 
appropriate HCP.72 
Whilst some of the recommendations in the NICE medicines optimisation 
guidelines are embedded in other policies, for example the 2009 NICE clinical 
guidelines on medicines adherence,87 other recommendations designed to help 
patients with their medicines, for example the Medicines Use Review (MUR), 
may not always work as intended.89 Section 1.2.5, therefore, will explore the 
role of community pharmacists in the medicines management system, exploring 
how they have been positioned to advance medicines optimisation through 
clinical practice. To begin, the next section explores the specific problems in the 
system of medicine management when patients’ care is transferred.  
1.2.4 Medicines management at the transfer of care 
There are key responsibilities in and principles of safe care transfer, which 
include ensuring accurate and timely communication of medicines information 
and encouraging patients to be actively involved in managing their medicines 
when they move between care providers.90–92 People whose care is transferred 
– for example when they are discharged from hospital – are subject to 
heightened risk of harm from their medicines if information sharing between 
GPs and hospitals is poor, if patient records are not updated with discharge 
information and if patients do not get the opportunity to discuss managing their 
medicines.91 The lack of a definitive list of medicines can lead to discrepancies 
between those lists held by different care providers and the medicines that the 
patient actually takes when they are discharged.39,93–95 Patients can also 
experience unintentional discrepancies in repeat medication: 43-60% items and 
affecting 57% of patients;86 although a 2014 literature review estimated that 
these discrepancies affect 14–87% of patients.96 
Communication between hospitals and primary care has been found 
inadequate, for example in the poor quality, level of detail and timeliness of 
discharge, and can potentially lead to prescribing errors.97,98 The Avery et al. 
study exploring the prevalence and causes of prescribing error in general   
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practice identified discrepancies in the post-discharge subsequent prescriptions 
of 43% of patients who had been discharged from hospital; however the small 
sample size for this part of the much wider study was small (n=37). Other 
evidence concurs that discharge information can be inaccurate or badly timed 
or GP practices can be slow to act upon it; 91,98–100 and, on discharge, patients 
are likely to have new medicines to which they may become non-adherent,101,102 
which can lead to sub-optimal outcomes, including readmission to hospital.49 
For other patients, medicines temporarily discontinued in hospital are not re-
instated after discharge.103  
Evidence from the international literature describing interventions to optimise 
continuity in medicines management was synthesised by Spinewine et al. in a 
systematic review.104 The target of the interventions ranged from those aiming 
to educate and counsel patients both before and after discharge, interventions 
to enhance communication between providers and interventions aimed at both 
patients and providers. The authors concluded that there is some evidence of 
effectiveness for interventions aimed at reducing adverse drug events and 
hospital re-admissions comprising patient education and counselling before 
discharge, and reinforced after discharge, some of which included enhanced 
provider communication.  
However, in the UK, lack of successful working between HCPs from different 
disciplines involved in care is recognised as a risk to safe use of medicines by 
both the Royal College of General Practitioners and the RPS.105 To mitigate the 
risk to patients this poses, there is an increasing drive for more focussed and 
consistent interprofessional collaboration for safe and effective care.73,105 
UK policy now champions the patient’s role in medicines optimisation and safety 
during care transfers.72,73 However, the most recent NICE recommendations do 
not specify how patients should be informed about their medicines when they 
are discharged, despite the comparatively detailed recommendations about how 
HCPs should communicate with each other.  
Also thought crucial by the WHO is involving patients and their families in 
multiple ways, including: medicines education; giving patients information about 
new and changed medicines; patients keeping lists of prescription and over-the-
counter medicines; and the use of one community   
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pharmacy provider.106 The WHO suggested developing a standardised form for 
the patient to carry lists of their medicines, however in principle this would need 
to be backed up by other central systems to ensure information remained 
available to HCPs in instances where the patient is unable to provide their list, 
for example when accessing emergency care, or if they become incapacitated. 
As yet there is a lack of evidence of the benefit of such patient-held records.107 
In 2005, collaboration between pharmacy bodies in England produced a 
guidance document about moving patients safely between care providers. 
Moving patients, Moving Medicines, Moving Safely: Guidance on Discharge and 
Transfer Planning mapped the weaknesses in medicines management when 
patient care is transferred between providers.92 Identified risks to patients at 
discharge were the failure to inform the patient’s GP of changes to medicines, 
lack of time at discharge to inform patients about their medicines, double dosing 
after discharge due to the patients having new and pre-admission supplies, 
poor patient understanding of medicines, intentional and unintentional 
adherence, and the continuation of medicines that were intended as a short 
course. The guidance unfortunately does not highlight the community 
pharmacist’s role in supporting the patient’s use of their medicines in this 
period. This role in patient care after hospital discharged is discussed further in 
the next section. 
1.2.5 Community pharmacy medicines management role 
Recognition of the risks patients have faced has led to exploration of the roles 
that community pharmacy can play in the more effective management of 
medicines. This section explores the policies that have attempted to redefine 
the role of community pharmacy within the medicines management system. 
Community pharmacists are an established part of the multi-professional 
primary care team and, as such, have a key role to play in delivering safe care 
to patients, a role previously defined as providing ‘pharmaceutical care’ to the 
patient.108,109  
In recent years, successive UK government policy initiatives have attempted to 
move community pharmacy towards a more meaningful and integrated role in 
safe and effective patient care. The 2003 Department for Health discussion 
paper A vision for pharmacy in the new NHS outlined ten key pharmacy roles.88   
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Amongst them were promoting patient safety by avoiding, detecting and 
reporting adverse drug reactions and medication errors, contributing to 
seamless, safe medicines management and supporting patients as partners in 
medicines taking. The paper emphasised pharmacy’s importance in safe 
medicines use and maximising the benefit gained from medicine and reducing 
waste. The following Community Pharmacy Contractual Framework contained 
several elements to implement this policy, for example the introduction of 
MURs, explored in more detail later in this section.110 The most recent 
Community Pharmacy Contractual Framework further developed these 
guidelines, formalising the alignment of target groups for the MUR more closely 
with NHS health priorities.111,112 
Plans for pharmacy teams to improve the care patients receive through 
personalised pharmaceutical services were outlined five years after the 
publication of A vision for pharmacy in the new NHS in the 2008 Department of 
Health White Paper Pharmacy in England: building on strengths, delivering the 
future.113 It set out how patient care could be made safer by integrating 
pharmacists in healthcare delivery, thereby developing their role in offering 
clinical services to patients in the community. Improvements championed in the 
paper included promoting better access to medicines expertise provided by 
pharmacists so that pharmacy teams lead and support safe and effective 
medicines use. It envisaged an enhanced role in supporting use of new 
medicines for patients with chronic conditions, and closer pharmacy 
involvement in developing clinical pathways in support of integrated care. It 
stressed that the risks of medicines-related harm can be mitigated by 
community pharmacists through various measures including: 
• Working with and training others about safe prescribing and safe 
medicines use;  
• Working with patients to enhance their medicines understanding; 
reviewing medicines use;  
• Screening prescriptions and identifying adverse drug events; 
documenting allergies;  
• Helping others calculate doses and administer medicines safely.  
 
In 2011, changes to the Community Pharmacy Contractual Framework went   
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some way to implementing this policy through the introduction of the New 
Medicines Service, to help orientate patients with newly prescribed medicines 
and through targeting a proportion of MURs to specific groups of patients, 
including those newly discharged from hospital.114 In 2015, further targeting was 
introduced, as described later. 
The change of government in 2010 brought about a major re-organisation of the 
National Health Service and the introduction of a new healthcare commissioning 
landscape. The 2010 Department of Health White Paper, Equity and 
Excellence: Liberating the NHS, published within two months of the change of 
government, laid out plans to create GP-led commissioning groups from April 
2013 and a national commissioning board.21 There was limited focus on 
pharmacy within the paper, however, it predicted that performance-related 
payments to pharmacists would incentivise services and achieve better use of 
medicines by informing and involving patients.  
Medicines Use reviews and the New Medicines Service 
The 2005 Community Pharmacy Contractual Framework included provision for 
three levels of community pharmacy service: essential, advanced and 
enhanced. Essential services include the safe dispensing of medicines and 
appliances, repeat dispensing, disposal of unwanted medicines. Advanced 
services include the MUR and later the New Medicines Service (NMS).110 The 
MUR aims to assess the patient’s use of their medicines, increase their 
knowledge of their medicines and identify where they are experiencing 
problems with them. Advanced pharmacy services such as the MUR and NMS 
should theoretically allow them to work in a more integrated way with other 
members of the healthcare team to provide support to patients in the use of 
medicines. Enhanced services (now referred to as locally commissioned 
services) include full clinical medicines review, minor ailment services, 
supplementary prescribing and out of hours medicines access. 
MURs are an opportunity for pharmacists to influence medicines safety and to 
work collaboratively with other members of the primary care team through 
improving the use and outcomes of medicines. The focus is on improving 
patient understanding of medicines and how they should take them and 
community pharmacists can use a standard feedback form to highlight with the   
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GP any potential drug interactions, potential side effects or adverse reactions, 
non-use of the medicine by the patient, difficulties using the medicine, problems 
with dosage, and concerns the patient has. The pharmacist can provide further 
information to the GP and make recommendations for possible action. 
Perceived by professional groups as, in principle, a facilitator of more integrated 
professional care, in practice the quality of the feedback provided by 
pharmacists has been the subject of criticism by GPs,115 and patients do not 
always understand or appreciate them.116 There is, however, evidence that 
MURs conducted after discharge improve the safety of patients’ medicines.117 
Three national patient target groups for MURs were introduced in October 2011: 
those taking high-risk medicines; those whose medicines have recently been 
changed whilst they have been in hospital and have recently been discharged; 
and those with respiratory disease. Initially 50% of MURs conducted annually 
by each pharmacy had to be with people in these groups. This was increased to 
70% from 31st March 2015 as part of NHS England’s commitment to support 
patients with chronic conditions. A further target group of patients at risk of 
cardiovascular disease who are regularly prescribed four or more medicines 
was also added. 
The NMS commenced in October 2011 to offer support to those patients with 
chronic health conditions who had been prescribed a new medicine. The aim of 
the service was to help improve patient adherence, increase patient 
engagement with their condition, reduce wasted medicines, reduce adverse 
drug events and hospital admissions, and increase reporting of adverse drug 
events. It was designed to focus on four clinical areas: respiratory (asthma and 
chronic obstructive pulmonary disease (COPD); type 2 diabetes; 
antiplatelet/anticoagulant therapy; and hypertension. In common with the MUR, 
the NMS feedback form allows the community pharmacist to highlight concerns 
with a patient’s new medicine, including possible drug interactions, side effects, 
patient non-use, patient difficulties using medicines, and patient concerns about 
medicines. Hospitals can refer patients to their community pharmacist for an 
NMS appointment to support their medicines use. The national referral form 
allows the hospital to list new medicines and the adherence support the patient 
is likely to need. The service was initially funded until March 2013 and, since 
then, decisions about the continuation of the service have been made annually;   
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although a recent evaluation indicated its success in increasing adherence by 
approximately 10% whilst also reducing costs.118 Improvements suggested 
were further support to pharmacists to improve the patient focus of the NMS, 
training and peer support for pharmacists and enhanced integration of the NMS 
into primary care. 
Recent policy has explored moving pharmacy even further towards integrated, 
clinical roles. In 2013, the RPS published the report of its Commission on 
Future Models of Care outlining its vision for the future role of pharmacy in the 
English NHS.119 Despite the complicated commissioning and NHS funding 
landscape, it emphasised pharmacy’s role in providing integrated care and how 
pharmacists could play a crucial role in urgent and out-of-hours care. It stressed 
how, as a profession, pharmacy needs to become less insular and that different 
contracting and delivery models may be required to provide care to meet NHS 
and patient needs. Amongst its recommendations was the shift in the balance of 
funding from pharmacy dispensing roles to medicines optimisation roles. 
In the same year, the Scottish Government published their Review of NHS 
Pharmaceutical Care of Patients in the Community in Scotland.120 It discussed 
how delivering effective pharmaceutical care is only possible if people and 
healthcare professionals view pharmacists as core primary care team members. 
The Scottish Government’s response, entitled Prescription for Excellence: A 
Vision and Action Plan for the Right Pharmaceutical Care through Integrated 
Partnerships and Innovation, set out its long-term vision for the profession.121 
This included multiple delivery models complementing and supporting GP 
services. Radically, it undertook that by 2023 all pharmacists working in primary 
care in Scotland will be NHS accredited clinical pharmacist independent 
prescribers offering community-based clinical care. Their role would work with 
other HCPs to manage long-term conditions. Little is yet known about how 
services within primary care will be re-organised to facilitate the delivery of this 
vision, however very recently the Scottish Government announced it had 
earmarked £16.2 million over three years to employ 140 pharmacists to work 
with GP practices as independent prescribers.122  
Most recently, NICE medicines optimisation guidelines identified a role for 
pharmacists, amongst others, in medicines reconciliation after patients have   
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been discharged from  hospital, in undertaking medicines review and in making 
strategic decisions about medicines (NICE, 2015).72 In addition, a recent report 
by the Health and Social Care Information Centre highlighted the success of a 
proof-of-concept project giving community pharmacy access to patients’ 
summary care records (centrally held electronic records of clinical patient 
information including a medication, allergies and adverse reactions to 
medicines) and approval for implementation of community pharmacy access.123 
The proof of concept report is noticeable for its lack of a patient viewpoint, and 
there was some media concern about the risk of patient information being 
misused by businesses owning pharmacy chains.124 
1.2.6 Community pharmacy at the transfer of care 
There is some evidence that an enhanced role for UK community pharmacists 
in post-discharge medicines management can bring about better patient 
outcomes. Studies have shown community pharmacists are able to identify 
medicines-related problems in discharge prescriptions;125–128 and improve the 
transfer from hospital to primary care through identifying and rectifying 
medication errors.129 In an earlier UK controlled trial of 501 patients aged 16-69, 
Duggan et al. gave an intervention group a letter listing their drugs and asked 
them to give it to their community pharmacist when collecting their drugs.93 The 
comparison group were given no letter. Patients were visited at home following 
receipt of their drugs. Lower rates of discrepancies were recorded for the 
intervention group 32% versus 53%, and those discrepancies that might have 
had a ‘definite adverse effect’ were lower in the intervention group (1.6% vs 
3.1%). The chances of being exposed to an ‘unintentional discrepancy’ 
increased with the number of drugs used. The researchers concluded that 
providing community pharmacists with discharge summaries reduces 
unintentional discrepancies. In a later 2007 review conducted to assess the 
impact of pharmacist-led post-discharge enhanced medicines management 
services for heart failure patients, Ponniah et al. found evidence that medicines 
management programmes had contributed to better patient outcomes and that 
the provision of pharmacist home visits may be valuable to patients in 
supporting medicines optimisation.130 Variation in study designs and patient 
characteristics made comparing the different effects of the studies difficult.  A 
Netherlands study involving 37 community pharmacists compared the   
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experiences of patients in receipt of a community pharmacist intervention 
following their discharge with those in receipt of normal care.131 The intervention 
comprised home medicines review and counselling at home. Those in the 
intervention group experienced more changes to their medicines and 
pharmacists took away unneeded medicines supplies. Patients in the 
intervention group reported higher levels of satisfaction. In summary, 
interventions offering home-based services may enhance patients’ safe use of 
their medicines, however it is a resource-intensive means of offering care and 
more research is needed to determine its feasibility. 
This section has described the system of medicines management and the risks 
that exist within the system, with a focus on the risks to safe medicines use 
when patients’ care is transferred after a hospital stay. It has also outlined 
successive policy to re-position community pharmacy in a role supporting 
patients’ safe and effective use of medicines, and discussed the risks. 
1.3 Summary of the introduction  
Evidence suggests that that there has been some success to date in 
programmes aimed at reducing the risks faced by patients caused by 
weaknesses in the overall system of medicines management. There is a global 
focus on patient safety and it is internationally acknowledged that patients 
experience risks to their safety when their care is transferred from hospital to 
home. UK government policy has acknowledged failings in the health system 
that place patients at risk and recommended that systems-based approaches 
are implemented to address them. Traditionally, however, systems-based 
approaches do not acknowledge the patient’s potential to increase system 
resilience. 
One suboptimal care system that places patients at risk is that which manages 
their medicines during the transfer of their care after they have left hospital. 
Models mapping medicines management have not viewed the system from the 
patients’ perspectives and so fail to be patient-centred, despite current UK 
policy to provide patient centred-medicines optimisation services. Patients have 
potential to add resilience to the medicines management system through their 
self-management of medicines and through their interactions with healthcare 
professionals.   
 30 
 
 
A range of policy initiatives and strategies to implement policy 
recommendations have attempted to enhance the role of community 
pharmacists in medicines management, and specifically after hospital 
discharge, for example through the MUR and the NMS. These services are 
designed to increase resilience through enhancing patients’ abilities to manage 
their medicines and identify potential problems with medicines sets. The WHO 
and NICE recommendations also champion the patient’s own role in the safety 
of medicines management when their care is transferred; however the patient’s 
own role in the system remains ill-defined. The literature review in the next 
section, therefore, will focus on exploring patients’ experiences of the medicines 
management system after discharge from hospital. Drawing on this literature, it 
will explain and appraise where possible the current role of patients in 
managing their medicines after discharge and the impact of the system on 
them. 
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Chapter 2 – Literature Review 
The narrative literature review in this chapter explores the international 
evidence about how patients experience medicines management after their 
discharge from hospital. It covers the period from 1990 to July 2014. This period 
was selected because the landmark Harvard Medical Practice Study detailing 
the level of preventable harm caused to patients was first published in the early 
1990s, introducing a new era in the study of patient safety in healthcare. It was 
decided that earlier research would arguably lack relevance to an 
understanding of modern healthcare systems. The review aims to determine 
what is already known about patients’ experiences of and roles in medicines 
management, understand the benefits and limitations of the methods used in 
the research studies and draw out inconsistencies. Whilst the benefits of 
systematic reviews are recognised, in particular their use of explicit and 
unbiased processes to synthesise the literature,132,133 a narrative approach was 
considered more effective at uniting the myriad study designs across a wide 
range of topic areas relevant to this study.134 A systematic review would have 
limited the breadth of research included in the review. A narrative method 
allowed a deep understanding of the impact of healthcare systems on patients 
during this period.  
2.1 Method 
A flexible and iterative approach to searching the literature was adopted. 
Searches were made using the keywords ‘hospital discharge’ and ‘patient 
discharge’ combined with the terms ‘medication(s)’; ‘medication error’, ‘drug 
errors’, ‘adverse drug events’, ‘patient experience’; ‘compliance’; ‘persistence’, 
‘continuity’ and ‘adherence’ in MEDLINE, PsychInfo, and CINAHL. The search 
was limited to January 1990 to July 2014 and to English Language publications. 
The search strategy produced 2,456 records. Titles were reviewed and 546 
abstracts were obtained for further review.  
Abstracts were reviewed against the following inclusion criteria: 
i) A patient voice was included in the research – studies that explored 
discharge medicines from the perspectives of HCPs  alone were 
excluded, as were those that examined documentary sources only;  
 32 
 
 
ii) Studies were conducted in the three months after discharge to capture 
the immediate post-discharge period; 
iii) Studies in which patients were discharged to their own home; 
iv) Studies about which the main focus was medicines, rather than hospital 
discharge generally; 
v) Empirical research studies.  
Excluded studies were:  
i) Studies exploring discharge to care facilities (because patients’ 
medicines would be the primary responsibility of staff rather than of 
the patient);  
ii) Studies of patients leaving emergency departments; 
iii) Studies reporting results of interventions as these do not report a 
‘normal’ patient experience;  
iv) Studies that solely validated scale measures;  
v) Studies not in the English Language; 
vi) Letters, conference abstracts/proceedings, editorials and other non-
research records. 
Full text papers (196) were reviewed and 65 retained. Additional studies (5) 
were identified through the references of the retained studies. Data extraction 
was conducted systematically, the following being recorded for all studies: the 
time period post-discharge when data were collected; the data collection 
method;  the number of participants and health condition of the participants; the 
main findings relevant to the patients’ experiences with their medicines; and the 
country in which the research was conducted. Whilst no studies were excluded 
because of their quality, an assessment was undertaken using a 16-item tool for 
studies with diverse designs.135 The tool requires the reviewer to allocate a 
mark ranging from 0–3 for each item. Items include the existence of an explicit 
theoretical framework underpinning the research, clear statements of objectives 
and research questions, and justification of sampling and analysis methods. It 
was chosen as a suitable tool because of the heterogeneity of research designs 
in the literature. The results of that assessment are detailed in Appendix 1.  
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2.2 Findings 
Seventy studies were included from 16 countries and a range of methods were 
employed at various times post-discharge. There were 30 studies from the 
USA, nine UK studies, and four each from Sweden, Israel and Canada. The 
other 18 were from other countries. One of the studies was conducted in six 
European countries. Only four studies made explicit reference to a theoretical 
framework underpinning the research. Most used quantitative methods: surveys 
and structured interviews were the main tools used (55); fewer studies used 
qualitative methods – 15 used semi-structured patient interviews, two used 
patient diaries, observations were used twice and focus groups just once. Few 
studies justified the timing of data collection relative to the time of discharge 
(10); this would have added context to the experiences researchers might have 
expected patients to have had, for example obtaining a repeat prescription or 
attending a follow-up clinic. Studies explored the experiences of the elderly (26), 
cardiology patients (14), those with mental health conditions (3), stroke (3) other 
health conditions (8) and some were not condition- or age-specific (16). Eleven 
studies included data from HCPs, comparing their views to those of patients, 
and two included the views of carers. Ten studies made explicit reference to 
involving patients in the research. In each of these, patients were involved in 
pilot testing or qualitative work to develop data collection tools. No studies made 
reference to patient involvement in the formulation of research questions, study 
design or the management of the research; however, one used data collected 
from patients to inform a later research phase with hospital staff. The review 
findings are described in seven thematic areas: receiving discharge medicines 
information; patient understanding of discharge medicines; managing discharge 
medicines; adherence, persistence and continuity of treatment; roles and 
experiences in medicines management; medicines problems identified in 
community pharmacy after discharge; and measuring adverse drug events. 
2.2.1 Receiving discharge medicines information 
A major theme in the literature was patients’ accounts of receiving information 
about their medicines, their perceptions of medicines information they received, 
and their role in managing that information. A total of 15 studies employed a 
range of qualitative and quantitative methods to either measure or explore their 
experiences. They are presented in Table 2 on page 56.  
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Measures of receiving medicines information 
The evidence about the recall of receiving discharge medicines information is 
conflicting. Measures were conducted in four studies;136–139 one reported 40% 
of patients (n=341) recalled counselling for new medicines and 64% recalled 
counselling for existing medicines.137 Over two fifths of patients (42%) wanted 
more comprehensive counselling, although their reasons were not explored. 
Patients reported preferring medicines counselling from doctors (85%). Another 
paper one year later from the same research group (possibly using the same 
data) also reported that 40% of patients recalled counselling.138 Other Swiss 
patients recalled receiving information for 15% of long-term medicines and 19% 
of new medicines.136 These patients (n=362) were significantly less likely to 
report receiving information in hospital if they reported having help with their 
medicines at home (CI 0.19-0.98; p=0.05); and significantly more likely to do so 
if the medicine had been introduced when the patient was in hospital (CI 1.2-
2.0; p=0.001). 
A further study of USA patients (n=104) found they were mostly (89%) in strong 
agreement that instructions were communicated in language they understood, 
80% were in strong agreement that instructions were communicated clearly, 
however many fewer (40%) were in strong agreement that the information they 
received at discharge had been easy to understand, although the measure used 
was unvalidated so it is not completely reliable.139 Inadequate written 
information was identified in a Danish study (n=200), in which 66 patients who 
used prescription medicines had no medicines list in their discharge letter.140 A 
USA study of those taking insulin (n=47) found the majority 81% received 
written instructions and all patients that were new to insulin received written 
information.141 
Qualitative studies of receiving discharge medicines information  
A set of nine studies explored views of medicine information and education 
qualitatively. One study explored Dutch patients’ perceived medicines 
information needs at discharge using a qualitative approach.142 Semi-structured 
interviews with cardiology, pulmonary and internal medicine patients (n=31) 
identified four aspects of information considered important by patients: basic 
drug information (name, purpose, use); side effects; alternatives that could be 
used; and what to do if problems occur. Patients preferred verbal and written  
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 information in combination. Unfortunately, the study does not attempt to draw 
comparisons between those who it described as receiving enhanced care and 
those who did not. In a Swedish study of patients following a heart attack, 
information was described as confusing and conflicting, for example information 
was difficult to understand because of the terminology used or the stressful 
environment it was given in, and GPs, nurses and hospital staff offered the 
patient differing accounts of their need for medicines.143 Views about discharge 
medicines information were examined in depth in a UK study by Knight and 
colleagues.144 Discharged elderly patients and carers (n=19) took part through 
responding to an advert and were given the option of completing an interview or 
keeping a medicines diary in addition to an interview. Their views of medicines 
information provision were found to be mixed, although most perceived the 
information they received to be inadequate, especially the level of explanation 
they received about changes to their medicines and new medicines. Patients 
and carers reported assuming that staff had no time to give them information. 
Written information was lacking for the majority and difficult to understand for 
those who had received a list of medicines. In another USA, information was 
judged lacking because it was thought not to be personalised to the patient.145  
In a study of 40 older patients in New Zealand many could not recall receiving 
information in hospital about medicines changes and were reluctant to ask 
questions of hospital staff.146 Lack of recall was more pronounced in those who 
had discontinued an antiplatelet medicine, rather than in continuers of 22 stent 
patients and patients described an lack of opportunity to ask questions about 
their medicines in hospital and a rushed discharge  and receipt of conflicting 
information;147,148 some did not recall receiving information and those who 
continued taking clopidogrel found other sources of information. An earlier study 
found that patients who had received information in hospital did not recall 
receiving medicines information 1-2 weeks after leaving hospital.145 This 
qualitative study (an ethnography) explored ‘medicines education’ at discharge, 
combining observation with telephone and face-to-face interviews in a sample 
of older US patients (n=114) with heart disease. The authors reported that 
patients received ‘unstructured education’ during their hospital stay and 
structured education at discharge. Education was offered in varying depths and 
was not tailored to the patient. Those patients using anti-coagulants, those with  
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 new medicines and those who asked more questions received more 
information. Patients experienced education about their medicines from both 
doctors and nurses, yet patients perceived the doctor to be responsible for 
giving them information, although nurses were seen as effective and acceptable 
in doing so. Patients reported preferring information before the day of their 
discharge to allow them time to understand it, and again at discharge so the 
information they received was relative in time to their departure from hospital. 
Education about medicines was valued when it was personalised and given 
verbally and in writing and, once back at home, patients were found to lack 
recall of their medicines education. This study might usefully have drawn a 
distinction between encounters that merely provided patients with information 
and those that used other methods to develop their medicines use capabilities. 
Qualitative studies in part described patients’ roles in using medicines 
information. Martens described how patients “need to be aware that a goal of 
the hospital stay is to learn how to safely and correctly manage their 
medications”;145(p347) thereby highlighting the role of self-management which is 
also mentioned in a study of patients taking warfarin who reported wanting 
enough information to enable confident self-management of their medicines 
after their discharge.149 Other elderly patients wanted deeper involvement in 
decisions about medicines and once they were discharged, and therefore not 
immediately able to access healthcare professionals, they reported difficulty 
interpreting the information they received;144 difficulty getting further medicines 
information;150 or needing help creating a personal schedule to self-manage 
their medicines.145 Heart attack patients used alternative sources of information, 
such as the internet;143 and clopidogrel discontinuers struggled to relay 
medicines information to the primary care team after their discharge or 
interpreted information incorrectly.147  
Summary 
In summary there is a small evidence base and a lack of consistent evidence to 
show that comprehensive, clear and structured medicines information is 
received by patients at discharge. International policy considers providing 
information to be only one means of educating patients about their 
medicines,151 and it is also understood that when attempting to influence health 
behaviours, providing information is only one of the range of methods   
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available.152 There is also little evidence that patients are positioned in any 
other role than of passive recipients of information. There is some evidence that 
patients receive information that they subsequently struggle to recall and that 
patients fail to receive a usable list of their medicines. Studies that measure 
patient satisfaction with their medicines are of limited value; rather research 
should focus on how patients use their medicines and what types of patient 
education are appropriate to support the effective use of medicines. Two 
studies attempted to associate recall of receiving information to outcomes or 
contextual factors, for example discontinuation of medicines, or support with 
medicines. Interestingly those patients with support in the home in one study 
had lower recall of receiving information, which may be either explained by the 
patient’s lack of ability to either recall or a lack of need to recall because they 
have help, although neither of these factors were explored. Conducting memory 
tests of what patients are told in hospital lacks value as an approach to 
understanding how patients might use information as part of a process of 
building their abilities to safely manage their medicine once they are home. 
2.2.2 Patients’ understanding of discharge medicines 
Closely linked to patients’ receipt of medicines information and how they 
managed their medicines before their hospital admission is how well they 
understand their discharge medicines. The methods employed were either pre-
constructed measures of knowledge, or qualitative to explore understanding of 
medicines. Here these two different types of study are discussed separately. 
Measures of knowledge  
Many of the studies attempted to produce a quantitative assessment of patients’ 
knowledge of their discharge medicines. A total of 13 studies used quantitative 
methods to measure patients’ knowledge; summaries of those measures are 
presented in Table 3 on page 59. The studies ranged from 1995 through to 
2011 and there is no evidence that over this period patients’ knowledge of the 
medicines which they left hospital with improved, although the exact focus of 
each study differed. Areas explored were: knowledge of medicines at 
discharge;153,154 after discharge;137,155,156 the association of medicines 
knowledge with use of health service;138 measured of understanding of changed 
or new medicines;138,155,157,158 the association of reports of receiving information 
at discharge with knowledge of medicines after discharge;136 the outcomes of   
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discharge preparation;159 the differing perceptions of patients’ knowledge 
amongst patients and doctors;160 and the medicines knowledge of elderly 
patients.161 Specific health conditions included cardiology and lung 
conditions;158,160 diabetes, hypertension, cardiology and lung conditions;138 and 
immunocompromised patients.154 None of the studies used a validated measure 
for knowledge of medicines.   
Each study measured patients’ knowledge of their medicines in a different way. 
Purpose and name of medicines were commonly asked, along with knowledge 
of side effects, whilst patients were questioned less often about their doses and 
dose frequency. However, medicines naming is a limited means of assessing 
patients’ knowledge of their medicines: names will change if prescribers choose 
to move between brands or from brand to generic and vice versa. Names are 
often complicated, and can sound very similar. Patients taking many medicines 
concurrently may also – quite justifiably – have problems remembering them all. 
A patient may be more likely to remember the name of a medicine that they 
were already taking before going into hospital and less likely to know the name 
of a newly prescribed medicine. Questions about the purpose of medicines may 
produce a more useful marker of medicines understanding, and possibly a 
superior indication of how well patients understand their medicines. In two 
studies patients were able to refer to notes, such as discharge summaries, 
which obviously would help with their ability to answer questions about their 
medicines, and is perhaps justifiable because it more closely reflects how 
patients may use their medicines, referring to any written information they may 
have about them. 
Patients were questioned about all their medicines;153,154,156,159–161some about 
only long-term medicines;136,138 and others about new and changed 
medicines.155,157,158 One study questioned patients about one continuing 
medicine and one new medicine.137 Variables negatively associated with 
medicines knowledge were reported to include age and the number of 
medicines taken.136,155,156 
In adjusted logistic regression analysis, reasons for taking medicines were less 
likely (0.4 times – CI: 0.22-0.76) to be known by patients aged 80 or over when 
compared to patients aged 20–59, more likely to be known by those who had   
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reported receiving information during their hospital stay (7.2 times – CI: 3.2-
16.1).136 Patients in this study who stayed longer in hospital were 0.96 times as 
likely for each additional day to know the reasons for taking their medicines 
once they were discharged (CI: 0.94–0.99) and it is possible that a longer stay 
in hospital may have given patients the opportunity to familiarise themselves 
with their medicines and also to receive more information about them. 
Logistic regression models were used to identify the best predictors of patients’ 
medicines knowledge: those on only one or two medicines at discharge were 
5.8 (CI: 1.7-17.02) times more likely to correctly report how to take their 
medicines.156  A slightly earlier study of 119 elderly patients measured a 
correlation between knowledge of medicines and cognitive function, and 
between knowledge and the number of prescribed drugs, but did not find an 
association between knowledge and age, although the mean age of the sample 
was 82.161 
A significant correlation (p<0.001) was found between recalling receiving 
medicines counselling and correct knowledge but not with gender, age, 
education, satisfaction with counselling, nor wanting more counselling in a study 
of 341 patients.137 Only one study compared patients’ knowledge with doctors’ 
assessments of patients’ knowledge.160 This single-site US study compared the 
responses of hospital doctors and patients (66 pairs) and found that there was 
general agreement about patients’ good understanding of their medicines, 
however doctors reported that 89% of patients understood the possible side 
effects and fewer patients (57%) reported that they understood. Doctors in this 
study were also found to perceive that more time was spent discussing post-
discharge care than patients did.  
Qualitative approaches to exploring patients’ medicines understanding 
Qualitative approaches have more recently been used to explore patients’ 
understanding of their discharge medicines. Studies that in part explored 
medicines understanding are presented in Table 4 on page 63. One study 
undertaken in New Zealand explored elderly patients’ experiences using their 
new and changed medicines after their discharge.146 Patients (n=40) described 
trusting their doctors’ decisions about their medicines and a reluctance and lack 
of opportunity to discuss changes with hospital staff. Nearly half the sample was   
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unaware of how their medicines had changed. The study focussed on patients 
taking four or more medicines, which may mean they have a more complicated 
medicines management role than those taking fewer medicines. Elderly patients 
in another study reported being confused by the set of medicines they were 
given at discharge and the complicated regimen they were asked to follow; and 
their lack of understanding affected their confidence.144 In another study of UK 
patients, understanding what their post-stent medicines were for was thought to 
impact on their adherence although patients believed knowing what their 
medicines were for was important.163 
Other aspects of knowledge explored were about specific medicines, for 
example USA patients discontinuing clopidogrel reported having poor 
knowledge of the duration of their treatment.148 Other research also found 
patients to have inadequate medicines knowledge: when participants were 
asked about their stroke medicines, understanding varied, but no participant 
had complete knowledge.164 A study conducted by Stafford et al. used 
qualitative semi-structured interviews to explore Australian HCPs’ and patients’ 
experiences and perspectives of warfarin management in the period after 
hospital discharge to identify issues in the existing medicines management 
systems.149 Interviews were conducted with nine patients, along with eight 
GPs/practice managers, eight special support service providers, five healthcare 
organisation representatives, and 12 community and hospital pharmacists. 
Amongst the themes identified in the phenomenological analysis was that 
patients who were well informed appeared comfortable with their warfarin 
therapy; and others described being confused or anxious about warfarin, which 
arose from a poorer understanding of their treatment. Medicines review services 
delivered at home after hospital discharge allowed patients to ask more 
questions because they were in a comfortable environment and were perceived 
by some patients to enhance the system of warfarin management because of 
improved access to services. 
Summary 
Overall, there is no compelling evidence that patients understand the medicines 
they leave hospital with and more vulnerable patients, for example those who 
are older and self-managing more medicines may, quite understandably, be 
less knowledgeable about aspects of their medicines. The number of studies,   
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especially qualitative studies is small and many of the quantitative measures 
used, for example testing patients’ memory of their medicines regimens, lacked 
relevancy to the way patients use medicines in real life. Moreover, there was no 
consistency in the range of methods employed to measure understanding or in 
the different lengths of time post-discharge data were collected. There is also 
little value in employing deterministic approaches to understanding whether 
more information, being younger, or being on fewer medicines impacts on a 
measure of understanding; instead, more focus could be placed on exploring 
how the model of service provision impacts on patients’ self-management of 
their medicines and research could explore how patients could be more 
effectively supported in developing understanding and becoming confident self-
managers of their medicines. Just one of the studies, for example, detailed how 
a home review of warfarin after discharge gave patients the opportunity to probe 
for the information they wanted and the studies detailed in this section do not 
take into account the roles of family and other personal contacts in helping 
patients develop an enhanced knowledge of their medicines. 
2.2.3 Patients’ experience and roles in discharge medicines management 
Patients’ self-management of their medicines once they have left the hospital 
was the focus of a range of studies. In total, 19 studies were identified exploring 
the experiences of different groups, including: elderly patients;144,146,161,165,166 
elderly non-English speaking background patients;167 inner-city US patients;157 
psychiatric patients;168 those discharged from intensive care;150 following a 
stroke;164 following a heart attack;143 following a stent procedure;147,148,163 after 
surgery;169,170 undertaking cardiac rehabilitation;171 taking warfarin;149 anti-
platelets;147,148 and insulin.141 These studies are presented in Table 5 on page 
64. 
Practical and emotional factors 
Patient responsibilities of getting and paying for medicines after discharge were 
highlighted as concerns in a number of studies. Patients had problems getting 
to the pharmacy;150,157 and those who had difficulty visiting the pharmacist were 
significantly less likely to fill prescriptions on the day of discharge.157 Other 
patients reported difficulties in getting timely supplies after leaving 
hospital.141,150  
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Some USA patients took less than prescribed doses because of the cost.157 
More than a third of these inner city patients (35%) thought it difficult to afford 
medicines and patients under 55 were more likely than those over 55 to report 
problems paying for medicines (48% vs 19%). Nigerian psychiatric patients also 
reported financial difficulties (44%).168 In a large US study of discharged 
patients (n=31,199), 7.2% reported having a prescription-related issue 
(including not collecting medicines or not knowing if they had been collected) 
after discharge and those with Medicaid or Medicare HMO insurance or no 
insurance were significantly more likely to experience problems (p<0.0001).162 
In this study, older patients reported fewer problems, but people prescribed six 
or more medicines were more likely to report problems (OR 1.39; CI 1.9-1.54). 
One Swedish study explored patients’ experiences of taking medicines after a 
heart attack.143 Interviews with 20 patients adopted a narrative approach. 
Patients described feeling the burden of taking medicines, lonely, and insecure. 
Needing to take medicines acted as a reminder that they had suffered a heart 
attack. They wanted reassurance from their doctor, experiencing side effects, 
yet feeling protected from further ill health as a result of taking medicines, which 
was also reported by stroke patients (n=30), along with concerns about side 
effects and interactions and negative beliefs about medicines.164 Studies of 
patients’ post-operative experiences have provided another perspective, 
specifically the management of pain medicines after discharge. Negative 
attitudes towards medicines and adverse effects also informed the use of pain 
medicines after discharge post-surgery.169,170 Influence of family and friends 
was important in deciding whether to use pain medicines;170 however refusal by 
family to be involved in care was associated with non-compliance amongst 
psychiatric patients.172 Warfarin patients reported being anxious and 
confused.149 
Other patients described problems adapting their medicines routines after 
changes made in hospital;146 and some developed strategies to remember to 
take medicines, including having a place for containers and established 
routines.163–165,171 Worries about medicines led to some patients adjusting their 
routines.150 Problems experienced by patients with medicines packaging were 
identified in studies from 1996 through to 2014.125,150,161,164   
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Support managing medicines 
Other studies have in part explored the role of patients’ personal contacts in 
managing their medicines. For example, half of US inner-city patients in one 
study (n=84) had help from friends and family collecting their medicines, 36% 
had reminders from friends or family to take medicines, 28% had help from 
friends and family organising medicines and 33% had help from friends and 
family paying for medicines. Women and patients over 55 had more help 
picking up their medicines.157 Over a quarter (26%) of patients had help from 
friends and family understanding how to take new medicines and 21% had help 
from friends or family deciding what to do with pre-hospital medicines. Younger 
patients were significantly more likely to report getting help understanding how 
to take new medicines and what to do with their hospital medicines. Social 
support with managing medicines and the types of assistance provided was 
also included in a US post-discharge medicines management study of elderly 
patients.165 The most common type of help was preparing medicines without 
being asked to do so; and the most common source of help was from a spouse. 
Similarly, UK stroke patients described the importance of carers, such as 
spouses, in managing medicines.164 
Impact of gaps in care 
Patients in different countries reported poor continuity of care and poor 
communication about their medicines management at transfers of 
care.144,147,148,164,167 Patients described a lack of contact with a GP or community 
pharmacist;164 a lack of follow-up care;147,165 and GP contact that lacked 
depth.143 Most patients in a 1990s UK study of older adults post-discharge had 
not been seen by their GP and had not had their medicines reviewed whilst they 
were present.173 Others had not received repeat prescriptions.174 Several other 
studies highlighted the poor communication that patients thought occurred 
between care providers, including incomplete, inconsistent and confusing 
information.144,148, 149,150,165,166  There is evidence that patients perceived a lack 
of co-ordination between hospital and primary care staff and they experienced a 
burden in performing a communication bridging role between their healthcare 
providers.144,150 Some UK patients were not aware of the role of community 
pharmacy in their medicines management.163   
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Summary 
This section has explored the range of research into how patients report 
managing their discharge medicines. Their roles comprised acquiring medicines 
after discharge, and creating and adapting strategies and routines to help them 
take medicines, including new medicines, and receiving help from personal 
contacts to manage their medicines. However, some patients found it difficult to 
adapt their routines to changes made in hospital. Patients were aware of care 
continuity gaps and some report bridging those gaps. No studies, however, 
explored how patients manage their medicines after discharge from a systems 
perspective or looked at the range of people and professionals involved in the 
medicines management system.  
2.2.4 Patient adherence, persistence and continuity of treatment  
Whether or not patients actually take the medicines they have been prescribed 
in hospital has been the focus of research with patients throughout the period 
covered in this review. Twenty four studies attempted to measure patients’ 
adherence, compliance or persistence with intended long-term medicines within 
three months of hospital discharge. The terms persistence and adherence have 
been defined as two different constructs:175 a patient is adherent if prescribed 
medicine instructions are followed, whilst persistence is characterised as 
continuing treatment for a prescribed period. Continuity of treatment in a further 
seven studies is explored as the extent to which discharge medicines continue 
to be prescribed by the patient’s GP. Continuity is considered alongside 
medicines discrepancies, which are defined as differences between what was 
prescribed at discharge and the medicines the patient actually takes. 
Discrepancies were measured in two studies, both using the USA medicines 
discrepancy tool (MDT).58 
Adherence and persistence 
In studies dating from 1992–2014 measures of adherence and persistence were 
taken at varying time-points from 48 hours after discharge up to the three-month 
post-discharge cut-off point for this review. Justification was rarely made for the 
timing of the patient follow-up. Rates of adherence were documented to be as 
high as 100% for stroke patients taking diabetic medicines;176 and as low as 
6.5% in USA medical-surgical patients.177 In some cases sample sizes were 
very small, limiting predictive value;177,178 and only seven of the studies were  
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conducted with patients discharged from multiple hospital sites. Reported 
adherence and persistence rates from each of the studies are detailed in Table 
6 on page 68. 
Measures of persistence 
Three studies measured persistence, defined as “continuing a therapy or class 
of therapy from discharge to the 3-month follow-up;179(p1457) Each of these 
studies also explored if non-persistent patients had self-discontinued or if they 
had discontinued with the knowledge of an HCP.179–181 One of the larger studies 
measured persistence with stroke prevention medicine after discharge amongst 
USA patients (n=2,598).179 Regimen persistence comprised taking all classes of 
medicines and composite persistence was calculated as the percentage of 
medicines classes patients were still taking. The sample was 95.5% persistent 
with all medicines prescribed at discharge. A year earlier, persistence with 
evidence-based medicines for USA patients with acute coronary syndromes 
(n=1107) was recorded three months after discharge.181 They found patients to 
be less persistent (71.8%) and in 61.5% of those cases the patient had decided 
to self-discontinue. Persistence was associated with fewer types of medicines 
classes, increasing age, medical history, less stroke disability, insurance, 
working status, knowledge of medicines, increased quality of life, hardship, 
region and hospital size.179 
Measures of adherence 
The studies identified used varying definitions of adherence and different 
measurement techniques or measurement scales, such as the Medication 
Adherence Report Scale (MARS),182 and the Adherence to Refills and 
Medications Scale (ARMS).183  Some studies measured rates of under-
adherence, over-adherence and overall adherence, whilst others characterised 
patients as fully and partially adherent. Differences between adherent and non-
adherent patients were reported as: being older (more adherent), having a 
greater perceived risk of not adhering, personal susceptibility to disease, 
satisfaction with previous treatment, cognitive memory failures, and patients’ 
subjective value of health;184 better self-reported health status and higher 
number of medicines predicted non-adherence in a study of Swedish 
patients;185 adherence levels between patients on a higher number of medicines  
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were different in elderly Italian patients on polypharmacy;186 whilst belief in the 
necessity of medicines significantly predicted adherence in a further study 
conducted in the Netherlands.187 Amongst schizophrenic patients being non-
compliant was associated with risk of readmission, accessing emergency care, 
being homeless and experiencing worsening symptoms;172 there was also an 
association with family refusal to be involved in treatment and non-compliance. 
Compliance was associated with drug misuse and recognising symptoms. 
Mansur et al. (2009) found an association between non-adherence to at least 
one medicine and inappropriate prescription drugs prescribed at discharge,188 
although a more interesting finding in their research is that nearly half of the 
elderly patients (45%), were discharged with at least one inappropriate 
prescription medicine. 
Exploring adherence qualitatively 
In the UK, adherence to medicines following a stent procedure was explored 
qualitatively with 20 patients. They reported good relationships with GPs to be 
an influencing factor, along with understanding of the purpose of medicines and 
their health condition, having a medicines routine and perceiving positive 
benefits to taking medicines. Some patients were unclear about the community 
pharmacy role in supporting adherence, although patients were interviewed 
within a  week of discharge so would not have had an opportunity to experience 
a post-discharge MUR or collect a repeat prescription.163 A sample of Australian 
patients found it difficult to adhere to new medicines because the new 
medicines altered their routine.167 Patient discontinuation of clopidogrel was 
explored in two comparative USA studies by a Kansas-based team.147,148 They 
compared those patients discontinuing (stopping completely) clopidogrel with 
continuers;147 and patient and clinician views on reasons for discontinuation,148 
however the clinicians interviewed were not involved in the care of the patients, 
which limits the value of the comparison. Both studies found that system-related 
factors, such as poor communication and gaps in care transitions, contributed to 
patients stopping taking their medicines. These studies are included in Table 5 
(previously referenced on page 41). 
Medicines discrepancies and continuity of treatment  
A range of studies looked at discrepancies in medicines use and the continuity 
of patients’ medicines in the period following their discharge. Studies used   
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primarily quantitative methods to generate evidence about the stability of 
patients’ medicines use after leaving hospital. They are presented in Table 7 on 
page 73. 
Discrepancies were identified in hospital medical records and patient reports of 
medicines for elderly US patients (n=80): congruence was found in only six of 
these patients and patients reported taking significantly more medicines than 
recorded in hospital records (p=0.001).139 A Swedish study using structured 
interviews one week after discharge, again with elderly people, identified 30% of 
patients to be using their medicines as documented in their medical record, 
which included changes made by their primary care team after their hospital 
stay.189 Discrepancies in medicines were also reported qualitatively by 
discharged patients from non-English speaking backgrounds in Australia.167 
A Medication Discrepancy Tool (MDT) constructed for use with elderly patients 
attempted to assess the prevalence and predicting factors of post-discharge 
medicines discrepancies.95 In this US study (n=375) based on one site with 
patients with different health conditions, 14.1% experienced one or more 
discrepancies and patients with discrepancies were on average taking 
significantly more medicines. Discrepancies were attributed either to the patient 
or to the system. Non-intentional, non-adherence was the most common 
discrepancy associated with the patient, whilst poor quality discharge 
information was the most common system discrepancy. Those patients taking 
more medicines (OR 1.13, CI 1.04-1.23) and those with congestive heart failure 
(OR 2.1, CI 1.09-4.03) were more likely to experience discrepancies. Rates of 
readmission within 30 days were also significantly higher for those patients with 
discrepancies (14.3%) than for those with no discrepancies (6.1%). 
Understanding the causes of discrepancies can reveal failures in the system, 
yet they fail to show how system-level and patient-level factors interact, for 
example, how poor quality discharge information or conflicting information may 
directly lead to non-adherence. They also fail to take into account individual 
variation in care interactions, for example, the nature of the network of 
professionals surrounding the patient. The MDT was later used in another USA 
study with 103 elderly patients.39 Over half the sample (52%) had discrepancies 
about one week after discharge, and an association was found between 
cognitive impairment and higher rates of discrepancy, as well as with lower   
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levels of medicines knowledge. A different USA study found that 56% of 
patients had medicines discrepancies two days after discharge. In this study 
taking medicines not listed on the discharge summary and not taking listed 
medicines were categorised as discrepancies as well as taking medicines 
incorrectly. The authors assessed the most common cause to be inaccurate 
discharge instructions, followed by intentional non-adherence.190 They found 
that those patients with inadequate or marginal health literacy were more likely 
to unintentionally be non-adherent. 
A Danish study (n=200) also found wide-ranging incongruence between 
discharge medicines lists and patient medicines use a few days after 
discharge.140 Reconciliation errors and poor communication were the main 
cause of incongruence. Continuity of treatment was explored by a number of 
studies throughout the 1990s through to 2012.39,161,173,174,191–193 The largest, 
conducted in Australia, combined in-patient medical record review, a GP 
survey, and a patient telephone survey three months after discharge for 1319 
patients from 49 hospitals after a heart attack.193 It found a significant decrease 
in prescriptions of antiplatelets, statins and beta-blockers, and all four 
recommended medicines in combination (which include ACE inhibitors / (AII)-
antagonists). Patients reported that GPs had stopped 44% of these medicines. 
The prescription of all four guideline-recommended medications was greater in 
male and younger patients. Little detail is offered about the structure of the 
questions patients were asked and whether they referred to any written 
information on their medicines during the survey.  
Eijsbroek et al. reported on the continuity of medicines focussing on intensive 
care unit (ICU) admission, ICU discharge and hospital discharge for 21 
patients.150 They reported that 107 medicines were prescribed regularly before 
ICU admission, 150 were prescribed on ICU discharge, 121 at hospital 
discharge, and 108 three months later. Eight (5.3%) chronic medicines were 
discontinued on the ICU and not restarted on discharge (mainly diabetic 
medicines). The authors did not report on any documented reasons why 
medicines had been stopped. Other assessments of medicines continuity 
explored the experiences of elderly patients using structured questionnaires and 
home visits.161,173,174,192 A small study (n=56) of UK elderly patients attempted to 
assess the extent of prescription continuity.174 They found 63% of prescriptions   
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were unaltered by the GP after discharge; however this figure only includes 
additions and omissions and not changes in dose, direction and name. 27% of 
patients had not received a new supply of medicines and nearly half (48%) had 
old supplies of medicines at home. In the same year another small study found 
that amongst 50 UK patients 45 were taking different medicines 6–14 days after 
their discharge.173 Changes included the name of the medicine (20 patients), 
new medicines (20), stopped medicines (10), changed directions (11) and 
altered doses (11). In the Mansur et al. study of 198 elderly patients one month 
after discharge, 16% had no changes to their medicines one month after 
discharge.192 Patients who visited their GP only one time in the month after 
discharge had significantly fewer changes than those who visited more times or 
didn’t visit at all (p < 0.05). Half of all changes were an addition of a medicine or 
an increased dose, over a quarter (26%) were discontinuing, 16% omitting it, 
and 8% switching it for an alternative. The majority of changes (70%) were due 
to recommendations by specialists or a change in the patients’ health, the 
remainder were mostly due to adverse effects, poor adherence by the patient 
and administrative reasons. Patients who were non-adherent to at least one 
drug had significantly more changes to their medicines than those who were 
adherent. 
A study of the effectiveness of the system of medicines management for 
discharged elderly patients conducted in the late 1990s (n=68) found more than 
half of patients experienced problems with their medicines, which were 
assessed to be due to actions or omissions of HCPs, such as incorrect drugs, 
doses and drug combinations being prescribed in primary care, and patients 
purchasing unsuitable over the counter medicines.166 This study is noteworthy 
as it examines system-related problems in UK healthcare in advance of more 
well-known work applying systems thinking in the healthcare and medicines 
context.63,194 That it was conducted on only one site limits generalisablity and its 
age restricts its relevance to current healthcare systems. 
Summary 
This section has described the literature about whether patients continue to take 
or continue to be prescribed the medicines they are prescribed at hospital 
discharge. It has found that rates of adherence vary greatly and studies have 
found association between adherence and a range of patient and care   
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characteristics. None of the studies explored the structure of patient care as a 
predictor of adherence, however two qualitative studies concluded that system-
related problems contributed to sub-optimal medicines use. A range of terms 
are used, each describing slightly different phenomena, for example adherence, 
persistence and continuity. Discrepancies and changes were also explored. 
Studies described here tended to be deterministic, rather than interpretivist; 
they attempted to measure and predict causes of behaviour, rather than 
describe, explore and understand them. They did not focus on contextual 
factors, such as the structure of the care experienced by patients relating to 
their medicines, how they accessed healthcare providers, or the level of support 
they had with their medicines at home. As a result, most of the reviewed studies 
provide varying numeric assessments of rates of adherence, persistence and 
continuity without an extensive narrative that explains the reasons why patients 
may not take medicines as the hospital intended. 
2.2.5 Medicines problems identified in community pharmacy after 
discharge 
Patient-reported experiences were identified in two studies focussing on 
medicines-related problems identified in community pharmacies after hospital 
discharge. These studies are presented in Table 8 on page 75. They analysed 
the nature and frequency of post-discharge drug-related problems (DRPs) and 
community pharmacy intervention.125,127 In the earlier study, 451 DRPs were 
identified during community pharmacists’ post-discharge medicines discussions 
in 277 of 435 patients in six European countries (63.7%) (Austria, Denmark, 
Germany, the Netherlands, Portugal, and Spain).125 The most common DRPs 
were patients’ uncertainty about the aim or function of the medicine (29.5%) and 
their side effects (23.3%). Proxy interviews were conducted with those who 
could not be interviewed because of age or illness, which may have limited the 
ability of the study to record problems for those patients. Cardiovascular 
medicines were the ones most frequently associated with problems (30.5% of 
358 medicines). The most common interventions performed by community 
pharmacists were medication counselling (39% of 305 interventions) and 
practical instruction (17.7%). A later Dutch study recorded existing or potential 
drug-related problems affecting 95.9% of 340 elderly patients using a checklist 
of common DRPs, the pharmacy computer system, record review and a semi-  
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structured interview.127 Using the checklist, the most common DRP was having 
no medicine prescribed but there being a clear indication (16.1% of 992 DRPs), 
followed by an unnecessarily long duration of treatment (10.7%), and 
interactions identified on the pharmacy computer system (9.8%). Over a sixth 
(17.5%) of the DRPs were fear of side effects reported in interviews and 14.6% 
of DRPs were insufficient patient knowledge of the medicine. The authors 
reported that, using linear regression, the number of DRPs was significantly 
associated with the number of medicines prescribed per patient (p<0.001), the 
ward (pulmonary vs cardiology) (p<0.05) and the disease (diabetes) (p<0.05); 
age and gender were not significant variables in the model.  
Summary 
Studies indicated that community pharmacy is able to identify problems that 
discharged patients may experience with their medicines after they have left 
hospital, and that between 64–96% of discharged patients experienced a 
medicines-related problem after their discharge. The different methods used by 
each of the studies to collect data, the older age group in the later study, and 
the different definitions of DRPs might explain the discrepancy in the rates of 
DRPs experienced by patients reported in each study. For example, semi-
structured interviews may elicit more information about problems than 
structured interviews; and ‘fear of side effects’ might arguably be more common 
than actually experiencing side effects. The studies record a higher incidence of 
DRPs and community pharmacy interventions than those conducted after 
discharge using records alone,126,195 which may indicate that involving patients 
is a more successful way of identifying problems, especially those involving 
patients’ knowledge of and attitudes towards their medicines. 
2.2.6 Measures of adverse drug events 
Measurements of error in healthcare and adverse events are considered 
problematic for several reasons, including the challenges inherent in developing 
robust measurement tools that are reliable, valid, sensitive and specific, and 
through the different ways data are collected and the variation in outcome 
measures.196 Six studies used quantitative methods to measure the incidence of 
adverse events (AEs) or adverse drug events (ADEs) after discharge through 
patient self-reports;48,166 and self-reports and medical record review / GP 
input.47,50,51,197 They are summarised in Table 9 on page 76. Each used slightly   
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different measures or operational definitions which makes synthesising their 
findings and drawing conclusions about the rates of ADEs difficult. One study 
measured adverse outcomes from fall-risk-inducing drugs (FRIDS), number of 
medicines and drug-drug interactions (DDIs) for ‘robust’ and ‘frail’ elderly 
patients (n=204) discharged after a fall.197 The total rate of adverse outcomes 
for the sample was 58% (39% of the robust sample and 76% the frail sample). 
Finally, a Croatian study followed up patients assessed to have potential drug-
drug interactions (DDIs) after thirty days to assess if an adverse drug reaction 
(ADR) had occurred assessed clinically via patient self-report;198 190 patients 
from a sample of 222 had potential DDIs, whilst only 21 (9.5%) had actual DDIs. 
ADEs occurred in 19 patients (8.5%), with ACE inhibitors being the most 
common medicine in instances of ADEs. Only patients with potential DDI were 
followed up, which might yield a higher incidence of adverse reactions, the 
incidence in this study was low. The incidence of potential DDIs at discharge 
was, however comparatively high. 
Summary 
Together, these studies suggest that the incidence of ADEs up to one month 
after discharge is 9-58%, and there is a pattern in the studies that might suggest 
that the risks include being older and taking a high number of medicines. Risk 
factors have also been found to include patient gender (female), and poor 
patient/health professional communication across sectors of care were thought 
to contribute. There are, however, problems interpreting the findings. For 
example, the three Forster-led studies (the Forster et al. 2005 study was a 
reanalysis of the data used in their 2003 study) used patient self-reports or a 
combination of records and self-reports to determine incidents and their 
severity.47,50,51 The earlier Gray et al. study on the other hand solely used self-
reports, which may underestimate symptoms.48 For example, patients may not 
wish to discuss their side effects or may not attribute how they feel to their 
medicines. In addition, studies using medical records to identify AEs may be 
subject to underreporting, as medical staff may be reluctant to document the 
cause of a readmission if they perceive a colleague or themselves to be at fault 
or they judge the events to be unlikely to cause harm. Furthermore, all patients 
in one study had a history of falling and may be more susceptible to further 
adverse events. Despite the different ages of participants, varying measures,   
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and that in some cases symptoms and problems were self-reported, the results 
still indicate a measurable incidence of problems with medicines after discharge 
from hospital. Interestingly, none of the studies asked patients whether they had 
reported the adverse drug events to a HCP, which would have given an 
indication of the rate at which post-discharge ADEs go unreported. 
2.3 Literature review discussion  
Seventy studies were identified as meeting the inclusion and exclusion criteria. 
Mapping each study against the quality assessment tool indicated that most 
were of limited quality. Whilst studies explored many areas of patients’ 
experiences with medicines after leaving hospital, there was a lack of consistent 
evidence that patients are effectively prepared to be confident and competent 
medicines self-managers after they leave hospital. In particular, there is little 
evidence that comprehensive, personalised preparation is given to patients in a 
way that is usable for them once they have been discharged and studies 
focussed on ‘information’ provision rather than exploring other ways of 
preparing patients to use their medicines. More vulnerable patients and those 
whose medicines have changed in hospital may have lower levels of medicines 
understanding, although there is little consistency in the way medicines 
knowledge is measured in the included studies. After discharge, some patients 
played a role in developing medicines routines and strategies to manage 
medicines, whilst others struggled to adapt to changes made in hospital. 
Patients reported poor continuity of care between secondary and primary 
providers, and sometimes they themselves bridged gaps in care, and studies 
recorded a lack of continuity in treatment regimen after discharge. Post-
discharge adherence and persistence rates were wide-ranging. Studies found 
an adverse drug event incidence of between 9–58% but there is little evidence 
in those studies that ADEs were due to changes made in hospital. There is also 
very little research focussing on the impact of people who support patients in 
managing their medicines. 
International differences in the provision of healthcare make it difficult to draw 
generalised conclusions or to understand transferability and relevance of 
findings of the included studies. Patients in the US, for example, may not 
receive a supply of medicines from the hospital at discharge as UK patients do; 
rather they may be expected to take a prescription to a pharmacy and patients   
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without comprehensive insurance may struggle to finance their medicines. 
Despite this, it was possible to synthesize studies into themes that give an 
indication of the types of experience patients have when managing medicines 
after hospital discharge. Many chose to look at one aspect of medicines 
management, such as patient medicines knowledge, information provision, or 
adherence to treatment. It was also possible to identify major methodological 
weaknesses that studies held in common. Very few studies used robust 
sampling methods or validated quantitative measures. Within the identified 
research, theoretical frameworks have rarely been used to guide the 
development of the research and none used a human factors framework. Given 
the evident risks to patient safety at discharge, future research might consider 
adopting a systems-based framework to explore patient experiences of this 
critical period of care. Positioning the patient as integral to the system, capable 
of playing an important role within it, rather than as a passive recipient of care, 
may enhance the impact of research in this area to effect safer patient 
outcomes. Also noticeable is the very limited focus on the involvement and 
importance of patients’ own friends and family in the safe management of 
medicines. 
Implications for patients  
International policy and UK national practice view transfers of care as a priority 
for improvement because of the threats posed to patient safety in current 
practice.91,199,200  On discharge from hospital, patients are likely to have new 
medicines and/or changes to doses of existing medicines and, for a range of 
reasons including poor communication about medicines, they may discontinue 
or become non-adherent to some or all which can lead to sub-optimal outcomes 
including readmission to hospital.49,101,102 Yet studies in this review found little 
evidence that hospitals and primary care practice effective patient preparation 
to self-manage medicines. The studies indicate that patients’ experiences of 
receiving written and verbal information about their medicines are variable and 
sometimes inadequate, and there is no evidence of improved experience in 
more recent research. What unites patients in these studies is that on leaving 
hospital they transfer from an environment where their care is monitored to one 
where they may be isolated, have limited access to HCPs and have limited 
power and control in the management of their own care.58 Patient care is   
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handed over and there is evidence that systems in primary care are not well-
calibrated to receive and continue care seamlessly. 
The research reviewed here has described patients’ experiences of medicines 
discrepancies and other problems post-discharge as well as of adverse events. 
Patients’ reports suggest they perceive that communication between HCPs in 
hospitals and primary care is not always effective and there is some evidence 
that patients’ own knowledge and resourcefulness are under-used within the 
system; however the evidence base is not robust enough to illuminate this. This 
indicates that a systems-based approach to exploring discharge medicines 
management would be a valuable addition to the evidence base. Additionally, 
an approach that includes the patient as an integral part of the system and also 
explores in more detail the role of patients, all the HCPs who they perceive as 
managing their medicines, and the patients’ own friends and family who support 
them would offer novel insight into the risks that patients face when the leave 
hospital with medicines, their roles in medicines management and how 
effectively the system functions to support them. The next section will therefore 
describe the methodological approach adopted to conduct that research. 
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Table 2: Studies of the provision and recall of discharge medicines information 
Study N= Average 
age (SD) 
Condition / 
Focus 
Data 
collection 
Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
Attebring et al. 
2005 Sweden 
143 
20  Acute myocardial 
infarction 
Semi-
structured 
interview 
7.5 weeks Explore secondary 
prevention 
experiences. 
Patients reported getting conflicting 
information from doctors and nurses 
which confused them and again by the 
primary care team. They found 
information difficult to understand 
because of the terminology and the 
stressful situation and physical 
surroundings.  
Bagge et al. 
2014 New 
Zealand 146 
40 Male 
median 
82; 
female 86 
Elderly with 
changed 
medicines 
Semi-
structured 
interviews 
 Understanding and 
management of 
changes . 
Patients were reluctant to ask questions 
of hospital staff. Some patients reported 
having the opportunity to ask questions 
and some did not. 
Borgsteede et 
al. 2011 
Netherlands 142 
31 
 
 Cardiology, 
pulmonary, 
internal medicine 
Semi-
structured 
interviews 
At 
discharge 
Explore patients’ 
medication 
information needs.
  
4 aspects of information considered 
important by patients: basic drug 
information (name, purpose, use); side 
effects; alternatives; what to do if 
problems occur. Prefer a combination of 
verbal and written instructions. 
Decker et al. 
2008 USA 147 
22 41-77 
(range) 
Clopidogrel 
continuers and 
discontinuers 
Semi-
structured 
interviews 
1 month Explore clopidogrel-
taking behaviours. 
Discontinuers often struggled relaying 
treatment information to their primary 
care team. Discontinuers interpreted 
information incorrectly or did not 
remember receiving information. 
Discontinuers reported limited time to 
get information from staff in hospital.  
Eijsbroek et al. 
2013 
UK 150 
21 patients / 13 
carers 
 ICU patients Medication 
history data; 
Semi-
structured 
interviews 
3 months Explore medicine-
related problems 
arising from ICU 
admission and post-
discharge. 
Patients described a lack of explanation 
of interaction, and their poor 
interpretation of adverse effects, and 
conflicting information from different 
sources. They talked about a lack of 
opportunity for discussion about 
medicines and medicines review. 
Enguidanos 
and Brumley 
(2008) USA 139 
104 76.3 (7.3) Elderly Survey 
(telephone plus 
physician 
survey and 
chart review) 
Within 
three days 
Satisfaction with 
discharge 
instructions. 
89% strongly agreed that instructions 
were communicated in language they 
understood. 80% strongly agreed that 
instructions were clearly 
communicated.. 40% strongly agreed 
that the information they received at 
discharge had been easy to understand. 
Garavalia et al. 22 (11 53 Stent patients Semi 1 month Congruence between Discontinuers explained a lack of 
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Study N= Average 
age (SD) 
Condition / 
Focus 
Data 
collection 
Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
2011 USA 148 continuers and 
11 
discontinuers 
structured 
interviews 
(patients and 
clinicians) 
patient and clinician 
views of reasons for 
discontinuing. 
awareness that they should still be 
taking clopidogrel. Lack of opportunity to 
seek information in hospital. Lack of 
recall of receiving information.  Rushed 
discharge. 
Glintborg et al. 
2007  
Denmark 140 
200  Non-specific Structured 
interview and 
record review 
Within 1 
week 
Communication with 
primary care 
66 patients using prescription medicines 
did not have a list of medicines in their 
discharge letter. 
Kerzman et al. 
2005 Israel137 
341 66 (13) Non-specific Telephone 
interview 
1 -2 weeks Sore range 0-4 for 
each medicine; 
impact of counselling 
on correct 
knowledge. 
36% of the respondents reported 
receiving no counselling for previous 
medicines; 60% reported not receiving 
counselling for new medicines. 88% of 
counselling  for previous medicines was 
given by doctors. Counselling for new 
medicines was given by doctors (45%) 
and nurses (40%). 42% of patients 
wanted more comprehensive 
counselling about. 85% preferred to be 
counselled by a doctor. 59% percent 
preferred counselling in hospital rather 
than at a community clinic. 18% had 
counselling with their family for previous 
medicines and 13% for new medicines. 
Kimmel et al. 
2010 USA 141 
 
47 (11 new to 
insulin) 
45-84 
(range) 
Insulin users Structured 
interviews 
1 week Receipt of 
appropriate pre-
discharge training. 
81% received written instructions (100% 
of those new to insulin); 51% received 
administration instructions (100% of 
those new to insulin) 45% receive self-
monitoring instructions (91% of those 
new to insulin). 96% had an insulin plan 
at discharge (100% of those new to 
insulin). Patients received instruction on 
insulin dosing and when and who to call 
for problems and questions.  
Knight et al. 
2013 UK 144 
19 (7 patient; 
12 carers) 
84 Elderly Diary and 
semi-structured 
interview 
  Most reported difficulties with 
information: either little or no information 
or an assumption that staff had no time 
to give information. Some generated 
their own lists. 
 
 
 
Martens 1998 114 76 Elderly with heart Observation, 1-2 weeks Describe the process Patient education is structured at 
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Study N= Average 
age (SD) 
Condition / 
Focus 
Data 
collection 
Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
USA 145 disease telephone and 
face-to-face 
interviews 
and experience of 
medication discharge 
education. 
discharge and unstructured during 
hospital stay. Patients forget being 
taught about their medicines. Patients 
experiences education from both 
doctors and nurses and perceived the 
doctor to be responsible for giving them 
information, although nurses were seen 
as effective and acceptable. Patients 
needed help creating a personal 
schedule from a list of medicines. Only 
10.5% (12) were discharged with a 
schedule. 
Micheli et al.  
2007 
Switzerland136 
362 68 
(median) 
Non-specific Telephone 
interview 
2-16 days Association of receipt 
of recall of 
information about 
medicines with 
knowledge about 
long-term medicines. 
Reported getting in formation for only 
15% of medicines (259/1693); 19% of 
new medicines  and 13% of previous 
medicines. New medicines were 
associated with reported of getting 
information. Patients who had help with 
medicines at home reported getting 
information less frequently. Patients who 
reported getting information in hospital 
were more likely (7.2 times (CI 3.2-16.1 
p<0.001)) to have correct knowledge. 
Stafford et al. 
2012 
Australia 149 
 
9 patients (38 
professionals) 
 Warfarin users Semi-
structured 
telephone 
interviews 
 Experiences of post-
discharge warfarin 
management. 
Patients want adequate information 
about warfarin to be confident managing 
it. Well-informed patients seemed 
comfortable with warfarin treatment.  
Toren et al. 
2006 
Israel138 
130 65 (12.9) Diabetes, 
hypertension, 
heart and lung 
condition; on new 
prescriptions for 
chronic diseases 
Telephone 
interview 
1 week 
and 1 
month 
Knowledge of new 
long-term medicines 
and association of 
knowledge with use 
of health services. 
40% of patients reported receiving 
counselling about medicines. 
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Table 3: Measures of patients’ understanding of their discharge medicines 
Study N= Average 
age (SD) 
Condition Data 
collection 
Components of  
knowledge 
Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
Brown et al. 
1995 USA159 
140 73 (6.9) Elderly Telephone 
interview 
Scores 6-18/ 
Unclear/ 
Several 
days 
Outcomes of 
discharge 
preparation. 
High and low 
medicines 
knowledge. 
Age (older p<0.01), gender (male 
p<.0.05), and additional health 
condition diagnosis (p<0.01) 
predicted lower knowledge scores. 
Low scorers were older, less mobile, 
had more health conditions, less 
satisfied with discharge medicines 
preparation, less satisfied with 
discharge preparation, had less 
knowledge of activity regimen 
change (p<0.01 – p<0.05). 
Calkins et al. 
1997 USA160 
83 patient 
/doctor 
pairs; 66 
pairs for 
components 
of medicines 
65.3 
(15.1) 
Myocardial 
infarction 
or 
pneumonia 
Telephone 
interview 
Purpose; side 
effects 
2 weeks 
and 2 
months 
Agreement of 
patients and 
physicians 
All patients reported understanding 
medicines purpose; 3 doctors did 
not; fewer patients than doctors 
(57.4% vs 88.9% p<0.001) reported 
patient understanding of side effects. 
Chau et al. 
2011 
France154 
55 41 Immunoco-
mpromised 
Self-
administered 
survey 
Name, dose, 
purpose, 
administration. 
At 
discharge 
Evaluate 
medicines 
knowledge and 
explore 
relationship 
between 
knowledge and 
patient 
characteristics. 
57% of medicines adequately known. 
Knowledge of administration 
guidelines was worse (62% of 
medicines; dose most often known 
83-97%. Adjuvant medicines 
(purposes other than chronic 
condition) less known than chronic 
medicines (except for those for 
infections) (OR 0.3; CI0.1-0.7; 
p<0.01). Being older (OR 0.6; CI 0.4-
0.8; p<0.001), less educated (OR 
0.2; CI 0-0.8; p=0.03), and shorter 
disease length (OR 1.7; CI 1.1-2.6; 
p=0.03), and the medicine being new 
or changed (OR0.2; CI 0.1-0.9; 
p=0.03) predicted lower knowledge. 
 
Kerzman et al. 
2005 
Israel137 
341 66 (13) Non-
specific 
Telephone 
interview 
Purpose; 
schedule; dose; 
side effects; 
tests needed; 
lifestyle 
requirements. 
1 -2 weeks Sore range 0-4 
for each 
medicine; 
impact of 
counselling on 
correct 
92% reported knowing the reason for 
taking their previous medication; 
83% gave the correct reasons. 73% 
know why they are taking new 
medicines and 80% of those knew 
the correct reason.16% reported 
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Study N= Average 
age (SD) 
Condition Data 
collection 
Components of  
knowledge 
Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
One previous 
and one new 
medicine. 
knowledge. knowing about side effects of 
previous medicines and 59% of 
those patients reported correctly. 
12% reported knowing about side 
effects of new medicines and 68% of 
those reported correctly. 60% of 
patients did not know the correct 
medicines schedule relative to 
meals. 32% had no correct 
knowledge of any areas of their new 
medicines compared to 18% with no 
knowledge of previous medicines. 
Correct knowledge and counselling 
are significantly correlated (p<0.001). 
Kripalani et al. 
2008 
USA 157 
84 54.4 
(11.1) 
Inner-city Telephone 
interview 
Differences 
between 
previous and 
new medicines; 
purpose; how to 
take. 
2 weeks Frequency 16% struggled to understand 
differences between previous and 
new medicines; 21% thought it 
difficult to understand why they had 
been prescribed new medicines; 
11% did not know how to take them. 
Those younger than 55 had more 
difficulty understanding how to take 
new medicines (18% vs 3%; p=0.03); 
those with impaired cognition had 
more difficulty understanding how to 
take new medicines (19% vs 3%; p= 
0.02) 
King et al. 
1998 
USA156 
133 50.8 
(19.8) 
 Telephone 
interview 
Name; purpose; 
how to take; 
effects including 
side effects; 
things to avoid 
lifestyle 
changes. 
 
2-6 weeks 
after 
discharge 
Relationship 
between patient 
characteristics – 
age, number of 
medicines, 
counselling and 
condition – and 
knowledge of 
medicines 
Number of medicines (fewer) was a 
good predictor of knowledge of how 
to take medicines (OR 5.38,CI 1.70-
17.02); of names of medicines (OR 
3.61, CI1.7-7.66) and what to expect 
(OR 4.88, CI 2.03-11.64); age 
(groups younger than 75) was a 
predictor of knowledge of the 
purpose of medicines. 
Makaryus and 
Friedman, 
2005 USA153 
43 13 
younger 
than 50; 
18 50-65; 
12 66 
and over 
Non-
specific 
Face-to-face 
interview 
Name; purpose; 
side effects. 
Patients could 
use notes. 
At 
discharge 
Proportion  able 
to correctly 
answer. 
27.9% (12) patients could list all their 
discharge medications; 37.2% (16) 
knew the purpose of their 
medications; 14% (6) could describe 
the side effects of all their 
medications. 
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Study N= Average 
age (SD) 
Condition Data 
collection 
Components of  
knowledge 
Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
Maniaci et al. 
2008 
USA28 
100 63.1 (SD 
16.5) 
Non-
specific. 
New 
medicines 
focus 
Telephone 
interview 
Name; number 
of new 
medicines; 
dose; frequency; 
purpose; side 
effects. 
New medicines. 
3-18 days Proportion 
answering 
correctly. 
86% were aware they had been 
prescribed new medication at 
discharge. 74% knew the number of 
new medications and 64% could 
name them. 56% knew dosages and 
64% knew the purpose of the 
medication. 22% could name an 
adverse effect. 11% thought they 
had been told about adverse effects 
at the time of discharge. Older 
people answered fewer questions 
about their medicines correctly. 
 
Micheli et al. 
2007 
Switzerland136 
362   Telephone 
interview 
Name, dose, 
frequency, 
purpose. 
2-16 days Association of 
receipt of recall 
of information 
about medicines 
with knowledge 
about long-term 
medicines. 
Reasons for taking medicines 
significantly less likely to be known 
for new medicines, among older 
patients and those staying longer in 
hospital. Those who received 
information during the hospital stay 
were more likely (7.2 times (CI 3.2-
16.1 p<0.001)) to have correct 
knowledge. 
Nikolaus et al. 
1996 
Germany161 
119 81.9 (6.3) Elderly Face-to-face 
interview 
Name; purpose. 3 months Factors 
impacting on 
adherence. 
65 patients knew the name and 
indication of their medicines. 
Knowledge correlated with cognitive 
function and number of medicines.19 
(28.4%) reported that an unclear 
medicines regimen was a reason for 
non-compliance. 
Sexton and 
Brown, 1999 
UK166 
29 
(subsample) 
80.9 Elderly Face-to-face 
interview and 
record review 
Name; purpose; 
colour; dose. 
2 weeks Proportion 
answering 
correctly. 
20 patients (69%) could describe all 
their medicines (purpose/colour and 
dose). With prompting 14 (48%) 
recalled name and dose. 
 
 
 
Toren et al. 
2006 
Israel138 
130 65 (12.9) Diabetes, 
hypertensi
on, heart 
and lung 
condition; 
on new 
Telephone 
interview 
Purpose; 
schedule; side 
effects; lifestyle 
changes. 
1 week 
and 1 
month 
Knowledge of 
new long-term 
medicines and 
association of 
knowledge with 
use of health 
7% knew the reason for taking their 
medicines. Fewer knew about side 
effects (11%) and lifestyle changes 
(8%). 46% visited a health services 
within a month. Patients who had 
used a health service reported higher 
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Study N= Average 
age (SD) 
Condition Data 
collection 
Components of  
knowledge 
Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
prescriptio
ns for 
chronic 
diseases 
services. medicines knowledge. Those with no 
knowledge visited health services 
less. Knowledge was a predictor of 
high levels of visits to health services 
(OR 4.76; CI1.74-13.06; ) 
Ziaeian et al. 
2012 
USA158 
377  77.1 (7.8) Heart 
failure, 
ACS, 
pneumonia
. Changed 
medicines 
focus. 
Telephone 
interview 
New medicines: 
name and 
frequency. 
Redosed 
medicines: 
name and dose 
or frequency 
change. 
Stopped 
medicines: 
name. Patient 
could use notes. 
1 week Patient 
understanding 
classified as full, 
partial or absent. 
Patients fully understood 33/205 
(16.1%) of redosed medicines and 
35/223 (17.5%) of stopped 
medicines. No understanding of 493 
(62%) of new medicines. Most 
patients (79.1%) had no 
understanding of at least one change 
or all changes (63.1%). Patients 
were most likely to misunderstand 
changes to medicines deemed non-
relevant to their condition  (OR 2.45 
CI 1.68-3.55; p<0.001) 
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Table 4: Studies that explored patients' knowledge of their medicines qualitatively 
Study N= Average age 
(SD) 
Condition / 
Focus 
Data 
collection 
Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
Bagge et 
al. 2014 
New 
Zealand 146 
40 Male median 
82; female 86 
Elderly with 
changed 
medicines 
Semi-
structured 
interviews 
 Understanding and 
management of 
changes . 
Patients were unaware of and confused by 
changes made to their medicines and some 
said they would not know what questions to 
ask 
Eijsbroek et 
al. 2013 
UK 150 
21 patients / 13 
carers 
 ICU patients Medication 
history data; 
Semi-
structured 
interviews 
 
3 months Explore medicine-
related problems 
arising from ICU 
admission and post-
discharge. 
 
 
Patients were confused about whether 
hospital medicines were still required. 
Garavalia 
et al. 2011 
USA148 
 22 (11 
continuers and 
11 
discontinuers 
Stent 
patients 
Semi- 
structured 
interviews 
(patients and 
clinicians) 
1 month Congruence 
between patient and 
clinician views of 
reasons for 
discontinuing. 
Discontinuers explained a lack of awareness 
that they should still be taking clopidogrel.  
Knight et 
al. 2013 
UK 144 
19 (7 patient; 
12 carers) 
84 Elderly Diaries and 
semi-
structured 
interviews 
  Some medicines not taken because the 
patient didn’t know the purpose. 
Rushworth 
et al. 2012 
UK 163 
20 60.5 (median) PCI (stent) Adherence 
score and 
semi-
structured 
interview 
7 days Explore adherence 
to medicines. 
Understanding what the medicines were for 
was thought to impact on adherence and 
some patients reported not knowing what their 
medicines were for.  
Stafford et 
al. 2012 
Australia 
149 
 
9 patients (38 
professionals) 
 Warfarin 
users 
Semi-
structured 
telephone 
interviews 
 Experiences of post-
discharge warfarin 
management. 
Patients want adequate information about 
warfarin to be confident managing it. Well-
informed patients seemed comfortable with 
warfarin treatment. Patients were anxious and 
confused about their warfarin. Some did not 
receive sufficient information in hospital. They 
felt ill-informed about INR testing frequency 
and why they were taking warfarin. 
Souter et 
al. 2014 
UK, 164 
30 69 (14) Stroke semi-
structured 
interview 
 Explore beliefs, 
concerns and 
barriers to 
adherence. 
No-one had ‘complete’ knowledge and 
patients reported having a current lack of 
information. 
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Table 5: Studies detailing patients' experiences and roles in medicines management 
Study N= Average age 
(SD) 
Condition / 
Focus 
Data collection Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
Adeponle et al. 
2009 
Nigeria 168 
81  Psychiatric  3 months Reasons for 
follow-up default 
and non-
compliance. 
77.7% felt well; 44.4% financial; 37.7% 
side effects; 25.9% distance; 22.2% 
feeling embarrassed about illness. 
Attebring et al. 
2005 
Sweden 143 
20  Acute 
myocardial 
infarction 
Semi-structured 
interview 
7.5 weeks Explore secondary 
prevention 
experiences . 
Felt that medicines intruded on their lives 
and having to take them reminded them 
they were ‘heart attack victims’. 
However, medicines also offered 
security from future ill health and they 
got conflicting information from HCP 
which affected their confidence; 
terminology was also stressful. They 
sought information on the internet and 
from pharmacy. Contact with HCPs 
lacked depth. After discharge they were 
lonely and insecure. 
Blennerhassett 
and Hilbers, 
2011 
Australia 167 
18   Non-English 
speaking  
Semi-structured 
interviews with 
patients. Focus 
groups with 
clinicians  
2 weeks Explore medicines 
management after 
discharge . 
Discrepancies between discharge 
summaries, GP records and hospital 
records. Interpreters not used in hospital. 
Received help from family members 
packaging or labels in their own 
language helped them. Education about 
changes and dose administration aids. 
Bremner et al. 
2010 
Canada 170 
14  Knee surgery Semi-structured 
interview 
3-9 weeks Investigate 
analgesic use. 
Advice of family and HCPs and physical 
and cognitive influenced use of pain 
medicines. Patients limited and reduces 
the medicines their used. 
Burns et al. 
1992 
UK 174 
56 82 Elderly Home visit and 
medicine 
therapy 
assessment 
5 days Explore post-
hospital 
discrepancies. 
15 had not received a repeat 
prescription. Four patients had been 
visited at home by their GP. 48% had old 
medicines at home. In total GPs had 
added 14 new medicines17 had been 
omitted. 
 
 
 
 
 
 
 179 75 (6.96) Elderly Structured  Explore medicines 53% had communicated with a doctor 
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Study N= Average age 
(SD) 
Condition / 
Focus 
Data collection Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
Conn et al. 
1992 
USA 165 
interview management after 
recent discharge. 
since discharge and 36% had been 
visited by a nurse. 94% reported 
different strategies to remember to take 
medicines (11 strategies). 
51% reported no-one helped them with 
their medicines. Types of help were 
preparing medicines, reminders, 
administering medicines and checking 
for accuracy.  
Decker et al. 
2008 
USA 147 
2008 22 Clopidogrel 
continuers and 
discontinuers 
Semi-structured 
interviews 
1 month Explore and 
compares 
clopidogrel-taking 
behaviour. 
Lack of continuity between in-patient and 
outpatient care. Described a lack of 
follow-up care. Perceived conflicting 
information. Extensive gap were not 
reported in continuers of clopidogrel. 
Eijsbroek et al. 
2013 
UK 150 
21 patients / 
13 carers 
 ICU patients Medication 
history data; 
Semi-structured 
interviews 
3 months Explore medicine-
related problems 
arising from ICU 
admission and 
post-discharge. 
Worries about medicines led patients to 
adjust routines and to poor adherence. 
Patients had problems getting supplies 
and opening packaging. 
Garavalia et al. 
2011 
148 
 22 (11 
continuers and 
11 
discontinuers 
Stent patients Semi structured 
interviews 
(patients and 
clinicians) 
1 month Congruence 
between patient 
and clinician views 
of reasons for 
discontinuing. 
Patients reported poor communication at 
care transfer. 
Kimmel et al. 
2010 
USA, 141 
 
47 (11 new to 
insulin) 
45-84 (range) Insulin users Structured 
interviews 
1 week Receipt of 
appropriate pre-
discharge training. 
10 patients had difficulties getting 
supplies. 
Knight et al. 
2013 
UK 144 
19 (7 patient; 
12 carers) 
84 Elderly Diaries and 
semi-structured 
interviews 
  Some patients created their own 
medicines charts. 
Participants felt the burden of 
responsibility of making sure primary 
care records and CP records were 
updated.  
 
Kripalani et al. 
2008 
USA 157 
84 54.5 (11.1) Inner-city Telephone 
questionnaire 
2 weeks Use of prescription 
medicines after 
hospital discharge.   
22% had not filled their discharge 
prescriptions two days after their 
discharge. Costs, transport and waiting 
times at the pharmacy were given as 
barriers. 35% said it was difficult to pay 
for medicines. 38% had difficulties 
getting to the pharmacy. 16% struggled 
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Study N= Average age 
(SD) 
Condition / 
Focus 
Data collection Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
to understand differences in previous 
and new medicines; 21% thought it was 
difficult to understand why they had been 
prescribed new medicines; 11% did not 
how to take them. Those younger than 
55 reported more difficulties paying for 
medicines (48%v19% p=.007) and more 
difficulty understanding how to take new 
medicines (18%v3%; p=0.03). Those 
with impaired cognition had more 
difficulty understanding how to take new 
medicines (19%v3% p=0.02). 
Kripalani et al. 
2008b 
USA 162 
31199 61.1 (17.8) 31199 Telephone 
interview 
48-72 
hours 
Rates of 
prescription-
related issues. 
7.2% had an issue: not obtaining 
medicines (79.8%); not knowing if they 
had been collected (2.4%); not taking 
(6.8%); not understanding how to take 
(11%).Being younger (p<0.0001);  with 
on medicaid, medicare or no insurance 
(p,0.001); more severe illness (p=0.008); 
more medicines (p<0.0001) predicated 
problems. Those on inhalers had more 
problems. 
Leegaard and 
Fagermoen, 
2008 
Norway 169 
11 (109 
diaries) 
55.7 Women after 
cardiac 
surgery 
Paid diary and 
semi-structured 
interviews 
 Experiences and 
management of 
pain 
Women tried to take as few pain 
medicines as possible. 
Nikolaus et al. 
1996 
Germany 161 
119 81.9 (6.3) Elderly Home visit, chart 
review, interview 
3 days; 3 
months 
Measure problems 
with containers 
and identify factor 
influencing poor 
adherence 
90% could open a blister pack; 83% a 7-
day compartment organiser; only 56% 
could open a flip-top bottle and 36.1% a 
child-proof bottle. There was an increase 
in prescription items after discharge.  
Rushworth et 
al. 2012 
UK 163 
20 60.5 (median) PCI (stent) Adherence score 
and semi-
structured 
interview 
7 days Explore 
adherence to 
medicines 
Understanding what the medicines were 
for was thought to impact on adherence 
and some patients reported not knowing 
what their medicines were for. Patients 
did not know what the role of the 
pharmacist was and did not want to 
undermine the prescriber. 
Patients had a system or a routine for 
taking medicines. And a fear of recurring 
symptoms which motivated them to take 
medicines.  
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Study N= Average age 
(SD) 
Condition / 
Focus 
Data collection Time / 
discharge 
Outcome  
measures / 
objectives 
Findings 
Sexton and 
Brown, 1999 
UK 166 
68 80.9 Elderly Patient visit, 
record review 
13.6 days Explore medicines 
management at 
discharge . 
Poor communication between hospital 
and GP. 50% had seen a doctor since 
discharge. Nearly all had obtained 
further supplies. Some had problems 
opening packaging.   
Stafford et al. 
2012 
Australia 149 
 
9 patients (38 
professionals) 
 Warfarin users Semi-structured 
telephone 
interviews 
 Experiences of 
post-discharge 
warfarin 
management. 
Patients were anxious and confused 
about their warfarin. Anxious about 
taking warfarin because of friends and 
family labelling it ‘rat poison’.  
Patients valued home delivered care.  
Souter et al. 
2014 
UK, 164 
30 69 (14) Stroke Semi-structured 
interview 
 Explore beliefs, 
concerns and 
barriers to 
.adherence 
Patients described the importance of 
carers (e.g. spouses) in medicines taking 
and having personal routines. Some had 
problems with packaging. 
Most thought medicines were necessary 
and protected them against further 
illness but were concerned about side 
effects and interactions. The physical 
and cognitive effects of a stroke meant 
some found it difficult to take 
medicines.Some patients reported a lack 
of GP and CP after discharge and some 
expressed dissatisfaction with the 
healthcare system. 
White et al. 
2010 
UK 171 
15 42-72 (range) Cardiac 
rehabilitation 
Semi-structured 
interview 
3 months Patient 
perspectives on 
lifestyle 
modification and 
medicines 
information. 
Some concern about taking medicines 
but patients were prepared to take them 
and had strategies to remember. 
They tolerated or sought advice about 
side effects. Some felt medicines helped 
their recovery and reduced risk. 
  
  
 
68 
Table 6: Rates of post-discharge medicines adherence and persistence 
Author / year Method Condition  Patient n= Time 
since 
discharge 
Outcome measures / 
objective 
Measures of adherence Rate 
Adeponle et 
al. 2008 
Nigeria168 
Survey Psychiatric 81 3 months Prevalence and pattern 
on follow-up default and 
non-compliance; reasons 
for non-compliance. 
Stopping medication or 
altering doses by 
themselves. 
48.5% fully medication 
compliant, 17.6% 
partially compliant and 
33.8% had stopped 
taking their medicines. 
Ahmad et al. 
2012 
Netherlands187 
Telephone 
interview 
Elderly – 
polypharmacy 
only 
245  Self-reported adherence. MARS. Mean 23.83 on MARS 
scale (5-25). 51.8% 
reported adherence (25) 
Ali, et al. 2009 
USA180 
Survey ACS 1054 3 months Persistence with EBCMs, 
reasons for non-use. 
Persistent if still taking 
EBCMs at three months. 
71.2% persistent. 16.9% 
through self-
discontinuation. 
Arnetz et al. 
2010 
USA201 
Survey Cardiovascular 449 8 weeks Association between 
patient involvement during 
hospitalisation and 
outcomes, including 
compliance. 
Compliant with taking 
medicines recorded at 
discharge.  
79% compliant. 
Beers et al. 
1992 
USA202 
Telephone 
interview and 
chart review 
Elderly 44 3 days Evaluate non-compliance.  Non-compliance – not 
taking a medicine; taking 
less than ordered, taking 
more than ordered; taking a 
medicine not ordered. 
Did not take 32% of 
medicines ordered, 
patients took an 
additional 61 medicines. 
64% of patients used at 
least one medicines not 
ordered at discharge. 
50% failed to take at 
least one medicine. 
 
Bushnell et al. 
2010 
USA179 
Structured 
interview 
Stroke  2598 3 months To measure use of stroke 
prevention medicines 
after hospital discharge. 
Defined ‘persistence’ as 
those taking prescribed 
medicines at 3 months. 
Regimen persistence = 
those taking all classes of 
medicines; Composite 
95.5% persistent with all 
medicines prescribed at 
discharge. 
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Author / year Method Condition  Patient n= Time 
since 
discharge 
Outcome measures / 
objective 
Measures of adherence Rate 
persistence = percentage of 
medicines classes subjects 
were still taking. 
Conn et al. 
1991 
USA203 
Face-to-face 
interviews and 
pill counts 
Elderly 178 10-20 
days 
Association of adherence 
with medicines 
complexity. 
Mean adherence calculated 
though number of doses 
and adherence for each 
medicine. 
Mean adherence = 
0.92.Complexity not 
significantly association 
with adherence. 
Ehrenreich et 
al. 2012 
USA204 
Interviews at 
baseline and 
follow-up 
Inpatients 
prescribed 
psychiatric 
medicines 
21 8 weeks Adherence to psychiatric 
medicines and 
continuance with 
psychiatric aftercare. 
% reporting taking 
psychiatric medicines 
prescribed and of those the 
% reporting taking 
psychiatric medicines every 
time as prescribed 
85.7% taking prescribed 
medicines and of those 
88.9% reported taking 
them every time as 
prescribed. 
Gray et al. 
2001 
USA205 
Face-to-face 
interview and 
pill count 
 147 2 weeks Prevalence of under-and 
over- adherence 2 weeks 
after hospital. 
At least one medicine with 
less than 70% adherence 
(under-adherence); at least 
one medicine with more 
than 120% adherence 
(Overadherence) 
30.6% (45) 
underadherent to at least 
one medication; 18.4% 
(27) overadherent to at 
least one medicine. 
Johnson et al. 
2009 
New 
Zealand176 
GP and patient 
survey 
Stroke 48 6 weeks 
and 6 
months 
Self-reported adherence; 
GP record and medication 
changes. 
Discrepancies between 
patient report; GP record 
and discharge. 
95% adherent to aspirin 
at 6 weeks; 92% with 
dipyridamole; 88% with 
Warfarin; anti-
hypertension 87%; 
statins 88%. Diabetic 
medicines 100%. At 6 
months: 91% adherent 
to aspirin; 100% with 
dipyridamole; 100% with 
Warfarin; anti-
hypertention 91%; 
statins 91%. Diabetic 
medicines 100%. 
 
 
 
Kripalani et al. 
2008a 
USA157 
Survey ACS 84 2 weeks ARMS (Adherence to 
Refills and Medications 
Scale). 
Scores 10-30 on 10 
questions with three answer 
options. 
52% high adherence 
(scores of 10); 48% 
some degree of non-
adherence.  
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Author / year Method Condition  Patient n= Time 
since 
discharge 
Outcome measures / 
objective 
Measures of adherence Rate 
 
Krishnan et al. 
2004206 
Survey   60 (52) 2 weeks Self-reported use of 
corticosteroid; pill counts 
and canister weights; 
electronic monitoring of 
inhalers. 
Use less than 50%. 49% poor adherence 
ICS; 27.1 poor 
adherence OCS. 
Lindquist et al. 
2011 
USA190 
Survey at 
hospital 
discharge, 
record review 
and post-
discharge 
interview 
Elderly 254 48 hours Explore association 
between health literacy 
and post-discharge 
discrepancies. 
Coded responses into 
intentional and unintentional 
non-adherence and 
inaccurate instructions. 
22.4% international non-
adherence; 21.9% 
unintentional non-
adherence. 
Mansur et al. 
2008 
Israel192 
Telephone 
interview 
Elderly 198 (145 
researched 
for 
adherence 
1 month The extent and reasons 
for modifications. 
Overall adherence – the 
proportion of medicines 
taken correctly as 
prescribed and averaging 
the proportion of medicines 
taken by each patient. 
Mean adherence calculated 
by averaging adherence for 
all patients. Also calculated 
non adherence to at least 
one medicine. Non-
adherence defined as 70% 
or less and over adherence 
110% or more to all 
medicines. 
Overall mean adherence 
of 96.7%. Non 
adherence to all 
medicines identified in 
6% of patients. Non-
adherence to at least 
one medicine in 30%. 
27% under-adherent; 6% 
over-adherent. 
Mansur et al. 
2009 
Israel188 
Structured 
interview and 
record review 
 186 1 month Explore prevalence and 
characteristic of patients 
discharged with an 
inappropriate prescription 
drug and association with 
continuity, adherence and 
readmission. 
 
Non-adherence defined as 
70% or less and over 
adherence 110% or more to 
all medicines. 
29.2% non-adherent to 
at least one medicine. 
23.3% underadherent; 
3% over-adherent. 
Melloni et al. 
2009 
USA181 
Telephone 
interview 
ACS 1107 3 months Patient reported 
persistence with EBM and 
factors associate with 
self-discontinuation. 
Persistent if still taking al 
EMB classes; discontinued 
with provider knowledge; 
EBM self-discontinued. 
 
 
71.8% persistent; 38.5% 
stopped with provider 
knowledge / input. 
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Author / year Method Condition  Patient n= Time 
since 
discharge 
Outcome measures / 
objective 
Measures of adherence Rate 
 
 
 
Mulhem et al. 
2013 
USA177 
Patient 
interviews 
Medical / 
surgical 
46 24-48 
hours 
Document the level of 
adherence. 
Comparing patient report 
with discharge list. Six 
categories of medicines 
errors – addition and 
omission or prescription 
medicines, addition and 
omission of OTC, errors in 
frequency, errors in dose. 
6.5% complete 
adherence, 78.2 
reported taking one 
additional prescription 
medicine, 43.4% missed 
one medicine, 43.4% 
wrong dose of at least 
one medicine, 41.3% 
taking at the wrong 
frequency. 
Nikolaus et al. 
1996 
Germany161 
Home 
interview 
Elderly 119 3 days and 
3 months 
Impact of problems on 
compliance. 
Non-adherence to 
directions on container 
label. 
43.7% taking medicines 
in accordance with 
prescriptions; 31.9% 
taking reduced dose; 
11.8% taking higher 
dose; 12.6% not taking 
at all. 
Olfson et al. 
2000 
USA172 
Structured 
interview 
before 
discharge and 
at follow up 
Schizophrenia 213 3 months Identify factors predicting 
non-compliance 
Those who acknowledged 
stopping their medicines for 
one week or more were 
judged non-compliant. 
19.2% non-compliant; 
80.8% compliant. 
Pasina et al. 
2014 
Italy186 
Structured 
phone 
interview  
 89 15-30 
days and 3 
months 
Patient-level and 
medication level 
adherence. 
% of patients with complete 
adherence – and mean 
medication level adherence. 
Adherent if taking 
medicines as prescribed. 
Mean adherence % of 
medicines taken according 
to the indication at 
discharge. 
 
 
55.1% non-adherent at 
first follow up; 69.6% at 
second follow up.   
Rushworth et 
al. 2012 
UK163 
Face-to-face PCI 20 Within  7 
days 
Quantify adherence and 
explore association with 
influencing factors. 
TABS – measures 
adherence behaviour (ABS) 
and non-adherent 
behaviour (NABS). 
6 patients had low ABS, 
of those 2 had high 
NABS. 
Stange et al. 
2013 
Survey before 
at discharge 
 108 35-49 
days 
Changes in adherence at 
interface of care; patients’ 
MARS-D. 61.2% non-adherent. 
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Author / year Method Condition  Patient n= Time 
since 
discharge 
Outcome measures / 
objective 
Measures of adherence Rate 
Germany207 and at follow-
up. GP survey. 
attitudes to medicines; GP 
reasons to accept or 
modify hospital 
prescriptions. 
 
Used MARS-D scale. 
 
 
 
Tarantino et 
al. 2010 
Italy184 
In hospital and 
follow-up 
questionnaire 
 84 1 month Adherence rate and 
sociocognitive factors 
impacting on adherence. 
Age significantly 
associated with non-
adherence. Younger 
patients more non-
adherent. Patients more 
adherence to chronic 
medicines; adherent 
patients perceived more 
risk in not adhering and 
more susceptible to 
disease. Non-adherent 
patients had greater 
cognitive failure. 
Adherent if followed the 
hospital schedule or 
subsequently change 
medicines (not checked). 
67% adherent. 
Ulfvarson et 
al. 2007 
Sweden185 
Structured 
interview 
Mean age 79 200 1 week Congruence of drug use 
and medical record;  
relationship between 
adherence and perceived 
health and perception of 
information received. 
Adherent if taking exactly 
the same medicines as in 
the medical record. 
30% adherence. 28% 
used less than 
prescribed; 42% more 
than prescribed. 
West et al. 
2010 
USA178 
Semi-
structured 
interviews 
Older women 
with coronary 
heart disease. 
32 3 months Explore adherence and 
identify barriers and 
facilitator to adherence. 
Used general adherence 
scale of the Medical 
Outcomes Study. Scores 1-
4 = non-adherent; score 5-6 
= adherent. 
65.6% adherent. Mean 
score 5.16. 
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Table 7: Studies exploring discharge medicines discrepancies and continuity 
Study N= Average 
age (SD) 
Condition 
/ Focus 
Data collection Time / 
discharge 
Outcome  measures 
/ objectives 
Findings 
Blennerhassett 
and Hilbers, 
2011 
Australia 167 
18   Non-
English 
speaking  
Semi-structured 
interviews with 
patients. Focus 
groups with 
clinicians  
2 weeks Explore medicines 
management after 
discharge . 
Discrepancies reported between discharge 
summaries, GP records and hospital records. 
 
Burns et al. 
1992 
UK 174 
56  82 Elderly Home visit; 
questionnaire 
5-10 days Changes to 
prescriptions and 
issue of a repeat 
prescriptions. 
15 had not had a new prescription; 14 drugs 
added; 17 omitted; 26 unchanged. 
Coleman et al. 
2005 
USA 95 
375 65-85 
(range) 
Elderly Home visit 24/72 
hours 
Prevalence of 
discrepancies. 
14.1% of patients experienced one or more 
discrepancies. 50.8% discrepancies were 
patient-associated, and 49.2% were system-
associated. Medication discrepancies were 
associated with the total number of medications 
taken and the presence of congestive heart 
failure. A total of 14.3% of the patients who 
experienced medication discrepancies were 
rehospitalised at 30 days compared with 6.1% 
of the patients who did not experience a 
discrepancy (P = .04). 
Cochrane et al. 
1992 
UK 173 
50 76.9 Elderly Home 
questionnaire 
6-14 days Changes in drug 
treatment after 
hospital discharge. 
45 patients had a changed drug regimen. 
Influencing factors included incomplete drug 
histories; continuation of prior medicines; and 
errors. 
Eijsbroek et al. 
2013 
UK 150 
21 patients 
/ 13 carers 
64.4 
(13.0) 
ICU Medicines history 
data and semi-
structured 
interviews 
3 months Explore medicines-
related problems. 
107 medicines were prescribed regularly before 
ICU admission, 150 were prescribed on ICU 
discharge, 121 at hospital discharge, and 108 
three months later.8 (5.3%) chronic medicines 
were discontinued on the ICU and not restarted 
on discharge (mainly antidiabetic drugs and 1 
analgesic agent). The number of medicines 
increased by ICU discharge, but then returned 
to the numbers prescribed before ICU 
admission – these were mainly Cardiovascular, 
gastrointestinal medicines, and analgesics were 
added by ICU and many were not continued.  
 
Enguidanos and 
Brumley, (2008)  
USA 139 
104 76.3 (7.3) Elderly Survey 
(telephone plus 
physician survey 
and chart review) 
Within 
three days 
Number of 
discrepancies. 
Only six cases matches between patient reports 
and medicines listed on the medicines sheet. 
The average number of medications listed in 
the hospital record was 4.31 (2.96) compared to 
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Study N= Average 
age (SD) 
Condition 
/ Focus 
Data collection Time / 
discharge 
Outcome  measures 
/ objectives 
Findings 
6.33 (4.24) reported by patients (p = .001). 
Hain et al. 2012 
USA39 
103 83.2 (5.3) Elderly Home visit and 
discrepancy tool 
1 week Relationship between 
cognitive impairment 
and errors. 
52% had discrepancies; association between 
discrepancies and cognitive impairment – 68% 
who had cognitive impairment had one or more 
discrepancy. 
Mansur et al. 
2008 
Israel 192 
198  80.7 
(7.03) 
Elderly Telephone 
interview 
I month The extent and 
reasons for 
modifications. 
36.7% of medicines had been modified; half the 
changes were additions or increased doses. No 
correlation between change and patient 
characteristics. Factors explaining change were 
GP visits and chronic disease. Non-adherence 
associated with change. 
Nikolaus et al. 
1996 
Germany 161 
119 81.9 (6.3) Elderly Home visit, chart 
review, interview 
3 days; 3 
months 
Measure problems 
with containers and 
identify factor 
influencing poor 
adherence. 
There was an increase in prescription items 
after discharge. 38.7% of prescription s 
changed within the first 3 days and 37.8% 
during the next three months. 
Sexton and 
Brown, 1999 
UK 166 
68 (56 
patient 
interviews)
  
80.9 (62-
100) 
Elderly Home interview; 
GP survey; 
documentary 
analysis; 
2 weeks Identify medication-
related problems; 
accuracy of 
documentation; 
communication with 
GP. 
32 (57%) had a drug-related problem, mostly 
attributable to HCPs. For 9 (13%) the discharge 
prescription differed from the ward prescription; 
for 16 (27%) patients the discharge letter 
differed from the TTO. GP could not find the 
formal discharge letter in case notes for 16 
(28%). Mean arrival time with GP of 26.9 days. 
55 patients obtained further supplies: 6 items 
stopped, 7 changed, 24 items restarted. 17 
(41%) experienced side effects.  
Ulfvarson et al. 
2005 
Sweden 189 
200 79 (6.9) Elderly Structured 
interview and 
record review 
1 week Congruence between 
hospital records and 
medicines use. 
30% reported use in congruence with the 
medical record, 28% used fewer medicines 
than prescribed; 42% used more. Patients 
prescribed more than five medicines were 
significantly more likely to under-use (5-10 
meds OR 15.9 (CI 3.3-77.8); more than 10 
meds OR 10.2 (CI 1.9-55.7)). 
Wai et al. 2012 
Australia 193 
1319 66 
(median) 
Heart 
attack 
Telephone 
survey, record 
review, GP 
survey 
3 months Describe baseline 
results  
from hospitals 
involved DMACS. 
 
At three months there was a significant 
decrease in prescription of antiplatelets (p = 
0.01), statins (p = 0.01), beta-blockers (p< 
0.0001) and all four guideline-recommended 
medicines (p< 0.0001). 44% stopped by the GP 
(side effects or unknown). 35% of stopped for 
other reasons ‘other reasons’ were most 
common reason for stopping by the patient 
(other than cost, side effects, too many 
medications and confusion about duration). 
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Table 8: Medicines problems identified in community pharmacy after discharge from hospital. 
Study N= Average 
age (SD) 
Condition 
/ Focus 
Data collection Time / 
discharge 
Outcome  measures 
/ objectives 
Findings 
Paulino et al., 
2004 
The 
Netherlands125 
435 59.1 / Patient 
questionnaire 
/ Explore the nature 
and frequency of drug 
related problems 
(DRPs) 
through community 
pharmacies and to 
document how 
community 
pharmacists  
resolve or prevent 
them. 
451 DRPs were identified in 277 out of 
435 patients (63.7%). 133 
(29.5%) were about uncertainty about/lack 
of knowledge of the aim/function of the 
medicine. 105 (23.3%) were side effects. 
No pharmacy intervention in 66 patients 
with DRPs; 305 interventions in 211 
patients. 80 interventions (26.2%) were to 
the prescriber 
Ahmad et al., 
2014 
127 
340 75.4 (8.7) Elderly Structured 
medication 
review and DRP 
checklist 
/  992 (potential) DRPs in 340 patients For 
nearly all patients (95.9%), at least one 
existing or potential DRP was detected. 
Two or more DRP in 78% of patients. 
Number of DRP significantly associated 
with the number of medicines. The most 
common DRP identified using the 
checklist were ‘no drugs prescribed but 
clear indication’ and ‘unnecessarily long 
duration of treatment’. Patients reported 
fear of side effects and no knowledge of 
drug use. 
 
  
  
 
76 
Table 9: Incidence and outcomes of adverse events after discharge from hospital. 
Study N= Average 
age 
Number 
of AEs 
Number 
of ADEs 
Avoidable 
ADEs 
Ameliorable 
ADEs 
Common medicines or 
problems 
Risk factors 
Gray et 
al. 
199948 
256 80  52 (20%) 
 
  Cardiovascular (19%) although 
high level of use; Antibiotics 
(17%); CNS (16%); Endocrine 
(16%); Analgesic (12.5%). 
CNS highest rate of ADE 
within drug class (11.8). 
Females (OR 2.26, CI 1.06-4.77) 
 
Interaction of number of new medicine and 
cognition. 
Sexton 
and 
Brown, 
1999166 
43   17 (41%)   Antibiotics, diuretics, 
analgesics. 
 
Forster 
et al. 
200347 
400 57 76 (19%) 50 (66% 
of AEs) 
12 
(50% of 
avoidable 
AEs) 
19 
(76% of 
ameliorable 
AEs) 
Antibiotics (38%); 
corticosteroids (16%); 
analgesics (10%); 
anticoagulants (8%). 
Provider-patient and provider-provider 
communication found to be the main problem. 
Forster 
et al. 
200450 
328 71 76 (23%) 72% of 
76 
  Antibiotics (27 patients); 
concomitant use of interacting 
medicines; contraindications; 
failure to monitor treatment. 
Risk factor of AE: Female (OR 2.3, CI 1.3-4.1), 
Type II diabetes (OR 1.9, CI1-3.6); pneumonia 
(OR 1.9, CI 1-3.6). 
Forster 
et al. 
2005 51 
400 57  45 (11%) 27% (of 45) 33% (of 45) Anti-infective agents (31%); 
corticosteroids (16%); 
analgesics (11%); 
anticoagulants (9%); 
antiepileptics (4%). 
 
 
 
Number of medicines; recall of medicines side 
effects being prescribed. 
Marusic 
et al. 
2013 198 
222 72 
(median) 
 19 
(8.5%) 
  ACE inhibitors 190 had potential DDIs, 21 (9.5%) had actual 
DDIs. ADEs occurred in 19 patients (8.5%), with 
ACE inhibitors being the most common 
medicine in instances of ADEs. 
Bennet 
et al. 
2014197 
204 80.5  
(+-8.3) 
119 
(58%) 
   Falls, hospitalisation, 
institutionalisation and 
functional decline. Adverse 
outcomes more common in the 
frail sample. 
 
FRIDs (OR 1.7; CI 1.3-2.1) and number of 
medicines at discharge (OR 1.2; CI 1-1.3) 
associated with recurrent falls. FRIDs (OR 1.3; 
CI 1.1-1.6) and number of medicines associated 
with functional decline (OR 1.1; CI 1.0-1.2). 
Number of medicines associated with 
hospitalisation (OR 1.1; CI 1.0-1.2). FRIDs 
associated with institutionalisation (OR 1.3; CI 
1.1-1.6). 
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Chapter 3 – Methodology 
This chapter sets out the design of the research studies described in this thesis, 
the rationale for the methodological approach adopted and describes the 
methods used. It sets out to demonstrate how the methods chosen were able to 
explore patients’ experiences of medicines management and were appropriate 
to the clinical settings, the patients themselves, who had experienced a health 
crisis, and to the researchers’ epistemological position.  
3.1 Study design 
The research in this thesis study was designed in the following stages: 
1 A structured narrative review of the literature to form an evidence base of 
how patients experience discharges medicines management. This was 
reported in Chapter 2. 
 
2a A two-centre prospective, descriptive study to establish how UK NHS 
hospitals discharge cardiology patients with medicines. This second 
stage used a mixed method design to collect observation data about how 
patients experienced medicines management at the point of discharge 
from hospital. A patient safety framework was applied to analyse the 
observation data. The results of this study are described in Chapter 4 
 
2b A two-centre prospective, descriptive, parallel mixed methods social 
network analysis to establish how UK NHS patients experience 
medicines management after they are discharged from hospital. This 
stage comprised four components: patient diaries; semi-structured 
interviews; network mapping; and a medicines experience survey. The 
first three components were designed to collect relational data so that a 
social network analysis framework could be developed and applied. The 
results of this study are reported in Chapters 5–7. 
 
The overall study design is presented in Figure 6.   
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Figure 6: Study design scheme 
The foundations of this research are embedded in the researcher’s interest in 
how the social world – the form of social contacts that the people experience – 
impacts on medicines experiences and roles after leaving hospital. A 
preliminary literature search indicated that very few studies took this into 
account. The studies subsequently identified and discussed in the literature 
review in Chapter 2 generally did not focus on understanding the social context   
Stage 1: Literature review of 
patient experiences of 
discharge medicines 
management.
70 studies identified 
from 2,456 records 
from 1990 to July 
2014. 
Five inclusion criteria 
and six exclusion 
criteria were applied.
All studies quality 
assessed using a 16-
item tool for studies 
with diverse designs. 
Evidence base 
constructed.
Stage 2a: Study 1 -
Observation of medicines 
management at discharge.
100 observations of 
hospital staff 
conducting discharge 
medicines tasks at two 
hospital sites.
34 individual staff 
members observed on 
36 randomly selected 
days.
Quantitative data 
analysed using 
descriptive statistics 
and non-parametric 
tests.
Qualitative data 
analysed using the 
Yorkshire Contributory 
Factors Framework.
Stage 2b: Study 2 -
Social network analysis of 
patients' experiences of 
discharge medicines 
management.
61 patients at two 
hospital sites.
39 patients kept 
contact records.
60 semi-structured 
interviews and network 
mapping.
61 medicines 
experience surveys.
Ego-networks 
constructed. Network 
data analsyed using 
social network analysis.
Qualitative data 
analysed using thematic 
analysis to interpret the 
network structure.
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in which medicines are managed. Instead, study designs concerning medicines 
adherence and adverse drug events have broadly taken a deterministic 
approach to empirically measuring phenomena such as medicines adherence 
or whether patients understand their medicines or have experienced harm from 
them. I am critical of such designs because they do not explore aspects of 
patient experience, such as the processes through which they have contact with 
healthcare professionals, the organisation of healthcare in their area and the 
level of immediate help and ongoing support each individual can access. This 
study is concerned with addressing those gaps. It is also concerned with 
exploring the medicines management system at the point of discharge in 
hospital, which may or may not influence how patients experience the system 
and how it supports their optimal medicines use once they are discharged. The 
challenges of doing this within a single paradigm are discussed in this chapter. 
First, the researcher’s epistemological position is discussed. 
3.2 Epistemology 
Ontology is a philosophical or metaphysical concept which is centred on 
questions of existence and truth, e.g. what is existence?  Is there a supernatural 
God?  Epistemology is concerned with the methods one might employ to 
investigate such truths, the nature of knowledge and its legitimacy.208 
Competing ontological theories mandate epistemological positions for research 
and set out the relationship with the methodologies and methods used.209 
Bryman describes two of the main ontological orientations that influence 
researchers’ epistemological positions:210 
Objectivism – The researcher objectively studies the social world which exists 
independently of the people who live within it. 
Constructivism – The researcher studies the social world and its members as 
a social construct, rather than as a real phenomenon. Those within the social 
world constantly modify it. 
This research takes a constructivist approach, accepting that patients and 
healthcare professionals act within a constructed reality that they create and 
modify through their contact with others and their experiences. It rejects the 
more traditional objectivist position that there is a social reality independent of 
those being researched, and that can be measured empirically.  
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As presented in Figure 7, various positions have emerged and competed to 
influence how research is conducted and appraised.  Positivism, based on an 
objectivist epistemology was the dominant research perspective in the 20th 
Century.208 It asserted that research findings and any associated inferences can 
be measured, objectively assessed, and that causal relationships can be 
identified. The researcher is viewed in a role upholding objectivity; the related 
methods tend to be experimental and quantitative. Post-positivists, however, 
rejected the certainty and objectivism of positivism by asserting that inferences 
can be made based on the combination of theoretical reasoning and evidence 
informed by experience.211 Emerging from post-positivism are the different 
theoretical perspectives that guide research design and methodological 
approaches. Critical inquiry challenges the power dynamic in society and 
traditional mainstream research practices. Interpretivism, as part of the 
constructivist orientation, focuses on people’s subjective interpretation of the 
social world and the part they play in it. Again, both qualitative and quantitative 
data can used to explore and interpret subjective experiences.  According to 
Angen: 
“Interpretive researchers assume that reality as we can know it is construed 
intrasubjectively and intersubjectively through the meanings and 
understandings garnered from our social world.”212(p385) 
According to McKenzie and Knipe, interpretivist/constructionist researchers will 
sometimes use mixed methods approaches (combining qualitative and 
quantitative research) arguing that “no one paradigm prescribes or prohibits the 
use of either methodological approach”.213 
The research in this thesis has adopted an interpretivist approach to explore the 
patient experience of the medicines management system. The analysis of 
patients’ medicines management ego-networks in Chapters 4–6 adopts an 
interpretive approach. In collecting primary data, I have worked with research 
participants to interpret how the system impacts on their experiences. The 
research combines a mixed-methods social network analysis with mixed 
methods observation research, which has been pragmatically informed by the 
complicated nature of the clinical environment and practical problems of 
researching it, such as the unscheduled nature of some healthcare activities, for   
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example discharge from hospital. In this approach, the research methods 
chosen are aligned to the problems or questions being considered.214 
 
Figure 7: Theoretical positions from Matthews and Ross (2010)215 
Blaikie identified four types of research strategy which are presented in Figure 
8: inductive; deductive; retroductive; and abductive.216 Inductive and deductive 
strategies are the most widely used and so warrant closer examination. 
Inductive strategies involve collecting data to explore and understand 
relationships between variables, whilst deductive strategies collect data to test 
hypotheses typically using an experimental or quasi-experimental design. 
Those critical of inductive strategies argue that researchers are naturally biased 
and so collect and analyse data they consider to be important. Deductive 
strategies are judged in part problematic because they can inhibit creativity in 
research because theories are pre-defined.216 This research applied an 
combination of inductive and deductive strategies to both describe and interpret 
patients’ experiences. 
 
 
Figure 8: Research strategies from Blaikie, 2000.216  
Positivist
•Social worlds are 
measured
•Causal relationships 
are sought
•Large data-sets and 
statistical analysis 
used
Interpretivist
•Uncovering 
subjective meaning
•Interpretation of 
meaning in context
•Empathic 
understanding
Critical inquiry
•Revealing hidden 
structures
•Uncovering power 
relations
•Research leading to 
action
•Collecting qualitative 
and quantiaitve data
Inductive 
strategy - data 
collection, then 
analysis, then 
generalisations 
are made
Deductive 
strategy -
observed 
phenomena, 
develop a theory 
and hypotheses, 
tested with data.
Retroductive
strategy - begins 
with observed 
phenomena, 
generate a 
model theory, 
test the theory.
Abductive
strategy -
Describes a 
phenonemon 
and its meanings 
and the motives 
of individuals. 
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The next section will explore the principles behind adopting a mixed-methods 
research design and the rationale for using mixed-methods in this research.  
 
3.3 Mixed methods research 
Mixed methods research combines both quantitative and qualitative approaches 
either sequentially or simultaneously.217 It is thought that the concept of mixing 
methods was formalised in the late 1950s and further developed in the 
1970s.218 One of its key strengths was considered to be its ability to reduce bias 
through triangulation of different sources of data.219 It is criticised by some 
based on the two different paradigms in which quantitative and qualitative 
research are embedded. Others, however, hold that whilst the two different 
types of data are underpinned by different epistemologies, that underpinning is 
not necessarily fixed.220 Cresswell and Plano Clark argue that the combination 
of the two data types offers a better understanding of research problems.217 
They identified six different types of mixed methods projects – shown in Figure 
9 – which collect and analyse data in different sequences.  Combining these 
different data types increases the depth of understanding into key concepts and 
is a form of methodological triangulation, allowing different perspectives on the 
same social phenomena and a more substantive view, yielding a stronger 
research design.221 
The first observation research study in this thesis, described in Chapter 4, 
adopts a convergent, parallel mixed methods design to maximise efficiency 
through concurrent data collection, which is essential in the clinical setting 
where patient discharge timing is unpredictable. The second study, described in 
Chapters 5–7, is a parallel, mixed-methods social networks analysis, 
simultaneously collecting structured social networks data and qualitative 
network data. 
More information about mixed methods social network research is detailed in 
Section 3.6.9 in this chapter.  In general, however, five key principles for mixing 
methods in social research have been adopted and applied: a flexible approach 
to research design; a questioning and reflexive approach about both the 
quantitative and the qualitative research paradigms; recognising that the 
different approaches are valid; a reflexive approach to interpreting the data; and   
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incorporating rich explanations that can include quantitative interpretation.222 In 
this research qualitative and quantitative approaches are integrated using these 
principles, recognising that the complementary nature of each method can yield 
positive outcomes to research which examines real-world problems and that 
mixing methods increases the capacity of the research to enlighten the 
“processual nature of social events and interactions”.223(p86) The mix of methods 
used and their underpinning is outlined in Figure 10. 
 
Figure 9: Six approaches to mixed methods from Creswell and Plano-Clark 
This section has set out the underpinning theories informing the research. The 
following section will describe the range of methods used in each of the studies, 
their strengths and weaknesses, and the alternative methods that could have 
been employed. It will also explain the study setting used and the choice of 
patients and their health condition.  
Convergent 
parallel
•Concurrent timing, data is analysed separately and mixed during the 
inference stage;
Explanatory
sequential •Collects qualitative data to explain quantitative results;
Exploratory 
sequential
•Collects qualitative data and then conducts quantitative research to 
generalise the results;
Embedded •One stage is embedded within another, for example, collecting quantitative and qualitative data within a qualitative design;
Transformative
•Shaped within a transformative theoretical framework and decisions 
about the type and sequence of data collection and analysis are made 
within that framework.
Multiphase •Sequential and concurrent data collection.
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Figure 10: Outline of the mix of methods used in the study. 
 
3.4 Methods 
This section begins by describing the research settings before moving on to 
describe how the patients’ health condition was selected and then to the design 
of each individual study. 
3.4.1 Study settings 
The studies described in this thesis were conducted with patients from the 
cardiology wards of two acute hospitals in different regions of Northern England.   
Epistemological 
position:
• Interpretivism: The research interprets the impact of the social world on 
patients’ medicines experiences.
Research strategy: 
Inductive and 
deductive
• The research aims to describe experiences and generate theories from 
the data generated.
Mixed methods 
approach:
• Parallel design mixed methods observation data in Study 1 explores how 
patients are discharged with medicines from hospital. Parallel mixed-
methods social network data in Study 2 interprets the structure, content 
and function of patients’ medicines management networks.
Data collected:
• Qualitative: Field notes and semi-structured patient interview data.
• Quantitative: Structured observation and social network data and a 
patient survey.
Analysis
• Descriptive and inferential statistics are used in studies 1 and 2. 
Thematic analysis is used in studies 1 and 2.
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This section gives some background about the study sites, the regions in which 
they are sited, and their local populations. Data about population and health 
outcomes are taken from the 2014 Public Health England Health Profiles.224 
Health outcomes for each area are presented in Table 10. 
3.4.2.1 Site 1 
Site 1 was a 900-bed hospital forming part of an NHS teaching hospital 
foundation trust serving a population of approximately 0.5 million people in 
100,000 households. The trust employed approximately 5,000 people across 
several hospital sites. It had an annual income in 2014 of £364 million. Over 
40% of residents lived in the most deprived national deprivation quintile. 
According to Public Health England, over a quarter of adults in the areas were 
classified as obese (26.7%) and smoking related deaths were worse than the 
English average. Early deaths (people under 75 years of age) from heart 
disease and stroke had been consistently higher than the English average: in 
2010– 2012 there were 107.7 early deaths from cardiovascular disease per 
100,000 people aged under 75, compared to 81.1 nationally. Emergency 
admission to hospital rates were slightly higher than the national average. 
3.4.2.2 Site 2 
Site 2 was a 690-bed hospital which forms part of a NHS trust, again serving a 
population of just over 0.5 million people. The total workforce in the trust was in 
excess of 7,000 people and it has an income of approximately £420 million. It 
covered the populations of several different unitary authorities and districts, 
most of which are highly deprived: nearly half the population of area 1, for 
example, were in the national deprivation fifth quintile (most deprived); and the 
under-75 mortality rate for cardiovascular disease in area 4 was 121.8 deaths 
per 100,000 people, compared to 81.1 nationally. Indeed, in all but one area 
served by the site, life expectancy for men and women was lower than the 
national average and the rates of cardiovascular disease and obesity were 
higher than the national average. Emergency admission to hospital rates varied 
within the different areas, but were generally higher than the national average. 
3.4.2.3 Selecting the patients’ health condition 
Cardiology patients were chosen as the focus for both studies for a number of 
reasons, not least because there are evidence-based therapies that when   
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managed optimally can contribute to the long-term management of 
cardiovascular disease;225–227 Furthermore, in the UK, cardiovascular disease is 
responsible for approximately 30% deaths annually;228 and it has a serious 
impact on the quality of life of those who live with the disease.229 Because of the 
wide ranging impact of cardiovascular disease, improving the UK’s performance 
in managing it is a key government priority.228 
3.5 Study 1 – Observation research 
3.5.1 Aims and objectives of Study 1 
This research is a convergent parallel mixed methods study of discharge from 
cardiology wards.  
Aim:  
• To determine how patients are discharged with their medicines from two 
hospital sites. 
Objectives:  
• To explore the context and content of staff-patient interactions about 
cardiology medicines prescribed and provided to patients at discharge. 
• To explore the contributory factors to preventable harm to patients when 
they are given their medicines at discharge.  
3.5.2 Introduction to observation research 
Observation research is a non-experimental research method allowing the 
researcher to generate data about current practice in its natural environment. 
Data are collected at the point that they are generated by the subjects under 
investigation.215 The roots of observation as a research method are grounded in 
multiple approaches including anthropological research (unstructured 
observation), and natural and laboratory based research (structured 
observation).  
Observation can be participatory, where the researcher may become a member 
of a group that is the subject of the research and non-participatory, where the 
researcher remains outside the group being observed and studies their actions. 
In this case, in a ward setting with a non-clinical researcher, a non-participatory 
approach was adopted. 
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Table 10: Health outcomes for the regions served by the two hospital sites.  Data compiled from Public Health England Health Profiles 2014224 and Office of 
National Statistics population estimates 2014. 
Region Population Deprivation (% 
people living in 
the 20% most 
deprived areas of 
England) 
Premature death 
rate from CVD 
(per 100,000) 
Proportion of 
adults obese % 
Emergency  
admission rates 
% 
Life 
expectancy 
women 
Life 
expectancy 
men 
England 53,900,000 20.4 81.1 23.0 40.8 83.0 79.2 
Site 1      526,000 45.1 107.7 26.7 40.3 81.5 77.5 
Site 2 area 1      148,000 52.4 121.5 26.3 46.6 80.9 76.5 
Site 2 area 2        68,000 19.1 99.4 25.5 41.6 81.6 77.6 
Site 2 area 3        90,000 38.2 96.4 25.3 40.8 81.7 77.9 
Site 2 area 4        87,000 49.4 121.8 24.3 45.0 80.5 75.5 
Site 2 area 5        58,000 0 74.3 18.6 36.4 84.0 80.5 
Site 2 area 6        80,000 41.5 109.3 27.7 44.7 81.0 76.5 
  
 88 
  
 
Critics of observation as a research method argue that the decisions about what 
to record and the analysis of the data are influenced by the researcher’s 
perceptions of what is important. One of the strengths of observation compared 
to other approaches, such as face-to-face interviews, is that it collects data as 
the phenomenon occurs,  rather than in retrospect, and it reduces the bias 
created by the researcher directly imposing their own social world on the 
phenomena being studied.230 Patient and staff accounts may also be subject to 
bias based on their perceptions of their limited role in the whole context of a 
system rather than of the system itself.  
An observation approach was selected to generate mixed qualitative and 
quantitative data about how hospital healthcare staff discharge patients with 
medicines from hospital. It was designed to understand the context in which 
patients leave hospital with medicines to offer a richer interpretation of the 
grounding of their experiences after they leave hospital. It was felt that this type 
of data could not be obtained through alternative research methods. 
Observation as a method affords this study a means of generating data about 
interactions with patients about medication at discharge because it overcomes 
the bias inherent in recalled accounts.231 Furthermore, the researcher can 
clearly directly witness the naturalistic setting, rather than relying on 
retrospective accounts.  In addition, and with specific reference to the topic of 
this study, the day of discharge can be a confusing and anxious time for 
patients;144 and they may not be able to remember the different interactions 
they had with multiple healthcare professionals and the content of those 
interactions if asked at a later date. For example, patients in one previous 
research study in the 1990s reported that they had not received any information 
about their medicines, however observations in the same research indicated 
that they did receive structured medicines information at discharge.145  
3.5.3 Overt and covert approaches 
It is generally accepted that covert observation approaches – ones where the 
subjects of the observations are unaware that they are being observed – are 
difficult to justify ethically. Those who champion covert methods argue that 
participant knowledge of the observer’s presence would bias the results and 
that sometimes the phenomenon being studied is difficult to observe overtly, for 
example if it is illegal. Overt participation, on the other hand, may lead to the   
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subjects adapting their behaviour because of the presence of the researcher. 
The four types of observation research (adapted from Gold’s 1958 typology) are 
presented in Figure 11.232 Complete observation and complete participation are 
only possible using covert methods, which are often ethically questionable. 
Additionally, complete participant and participant as observer roles in this 
clinical environment would require the researcher to be a clinician involved in 
patient care. More detail is offered by Bryman who goes on to outline six 
different observation roles, which are presented in Figure 12.210 This study 
adopted Bryman’s non-participating observer with interaction approach. This 
approach accepts that the observer was not involved with the team delivering 
patient care and consequently interaction with staff and patients was limited, 
however, because of the long periods of time spent observing and waiting for 
discharges to occur, some interaction with both staff and patients naturally 
occurred. 
 
Figure 11: The four types of observation research. Adapted from Gold.232 
 
Figure 12: Observer roles from Bryman.210  
Complete participant
•A covert member of 
the group being 
observed.
•Benefits: Research 
subjects behave 
normally in their 
natural setting.
•Disadvantages: It is 
difficult to infiltrate 
a group and it can 
be dangerous.
Participant as 
observer
•Researcher is part of 
the group but the 
role of the 
researcher is overt.
•Benefits: More 
ethical approach.
•Disadvantages: 
Particpants may 
modify behaviour if 
they know they are 
being observed
Observer as 
participant
•Less involvement in 
the environment 
being studied.
•Benefits: A more 
objective and 
detatched 
observation style. 
•Disadvantages: 
Interactions in the 
setting may be 
difficult to interpret.
Complete observer
•Detatched and 
uninvolved 
observation
•Benefits: Less bias 
because of 
detachment
•Disadvantages:May 
misunderstand or 
misinterpret events.
Covert full member
Part of the group and 
researcher role remains 
unknown.
Overt full member
Part of the group but 
researcher role is 
known.
Participating observer
Participates in group 
activites but is not a full 
group member.
Partially partcipating 
observer
Paticipates  but 
observation is not the 
main data source.
Minimally participating 
observer
Limited participation 
and observation is not 
the main data source.
Non-participating 
observer with 
interaction
Observes and interacts 
but does not participate.
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3.5.4 Structured and unstructured observation 
Structured observation generates quantitative data through observational 
schedules that record the frequency of events or behaviours using 
predetermined categories. This approach requires the researcher to participate 
less in the environment being studied. It allows the researcher to collect data 
that can be replicated in different places, at different times and also by different 
researchers.208 However, critics of this approach claim it overlooks the context 
in which the data is collected, in this case the hospital environment, and that it 
imposes assumptions on the setting and overlooks the complexity of that setting 
in the analysis and as a consequence, the researcher may impose an 
inappropriate coding framework.210 Structured observation requires the 
researcher to pre-determine and categorise the focus of the research in order to 
create variables for a quantitative analysis. Qualitative data is collected during 
unstructured observation through narrative field notes, which then are subject to 
processes of data reduction, data display, conclusion drawing and verification. 
Through these iterative processes data are selected and extracted, organised 
into narrative text, explained and confirmed for their plausibility.233 In this study, 
a combination of structured and unstructured observation was used, and a 
comparison of the methods is shown in Table 11. 
Table 11: A comparison of observation approaches from Bryman.210 
Structured Unstructured 
Pre-determined categories and schedules Field notes or recordings taken by the 
observer 
Pre-specified procedures Limited pre-defined procedures 
Concentrates on the observable behaviour of 
the research subjects 
Able to observe events as they happen 
outside the window of observation 
Breaks analysis down into units of action Sees the context as a whole 
 
3.5.5 Designing the observation schedule 
An observation schedule was constructed (See Appendix 2) which allowed the 
researcher to note what staff explained during the discharge, including:  
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• The purpose of the medicines, for example what conditions they are for, 
and what their intended effect is. 
• Side effects the patient may experience, for example fatigue, headaches, 
muscle cramps. 
• How medicines should be taken, for example orally or via a spray. 
• Dose information, for example the number of milligrams per dose. 
• Frequency information, for example once per day or twice per day or as 
required. 
• Timing information, for example the time of day it should be taken. 
• Hospital communication with primary care, for example whether 
information about medicines would be sent to the patient’s GP practice. 
• Obtaining repeat medicines in primary care, for example how to go about 
getting a repeat set of medicines once the patient has left hospital.  
• Giving written take-home information, for example if the member of staff 
gives the patient a list of their medicines and information about changes. 
Items on the schedule were devised based on previous research indicating that 
patients‘ preferences for medicines information include the purpose of the 
medicines, side effects, the ‘dos and dont’s’ and how to take them.234 Indeed 
BMA guidance stresses the importance of patients being aware of the 
medicines they are taking, what they are for, associated side effects and how to 
take them.235 Previous research has also found that patients did not receive a 
written list of their medicines;144 and the BMA guidance stresses the importance 
of timely communication between care providers and how patients often are in 
receipt of information about their condition before their GP.235 Information about 
how to obtain further supplies – along with purpose and side effects – is an item 
on the validated Satisfaction with Information about Medicines Scale;236 indeed, 
the patient representative involved in this study documented several problems 
inherent in the process of obtaining repeat prescriptions.237 
Schedule development followed best-practice guidelines including ensuring a 
clear focus for what and who is being observed and an easy-to-operate coding 
system.210 Data were systematically recorded.  
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3.5.6 Sampling 
Sampling approaches can be time based – for example observing for structured 
time periods – this would not have been feasible for this study as its focus was 
the act of discharging patients and a time-based approach would have failed to 
yield data if no discharges took place within the allocated time. Sampling can 
also be event based, which for this study was considered a more appropriate 
approach because the patient discharge was a milestone event in their care. In 
advance of the study, the researcher was unaware of the number of patient 
discharges it would be possible to observe. This necessarily gave rise to an 
emergent sampling approach which allowed the researcher to make decisions 
about the sample as the research progressed. The researcher undertook to 
attend the wards on randomly selected days and continued to do so until 
theoretical saturation had been reached and no new phenomena were 
observed.238 
3.5.7 Data collection 
The researcher recorded the name of the medicine on each occasion and also 
the amount of time the discharge took. It was documented whether the staff 
member solicited questions from the patient and if staff were asked questions 
and the nature of those questions. One observation sheet was used to record 
one staff and patient interaction. The reverse of the sheet and continuation 
sheets were used to make detailed field notes about the interactions, for 
example the length of the interactions or if carers or relatives were present, 
actions of staff, rapport between staff and patients and problems experienced. 
Observations took place on weekdays between 8.30am and 5pm. When the 
researcher arrived on the ward a consultation with the ward manager 
established which patients might be discharged that day. The researcher 
approached patients to explain the study and ask for their consent to take part. 
This process is detailed in section 3.7. The researcher explained the study to 
staff working on the ward and took the appropriate consents (see section 3.7). 
The researcher would then ask to be informed if staff were going to undertake 
discharge-medicines related activities with the patient so it could be observed.  
At Site 1 each patient was listed on a series of white boards positioned in the 
central ward area. If the patient was due to be discharged that day a mark (‘D’) 
would be put by their name on the board. Staff would usually then try to transfer   
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patients to the hospital’s ‘discharge lounge’, which was on a different level on 
the site and at some distance from the ward. Staff would inform the patient that 
they were being transferred and, if the patient did not object, they would 
telephone the discharge lounge and a healthcare assistant would be sent to 
collect the patient and their notes and transfer them. In practice this added an 
additional transfer of care from the ward to a different hospital department in 
advance of the transfer of care to primary care. Some nurses were permanently 
based in the discharge lounge which was managed by a nursing sister. 
Observations, therefore, took place in the discharge lounge at Site 1 if 
cardiology patients were transferred there, whilst some patients remained on 
the ward and were discharged from there. During the data collection period, 
wards at Site 1 were encouraged to send as many patients as possible to the 
discharge lounge and internal recognition was given to those wards which 
transferred the most patients. Because the time and location of the discharge 
were unpredictable the researcher spent time on the ward and in the discharge 
lounge taking notes about how the discharge medicines system appeared to 
operate. Staff in all locations also informed the researcher if they were about to 
counsel a patient. Ward-based nursing staff were cardiology-specific whereas 
those located in the discharge lounge had a more general background. 
At Site 2, a three-tick system on a white board tracked the discharge process 
and acted as a means of internal ward communication about completed actions. 
Patients due to be discharged each day would be listed on the white board and 
a series of ticks would be added to their names at different stages of the 
discharge process. One tick indicated that a prescription for the patient’s to-
take-out (TTO) medicines had been prepared; a second tick indicated that the 
prescription had been reviewed and validated; and a third tick indicated that the 
medicines were prepared and the patient was ready for discharge. Again, 
because the time of discharge was unpredictable the researcher spent time on 
the ward taking notes. Staff informed the researcher if they were about to speak 
to the patient about their medicines and, similarly to Site 1, some nurses were 
observed discharging patients on more than one occasion, whilst others were 
observed on single occasions. Site 2 had a permanent ward-based pharmacist 
and a supply room of some medicines that were regularly prescribed on the 
ward. Part of the ward pharmacist’s role was to prepare TTO medicines, or 
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order those not available on the ward from the dispensary, and talk to patients 
about their medicines before they left the hospital. At this site all patients were 
discharged from the ward. 
3.5.8 Data analysis 
Data were analysed using two distinct methods: structured observation data 
were analysed using descriptive statistics and non-parametric tests, whilst 
qualitative field notes were analysed using a human factors framework.  
3.5.8.1 Structured observation data 
Structured observational data (e.g. the type of medicine and the content of the 
discharge) were recorded in a SPSS database and analysed descriptively. Any 
differences between hospital sites and between medicines were explored using 
Kruskal-Wallis and Pearson’s chi-squared non-parametric tests. 
3.5.8.2 Qualitative observation data 
Qualitative data in the form of field notes were analysed using the Yorkshire 
Contributory Factors Framework (YCFF), which is a 19-domain framework of 
contributory factors that could contribute towards patient safety incidents (see 
Figure 13).30 It was developed from a systematic review of the analysis of 
patient safety incidents. A patient safety incident is any unintended or 
unexpected incident which could have or did lead to harm for one or more 
patients receiving NHS care.239 Field notes were analysed and phenomena 
observed were grouped together and described under each of the domains. 
Whilst the YCFF was developed specifically to look at contributory factors that 
could contribute to a patient safety incident, this study also took into account the 
context in which patients might use their medicines after leaving hospital and 
the processes that might affect their ability to safety manage their medicines 
after their discharge. 
3.5.9 Limitations of the study design 
There are several criticisms of observation research as a method. One often 
cited limitation is its vulnerability to observer / reactive effect: participants may 
behave differently because of the presence of the researcher, described by 
Webb et al. in 1966 and restated by Bryman and often referred to as the 
Hawthorne effect.210 There are four components of the reactive effect:  
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Figure 13: The Yorkshire Contributory Factors Framework.30 Reproduced with kind permission. 
• The subject may try to adopt a specific role or style, for example they may 
adjust their behaviour in line with what they perceive to be the study aims. In 
the case of this study, a staff member may misconceive the research to be 
about counselling styles and subsequently adopt a particular style they may 
think advantageous. The researcher saw no evidence that staff adapted 
their behaviours in this way. 
• The researcher affects the environment simply by their presence, for 
example taking up a seat on the ward may fundamentally change the 
physical layout of the ward or take up space usually used by a staff member. 
The researcher thereby becomes a ‘change agent’. The researcher was 
aware of this potential threat to the research and undertook to limit their 
impact on the day-to-day running of the environments under observation. 
• The participant consistently and inappropriately adapts how they respond, 
referred to as ‘response set’. The original study protocol for the research had 
acknowledged that this was a potential issue and the researcher took   
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care to inform staff that they individually were not being scrutinised; rather it 
was the system they worked within. Despite this, some staff members asked 
the researcher how they had performed so it is possible that their awareness 
of being observed led them to adapt their behaviour. However, the 
researcher observed wide-ranging practices so it is unlikely that all 
participants were able to change their behaviour to achieve a form of ‘best-
practice’. Alternative methods may have produced data about the reasons 
staff conducted discharge medicines management in the way they did, 
however,  this would not have yielded the naturalistic data thought 
necessary to describe what patients experience when they leave hospital. 
• The WHO warns that observation of healthcare providers may be perceived 
as a threat.240 Participant information sheets were drafted to be clear that 
the observations were about the systems in place, rather than the actions of 
any individual staff member. 
This section has described the methods used in Study 1 of this research, 
including the range of data collection tools developed or employed and the 
context that data were collected in. It has also critically reflected on the 
appropriateness of those methods and the alternative methods that might have 
been used. The following section will outlines the methods designed for     
Study 2. 
3.6 – Study 2: Patients’ medicines management ego-networks  
3.6.1 Study 2 aims and objectives  
Aim: 
To understand how patients experience post-discharge medicines 
management. 
Objectives:  
• To identify the range of healthcare professionals and support staff who 
patients interact with after their discharge from hospital. 
• To explore the contribution of patients’ own personal contacts to 
discharge medicines management (‘hidden’ system components). 
• To understand the functions provided by different network members and 
the value placed on those functions by patients. 
• To visualise patients’ networks to better understand the extent of 
variation between different patients.  
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• To measure patients’ experiences with their discharge medicines and 
explore variables associated with those experiences. 
3.6.2 Social network analysis as a research methodology 
Social network analysis (SNA) grew from two separate traditions: sociology 
exploring group processes; and anthropology exploring complex societies.241 It 
is applied to understand how outcomes and future characteristics may depend 
in part on the structure of personal or organisational networks.242 Previously 
defined as a “specific set of linkages between a defined set of persons”243(p2) it 
aims to visualise those linkages, usually using graphing techniques such as 
sociograms, measure them, describe them and model them. Modelling the 
networks can help predict the impact networks have on outcomes; and the 
nature of linkages between people can be used to interpret people’s 
behaviour.243 The unit of analysis can be the “network” of linkages itself or the 
linkages between people, which are often termed “network ties”. Analysis of the 
networks of individuals (ego-networks) rather than groups explore how 
individuals are influenced by their social ties.244 Types of “network ties” between 
people in networks are in four basic groups: similarities, for example co-
location, or similar genders; social relations, for example, being someone’s 
colleague; interactions, for example seeking advice or help; and flows, for 
example information or knowledge flows between individuals.242  
The focus on interactions in the social world, rather than attributes, such as 
demographics, is the quality that sets SNA apart from the methods used in 
more traditional empirical epidemiological studies. Those that champion SNA 
argue that those studies mistakenly ignore the structure of interactions and 
relationships and the impact of those structures on people, organisations and 
outcomes. In Pescosolido’s work on how social network theory and analysis can 
be integrated into the health sciences, she described how overlooked factors 
often take on the “flavour of luck’’ and how the patterns and predictability of 
people’s social world are ignored. She argues that “the underlying engine of 
action is real human contact.” 245(p194)  
Networks are built by people’s interactions which can restrict or facilitate access 
to resources and services, such as medicines information, and create cultures, 
beliefs and behavior patterns.245–247 People may also use their networks to   
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understand their health conditions and use the information they gain from 
people in their networks to make decisions about their health and their 
medicines.248,249 Thus the nature, frequency and value of interactions between 
patients and the people they interact with – not just attributes such as age, 
gender and ethnicity – can affect patient outcomes, such as morbidity and 
mortality.250 
3.6.3 Whole networks and ego-network approaches 
There are two distinct types of social network analysis.  Whole (socio-centric) 
networks explore interactions between people in a bounded group, such as all 
those who work within a community pharmacy, or within geographically 
bounded areas, for example all community pharmacists working within a district. 
The ego-centric (or person-centric) approach explores the impact of the social 
context on the outcomes of individuals. The ego-centric approach is appropriate 
when the population of interest does not exist within a bounded social context. 
Ego-centric approaches collect data on the social relations of the ‘ego’ (the 
person of interest) and the relations between their ‘alters’ (the people they have 
social relations with). Using an ego-network approach rather than a whole 
network approach allows exploration of the experiences of many people rather 
than just the few patients that a whole network approach could include. The 
resources required to document the whole networks for many patients would 
have been beyond those available to the researcher.  
Ego-networks allow us to see the network as the patient views it. This type of 
perceived social structure allows a view of the system as the patient 
experiences it and interprets it,251 rather than how it is designed to be delivered. 
This places the patient in the role of the “perceiver” of the relationship. Ego-
networks are ideal for this study as they allow a total focus on the individual, 
rather than on organisations. They allow us to take into account the multiple 
types of formal or informal ties that people form in their experience of 
healthcare, rather than just those that form between professionals in the 
delivery of that care. It allows us to view the patient’s actual world and their real 
situations, exploring how medicines interaction occurs within those worlds both 
in formal settings and away from formal patient-provider contexts. Above all, 
putting the patient in the centre of the networks makes sense against a 
backdrop of increasing interest in patients’ role in enhancing system resilience.  
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3.6.4 Social Network Analysis and the safety and quality of healthcare 
Since 2000 there has been an increase in the number of published studies 
using SNA across a range of disciplines.252 Notably of late, it has been used in 
health services research to examine relationships between healthcare 
professionals and between professionals and patients.253,254  
Previous social network studies have concluded that social relationships impact 
on people’s health outcomes. In their landmark study, Berkman and Syme's 
1979 work demonstrated that four different sources of social relation (being 
married, having contact with friends or relatives, belonging to a church and 
being members of groups) impact on the risk of mortality.255 Those who lacked 
social ties, and were therefore isolated, were more likely to die earlier, after 
controlling for other factors, than those who were more connected. There is also 
a range of studies that have explored the impact of social support on health 
outcomes, including adherence to medicines.256 More recently, work has 
explored the impact of social networks on managing chronic illness.257  
Studies of social networks in the healthcare domain involving service providers 
have explored the structural relations between HCPs, the social context of 
HCPs, partnerships and knowledge sharing.254 Research on the effectiveness 
of team delivery of medicines safety has primarily focussed on the experiences 
of healthcare providers and their interactions and interventions. For example 
social network analysis has been used to explore how teams in hospital settings 
work together to make decisions about medicines,258 however, their work did 
not focus on the agency of the patient in that setting.  
Only one published study identified has used SNA to look at the patients’ 
perspectives on the structure of collaborative healthcare relationships that 
include community pharmacists.249 It aimed to understand the patients’ roles in 
multi-disciplinary asthma care, described and compared patients’ health 
networks, gained an understanding of their interactions, and identified the 
pharmacists’ roles within asthma patients’ networks. The study used a mixed 
methods, embedded design involving patient interviews (n=47), personal 
network diagrams and asthma-related questionnaires. Two different patient 
groups were identified and compared: 26 participants who attended community-
based asthma groups; and 21 participants who attended asthma clinics. The   
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researchers found that patients do not experience joined up multidisciplinary 
care and they view the community pharmacist to be on the periphery of their 
condition-management networks. Whilst a concern with patients’ perceptions of 
the quality of their collaborative care and the role of the pharmacist is evident in 
the study, there is no direct focus on the safety of their care or the system within 
which they use their medicines. More recently, Cheraghi-Sohi et al. explored 
how personal network members influenced medicines-taking amongst 20 
people with long-term conditions.247 The authors used the concept of ‘medicines 
work’ to explore the roles of others in enabling medicines taking. They found 
that personal network members performed tasks such as collecting and 
monitoring medicines, offered emotional support, and provided information to 
patients. 
3.6.5 Structure, content and function 
When examining social networks the three main measurement features of 
interest are structure, content and function.245,248 Network structure is the 
architecture of the network. Measures of structure include the size of the 
network and the density of the network, which is the proportion of possible 
connections in the network that are made. The content in the network is the 
nature of flow between people, i.e. material and non-material resources.241 
Content could be friendship, advice, information and communication. The 
function of the network is its purpose, for example protecting patients or 
caregiving. 
Kjos et al. used SNA to explore patients’ medicines information-seeking 
behaviour.248 In this study, the structure of patients’ networks was defined as 
the people the patient derived or sought medicines information from, its content 
was medicines information in the form of factual information, attitudes and 
beliefs about medicines information, and its function was the patient’s 
application of the information they received. The study used qualitative 
techniques comprising 40 semi-structured interviews in a range of settings. Lay 
and professional contacts were identified: professionals offered factual 
information, whilst lay contacts provided factual information, beliefs about 
medicines and attitudes towards them. Patients used information from both 
types of sources in similar ways. Whilst the study concluded that HCPs should 
be aware of the patients’ social environment so that they can align their role   
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with it, it is unrealistic to expect a provider to do this. Rather, providers should 
be aware of where patients lack factual information about their medicines to 
negate their need to seek it from ‘unsuitable sources’. 
3.6.6 Formal and informal ties 
By exploring patients’ medicines management ego-networks this study will 
describe the extent to which patients benefit from the formal professional and 
inter-professional ties in the healthcare team around them and from the informal 
ties they have to others such as family members or friends, who might be 
considered ‘hidden’ components of the medicines management system. 
Research into health social networks has categorised ties as either ‘formal’ and 
‘informal’;248 or other such categories, for example ‘family’ and ‘HCP’.247 Formal 
ties are those with health services providers, for example healthcare 
professionals, and informal ties are those with family, friends and more distant 
informal contacts such as friends of friends.  
3.6.7 Social network analysis and systems 
As SNA uses the analysis and visualisation of people’s social relations to 
understand the structure of their social networks, it can be applied to analyse 
the structure of networks in socio-technical systems, for example in the system 
of medicines management. At present this is a largely unexplored area. 
Creswick and Westbrook used the bounded network of a hospital renal ward to 
explore medicines information and advice interaction networks of ward staff 
including doctors, nurses, allied health professionals and a ward clerk.258 The 
study of reciprocated interaction indicated which staff were central to how 
communication about medicines on the ward operated. They uncovered low 
levels of interaction between staff in different professional groups, with the 
exception of pharmacists who were central to advice-seeking networks. This 
was not a systems-based approach, however, it highlights the usefulness of 
Social Network Analysis when looking at and appraising whole systems. 
However, it does not take into account the complicated multi-site nature of 
medicines management in long-term condition management, and also the 
patient’s potential involvement in the optimal use of their medicines.  
Salmon et al. suggested a novel use of network analysis for accident analysis 
and investigation.259 They maintain that the analysis of interactions between   
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people in a system can offer new insight into system failures. It can also identify 
where communication should have happened, but failed to happen or where 
communication is erroneous or conflicting. 
This approach can be applied to medicines management systems to explore 
where interactions between professionals and patients should happen, lack 
value, or introduce risk into the medicines management system. Whilst time and 
resources preclude the exploration of interactions between every actor in the 
system, the method enabled exploration of the system as patients experienced 
it – or their ‘lived experience’ of the system. There are several advantages to 
this approach: 
• Patients are central parts of the system and experience the intended and 
unintended outcomes of the system. This research will offer a view of the 
system from their perspective; 
• Patients are susceptible to risk in the system. This approach will enable 
an understanding of the relationships between actors in the medicines 
management network and how they impact on risk or enhance system 
resilience. 
• Patients may act as brokers to other unknown people in the system that 
influence their use of medicines, for example, friends and relatives, 
alternative therapists, or more distant acquaintances. This approach will 
explore the ‘hidden’ people in the system who may either fill gaps 
through intervention or patient support, or who adversely impact upon it. 
One drawback of this approach is that the understanding of the system will be 
limited to patients’ knowledge of it, so it will overlook elements of the system 
that are hidden from the patient. However, it affords a view of how the patient, 
based on experience, perceives the system and how it does or does not work.  
A whole network approach, for example through extensive documentary 
analysis and multi-professional and patient interviews, might have yielded this 
data, but this was judged to be beyond the scope of a three-year doctoral study. 
3.6.8 Social support 
Levels of social support have long been thought to impact on people’s health 
outcomes;255,260–263 and belonging to and participating in social environments 
has predicted disease outcomes and the onset of disease.264,265 In particular,   
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research has found that lower levels of social support are associated with 
higher readmission and mortality rates from cardiovascular disease;266–268 and it 
is now recognised that social support is a dynamic function that “plays multiple 
roles in the social organization of health and illness”.269(p125) 
Song et al. (2011) explained how social support, along with other concepts such 
as social cohesion, social integration and social capital, were developed from 
social network perspectives and are, as such, characteristics of social 
networks.269 For example, social support is accessed through the network 
through social integration and cohesive network relationships. In this way, there 
is evidence that social support accessed through social networks, and 
especially instrumental support functions, can positively impact on adherence to 
medicines.256,270 
3.6.9 Mixed methods in social network analysis 
As in many branches of social and behavioural sciences there is a debate 
between the benefits of empirical versus more interpretive approaches and 
there has been an increase in the use of composite methods in recent years to 
bring a greater depth of understanding to networks data. Combining qualitative 
and quantitative approaches adds context to the data through offering a 
perspective on the ‘lived reality’ of the network.271 It aids interpretation and 
appreciation of the meaning and value of relationships and offers an 
understanding of how networks change over time.271 As a result, views of SNA’s 
epistemological foundations have now been extended from structuralism to 
encompass more interpretive approaches such as symbolic interactionism. 
Combining a qualitative and quantitative approach allows the exploration of both 
the structure of the network and the meaning of it.272 Crossley argues that 
marrying these strands facilitates the study of social entities rather than solely 
structures.273 He maintains that searching for structure without contextual 
factors overlooks the network actors’ interconnectivity, arguing that the 
detached quantitative mapping of network structure creates a valuable 
perspective, yet it overlooks the complexity of interactions and simplifies 
people’s ‘social worlds’. The fact that we can view ties as interactional and 
structural increases their complexity and introduces the need to collect different 
types of data. This is what Coviello terms a ‘bifocal’ approach,274 and one that   
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has been used effectively in previous doctoral work.275 As an approach it 
accepts that the ‘individual self’ can be explained in relation to other people, 
which directly inherits the perspective of Mead that the ‘self’ arises from 
interactions between individuals and co-operative activities.276 
Mixed methods studies can offer superior data quality and explanatory power to 
studies that use either type of method in isolation through combining qualitative 
and quantitative data and, importantly, strategies of analysis.277 This study 
adopts a mixed methods parallel design to explore network structures and how 
patients interpret and experience them, thereby linking structure with the ego’s 
perspective. It collects qualitative and quantitative data simultaneously, which 
necessarily limits the sample size.277 Methods were adapted from previous 
successful parallel designed studies that apply methods to the same set of egos 
producing complementary data for methodological and practical reasons.278  
Furthermore, methods in that study analysed qualitative data thematically and 
also quantified qualitative data to bring additional insight and egos were 
sampled purposefully. 
3.6.10 What does Social Network Analysis offer this research? 
SNA offers a new perspective on medicines optimisation and patient safety 
through examining and interpreting the informal and formal structure around 
patients after they have left hospital. SNA also offers a systematic appraisal of 
the contribution of multiple healthcare professionals who operate within the 
system of medicines management and patients’ own lay contacts to medicines 
optimisation. This mixed-methods approach collects quantitative data in the 
form of the structure of the network and value of interactions, as well as 
qualitative data to aid interpretation and add context to each patient’s network; 
understanding how their interactions impact on the their medicines use.  
3.6.11 Sample 
Various sampling approaches can be applied to different types of network 
studies, and from the outset an item of concern was creating a robust sample of 
egos in a setting that is difficult to access and predict. For example, there is no 
source data available about the number of discharged patients per week and 
creating a random sample of patients was not possible because admissions 
were generally emergency admissions and the decision to discharge the patient   
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would usually be taken on the morning of discharge. Hanneman and Riddle 
suggest beginning with a selection of egos and asking the ego to report the 
alters to which they are connected.279 
A quota sample was constructed (see Table 12) based on a range of variables 
that published literature suggest may impact on patients’ use of their medicines 
and approaches to health and to reflect the demographics of those undergoing 
treatment for cardiovascular disease. The mean age of those undergoing 
procedures nationally in 2011 was 65, and in Site 1 and Site 2 the mean age 
was (63 and 64 respectively), and 74% of patients were male.280 Socio-
economic status is known to impact on health outcomes: mortality rates from 
cardiovascular disease are consistently higher in both men and women from 
lower socio-economic groups, for example mortality rates are 2.8 times higher 
for those in routine employment compared to those in higher managerial and 
professional roles.281 The 2010 Index of Multiple Deprivation (IMD) was used to 
categorise the level of deprivation in the patient’s home area by using their 
postcode.282 The IMD is constructed through a range of deprivation indicators, 
for example income levels, employment, educational attainment, health 
outcomes and crime. A quota of 30 patients was set at each site, which was 
judged sufficient to draw comparisons between sites. A total sample of 60 
exceeds the samples used in studies using similar social networks 
methods.248,249 Selection bias was offset through matching participants to the 
quota as closely as possible. Patients included in the study were: those about to 
be discharged from hospital; those discharged back to their own homes; those 
discharged with at least one prescribed medicine. The principal exclusion 
criteria were: patients who usually live in care homes; and those who lacked the 
capacity to consent. Patients were approached on the ward by the researcher, 
given the study patient information leaflet and were given the opportunity to ask 
questions. This process is described in section 3.7. 
Using the ego-centric framework this sample of unrelated patients was recruited 
on 36 randomly selected days on two hospital sites. Information about their 
home address, and the GP and pharmacists they used was collected to explore 
any overlap in the healthcare professionals (alters) they came into contact with 
in the weeks following their discharge. If patients had all used the same GP 
practice then they may have all had similar experiences because of the care   
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offered by overlapping HCPs. Data relating to a total of 392 network alters were 
collected from patients using  name generator and name cueing methods.283  
This approach yielded seventy-five egos for the study, representing a deliberate 
over-recruitment to compensate for predicted drop-out. Patients recruited 
included those whose medicines checks and discharges were observed during 
Study 1. Egos were self-selecting on the wards and 25 of those approached 
refused to take part. The main reasons for not wishing to take part were severity 
of illness, and time commitments. Two patients additionally expressed concerns 
about data security. 
Table 12: Sampling matrix detailing the quota (and the achieved sample following drop-out) 
Sampling Variable Categories Quota (achieved sample following drop-out) 
1. Location Site 1 30 (30)    
Site 2 30 (31)    
2. Patient age <64    20 (31) 
>64    40 (30) 
3. Patient gender Male   40 (43)  
Female   20 (18)  
4. Level of deprivation 
 
 
Low  15 (11)   
Medium  20 (18)   
High  25 (32)   
Total Sample 60 (61) 60 (61) 60 (61) 60 (61) 
 
3.6.12 Designing the data collection tools 
3.6.12.1 Patient diaries   
A diary method was implemented which allowed patients to keep a record of 
their interactions with HCPs and friends and family after they left hospital.  
Diary data collection methods have several key attributes that make them a 
valuable way of collecting event data. Data are recorded regularly and can be 
organised around specific events, such as medicines contact. Diaries can be 
completed at the time or close to the time that events take place, and they 
contain information about what the person completing the diary considers 
important. Their main advantages are that they record events that may be hard 
to observe and they can also overcome problems of recall if interview or survey 
data is collected sometime after events occur.284 In SNA research, diaries have   
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been used to record instances of communication and they are thought to collect 
more accurate data than questionnaires because they are a more immediate 
medium than a retrospective survey or interview.285 A drawback is that they can 
harbour particular biases; for example under-recording of some types of 
encounters or events such as short meetings.286 Effective participant briefing 
was designed to compensate for some of those effects. 
A contact diary sheet was constructed see Appendix 2 allowing patients to 
record the contacts they had regarding their medicines. Recruited patients were 
given the option of keeping contact diary sheets for six weeks from the point of 
their discharge. A paper method was chosen to make the study as accessible 
as possible to most patients. Other methods, such as internet diaries and audio 
recorded diaries were considered and discounted due to the potential additional 
burden these methods may have placed on patients. Draft diary sheets were 
reviewed by a patient volunteer and by a former senior pharmacy practitioner 
and their feedback was incorporated in the design. Six weeks was chosen for 
the diary period to allow enough time for patients to have follow-up contact with 
their GP surgery and community pharmacist to organise repeat prescriptions. 
By this time any hospital discharge information should have been received by 
the patient’s GP and transferred onto the appropriate records. Contact diary 
sheets were designed to document the following: 
• The name of the person; 
• The communication channel: telephone, face-to-face, email, letter; 
• The person’s professional role or relation to the patient, for example GP, 
nurse, pharmacist or spouse, daughter, other relative or friend; 
• The outcome of the contact. 
To further reduce participant burden the diaries were constructed in the form of 
a concise contact sheet where basic information about the contact that had 
occurred could be easily recorded by patients and notes made on the reverse of 
the sheets. Diaries were presented with easy-to-understand instructions. 
In this study, contact diary sheets collected social network data about patients’ 
medicines contacts which were used to inform the subsequent semi-structured 
interview as a prompt for patients to discuss the role of each of their medicines’ 
alters. A decision was taken to make the study available to those patients who   
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did not feel able to complete a diary either because they felt they would not 
have the time or because they did not have the confidence to do so. This meant 
that less data was collected from a subset of patients; however those who did 
not feel able to keep a diary could still be included in the study. Of the sample 
who kept diaries (39) the ages ranged from 44-80. The mean age was 62.4 and 
the SD was 10.27. Eleven of those patients were 70 and older. One diary had 
only one entry and that patient was 61; one diary only had three entries and that 
patient was 80. Of those who participated but did not keep diaries (22) the ages 
ranged from 35-80 with a mean of 62.2 and a SD of 11.9. Seven of those 
patients were 70 or older. One patient kept a diary but was too ill to participate 
in an interview. 
3.6.12.2 Patient interviews 
At the end of the six-week diary period, patients took part in a qualitative semi-
structured interview at a place of their choice to explore their experiences of 
using their medicines since discharge. Embedded within the interview was a 
hierarchical personal network tool which collected quantitative data about 
patients’ medicines ego-networks following previously applied methods (see 
Figure 14).249,287 This was done by showing patients a circular diagram with 
concentric circles which was used to position their contacts. The closer they 
placed them to the middle of the diagram the more valuable the patient 
perceived that alter to be in managing their medicines. This type of tool is a way 
of determining the assessment of the closeness of relationships;288 and it was 
adapted for this study to assess patients’ perceptions of the value of their 
medicines management network alters. 
An interview schedule with a range of questions, probes and prompts was 
designed to collect relational data about their medicines management networks 
in additional to rich data about patients’ experiences with their medicines. 
Different types of specific network questions were included in the interview 
schedule: 
• Name generators: these questions aimed to identify members of patients’ 
medicines management network. 
• Name interpreters: these types of questions aid interpretation of the type 
of network member the alter is, for example how they are related and 
what type of function they perform.  
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• Relationship questions:  these questions establish the levels and nature 
of contact between different alters in the networks. 
The map also acted as a narration generator to encourage participants to talk 
about their networks and why some network members were more valued than 
others. 
Interviews were constructed based on patients’ experiences identified in the 
literature review to probe about the information they received about their 
medicines and doses, their experiences at discharge, their experiences with 
their medicines, and getting further medicines from their GP. During the 
interviews those participants who had kept contact diaries were asked to 
discuss their records, the people and HCPs they had contact with about their 
medicines, their experiences of using their medicines since their discharge from 
hospital, and the role and perceived value of different people and professionals 
they encountered in helping them safely use and optimise those medicines. 
They were also asked about their perceptions of how the healthcare team 
worked together to help them safely use and optimise their medicines and how 
confident they were in their medicines. Additional questions were developed so 
that they followed the patient pathway from discharge identified in the literature 
review, exploring contact with HCPs and others, and patients’ attitudes towards 
their medicines. A patient volunteer reviewed the interview schedule and it was 
piloted with a different patient. All feedback was incorporated. The participants 
were fully briefed, the researcher established trust and rapport with the subject 
and steered the interview by moving flexibly through the interview schedule, 
focussing on what was important to answer the research questions. Semi-
structured interviewing is a flexible tool that enables complex issues to be 
explored in depth.215 In this context, it allowed participants to discuss aspects of 
their medicines they found important without constraining the interview to topics 
about which the researcher was already aware.  
An early version of the interview schedule was piloted with three volunteers. 
The purpose of the pilot was to establish if terminology used in the schedule 
was understandable, that it did not omit areas that were important to patients 
and that the interview was manageable within approximately one hour. The 
results of the pilot indicated that the questions were appropriate; however, there   
 110 
  
 
was a danger that it could produce a lengthy interview so the interviewer 
reduced the number of questions. Specifically questions that focussed on an 
imagined timeline since hospital discharged were felt to encourage a focus on 
non-relevant events in the patient pathway. The interview schedule is presented 
in Appendix 2. 
 
Figure 14: A hierarchical mapping tool adapted from Cheong et al.249 Ring 1 = most valued; ring 4 = 
least valued. 
Extracting safety incidents 
During the interviews all patients were asked if anything had happened to them 
that had made them more or less confident in their medicines. Their answers 
were extracted and reviewed by two healthcare experts, who were members of 
the supervisory team, to establish whether a patient safety incident had 
occurred. A Cohen's κ was calculated to determine the agreement levels 
between the assessors’ judgements about whether the extracted events relating 
to the 31 patients were patient safety incidents. There was a high level of 
agreement κ = 0.753 (+/- 0.108), p <0.0001. The definition of a patient safety 
incident was taken from the former National Patient Safety Agency which has 
since been adopted by NHS England:  
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“A patient safety incident is any unintended or unexpected incident which could 
have or did lead to harm for one or more patients receiving NHS care.”14 This 
allowed the construction of a binary variable recording whether or not patients 
had experienced a safety incident.  
3.6.12.3 Medicines experience survey 
A survey was developed as a way of measuring patients’ experiences of the 
discharge medicines management system. At the end of the interview patients 
were asked to complete this short 9-item questionnaire. The Medicines 
Experience Survey (see Appendix 2) measured experiences including: patients’ 
self-efficacy to take their medicines; the ease with which they can access and 
understand information about medicines, or speak to healthcare professionals 
about them; and their perceptions of the services offered. Where possible, items 
were included or adapted from previously validated measurement tools and 
from other peer-reviewed sources. Based on the range of patient experiences 
identified in the literature, no single existing measure captured the full range of 
experiences considered important. For example, there are several adherence 
measures available, as demonstrated in the literature review in Chapter 2 and 
reviewed by Lavsa et al.289 however, none captured the interactions with 
professionals, perceptions of a multi-professional approach, along with 
understanding, and self-efficacy to use medicines.   
Four items about the ease of communicating and understanding medicines 
were adapted from the medication understanding and use self-efficacy scale.290 
This was considered appropriate as questions concerned getting information 
about medicines and understanding the instructions given. These adapted items 
are: 
• It is easy for me to ask my community pharmacist questions about my 
medicines; 
• It is easy for me to ask my GP questions about my medicines; 
• It is easy for me to get all the information I need about my medicines; 
• It is easy for me to understand the instructions I was given for my medicines. 
Questions were adapted to account for the fact that patients may interact with 
GPs as well as pharmacists about their medicines. Also, the original scale 
referred to medicine bottles; however, patients are likely to encounter other   
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types of packaging.One item about perceptions of joined up care was adapted 
from Cheong et al:249 
• Different healthcare professionals work together to support me in managing 
my medicines. 
This question aimed to capture levels of agreement as to whether there is a co-
ordinated inter-professional approach to medicines management. 
Three items about the understanding of medicines on discharge and afterwards 
were adapted from the Care Transitions Measure:291  
• When I left the hospital, I clearly understood the purpose for taking each of 
my medicines; 
• When I left the hospital, I clearly understood how to take each of my 
medicines; 
• I currently understand the purpose for taking each of my medicines. 
During piloting it was decided that the original wording in some of the questions 
should be adapted in order to make the questions less complicated. For 
example, the question: “When I left the hospital, I clearly understood how to 
take each of my medications, including how much I should take and when” has 
been simplified so that only one phenomenon is considered and is shorter, 
which was considered easier for the patient to answer. The third question in this 
set captures any change in understanding that might have occurred in the six 
weeks since discharge.  
The questionnaire was constructed following robust design principals to create 
reliable and valid measures:292 historical events were placed in chronological 
order, each question asked only one thing, and respondents answered using a 
five-point Likert agreement scale. 
3.6.13  Data collection 
Interviews took place in the patient’s own home, at the hospital when they 
returned for a follow-up appointment, or in a different place of their choice 
where they felt comfortable, for example two patients were interviewed in cafes. 
Occasionally spouses and other family members were present during 
interviews. Each interview lasted approximately one hour, was audio recorded   
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and transcribed verbatim. Interviews took place between January and July 
2014. 
3.6.14 Analysing the data 
Network grid 
A network grid was designed to be completed by the researcher after the 
interview based on patients’ responses about their perceptions of the contact 
between each of their alters. The network grid (see Appendix 2) was based on 
those described in another similar study.278 It records the existence of network 
connections between alters in a structured way. 
Grouping alter types 
Alters were grouped into two main groups (personal and professional) and ten 
sub-groups. Professional alters were grouped into eight categories listed below: 
• GPs 
• Community pharmacists 
• GP receptionists  
• Community pharmacy staff 
• Cardiac rehabilitation nurses / heart failure nurses 
• Other nurses 
• Hospital doctors  
• Others (for example gym instructors). 
Personal alters were dichotomised into groups: spouses and other friends and 
family.  
Developing sociograms 
Two different types of sociograms were produced for patients in the study. 
Composite sociograms were produced showing all patients at each site and 
their connections with their alters (first order stars). Individual sociograms were 
produced for each patient showing their alters and the perception of contact 
between those alters (first order zones). An example of a first order star and a 
first order zone are shone in Figures 15 and 16 respectively. An SPSS 21 
database was constructed to capture the quantitative data collected during the 
interviews, including the number of personal and professional alters, their role 
and their value to patients.293  
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Figure 15: An example of a sociogram showing a first-order star 
 
 
Figure 16: An example of a sociogram showing a first-order zone 
Roles were classified into ten different categories. Data were captured so that 
each case in the data referred to an alter and ego pairing. Data were then 
imported into the ‘ergm’ software package for network data in the open-source 
R project for statistical computing and the composite sociograms for the first 
order stars at each site were graphed.294,295  
Data from the networks grids for each patient were then entered into the Social 
Network Analysis UCINET 6 and graphed using the Netdraw function.296 Using 
this method sociograms were drawn for the perceptions of the first order zones 
of each patient taking part in the study. These sociograms showed the 
perceptions of contact between patients’ alters and are shown for all patients in 
Appendix 3. 
Ego-network measures 
UCINET 6 and SPSS 21 were used to calculate standard ego-network 
measures used to describe network characteristics and relate them statistically   
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to other variables, for example behaviours and demographics.244 Following the 
methods of Hanneman & Riddle and McCarty, the following measures were 
calculated:279,297 
Degree – the degree of an ego-network is the number of alters in it. This 
research performed separate calculations for patients’ friends and family alters 
and their professional alters (formal and informal ties). 
Diversity – a separate calculation was made for diversity in the network. This 
was done by assessing the number of different types of alters, for example if a 
patient had one cardiac rehabilitation nurse and three GPs, they would be 
allocated a diversity score of 2. 
Number of ties – the number of connections perceived by the patient among all 
the actors in the ego-network, not counting the ego itself. Ego-networks were 
undirected so a tie between two alters was counted as two ties. 
Density – the number of ties in the ego-network (not including the ego) divided 
by the number of possible ties. This provides a measure of how tightly 
connected the network is. The density calculation for an ego-network is:  2𝑇𝑇
𝑁𝑁(𝑁𝑁 − 1) 
Where T is the number of ties and N is the number of alters.278 Values of 0 
indicate that none of the patients’ alters are connected whilst a measure of 1 
indicated that all alters are connected. Traditionally density measures are 
viewed as measures of constraint:243 those in denser networks are constrained 
by the existence of relationships between their alters. In this study it is possible 
that denser, more joined up networks represent more caring or safer situations 
for patients.  
Weak components – groups in the ego-network that are connected to each 
other and the ego but not to others in the network. This indicates where the ego 
has connections that are in cohesive subgroups or different social worlds.244 
This was also calculated as the proportion of weak components in relation to 
the size of the network. 
Brokerage – a calculation of the number of pairs of alters in the ego-networks 
that are not connected. This offers a measure of how many times the patient is   
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acting as a go-between. Normalised brokerage divides the brokerage value by 
the number of pairs to offer an idea of the extent to which the patient acts as a 
go between given the size of their network. 
Betweenness – the proportion of times the patient is positioned on a direct path 
between others in their network. Normalised betweenness is a comparison of 
the values of betweenness and the size of the network. This measure is often 
view as one of control.297 
These measures were analysed descriptively and student’s t-tests of 
independent samples were used to look for differences between patients at 
different sites and of different genders and correlations between the measures 
and age were explored. 
Homophily – homophily is the concept of similarity in a network based on 
theories that people have contact with others who are similar to themselves , 
sometimes summarised as ‘birds of a feather flock together.’298 Gender 
homophily was calculated through generating an E-I index measure.244 The 
index is calculated as follows: 
𝐸𝐸𝐸𝐸 = b − a
𝑏𝑏 + 𝑎𝑎 
Where a is the number of similar ties and b is the number of different ties. It is a 
suitable calculation for ego-network data and as such is a superior calculation 
than the alternative Yule’s Q calculation, which also factors in missing ties in 
socio-centric networks.244 
Alter value 
The value ratings given to alters by patients were compared for each category 
of alter. The scores were also dichotomised to give an indication of which alters 
were of high value to patients. 
Qualitative analysis 
Transcribed interview data were analysed thematically following the methods of 
Braun and Clarke,299 in which text is broken down into units of meaning and 
grouped into themes that describe participants’ views and experiences. 
Thematic analysis is a flexible and accessible method of analysis, developed 
from grounded theory. It can yield unexpected insights and is particularly suited   
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to translational research. Braun and Clark describe the six phases of analysis, 
which are detailed in Figure 17. Each of these phases was followed and NVivo 
10 software was used to manage the data.300  
 
Figure 17: The stages in thematic analysis from Braun and Clarke (2006).299 
Survey and scale analysis 
Medicines experience survey data were captured into SPSS 21. Likert scale 
values for each questionnaire item were captured numerically: strongly disagree 
= 1; slightly disagree = 2; neither agree or disagree = 3; slightly agree = 4; 
strongly agree = 5. Frequencies and mean values for each question were 
calculated and inter-item comparisons were drawn and output displayed in 
graph format. 
Item values for each patient were combined to form a scale (the Medicines 
Experience Scale) and a Cronbach’s Alpha scale reliability analysis was 
performed following the methods of Field.301 Inter-item correlations were 
checked to ensure that none of the scale items were highly correlated. The 
scale was assessed by determining its Cronbach’s α scale statistic;302 a 
reliability statistic of α > 0.70 is judged to be acceptable. A further investigation 
into whether the scale was more reliable if any items were deleted was 
undertaken. A principal components analysis (PCA) – a technique that identifies 
linear components within a set of variables – was undertaken using a   
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varimax (orthogonal) rotation to ascertain if there were underlying constructs 
within the scale and to ascertain whether the data could be formed into 
subscales. There is some debate about the sample size necessary to perform a 
PCA.301 Field described how views on the ratio of participants to variable range 
from 5-15.301 He goes on to describe empirical research that concludes that 
factors with four or more loads of 0.6 are reliable. A Bartlett’s test of sphericity 
was performed to ascertain if the inter-item correlations were large enough to 
conduct the analysis and a Kasier-Meyer-Olkin measure of sampling adequacy 
(0.72) was undertaken for each variable. The analysis was performed and 
components with an eigenvalue (the substantive importance of each 
component) in excess of 1 were extracted and compared. 
Linear regression 
A multiple linear regression analysis was undertaken to explore the relationship 
between the scale score and patients’ demographic and network variables. 
Regression was chosen because it described relationships statistically, it 
estimates values of independent variables and it identifies risk factors that 
influence outcomes.303  A decision was made about the appropriateness of 
linear regression for this data. In their guide to social network analysis Borgatti 
et al. described a study in which small-sample personal network data were used 
statistically with other data in a series of regressions, in that case measures 
were of depression and wellbeing.244  
In advance of modelling the data correlations were explored between variables 
to negate the risk of multicollinearity and to decide which variables would be 
included in the models. A hierarchical blockwise approach was used to 
ascertain the change in squared residual values as each variable was added, to 
assess the effectiveness of each model in explaining the variation in medicines 
experience scale values and the impact of additional variables of the 
significance of the model. A decision was made not to undertake a post-hoc 
correction as the regression enters the variables using a stepped approach and 
the research is exploratory rather than confirmatory. Residuals were examined 
for heteroscedasticity and non-linearity. Cook’s distance measures were 
calculated to ascertain whether individual cases had an overly large influence 
on the model and a case-by-case analysis of standardised DFBeta values – 
which calculate the differences in parameter estimates should cases be   
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removed – were not greater than +/- 1. The average leverage for the model was 
calculated and each case was explored to check that none had a leverage 
value greater than twice the average.  
3.6.13  Limitations of the study design 
Two important limitations will be discussed. First of all, this study used self-
reported data which yielded insight into how patients experienced the system of 
medicines management, but not how the system operates from multiple 
viewpoints. Patient views of how healthcare systems operates have rarely been 
canvassed and research to understand their experiences and hear patient 
voices have been fragmented, and often limited to individual system outputs, 
such as providing patients with information about their medicines, or measures 
of whether or not patients actually take them. These measures are useful 
insofar as they offer an assessment of how well the system works, but they offer 
little insight into the underlying causes of risk in the system and how resilience 
can be enhanced. Patient views of healthcare are increasingly important in 
assessing the quality and safety of care, such as the friends and family test, 
which is essentially a net promotor score;304 and which places individual patient 
perceptions of their care at the heart of the NHS quality improvement agenda. 
O’Hara and Isden argue that patients are the “one common denominator across 
all their care experiences” and as such have a “unique observational position” to 
identify risks in the system that may be hidden to staff.305(p4) 
Secondly, although the use of mixed methods was an important way of 
understanding how the patients’ networks impacted on them, it necessitated 
small-sample research. However, it is not uncommon for mixed methods social 
networks studies to use small samples, which is, indeed, a general criticism of 
mixed methods social network research.277 
3.7 Ethics 
This section will provide an overview of the processes followed to gain ethical 
approval to conduct the research and also the steps taken to ensure the 
research was conducted in an ethical way.  
Ethical approval was sought from and granted by an NHS Research Ethics 
Committee (see Appendix 4); and Research and Development approval was 
sought and granted by two hospital trusts. A summary of the approvals is   
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presented in Table 13. This process took several months to complete for 
reasons that included: 
• Differing processes in the two sites and the need to seek permission 
from a senior cardiology consultant in one Trust before an application 
could be made; 
• The lengthy process of applying for a research passport. Permission to 
conduct research could not be granted unless the researcher had a NHS 
contract or a NHS research passport. The passport required that several 
processes were completed and documented: 
• That the sponsor organisation, in this case the University of Bradford, 
completes a Disclosure and Barring Services criminal records check; 
• The sponsor organisation provided evidence of an occupational 
health screening, including a vaccination record; 
• That the sponsor organisation verified the researcher’s project and 
their qualifications and ability to conduct the research. 
• One Trust had a “feasibility” process that needed to be completed 
before a Research and Development application could be made. This 
took several weeks to complete. 
Table 13: Ethics and research and development approvals 
Approval type References Date granted 
NHS Research Ethics 
Proportionate Review 
REC: 13/NI/0118 
IRAS: 136510 
12/08/2013 
Research and development 
approval Site 1 
ReDA:  1595 28/10/2013 
Research and development 
approval Site 2 
2013/053 12/11/13 
 
Before data collection began, informed consent was gained from participants in 
the study. Patients received an information sheet whilst they were in hospital 
and awaiting discharge detailing both the ward observations and the follow-up 
diaries and audio-recorded interviews. It informed them about the study and 
what their involvement might entail and included a consent form. The patient 
information sheet was designed following research ethics guidelines.306 The 
researcher discussed the study with interested patients and answered any   
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questions. Patients were told by the researcher that they could participate in the 
whole study if they wished to do so, just consent to observations, or to take part 
diaries and/or follow-up interviews. Some patients also did not wish to 
participate in the diary component of the study. The researcher’s contact details 
were provided in case patients had any questions or concerns about the 
research after they had left hospital. Information sheets were assessed for plain 
English by a member of the supervision team and piloted with a volunteer 
patient.  
Informed consent was obtained from staff at the research sites involved in 
patient care. They were approached by the researcher at the beginning of the 
study and on each subsequent observation day. An information leaflet about the 
study was given to them which explained what their participation would involve 
and the researcher answered any questions they had about the study. They 
were re-assured that the subject of the study was not them as individuals, rather 
the system of medicines management they worked within. The briefing 
attempted to minimise the impact of staff awareness of the researcher 
observing their work on their behaviour to offset the risk of observer effects. 
Establishing a good relationship with staff was essential to making observations 
on the ward that were non-threatening so that duties were performed in their 
usual way, despite the presence of the researcher. The researcher asked for 
their written informed consent to be observed. Staff had the choice to ask the 
researcher to stop observing at any time if they wished; they were reassured 
that this would not affect their relationship with the researcher or their employer. 
Data collected about individuals were anonymised through the substitution of 
names with case numbers that also describe the individual’s role, for example 
CP1, for a community pharmacist. Patient names were kept separately from 
information collected about them and linked to stored data via a unique identifier 
generated by the researcher. 
The level of risk to participants and researchers was judged to be low. Whilst 
some patients kept contact diary sheets for a six-week period we expected the 
number of encounters that they recorded would be low, and therefore not 
burdensome. Additional data collection tools in the form of questionnaires and 
interview schedules were purposefully designed to reduce respondent burden.  
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The researcher advised patients at the end of each qualitative interview to 
contact their pharmacist, GP or nurse if they had questions or concerns about 
their medicines. If the researcher had concerns that the patient was at risk 
because of the actions or omissions of someone in their healthcare team or 
because of their own actions or understanding of their medicines, then they 
were advised by the researcher to contact a relevant healthcare professional. 
Patient interviews were usually conducted in the patient’s own home. All home-
based interviews took place in a main downstairs room. The researcher was 
also aware that the patient may recount adverse events or become upset about 
their health or healthcare experiences, which is classified elsewhere as the risk 
of psychological abuse or injury arising from the research.223 The researcher 
pointed out to the patient that they could stop at any time should they wish to, 
for example if they were fatigued, upset or ill. Only one patient became upset 
about their experiences during the interview.  
The researcher, who was a member of the Social Research Association (SRA), 
followed the SRA Safety Code of Practice which includes making sure 
colleagues knew the time and place of the interview.  
3.8 Reliability and validity 
Finally in this overview of methodology, the reliability and validity of the 
research will be discussed, highlighting the different steps undertaken to ensure 
the results of the research can be viewed with confidence. 
Reliability and validity are concepts that are concerned with credibility of 
research.307 They offer research audiences confidence in the results and 
confidence that the research tools have measured what they intended to 
measure. Hammersley’s definition of validity suggests that research is valid if it 
accurately represents features of the phenomena it describes or explains.308 
Reliability is usually defined as the ability to measure a phenomenon 
consistently and precisely;309 and whilst validity and reliability in research are 
not generally considered to be fixed concepts, rather they are firmly linked to 
the methods and intentions of each research project.309 Structured observation 
and survey research collect primary quantitative data and as such seek to 
measure phenomena so that they can be described numerically or 
statistically.216 Such research is often deterministic in nature in that it seeks to   
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identify causes of behaviour or phenomenon or to determine relationships 
between variables. As these types of research seek to measure phenomena 
objectively, there is a keen focus on the validity and reliability of the instruments 
used to collect the data. Many qualitative researchers reject these assessments 
– rooted in empirical traditions – as irrelevant to naturalistic enquiry;310 instead 
trustworthiness is widely accepted as the benchmark for validity and reliability in 
qualitative research.311  
The research described in this chapter employed mixed qualitative and 
quantitative measures and used different ways of evaluating the credibility of 
the methods used. This section sets out how the methods maximised the 
reliability, validity and trustworthiness of the research. 
3.8.1 Reliability and validity in the quantitative components 
In quantitative research, the data collection instruments are considered 
externally reliable if they are capable of producing data in a consistent way in 
different settings or by different researchers. This research used an observation 
schedule and a survey to collect quantitative data. Observation data may offer 
additional reliability and less biased data because they are collected as events 
happened rather than in retrospect; it could be argued that the more objective 
researcher generates the data, rather than a more ‘subjective’ participant. Thus 
observation narrows the gap between actual and recorded behaviour.  During 
the observation stages of this research, data were collected by the same 
researcher using the same tool at both the study sites. As it was researcher-
completed, in practice it was completed by an objective observer and completed 
in the same way each time it was used.  
Survey scale reliability can be assessed using statistical methods. The internal 
reliability of the medicines experience survey question set used in this research 
was assessed using a Cronbach’s alpha measure, which assesses the extent to 
which items in a multi-item set measure the same concept.312 The survey was 
administered in the same way to patients at both sites. 
Validity in quantitative research assesses whether the data actually record the 
phenomena or behaviours under investigation.313 Validity is assessed through 
three routes: Criterion validity; content validity; and construct validity.  
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Criterion validity 
Criterion validity describes how able the research instruments are to sensitively 
distinguish between respondents belonging to different groups.314 As no existing 
observation schedule could be found to record the content of patients’ hospital 
discharge with medicines, categories were decided through examination of 
previous research and policy about what patients want or need to know about 
their medicines. This is described in section 3.5.5. The schedule was reviewed 
by a patient representative and a supervisory team of healthcare experts. 
The question set used in the medicines experience survey was developed 
based on a number of different measures, as described earlier in this chapter, 
and a thorough review of the literature about what patients have experienced. 
The question set was reviewed by a patient representative and a supervisory 
team of healthcare experts. It was also piloted with a volunteer patient in 
advance of its use in the field. 
Content validity 
Content validity is the extent to which an instrument captures or measures a 
whole concept, for example happiness. The observation schedule and the 
medicines experience survey were reviewed by three expert clinicians to judge 
if they collected the data they intended to collect. This ensured the face validity 
of the tools. In addition they were reviewed by a patient volunteer prior to their 
use who did not suggest any changes.  
Construct validity 
Construct validity is the extent to which the concepts in the research have been 
successfully operationalised. In designing the survey, instruments were 
constructed through triangulating patient accounts made about discharge 
medicines management in other research with the real-life more immediate 
problems described by the patient representative. The research has been 
informed by human factors and care was taken to embed human factors theory 
into the analysis of collected data through applying systems frameworks. 
3.8.2 Reliability and validity in qualitative research 
Golafshani emphasises that reliability in qualitative research is assessed 
through how trustworthy and credible it is.310 In this research qualitative data 
comprised field notes made about discharge from hospital, patient diaries and   
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semi-structured interviews with patients. The interview schedule was 
constructed based on literature review, guidance from a patient representative 
and on feedback from three patients with whom an early version of the interview 
schedule was piloted. Themes identified in the data were reviewed, discussed 
and modified by the supervision team. As the main researcher was not a 
clinician, this meant that the patient experiences reported during interviews 
could be viewed from a lay perspective rather than through a professional lens 
with a priori professional assumptions about the delivery of care or ideal patient 
pathways. That notwithstanding, the researcher was aware that personal 
perspectives and concerns about the quality and safety of care could influence 
how the research was designed and conducted.315 
Maxwell developed five general categories for judging the validity of qualitative 
research, which are discussed below in the context of the qualitative 
components of this research:316 
Descriptive validity 
Descriptive validity refers to how accurately the data record what participants 
experienced. After each discharge observation the researcher made detailed 
field notes about what had happened. During semi-structured interviews 
patients’ accounts of their treatment were audio recorded and transcribed 
verbatim so the researcher did not need to rely on notes or memory to keep 
accurate records of what had been described. 
Interpretive validity 
Interpretive validity is an assessment of how well the researcher reports 
participants’ meaning in the study. During the observation stage the 
interpretation mainly lay in the researcher’s ability to record the meaning of non-
verbal cues in relation to how staff discharged patients for example assessing 
whether participants appeared frustrated or distressed. If phenomena such as 
this occurred, the researcher made notes explaining what had been seen. 
During semi-structured interviews the researcher followed good practice and 
checked how patients’ different potential meanings were understood during 
interviews. This minimised the risks of misinterpretation.  
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Theoretical validity 
Theoretical validity assesses how well the researcher uses or develops 
concepts or theories based on data. During the analysis of observation data a 
previously defined framework of contributory factors was used in order to 
develop evidence about the contributory factors to risk during patient discharge. 
During analysis of semi-structured interviews, concepts developed to describe 
the function of patients’ medicines management networks were reviewed and 
discussed in detail to ensure their validity. 
Generalisability validity 
Generalisability in qualitative research often relates to the ability of the data to 
describe a phenomenon for a particular group. A range of staff were observed 
in three settings across two sites. Observations were performed on random 
days and discharges were observed with different types of patients, for example 
those of different ages, ethnicities, genders and conditions.  
Sampling for the second phase of the research was based on a quota to ensure 
patients with a range of demographic variables were included. 
Evaluative validity 
Evaluative validity assesses how well the researcher’s conclusions are 
grounded in the data. During the observation research, field notes were made in 
situ by the researcher and used as the basis for the thematic analysis. Analysis 
and inferences were drawn directly from the field notes and quotations from 
field notes were used to provide evidence of the conclusions drawn. 
Conclusions drawn from the semi-structured interview data were data-driven 
and quotations from field notes were also used as evidence. Discussion within 
the supervisory team focussed on how inferences drawn were data-driven. 
Triangulation 
Due to the sequential embedded nature of the research design it was possible 
to verify the researcher’s observations and analysis in Chapter 4 with patients’ 
retrospective accounts of their discharge from hospital made during semi-
structured interviews and questionnaire responses reported in Chapters 6–7. 
This is a form of methodological triangulation, which is a further means of 
enhancing the validity of this research.221  
 127 
  
 
Overall quality assurance 
The following steps were taken to ensure the overall quality of the research: 
• Regular research supervision meetings enabled discussion of all stages 
of the research from discussion about the sites chosen, the patient health 
condition and the data collection tools to the themes developed and the 
inferences drawn. The researcher was also able to regularly and 
objectively reflect on the data collected with the team. 
• The research was informed by the views of a patient representative who 
advised about the issues faced by patients when leaving hospital with 
medicines, the quality and suitability of the data collection tools and the 
suitability of patient information about the research. 
• At the beginning of the project, advice was sought from the Mitchell 
Centre for Social Network Analysis at the University of Manchester about 
the research design and again later about social network data analysis.  
• Conference presentations about the work encouraged peer review of the 
research and its findings. 
3.9 Summary 
This chapter has detailed the methodology and methods used in this research. 
Many different data collection tools were developed and applied, including an 
observation schedule, a semi-structured interview schedule and a medicines 
experience survey. The analysis methods used included descriptive statistics, 
social network analysis, inductive thematic analysis, a principal components 
analysis and linear regression.  
Chapters 4–7 will describe the results of the research: firstly, Chapter 4 will 
present the results of the observations made of staff discharging patients on two 
cardiology wards; and secondly, Chapters 5–7 will present the social network 
analysis of post-discharge medicines management from the patient’s 
perspective. 
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Chapter 4 – How are patients discharged with medicines from 
hospital? 
4.1 Introduction  
The aim of this study was to explore how medicines are managed at hospital 
discharge by the hospital care team. This was to understand more about what 
patients are told about their medicines and how staff develop patients’ 
capabilities to use their medicines once they return home. It is presented in two 
parts: a quantitative analysis of the information staff offer to patients when they 
discharge them; and a structured deductive qualitative analysis of the field 
notes taken during the observations using the YCFF.30  
The study comprised 100 observations of hospital staff and cardiology patient 
interactions on the day the patient was discharged from two hospital sites. 
Observations were of 55 patient hospital discharges conducted by nurses with 
the patient’s medicines present. During these discussions patients would be told 
what medicines they were leaving the hospital with. The researcher also 
observed 19 pre-discharge checks of medicines where a nurse, a pharmacist or 
a pharmacy technician would approach the patient and explain that they were 
organising their discharge medicines and check which medicines were in the 
patient’s locker. Observations were also made of 23 instances of a ward 
pharmacist discussing patients’ medicines with them with the medicines present 
and three pre-discharge warfarin counselling sessions conducted by ward 
pharmacists. Observations took place on 36 randomly selected days between 
November 2013 and May 2014. The total number of observations and the type 
of observations made at each site is shown in Table 14.  
Table 14: Numbers of observations made by type and site 
Observation type Site 1 ward Site 1 
discharge 
lounge 
Site 2 
Ward 
Total 
Discharge discussion 12 19 24 55 
Pre-discharge check 5 0 14 19 
Pre-discharge discussion 1 0 22 23 
Pre-discharge warfarin counselling 1 0 2 3 
Total 19 19 62 100 
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At Site 1 a total of 17 nurses and two pharmacists were observed, either on the 
cardiology ward or in a hospital-wide discharge lounge where patients were 
sent from the ward to wait for their medicines. At Site 2 a total of two 
pharmacists, one pharmacy technician, one pre-registration pharmacist, 10 
nurses and one student nurse were observed, and all patients were discharged 
from the ward. The presence of a discharge lounge fulfilling the function of 
supplying patients with their to-take-out (TTO) medicines was the main 
difference between the two hospital sites. In this chapter the discharge lounge is 
treated as a separate entity. In the three places discharges were conducted, the 
following numbers were observed: Site 1 ward (12 patients); Site 1 discharge 
lounge (18 patients); Site 2 ward (18 patients). 
Discharges were exclusively conducted by nurses, whilst pre-discharge 
medicines discussions were undertaken by nurses and pharmacists. The 
slightly different processes noted during data collection are shown in Figures 18 
and 19, which map the discharge stages as they were observed at Site 1 and 
Site 2 respectively. 
National policy about how patients are discharged with medicines gives little 
detail about what patients should be told about their medicines at hospital 
discharge.72,91 The focus of these policies is to set out the inter-organisational 
responsibilities involved in patient transfer. Local policies are similarly vague 
about how patients are told about their discharge medicines. 
At Site 1 policy states that patients should know how, when and what medicines 
they should take after discharge; at Site 2 staff guidance simply states that the 
patient should be given information related to their discharge medicines. 
This study, therefore aimed to establish what patients are told at discharge 
about their medicines at these sites. The results are described in the following 
sections.  
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Figure 18: Site 1 discharge process 
 
 
 
 
 
 
 
 
 
 
Figure 19: Site 2 discharge process 
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 4.2 What do nurses tell patients about their discharge medicines when 
they are discharging them?  
This section of the results explores how nursing staff told patients about their 
discharge medicines at the point when they were being discharged with their to-
take-out (TTO) medicines. It is presented in the following sections: time spent 
face-to-face with patients at discharge; what are patients told about their 
cardiology medicines; and additional information given to patients. 
4.2.1 Time spent face-to-face with patients when they are being 
discharged 
Face-to-face interactions at the point of discharge were recorded through noting 
the time that the discharge started and the time it ended using a watch or a 
discharge lounge clock. Interactions between nurses and patients lasted 
between 1–24 minutes (mean=7.2; median = 5) (see Table 15); and nurses 
talked to patients about between 1–16 (mean = 6.7; median = 7) medicines on 
each occasion.  
Mean times spent face-to-face discharging patients were similar at the wards at 
Site 1 and Site 2; however the mean time spent face-to-face with patients 
explaining medicines in the discharge lounge at Site 1 was much lower.  
Discharges conducted in the discharge lounge at Site 1 took less time on 
average than those conducted on the wards at both sites. A non-parametric 
Kruskal–Wallis test of the distribution of independent samples indicated that the 
distribution of time was significantly different across the three places patients 
were discharged from (p<0.05), and the median (p<0.01) of the time taken to 
tell patients about their medicines at the discharge lounge was lower than on 
either ward. There was a weak association between the number of medicines 
discussed and the time the discharge took (r=0.32). 
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Table 15: Central measures of time taken face-to-face with patients and the number of medicines 
discussed. 
Discharge 
location 
Number of 
observations 
Mean time in face-
to-face discharge 
with medicines 
(SD) 
Median time in 
face-to-face 
discharge with 
medicines 
Mean number 
of medicines 
(SD) 
Site 1 Ward 12 8.85 (3.98) 9.5 5.92 (3.55) 
Site 2 Ward 24 8.75 (6.82) 7.5 6.88 (4.14) 
Site 1 
Discharge 
lounge 
19 4.23 (3.93) 2 6.89 (3.67) 
Total 55 7.21 (5.74) 5 6.67 (3.81) 
 
4.2.2 What were patients told about their cardiology medicines? 
Discharges were observed for 48 patients that included specific reference to 
one or more of six commonly prescribed cardiology medicines. These were 
aspirin, beta-blockers, statins, ACE-inhibitors/angiotensin receptor blockers, 
anti-platelets and glyceryl trinitrate (GTN) sprays.   
The number of instances where each medicine was given to patients and 
discussed at discharge is shown in Figure 20. Beta-blockers were the most 
commonly given medicine (36 instances) followed by statins (33). ACE-
inhibitors /angiotensin receptor blockers were the least commonly given 
medicines (22). 
 
Figure 20: The frequency of each cardiology medicine given at discharge. Base = 178.  
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The researcher recorded the content of each patient’s discharge and recorded 
the frequency of specific items of information to the patient. Those items were:  
• The purpose of the medicine: information to help patients understand 
why they are taking each medicine. 
• The prescribed dose: to help patients understand the amount of each 
medicine they should take.  
• The frequency and time the medicine should be taken: so that patients 
understand the structure of their medicines regimen. 
• How to take the medicine: this is important for certain medicines which 
need to be taken in a specific way. Some medicines, such as some 
aspirins, are soluble whilst others, such as a GTN spray, are taken in 
stages with specified time gaps between each stage. 
• Side effects of the medicines: specific side effects of the medicines 
included in the study were muscle cramps (statins), fatigue and coldness 
(beta-blockers); headaches and dizziness (GTN spray). 
• Tests: periodic tests are recommended for patients taking some 
medicines as part of safety monitoring, for example blood tests are often 
required for patients taking ACE inhibitors to monitor kidney function. 
  
The researcher noted if the nursing staff member checked whether the patient 
understood the instructions for each medicine and whether patients asked any 
questions about any of their medicines.  
The frequency with which nursing staff discussed specific items is shown in 
Figure 21 by medicines type and Figure 22 by site. Overall, nursing staff most 
commonly told patients about the timing of their medicines (127 medicines, 
71.3%) and the dose of their medicines (124 medicines, 69.7%). They were told 
the purpose of their medicines on less than half the observed occasions (85 
medicines, 47.8%) and the frequency with which they should take them on just 
over two fifths of the observed occasions (75 medicines, 42.1%). Nursing staff 
rarely told patients how to take medicines, although only certain medicines 
required special instructions (28 medicines, 15.7%) and about side effects on 
very few occasions (14 medicines, 7.8%). Tests necessary for medicines were 
rarely mentioned (6 medicines, 3.4%). Nursing staff occasionally checked that 
patients understood what they were told (23 medicines, 12.9%), and patients   
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asked questions about individual medicines for just over a tenth of the observed 
occasions (19 medicines, 10.7%). Nursing staff explained how to take GTN 
sprays more often than any other medicine (20 times, 80%), which is a positive 
result as there are complicated instructions for the use of GTN sprays that 
involve staged use of the spray device with time gaps between each use. 
Nurses explained the purpose of Aspirin less frequently than any other medicine 
(8 times out of a possible 33). Nursing staff in the discharge lounge at Site 1 
told patients less often about most aspects of their medicines apart from the 
frequency of their medicines (37 times, 49.3%). 
A series of chi square tests explored the association between the different 
medicines given to patients and the information they were given about them. 
The tests are described in full in Appendix 5. Overall, there was a significant 
association between medicines type and whether nursing staff told patients how 
to take their medicines (X2(5)= 98.885, p<0001): they were told this more 
frequently for their GTN spray, which is to be expected due to its complicated 
administration. Significant associations were also identified between the type of 
medicines and the dose (X2(5) =16.891, p<005) (in this case for beta-blockers) 
as well as the timing (for example as required, or at night) (GTN spray (X2 (5) = 
14.336, p<0.05). Staff also checked patients’ understanding of their GTN spray 
more frequently than for other medicines (X2 (5) = 20.033, p<0.05). 
4.2.3 What were patients told about their medicines at discharge at 
different sites? 
Tables 17, 18 and 19 show the frequency (%) of the categories of information 
nurses gave patients about their discharge medicines by site and by medicines 
category. A further series of chi-square tests explored the association between 
what patients were told about their medicines and the place from which they 
were discharged. The results of these tests are presented in Appendix 5. 
Overall, significant associations were found between where the discharge took 
place and what nursing staff told patients. Nurses on the wards at both sites told 
patients more frequently about the purpose of their medicines than nurses in the 
discharge lounge (X2 (2) = 42.185, p<0.001). Nurses on the ward at Site 1 
explained how to take medicines more frequently than at other sites (X2 (2) = 
8.317, p<0.05); and nurses on the ward and nurses in the discharge lounge at 
Site 1 told patients when to take their medicines more frequently than nurses at   
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Site 2 (X2 (2) = 7.870, p<0.05). Side effects were explained more frequently on 
the ward at Site 1(X2 (2) = 20.003, p<0.001); and nurses checked patients’ 
understanding more frequently at Site 2 and less frequently in the discharge 
lounge at Site 1 (X2 (5) = 12.798, p<0.005). 
 
Figure 21: The frequency of staff informing patients about medicines by medicines type. Base=178 
medicines.  
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Figure 22: The frequency of staff informing patients about different aspects of their medicines. 
Base=178. 
4.2.4 Additional information given to patients 
The researcher noted during all patient discharge observations (n=55) whether 
nurses highlighted the written information about their medicines they could take 
home, whether they were told about how they should obtain repeat medicines, 
and whether they were told how the hospital would communicate with the 
primary care team. These are important pieces of information for patients to 
know to support their ongoing use of medicines once they have left the hospital. 
The results of those observations are presented in Table 16. Staff highlighted 
written information to take home and information about how the hospital would 
communicate with their primary care team to half of the patients discharged 
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83.3%
72.2%
30.6%
44.4%
86.1%
25.0%
8.3%
16.7%
19.4%
21.3%
65.3%
9.3%
49.3%
61.3%
0.0%
1.3%
22.4%
10.4%
58.2%
73.1%
14.9%
32.8%
74.6%
7.5%
2.0%
2.7%
6.7%
0% 20% 40% 60% 80% 100%
Purpose
Dose
How to take
Frequency
Timing
Side effects
Tests required
Checked understanding
Patient asked question
Site 2
Site 1 Discharge lounge
Site 1 Ward
 137 
  
 
was higher (75%) on the ward at Site 2. In the discharge lounge at Site 1 just 
over two fifths (42.1%) of staff highlighted written information and just over a 
quarter (26.3%) explained how the hospital would communicate with the 
patients primary care team. 
Table 16: The frequency with which additional information was given to patients by site 
 Site 1 Ward 
(base 12) 
Site 1 Discharge 
Lounge (base 19) 
Site 2 Ward (base 
24 
Total (base 55) 
Getting repeat 
medicines 
0 1 (5.3%) 7 (29.2%) 8 (14.5%) 
Highlighting 
written 
information 
6 (50%) 8 (42.1%) 18 (75%) 32 (58.2%) 
Hospital 
communication 
with primary care 
6 (50%) 5 (26.3%) 18 (75%) 29 (52.7%) 
 
Chi square tests indicated a significant association between where the 
discharge took place and whether patients were told how to get repeat 
medicines (X2 (2) = 6.337, p<0.05). Nurses on the ward at Site 2 gave this 
information more frequently. A significant association was also detected 
between where the discharge took place and whether nurses explained how the 
hospital would communicate with their primary care team. Nurses gave this 
information more frequently on the ward at Site 2 and less frequently in the 
discharge lounge at Site 1(X2 (2) = 10.130, p<0.01). 
4.2.4 Summary of findings 
• The time taken to discuss medicines at discharge with patients varied. 
Staff in the discharge lounge took less time discussing patients’ 
medicines with them. These nurses had not been involved in the care of 
patients before they arrived in the discharge lounge. 
• Nurses told patients more often about the timing and dose of their 
medicines than about other aspects. Timing would involve giving an 
indication of whether it is in the morning and at other times of day or as 
needed. Frequency, for example, was once per week or once per day. 
Often timing of doses is important to get optimal benefit from some 
medicines. Dose would involve the number of milligrams. Tests that 
might be needed were   
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mentioned infrequently to patients, which means they may not alert their 
GP practice to the need for tests should those tests not be arranged. 
• Nursing staff rarely discussed side effects with patients, however as data 
presented later in this thesis will show, there are side effects associated 
with these medicines that may cause patients to discontinue them. 
• Patients were rarely told about how to get repeat medicines. It may be 
assumed by staff that patients are aware of the processes involved and 
so do not think it is important to communicate this. 
• Half of patients were not told how the hospital would communicate with 
the primary care team. A similar proportion were not alerted to the written 
information on the discharge summary to patients on just over half of all 
occasions. Staff on the wards did this more frequently than staff in the 
discharge lounge. 
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Table 17: Information given about medicines by staff at Site 1 Ward 
Site 1 Ward 
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Aspirin 6 1 (16.7%) 3 (50%) 5 (83.3%) 2 (33.3%) 4 (66.7%) 1 (16.7%) 0 1 (16.7%) 1 (16.7%) 
Beta-blocker 8 8 (100%) 8 (100%) 1 (12.5%) 4 (50%) 7 (87.5%) 3 (37.5%) 0 0 1 (12.5%) 
Statin 7 7 (100%) 6 (85.7%) 0 2 (28.36%) 7 
(100%) 
2 (28.6%) 0 0 2 (28.6%) 
Anti-platelet 4 4 (100%) 2 (50%) 0 2 (50%) 3 (75%) 1 (25%) 2 (50%) 1 (25%) 1 (25%) 
ACE-I/ARB 6 6 (100%) 6 (100%) 0 3 (50%) 6 (100%) 1 (16.7%) 1 (16.7%) 1 (16.7%) 2 (33.3%) 
GTN spray 5 4 (80%) 1 (20%) 5 (100%) 3(60%) 4 (80%) 1 (20%) 0 3 (60%) 0 
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Table 18: Information given about medicines by staff at Site 1 Discharge Lounge 
Site 1 Discharge 
Lounge 
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Aspirin 14 0 (0%) 8 (57.1%) 1 (7.1%) 9 (64.3%) 9 (64.3%) 0 1 (7.1%) 0 1 (7.1%) 
Beta-blocker 15 6 (40%) 10 (66.7%) 0 8 (53.3%) 10 (66.7%) 0 0 0 2 (13.3) 
Statin 14 4 (28.6%) 12 (85.7%) 0 6 (42.9%) 9 (64.3%) 0 0 0 0 
 
Anti-platelet 13 3 (23.1%) 9 (62.9%) 0 7 (53.8%) 10 (76.9%) 0 0 0 1 (7.7%) 
ACE-I/ARB 9 1 (11.1%) 7 (77.8%) 0 5 (55.6%) 7 (77.8%) 0 0 0 0 
 
GTN spray 10 2 (20%) 3 (30%) 6(60%) 2(20%) 1 (10%) 0 0 2 (20%) 1 (10%) 
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Table 19: Information given about medicines by staff at Site 2 Ward 
Site 2 Ward 
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Aspirin 13 7 (53.8%) 9 (69.2%) 1 (7.7%) 2 (15.4%) 8 (61.5%) 0 0 1 (7.7%) 0 
Beta-blocker 13 6 (46.2%) 12 (92.3%) 0 2 (15.4) 10 (76.9%) 1 (7.7%) 0 3 (23.1%) 2 (15.4%) 
Statin 12 8 (66.7%) 9 (75%) 0 6 (50%) 11 (91.7%) 1 (8.3%) 1 (8.3%) 2 (16.7%) 2 (16.7%) 
Anti-platelet 12 8 (66.7%) 7 (58.3%) 0 3 (25%) 11 (91.7%) 0 0 3 (25%) 2 (16.7%) 
ACE-I/ARB 7 4 (57.1%) 5 (71.4%) 0 2 (28.6%) 4 (57.1%) 1 (14.3%) 1 (14.3%) 1 (14.3%) 1 (14.3%) 
GTN spray 10 2 (60%) 7 (73.1%) 9 (90%) 7 (70%) 6 (60%) 2 (20%) 0 5 (50%) 0 
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4.3 How safe is medicines management at the point of discharge? 
The following section presents the results of the qualitative analysis of 
discharge observation field notes using the YCFF,30 which is shown in section 
3.5.8. During observations it was sometimes apparent that errors had been 
made earlier in the patient’s care or were arising in the discharge process as it 
was being observed. The YCFF allowed categorisation of the contributory 
factors in these errors (or medication safety incidents) which were apparent in a 
number of the observation periods. Defences against these contributory factors 
– as they were observed and interpreted – are also described. Although the 
YCFF provided a helpful structure for analysis, there are several caveats. 
The contributory factors in these errors were not always clear. Firstly, that the 
people being observed simply found the impact of an error and had no prior 
knowledge of how it had occurred. Secondly, that observation alone cannot 
make evident the cognitive processes of the people involved. It is difficult, 
therefore, to establish if (e.g.) a lapse occurred, and if so, why. However, where 
there was some evidence of the likely contributory factors, these are suggested. 
Where staff members offered explanations for why errors had occurred then 
these are reported with the understanding that the staff member’s account may 
not be accurate, either because they did not wish to tell the patient or the 
researcher the real cause of the error, or because they themselves had 
misinterpreted the causes. 
4.3.1 Active failures 
Definition: Any failure in performance or behaviour (e.g. slip, lapse, mistake, 
violation) of the person at the ‘sharp-end’ (the health professional). 
During observations, it was possible to identify active failures by staff involved in 
discharging patients with medicines and also the consequences of errors that 
may have happened earlier in the patient’s pathway of care. At Site 2, skill-
based mistakes included not checking the patient’s locker for medicines before 
beginning a discharge. In one case, a nurse began talking to the patient about 
their medicines, explaining that the medicines on the list which were not in the 
bag of medicines must be the patient’s own, which they should have at home. 
After a while, she realised that the missing medicines may be in the locker so   
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she checked, located them and continued to discharge the patient with the 
complete set.  
Execution failures, such as slips and lapses, were also observed. For example, 
a ward pharmacist was able to pick up written information about the wrong 
patient, stored in a corridor on the ward, and begin speaking to the patient 
about the wrong medicines. Lapses included forgetting to give patients 
medicines that they needed to take home. For example, a patient left the ward 
without being given a GTN spray. This was noticed by a ward pharmacist who 
chased after the patient to hand him a GTN spray, counselling him about its use 
in the corridor. During some observations, staff began discharging patients 
without complete sets of medicines. One nurse on the ward in Site 2 started 
explaining the patient’s discharge medicines to them using only one bag of 
medicines when there should have been two. She explained to the patient that 
the medicines bags were not labelled ‘1 of 2’ and that this was an easy mistake 
for her to make and later found the second bag.  
Sometimes it was hard to discriminate between lapses and violations, for 
example, making sure that a patient had all their TTO medicines at the point of 
discharge. In one case, a patient’s statin seemed to be missing from the TTO 
medicines bag and the pack in his luggage only had three remaining tablets. 
The patient said that perhaps he had more at home. The nurse continued the 
discharge without any further mention of the statin or advice to the patient about 
getting further supplies should he need to once home.  
In other cases, violations against established ward protocol seemed to be rather 
more obvious; some patients were allowed to leave the ward without waiting for 
their medicines – patients told staff members that they would either return 
themselves later or a relative would return later for the medicines. On another 
occasion a nurse discharged a patient without talking to them about their 
medicines – she explained that the pharmacist had already talked to the patient, 
although the same staff member was observed on other occasions talking to 
patients about their medicine at discharge after the pharmacist had previously 
done so. It remains unclear, however, as to whether the violations were 
erroneous (i.e. the staff concerned did not know they were breaking protocol) or 
not.    
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Defences 
During observations, most staff took care to ensure patients received the 
correct prescribed medicines: staff members confirmed patients’ names and 
dates of birth. All staff familiarised themselves with each patient’s notes before 
initiating the discharge.  
A ward pharmacist at Site 2 checked inside the boxes of medicines stored in 
patients’ lockers and explained to patients that she needed to check with a 
doctor if she had a query about what had been prescribed. Most staff checked 
that all medicines were present before talking to the patient and some staff used 
the discharge summary as a guide for the conversation with the patient or cross 
checked all the medicines in a compliance aid with those listed on the discharge 
summary. Others ticked off each medicine on the discharge summary once they 
had talked to the patient about it. 
“The nurse checked the patient name and address and checked the 
medicines against the discharge summary. The discharge summary was used 
as a reference by the nurse.” (Field notes, Site 1, Ward 21/11/13) 
“The pharmacist checked the medicines against the discharge summary 
and the patient records before speaking to the patients and checks any queries 
with the prescribing doctor. Pharmacist checks inside the boxes and checks the 
labels.” (Field notes: Site 2, Ward, 04/02/14) 
Helping patients to understand changes to their medicines may guard against 
errors occurring once they are home and beyond the care of the ward. Some 
staff would talk about medicines in groups, for example those that were taken at 
the same time, or those that worked together, for example clopidogrel and 
aspirin. At Site 2, a ward pharmacist would usually go to see patients with their 
medicines before their discharge was conducted by a nurse to explain the 
changes that had been made and occasionally why those changes were 
necessary.  
“The [ward] pharmacist explained changes and some reasons for 
changes, for example that there is evidence that the new blood pressure 
medicine is more clinically effective after a heart attack. She also explained that 
the dose of statin will drop after six months.” (Field notes: Site 2, Ward, 
22/01/2014)  
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Additional practical help from staff during discharge tried to offset the risk of 
patients becoming confused by their medicines after discharge and 
experiencing active failures once home. For example, some staff wrote 
additional notes for patients on medicines boxes or discharge summary. Notes 
included the reasons for taking the medicines or the time of day they should be 
taken. Others would give explanations, such as how blister packs worked or 
asked the patient to explain it.  
“[The] patient complained that he doesn’t know what they are for. He 
says he gets confused and will forget. He gets upset. The nurse wrote down on 
the discharge summary what each medicine was for: ‘blood-thinning’; ‘blood 
pressure’; ‘diabetes’; ‘protects stomach’; ‘cholesterol’; ‘cramps’; ‘pain’; ‘angina’.” 
(Field notes: Site 2, Ward, 04/02/14) 
Staff gave advice to help patients continue to take their medicines, for example 
taking paracetamol for two weeks to help with the side effects (headaches) of 
nicorandil and advising them to see the GP if side effects continue. Other staff 
would only re-inforce that patients should not stop taking medicines should they 
perceive side effects. 
4.3.2 Situational factors 
4.3.2.1 Individual factors 
Definition: Characteristics of the person delivering care that may contribute in 
some way to active failures. Examples of such factors include inexperience, 
stress, personality, attitudes. 
Staff were observed to conduct discharges with medicines in different ways, 
with observed variation in the styles used and depth of content offered to 
patients. For example, staff offered different levels of detail to patients about 
their discharge medicines and some did not check at all if the patient 
understood what they had been told and gave very limited information about the 
medicines, for example not telling patients what the effects of the medicines 
would be or not telling patients about side effects. This may be related to the 
individual attitudes of staff members concerning the importance of talking to 
patients about their discharge medicines.    
“[The] HCP didn’t check understanding. Didn’t solicit questions. No 
mention of what to expect from any of the medicines or any side effects. Patient   
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was on their own. Medicines [were] handed over in a bag. The yellow patient 
copy of the discharge was placed in the bag. The discharge summary was used 
as reference point during the discharge.” (Field notes: Site 1, discharge 
lounge,19/11/13) 
Medicines were sometimes handed to patients in a bag with little explanation 
about them, or boxes were shown to patients for just a few seconds whilst 
medicines names and doses were read out from the discharge summary.  
There was a great deal of variety observed in the verbal communication style 
displayed by staff. Some appeared to talk to the patients in a friendly and caring 
way about their TTO medicines but gave limited detail. Conversations were 
often dominated by the nurse giving information to patients, sometimes showing 
them the medicines packaging whilst talking through the list of medicines on the 
discharge letter. They offered basic information about medicines purpose, dose 
and frequency and occasionally side effects and changes to medicines. Some 
solicited questions from the patient at the end of the discharge discussion. 
Whilst discharge discussions were brief, nurses were also observed to 
sometimes take time to explain to the patient how to use medicines and check 
the patient’s understanding. Other staff members, however, were observed to 
quickly read through the list of medicines from the discharge summary, detailing 
some information such as doses and frequency of medicines and then placing 
the patient’s copy of the letter in the bag of medicines without showing it to the 
patient or explaining what it was.  
During discussions, medicines would often be left in the plastic bag in which 
they were issued so patients were not shown the medicines boxes, limiting their 
ability to familiarise themselves with their medicines before leaving hospital. 
These staff members rarely spent more than one or two minutes discussing 
TTO medicines with patients and did not seem to explain the medicines in a 
meaningful way that could help the patient use them once they were home. 
Patients rarely asked questions in these situations and questions were seldom 
sought by nursing staff. In one occasion in the discharge lounge at Site 1, a 
staff member commented that the patient may know more about the medicines 
than she herself did and struggled to pronounce the names of some of the 
medicines.   
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Defences 
Most staff members told patients the name of the medicine and the dose and 
frequency with which their medicines should be taken. This may contribute to 
the patient’s understanding of their medicines and therefore help them avoid 
administration errors once home. Some staff additionally offered information 
about the purpose of medicines, side effects and whether the medicine was 
new or changed, which may help the patient develop a deeper understanding of 
their medicines regimen and prevent them mistakenly taking medicines that had 
been discontinued. Some also checked that the patient understood each 
individual medicine; others asked the patient if they understood after they had 
listed all medicines.  
Some staff members presented medicines to patients in a way that would help 
them organise or use them once home, and therefore guard against errors, for 
example by taking medicines boxes out of the bag and grouping them together 
into times of day they should be taken, or grouping together those that 
complement each other to treat a health condition. Other staff members would 
sit down with the patient to explain their medicines. Some appeared to explain 
medicines and their effects in detail, helping patients prepare for and recognise 
side effects. These nursing staff members observed were exclusively based on 
cardiology wards, rather than discharge lounges. Their conversations appeared 
patient-centred, thoughtful, in-depth and personalised to the patient’s health 
condition and set of medicines. They appeared to be sharing medicines 
expertise with the patient in an easy-to-understand way. They took time sitting 
with the patient, soliciting questions, asking what other medical staff had told 
them about their medicines and checking the patient’s understanding. Some 
explained medicines in easy-to-understand language using terms like ‘controls 
and steadies the heart beat and helps the heart beat stronger and be a more 
effective pump’ to describe the effect of a beta-blocker; and an anti-platelet 
worked by ‘stopping stickiness of the artery walls.’ Some of these nurses drew 
diagrams to explain the effects of medicines to patients; others attempted to 
empower the patient in their subsequent interactions with other HCPs, for 
example encouraging them to question their GP if the GP suggested changing 
doses or discontinuing the medicine. One patient was able to have a very 
detailed discussion about the side effects of a beta-blocker with the nurse who   
 148 
  
 
discharged him. The nurse tried to help the patient worry less about the effects 
of the medicine and she emphasised that he should not stop taking any of his 
medicines if he was worried about them, rather he should see his GP if he had 
any questions.  
4.3.2.2 Patient factors 
Definition: Those features of a patient that makes caring for them more difficult 
and therefore more prone to error. These might include abnormal physiology, 
language difficulties, personal characteristics (e.g. aggressive attitude). 
Patients were observed to display different levels of interest in the discharge 
consultation which impacted on the likelihood of them leaving hospital with a 
good understanding of their medicines. Some appeared disinterested and 
bored. Some patients had been waiting many hours to go home which caused 
them to express frustration and sometimes distress, which may have influenced 
how much attention they were able to pay to information about their medicines. 
Others who hadn’t waited so long were often seemed just as keen to leave 
quickly. 
Some patients appeared to struggle to keep up with what they were being told 
and were unable to quickly make notes during the time the discharge took 
place. One patient complained how he struggled with his memory and others 
appeared overwhelmed when their lists of medicines were read out to them. 
“The patient was concerned to keep a list of medicines because he says 
he forgets what he’s been told “five minutes later”. The patient is struggling to 
keep up with what he is being told about his medicines and write things down at 
the same time.”  (Field notes: Site 2, Ward, 22/01/2014) 
Patients occasionally became distracted during the consultation, for example 
one patient began making a telephone call on his mobile whilst the nurse began 
the process of discharging him. Other patients seemed confident in their 
medicines and so did not actively pay attention to what they were being told. In 
one case, the patient was so adamant that he needed no explanations that the 
HCP gave up trying to explain them to him.  
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Defences 
Many patient-factor defences overlapped with individual-factor defences 
because some individual staff member’s characteristics would try to offset 
patient factors. For example, staff would write things down for patients, such as 
‘Morning’ or ‘Evening’ on medicines boxes to help patients organise them once 
they had left the hospital, on some occasions patients asked staff to do this as 
they explained they would be able to organise their medicines more effectively 
should this be written on the boxes for them. Other staff members would write 
phrases to summarise the medicines purpose, for example ‘For heart’, or ‘Thins 
blood’ on the discharge summary, which may help patients better understand 
the purpose of their medicines. 
Some patients were very attentive during the discharge and attempted to take 
notes whilst they were being shown their medicines. Some appeared to be 
listening very intently and some asked detailed questions about aspects of their 
medicines that interested or concerned them, for example whether their GP 
would be informed about their new requirement, or if medicines had side 
effects. Other patients had family members, such as spouses and children, with 
them during their discharge who paid attention, or took notes. 
4.3.2.3 Team factors 
Definition: Any factor related to the working of different professionals within a 
group which they may be able to change to improve patient safety. 
Team factors were rarely directly observed although sometimes nurses 
explained that the timing of patients’ discharge relied on team members 
performing medicines-related tasks, such as writing discharge prescriptions or 
faxing requests for follow-up appointments. If this did not happen in a timely 
way, then the discharge would be delayed which may impact on the patient’s 
willingness and ability to understand detailed information about their medicines 
Defences 
Few defences in this domain were observed, mainly because observations took 
place when only one staff member was talking to the patient. However, a ward 
pharmacist at Site 2 often took responsibility for charting the discharges 
occurring that day and their progress towards completion. The pharmacist 
would re-write the list of patients on the ward white board so it was easy to   
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understand and mark whether the patient’s TTO prescription had been checked 
by the pharmacist and whether the patient was ready to be discharged with their 
medicines. 
In addition, there was sometimes an overlap in what patients were told before 
discharge by different members of staff. For example, at Site 2 where a ward 
pharmacist was present, patients were told the name and purpose of new and 
changed medicines by the ward pharmacist and then often told this again, 
sometimes along with additional information, by the nurse who discharged 
them. This may have acted to re-inforce the information given and give patients 
the opportunity to hear the information again.  
4.3.2.4 Task characteristics 
Definition: Factors related to specific patient related tasks which may make 
individuals vulnerable to error. 
The task of discharging patients with medicines required multiple professionals 
working to deliver the correct medicines to the correct patient and ensuring they 
are able to use them correctly. As such it is a complicated task and, as such, 
one which is potentially error-prone. 
At Site 1, many patients were moved from the ward to the discharge lounge 
where staff had not been previously involved in their care and did not know 
them. This essentially represented an additional patient transfer (or step in the 
process) so opportunities to create risks were heightened because of this 
transfer and the different context of care. This made the task of discharging the 
patient something that occurred after the care of the ward had ended and that 
could be performed by non-specialist staff member. The ward would telephone 
the discharge lounge to say there was a patient to collect. The discharge lounge 
then listed the patient’s name and ward number on a white board whilst a 
healthcare assistant (HCA) went to collect the patient and their notes. HCAs 
also regularly went to the pharmacy to collect the medicines. TTO prescriptions 
were prepared on the ward before the patient was collected and a note was 
made that medicines were not to be delivered to the ward, rather they were to 
be diverted to the discharge lounge. Staff in the discharge lounge did not know   
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the patients and when the lounge was busy staff would call out patients’ names 
to locate them so that their discharge could begin. 
Defences 
Staff checked the patient’s name and date of birth before talking to them about 
their medicines to guard against giving medicines to the wrong patients. Staff 
also checked if the patient had any allergies. 
4.3.3 Local working conditions 
4.3.3.1 Lines of responsibility 
Definition: Existence of clear lines of responsibility clarifying accountability of 
staff members and delineating the job role. 
At both sites the staff member discharging patients was not necessarily the staff 
member who had been in charge of caring for the patient that day. This 
happened if the charge nurse thought the discharge should happen when the 
usual staff member was not available. The discharge lounge at Site 1 was 
managed by a nursing sister and one of a number of nurses – usually the next 
nurse available – would undertake the discharge when patients’ medicines 
arrived in the lounge. These staff members had not previously been involved in 
the patients’ care. 
At Site 2, the Ward pharmacist and the nursing teams reported to different 
departments, however, in terms of explaining medicines to the patients, the 
level of role co-ordination was not clear. The content of patient discharges often 
duplicated, rather than complemented, the content of discussions about 
medicines with the pharmacist – it was unclear whether this was by design or 
because the different roles of the ward pharmacist and the nurse were unclear. 
Defences 
At Site 2, the staff member conducting the discharge was normally, but not 
always, the nurse in charge of the room on the ward where the patient’s bed 
was situated. At Site 1, the charge nurse or the ward manager decided if 
patients were to be transferred to the discharge lounge, where they would wait 
for their medicines to be delivered. Discharges conducted on the ward were 
usually the responsibility of the nurse in charge of the patient on the ward that 
day.   
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4.3.3.2 Staff workload 
Definition: Level of activity and pressures on time during a shift. 
Staff observed on both wards appeared extremely busy at all times and 
workloads appeared to influence their prioritisation of tasks, for example staff 
sometimes appeared too busy to spend a lot of time with their patients talking 
about medicines, which would limit the detail they would offer. However, it was 
not always clear whether the limited detail offered was due to staff attitudes 
(individual factors) or to staff workload. Time with patients seemed hurried if the 
staff member was due elsewhere, for example back in the dispensary, or if staff 
members were due to take breaks. Time spent with the patient often varied, for 
example some staff members would conduct the discharge standing by the 
patient’s bed reading the medicines from a list, and in one case whilst the 
patient was also standing with a coat on waiting to leave the ward. 
Discharges were observed to be delayed by lunch and performing care 
activities for other patients, for instance being asked to help a patient from his 
chair. Workloads meant that discharge could be conducted by a nurse that the 
patient did not know because they had not been allocated to that patient’s room. 
Discharges were sometimes observed to happen very quickly in order to fit the 
task in around other duties and breaks. 
“The discharge happened quickly. Only one new medicine (isosorbide 
mononitrate) and slightly more time was taken to discuss this one. The nurse 
took the leaflet out of the box to discuss the side effects of this medicine with 
the patient. The patient was standing up, dressed and ready to go home. The 
nurse was also standing up and tipped the medicines onto the bed. The nurse 
was about to go on a break. The patient asked for information about exercise 
but was given a leaflet about diet. The patient had been worried about doing 
exercise because he enjoys the gym and walking.” (Field notes: Site 2, Ward, 
7/1/14) 
Once they were underway, discharges could be interrupted by staff members 
consulting the nurse about problems or asking for help. On more than one 
occasion this led to the patient’s discharge being suspended whilst the nurse 
attended to other duties.  
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Defences 
No defences were observed in this domain 
4.3.3.3 Supervision and Leadership 
Definition: The availability and quality of direct and local supervision and 
leadership. 
Nursing line management reinforced that patients should be moved to the 
discharge lounge at Site 1, which was an internal transfer of care which 
impacted on the continuity of care that patients experienced. 
Defences 
At both sites, it was clear each day which team member was in charge of the 
ward, and activities in the discharge lounge were co-ordinated by a nursing 
sister.  
4.3.3.4 Management of staff and staffing levels 
Definition: The appropriate management and allocation of staff to ensure 
adequate skill mix and staffing levels for the volume of work. 
The number of discharges varied from day to day, ranging from none to as 
many as nine. On days where comparatively large numbers of patients were 
discharged from wards, there were increased levels of work for staff members 
involved in preparing patients and their medicines for discharge, yet staffing 
levels did not appear to be influenced by the number of patients leaving the 
hospital. This may have impacted on the time available to staff to spend with 
each patient. 
Defences 
None were observed in this domain. 
4.3.3.5 Equipment and supplies 
Definition: Availability and functioning of equipment and supplies. 
The availability of medicines appeared to influence how patients were 
discharged. Many patients waited a long time for their medicines, either on the 
ward or in a discharge lounge. In one or two cases staff counselled patients 
about their medicines without the medicines being present, sometimes 
describing colours or shapes of tablets. In another case, the medicine   
 154 
  
 
prescribed (Valsartan) was not available in the hospital so the pharmacist 
advised the patient to obtain the medicine from an alternative source, which 
meant they may not have been able to obtain that medicine.  
Patients were rarely given information about how to get further supplies of their 
medicines once they were back in primary care. 
Defences 
At Site 2, a ward pharmacist was able to dispense commonly prescribed TTO 
medicines from a supply on the ward. This meant that for some patients the 
waiting times for medicines before discharge was reduced, which may have 
meant they were less fatigued and more able to understand the information they 
were given. 
4.3.4 Latent / organisational factors 
4.3.4.1 Physical environment 
Definition: Features of the physical environment that help or hinder safe 
practice. This refers to the layout of the unit, the fixtures and fittings and the 
level of noise, lighting, temperature and so on. 
Staff were observed in three different environments: in two wards and in one 
discharge lounge and most observations took place in a semi-public domain. 
For example, in the discharge lounge patients were given their medicines in one 
of three rooms or in a corridor, usually with many other patients and relatives 
present. The main room in the discharge lounge had a television which was 
constantly switched on and a kitchen area where staff would prepare drinks for 
themselves and the patients. This environment lacked privacy for patients and 
may have inhibited their confidence to ask questions about their medicines. It 
was also a loud and potentially disorientating environment.  
On the wards, most discharges took place at the patient’s bedside and other 
patients (and sometimes other patients’ family members) were often present. 
These environments made it possible for others to overhear the patient’s 
diagnosis and the medicines they had been prescribed, which was potentially 
embarrassing for patients and may have inhibited them from asking questions 
about their medicines. One patient, for example, was concerned about the   
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impact of newly prescribed medicines on his libido and did ask questions about 
this, however, other patients may have been embarrassed to do so. 
Defences 
No defences were observed in this domain. 
4.3.4.2 Scheduling and bed management 
Definition: Adequate scheduling to manage patient throughput minimising 
delays and excessive workload. 
At both hospital sites there appeared to be a high demand for beds, which 
placed pressure on staff to discharge patients, asking them to wait for their 
medicines in a different place, or transferring them to the discharge lounge. 
Patients were sometimes asked by a senior nurse to relocate to the discharge 
lounge at Site 1 if they had expressed their reluctance to do so to their own 
nurse. This pressure to free up beds may have limited the time taken with 
patients on the ward by specialist cardiology staff to explain medicines. Some 
patients at both sites refused to leave their beds until they had been given their 
medicines, one because he had done this before and waited a long time for his 
medicines. 
“Patient’s medicines were sent up on request from the pharmacy 
because the ward was under pressure to free up the bed. The patient refused to 
leave the bed to sit in the quiet room. He said he had done this before and 
waited ages for his medicines to arrive.” (Field notes. Site 2, Ward, 7/1/14) 
Defences 
None were observed in this domain. 
4.3.4.3 Training and education 
Definition: Access to correct, timely and appropriate training both specific (e.g. 
Task related) and general (e.g. Organisation related). 
Some staff in the discharge lounge at Site 1 appeared to be less knowledgeable 
about the medicines and some were observed to struggle to pronounce them. A 
lack of knowledge about cardiology medicines would clearly restrict their ability 
to offer an in-depth explanation about patients’ medicines.  
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Defences 
The depth and detail of training about discharging patients undertaken by staff 
at both sites is unknown. All staff were healthcare professionals and many of 
the staff appeared highly knowledgeable about the cardiology medicines when 
they talked to patients. Nursing and pharmacy trainees were mentored in the 
ward by more experienced staff. This meant that the style of discharge 
consultation could diffuse from experienced to non-experienced staff. Staff 
mentors would intervene if they perceived the trainee was not giving enough 
detail about the patient’s medicines. 
4.3.4.4 Support from central functions 
Definition: Availability and adequacy of central services in support of the 
functioning of wards/units. This might include support from information 
technology and human resources, portering services, estates or clinically 
related services such as radiology, phlebotomy or pharmacy. 
The timing of discharge appeared to be influenced by the capacity of the 
pharmacy to dispense medicines and for them to be delivered to the ward. 
Sometimes staff would not know the whereabouts of the patient’s medicines 
because they had been placed on a delivery round. Delays appeared to impact 
on patients’ capabilities and attitudes to discussing medicines.  
Defences 
The presence of a ward pharmacist on the ward at Site 2 resulted in medicines 
checks and queries being made and problems resolved quickly. The pharmacist 
was available to answer any questions patients had and whilst the pharmacist 
had a busy workload, it was possible to prioritise the organisation of discharge 
medicines. As many medicines were also dispensed on the ward, patients at 
Site 2 often went home after a comparatively shorter waiting time. 
4.3.4.5 Policies and procedures 
Definition: The existence of formal written guidance for the appropriate conduct 
of work tasks and processes. This can also include situations where processes 
are available but contradictory, incomprehensible or of otherwise poor quality. 
Whilst medicines management and discharge policies stated that patients were 
to be given information about their medicines, they gave little detail about how   
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and where this should be done and what constituted a sufficient level of 
information. At Site1, policies stated that medicines management should be 
patient-centred, however, no additional detail or examples were given about 
how this should be achieved at discharge. 
The discharge and medicines policies provided only very general guidance 
about what level of detail staff should offer patients. At Site 2 policy stated: 
“The person concluding the discharge will ensure as a minimum that 
appropriate follow-up information is provided if applicable, medication if 
applicable is given, and information in relation to medication is given to the 
patient or relative/carer on discharge.” (Site 2 Discharge Policy) 
Policy at Site1 specified that: 
“[At discharge or transfer] Patients (or their parents, carers or advocates) should 
be encouraged to be active partners in managing their medicines when they 
move, and know in plain terms why, when and what medicines they are taking.” 
And that:  
“Communications with GPs, patients, carers and community pharmacists about 
discharge medication should be timely and comprehensive.” (Site 2 Medicines 
Policy) 
In addition, when medicines were missing from sets of TTO medicines there 
seemed to be no process to identify whether the patient had supplies at home, 
especially if the patients themselves were unsure, or whether they were missing 
from the set delivered to the ward or discharge lounge. 
Defences 
Both wards appeared to follow processes to discharge patients, as detailed in 
Section 3.5.7, albeit with observed individual variation. 
4.3.5 Latent external factors 
4.3.5.1 Design of equipment and supplies 
Definition: The design of equipment and supplies to overcome physical and 
performance limitations. 
The names of medicines staff discussed with patients were often long and 
sometimes difficult for both staff and patients to pronounce and understand. 
Some patients questioned terms they did not understand, such as ‘ACE   
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inhibitor’; and it is possible that other patients did not ask questions when they 
did not understand their medicines. 
Defences 
None observed in this domain. 
4.3.5.2  External policy context 
Definition: National driven policies / directives that impact on the level / quality 
of resources available to hospitals. 
It was not possible to directly observe how external policy impacted on how 
patients were discharged. However, current policy to involve community 
pharmacy in supporting patients with their medicines once they are discharged 
largely did not appear to routinely influence what patients were told by staff. 
Even ward pharmacists at Site 2 did not suggest patients attended community 
pharmacy for a MUR or enquire about an NMS appointment. 
Defences 
In two observations community pharmacy was mentioned to patients: one 
patient was explicitly told by a nurse that there were community pharmacy 
services available to help him with his medicines; and one patient was told to 
take a copy of his discharge summary to his community pharmacy after his wife 
mentioned that his medicines were on repeat prescription. This patient was 
newly prescribed aspirin and a beta-blocker in hospital. 
4.3.6 Communication systems  
Definition: Effectiveness of the processes and systems in place for the 
exchange and sharing of information between staff, patients, groups, 
departments and services. This includes both written (e.g. documentation) and 
verbal (e.g. handover) communication systems. 
Patients were sometimes told that their GP practice would receive a copy of 
their discharge summary, however, none were told to ensure that their GP had 
received the information about their medicines and taken the appropriate action. 
Additionally, patients were not always made aware that they had a written list of 
their medicines as this was sometimes placed in their bag of medicines before it 
was handed to them.  
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Occasionally there was a contradiction in the medicines information given to 
patients. For example, a patient explained to the ward pharmacist that the 
doctor had told him to take isosorbide mononitrate differently to how the 
pharmacist had. 
“The pharmacist explained why the patient should take it twice a day. 
The patient explained how he had usually taken it. The pharmacist explained 
the reason why it should be taken at 4pm as well as in the morning was to have 
a nitrate-free period at night-time to not become tolerant. The patient said he 
was told differently by the doctor.” (Field notes, Site 2, Ward, 24/1/14) 
On another occasion a patient was told to use a GTN spray differently by two 
different members of staff. In this case the gap in the time between 
administering the spray was of a different duration. 
Potential errors that occurred outside the observation window but affected 
activity during observation were identified during discharge encounters. At Site 
1, staff were sometimes observed to explain that ward staff might forget to mark 
on the to-take-out (TTO) prescription that the medicines were to be delivered to 
the discharge lounge and not to the ward. This would result in medicines being 
delivered to the wrong place, thereby increasing patient waiting time and 
sometimes their frustration. Staff on the ward were also observed explaining to 
patients that their medicines were being delivered to the wrong place which 
increased the waiting time and prompted discharge lounge staff to explain they 
were trying to track down medicines if patients complained. Nurses explained 
that medicines would be in the process of being delivered to the ward so they 
were in transit somewhere in the hospital and staff were not aware of the 
medicines’ exact location. 
Occasionally, not all medicines listed on discharge paperwork were delivered to 
ward or to the discharge lounge for the staff member to use when discharging 
the patient, for example some medicines were missing from bags of delivered 
medicines and this was noticed and communicated to patients during their 
discharge. There may have been a number of reasons for this, for example 
errors made by staff on the ward when ordering patients’ medicines or errors in 
the dispensary when preparing and issuing them. In some cases it became   
 160 
  
 
unclear during the discharge if patients had supplies of missing medicines 
themselves at home. 
Defences 
Patients were sometimes told their GP would be informed of their hospitalisation 
and their medicines regimen.  
“The nurse explained that the discharge summary would be faxed and 
posted to the GP and that [the consultant] would write to the GP. Told that a 
copy of the discharge summary would be kept on the ward. Told to call the ward 
if they had concerns.” (Field notes Site 1, 21/11/13) 
Each patient was given a written list of medicines to take home and whilst at 
Site 1 this was initially a poor-quality, hard to read copy, they changed their 
systems so that patients received printed copies during the observation period. 
Before this change, one staff member pointed out to a patient that their ‘yellow’ 
copy of their discharge summary might be difficult to read and photocopied a 
better copy for the patient. 
4.3.7 Safety culture 
Definition: Organisational values, beliefs and practices surrounding the 
management of safety and learning from error. 
Values and beliefs cannot be directly ascertained during observations, however, 
some cautious inferences can be drawn from these observations. Processes 
and individual behaviour observed at the ‘sharp-end’ can be indicative of the 
safety culture of an organisation. The two sites were observed to operate very 
different methods for managing medicines at discharge. Site 2 had an allocated 
ward pharmacist who would see each patient shortly before they were 
discharged to highlight which medicines were new and which had been 
changed or discontinued, which potentially enhanced patients’ knowledge of 
their new medicines regimens and may prevent medicines errors once they 
were home. Site 1 also had an allocated ward pharmacist, who changed three 
times during the observation period. The pharmacist at Site 1 was less involved 
with the patient at discharge, even though they would have had a face-to-face 
interaction at some point during the patient’s hospitalisation.  
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Site 2, like Site 1, had a discharge lounge where patients could wait for 
transport, however medicines were always handed to the patient on the ward, 
usually by a member of staff who had been involved in their care. Medicines 
explanations to patients were usually given more emphasis on wards compared 
to the discharge lounge, where giving patients’ medicines seemed to be more 
process driven, aimed at completing the discharge rather than on the needs of 
the patient.  
Defences 
No defences were observed in this domain. 
4.5 Discussion 
This section has explored the various contributory factors to risk from medicines 
and defences that come into play when patients are discharged from hospital.  
Contributory factors included: 
• Active failures: execution failures, for example lapses; skill-based 
mistakes; and violations; 
• Individual factors, such as staff attitudes to counselling patients; 
• Patient factors, such as tiredness, frustration, becoming distracted and 
eagerness to return home; 
• Team factors, such as waiting for colleagues to perform tasks; 
• Task characteristics, such as the complex nature of discharging patients 
with medicines and internal patient transfer; 
• Lines of responsibility, for example the responsibility for discharging 
individual patients; 
• Staff workload, which may result in interruptions and limited time to 
conduct discharge conversations about medicines. Importantly, no 
defences were observed in this domain; 
• Management of staffing levels, for example on some days large number 
of patients was discharged and staffing did not change accordingly; 
• Communication systems, such as the ordering and internal delivery of 
medicines; 
• Scheduling and bed management.  
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Defences included: 
• Defences against active failures, such as using the discharge summary 
as a checklist; 
• Patient factors, such as note-taking during the discharge and having 
relatives present; 
• Individual factors, such as in-depth, person-centred conversations about 
medicines; 
• Team factors, such as a ward pharmacist charting discharge progress; 
• Equipment and supplies, such as medicines being available on the ward. 
• Training and education, such as having staff who were knowledgeable 
about cardiology medicines (nurses and pharmacists) on the wards; 
• Support from central functions, such as the presence of a ward 
pharmacist; 
• Communication systems, such as giving patients a written list of their 
medicines. 
It was clear that in some cases the safety of patients could be improved if the 
discharge took into account patients’ individual capabilities, for example a 
patient’s ability to take notes and absorb large amounts of complicated 
information. Discharge with medicines was also sometimes conducted with staff 
who had no prior involvement in the patient’s care. Risk was introduced when 
team pressures affected the timing of discharge and the amount of time the staff 
member had to spend with the patient explaining their medicines. At one of the 
sites hospital policy had introduced an additional patient transfer to a discharge 
lounge to wait to be discharged. The rationale for this transfer off the ward was 
to free-up bed space once it had been decided that the patient was well enough 
to go home. It is possible that giving the patients their medicines is not seen as 
a core element of their care, rather it is a process that must be completed 
before they can go home. The ward needs to see medicines as a central patient 
care issue with a demonstrable knock-on effect in primary care. 
Using the YCFF as a framework to exploring the safety of discharging patients 
with medicines presented some difficulties. First of all the tool was compiled 
from a systematic review which explored the contributory factors in patient 
safety incidents. To use the framework it was necessary to predict how   
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observations in some of the domains might impact on the safety of how 
medicines were managed by the patient, their families and healthcare 
professionals. For example, not encouraging patients to ensure their GP 
practice had been made aware of changes to their medicines may have 
resulted in some patients receiving prescriptions for incorrect medicines. 
Indeed, Chapter 6 will describe patients’ accounts of receiving incorrect repeat 
medicines sets after leaving hospital. However, at the time observations were 
made, the researcher could not be aware of whether subsequent patient safety 
incidents occurred. In addition, incorrect sets of medicines arriving on a ward to 
be given to a patient would qualify as a patient safety incident, even if the staff 
member at the ‘sharp end’ noticed and took action. However, observation at the 
‘sharp end’ made it extremely difficult to identify the contributory factors to such 
events. It was also difficult using observation alone to identify where latent 
organisational factors and latent external factors, such as internal and external 
policies, might have contributed to a potential patient safety incident. In the 
same way, observing and identifying safety culture is difficult and inferences 
needed to be made to assess how culture impacted on practice on site.  
This study has explored the variation in the practice of discharging patients with 
medicines from hospital. Recent NICE guidance on medicines optimisation 
states that medicines-related communication systems should include transfer 
information about what the patient, their family members and carers have been 
told about the patient’s medicines when their care is transferred between 
providers.72 It offers no suggestions about what patients should be told about 
their medicines when their care is transferred, although it does emphasise that 
medicines optimisation should be patient-centred. This lack of detail in external 
policies is reflected in the internal policies of both hospital sites, which also do 
not give guidance about what patients should be told about their medicines 
when they are leaving the care of the hospital with their medicines in front of 
them and an HCP at their side. Whilst we do not know from this study what 
patients were told about their medicines during their stay, for some patients the 
point of discharge may be the first time they had been talked through their 
medicines as a group and in a systematic fashion. The depth of preparation 
patients receive to self-manage their medicines is likely to impact on their 
capability to safely manage them and also their confidence in them once they   
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have left hospital. Given that patients have reported feeling confused by their 
medicines after discharge and can find it difficult to co-ordinate support in 
primary care, additional time spent talking about sets of medicines with 
caregivers may help enhance their abilities with their medicines and reduce 
both re-admission and preventable harm. Chapter 6 will describe how confused 
about their medicines some patients were after leaving hospital. 
Medicines information has been found to enhance understanding and reduce 
anxiety about side effects.317 The number of patients being told about side 
effects in this study was low compared to other aspects of their medicines, such 
as medicines purpose. Nationally, there is a similar picture: the most recent 
CQC/NHS in-patient survey reported that 41% of patients who had TTO 
medicines were not told about medicines side effects to look out for.318 There is 
debate about the impact of explaining side effects of medicines to patients; and 
the ‘nocebo effect’ of giving patients negative expectations about their 
medicines has been discussed in depth.319–321 However, explaining effects to 
look out for in a patient-centred way, exploring the level of detail that is right for 
each patient and empowering them to seek help should they wish to or need to, 
might contribute to the safe management of their treatment.322 Giving structured 
information about levels of risk may also be an important step.323,324 
In this study, the task of giving patients their discharge medicines occurred just 
before they left the ward and medicines education activities at this time 
concerning their medicines varied from care-giver to care-giver, and as such it 
was an individual factor in sub-optimal practice. Although all patients were given 
written information, not all staff highlighted this information to patients, which 
may explain why patients in another study reported not receiving written 
information.144 On the ward, the staff discharge style seemed to be the 
individual choice of the staff member, mediated by the relationship between the 
staff member and the patient, and the pressures on the individual staff 
members. The discharge lounge appeared to be highly process-driven: its focus 
was on completing the process of discharging the patient by handing them their 
medicines and requesting their signature on the discharge summary. From the 
observer’s perspective, it appeared to be a task that occurred after the ‘caring’ 
duty of the hospital had ended, despite the best intentions of the staff on duty. 
In this way, the task characteristic became a contributory factor because it was,   
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in many cases, detached from other care tasks and managed discretely. The 
fact that patients were transferred to the discharge lounge risked their safety as 
it constituted an additional gap in the continuity of care;41 and so required an 
additional hand-off of care to discharge lounge staff.44 
Patient factors were evident during many observations: many patients appeared 
to be anxious to be discharged and perhaps did not pay full attention to the list 
of medicines that was read to them. They had, after all, been in hospital after 
experiencing a health crisis or intervention. In 2005, a multi-agency report 
identified that giving patients medicines just before discharge was a problem in 
the patient journey because it allowed no time for meaningful patient education 
or advice.92 In this way, giving patients their medicines and helping them 
understand them is not perceived as an integral part of the care that the hospital 
offers. Providing more in-depth support with medicines at discharge and 
bridging the gap in care by continued support after discharge may have a 
significant impact on hospital resources and it is debatable whether the time, 
skills and money are available to do so.55  
 
External policy for patients with cardiology conditions to access the clinical 
services of community pharmacy did not, in most cases, impact on what they 
were told at discharge. Patients were signposted to their community pharmacy 
for help with their medicines only twice. This suggests a continued lack of 
integration of community pharmacy into the discharge pathway in a role 
supporting medicines use. Nevertheless, community pharmacists can play a 
valuable medicines management role for patients after discharge.129,325,326 
Recent guidance from the RPS Innovators Forum suggests that hospital 
patients should be routinely referred to community pharmacy services after their 
discharge to support their medicines use,327 not least because community 
pharmacy can help identify problems patients may have with their medicines 
after they have left hospital.125–127,129,195 The role of community pharmacy after 
discharge is explored in more detail in Chapter 6. Patients were also told that 
their GP would be informed that they had been in hospital, although they were 
not given any additional information about what to expect (or not to expect) from 
their GP practice. A clearer care pathway set out to patients at discharge would 
help them understand more about who is responsible for their ongoing care and 
who they should seek support from after they arrive at home, especially if they   
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have co-morbidities which may increase their chances of readmission.328,329 
 
Who should talk to patients about their discharge medicines?  
In many instances in this study a nurse who knew the patient and had been 
involved in their care conducted the discharge. If the staff member knows the 
patient then it is likely that their understanding of that patient will impact on their 
ability to provide person-centred as well as safe care. For example, the patient 
may have previously expressed preferences or concern about medicines to staff 
on the ward that other staff members might not be aware of. Much has been 
written about the concept of ‘knowing the patient’. In the 1970s patterns of 
knowing the patient were described by Carper,330 encompassing professional 
skills; professional knowledge and personal knowledge of the patient. A later 
review of the literature subsequently identified several key areas of knowing the 
patient:331 
• Understanding and treating the patient as an individual – which upholds 
a professional nursing value; 
• This results in individualised care; 
• It is an integral part of nursing decision making; 
• That the amount of time the nurse can have with the patients affects how 
well they can know them, which is influenced by staffing policy; 
• That it enhances outcomes and earlier recovery. 
Further work drew a distinction between ‘knowing’ the patient through 
information sources such as the medical records, a personal care record used 
by different staff on the ward who care for the patient, and other sources of 
information such as verbal information from the patient and their family, and 
verbal information, such as hand-offs, from colleagues.332 Staff on the wards in 
this study often had more time to ‘know the patient’ through using these sources 
of information than staff in the discharge lounge. They also had more specialist 
knowledge of cardiology conditions and knowledge of the medicines prescribed 
to treat them, which constitutes a higher level of specific clinical expertise. Staff 
in the discharge lounge had fewer resources to rely on, such as hand-off 
information and medical notes. Not knowing the patient is more aligned to a 
process led, managed model of healthcare,333 which reflects the nature of the 
observations made in the discharge lounge at Site 1. Indeed, recent work in the   
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area of knowing the patient acknowledges the challenges posed by 
discontinuity of care and staff workload in acute healthcare environments which 
mean the process of knowing patients is not supported.334 
This chapter has explored how patients are discharged from hospital with their 
medicines. It has set the scene describing how safely the hospital prepared 
patients as they were discharge to manage their medicines once they were 
back at home. Using Social Network Analysis, Chapters 5–7 will explore how 
patients and their medicines are subsequently managed once they have been 
transferred back to primary care. In the first instance the structure of the 
patients’ medicines management networks will be described through ego-
network analysis. 
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Chapter 5 – The structure of patients’ ego-networks 
5.1 Introduction 
This chapter presents the results of the structural analysis of 61 patients’ 
medicines management ego-networks. It is based on data collected in patient 
diaries (n=39) and augmented with semi-structured interviews (n=60) and 
network visualisation six weeks after hospital discharge. 
The results are in the following four sections: ego network size; alter roles in 
patients’ ego networks; ego-network connectedness; and medicines 
management alter value to patients. To aid interpretation of this chapter 
definitions of some of the commonly used terms in SNA are detailed below: 
Actor   An individual (a patient or a contact of a patient)  
Alter  Another individual present in the ego’s network 
Betweenness A measure of the extent to which an actor connects other 
actors 
Broker   An individual who connects other individuals to each other 
Degree  The number of ties of one individual 
Density   A measure of the proportion of connections in the network 
Dyad   Two individuals who are connected 
Ego network  The personal network of one individual (patient) 
Ego   The individual (patient) who is the focus of interest 
Homophily The similarity between actors in a network 
Sociogram A visualisation of the network showing individuals and the 
connections between them 
Ties    Connections between individuals 
 
5.2 Patients’ ego-network size 
The mean age of the achieved sample of 61 patients was 62.9 (SD 10.7) and 
their ages ranged from 35–80. At Site 1 patients’ mean age was 60.4 (SD 12.0) 
with an age range of 35–79; at Site 2 the sample mean age was 64.9 (SD 9.1) 
with an age range of 44–80. Patients reported different personal and 
professional alters fulfilling medicines management functions during the post-
discharge period. Together, patients reported 392 medicines management   
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alters in networks of different sizes. Individual patients reported between 1–15 
alters. 
The ‘degree’ of a network is the number of ties recorded for one individual. It is 
possible for directed networks to measure ‘in-degree’, which is the number of 
inward connections present, and ‘out-degree’, which is the number of outgoing 
connection present. However, patients’ ego-networks in this study were 
undirected and so a total degree measure is appropriate. Overall, patients 
recorded a mean degree of 6.50 (2.72) and a median of 6. Men had a mean 
network degree of 6.30 (2.76) and a range of 1-15 alters whilst women had a 
slightly larger mean degree of 7.0 (SD 2.63) and a range of 4-14 alters. Males 
at Site 1 recorded a mean degree of 5.9 (SD 2.91) and a median of 5. Females 
at Site 1 recorded a mean degree of 6.22 (SD 2.39) and a median of 5. Males at 
Site 2 recorded a mean degree of 6.55 (SD 2.58) and a median of 6.5. Females 
at Site 2 recorded a mean of 7.67 (SD 2.87) and a median of 6.  
Two-tailed independent samples t-tests indicated there was no significant 
difference in the degree recorded between males and females (t = -1.108 (58), 
p = 0.313) or between people at different hospital sites (t = -1.401 (58), p = 
0.166). Using a Pearson correlation calculation, no significant correlation was 
found between ego network degree and patient age (r = -0.149, p = 0.251). This 
suggests that patients had similar numbers of network alters regardless of the 
hospital site they were discharged from and their age and gender. It is likely that 
other factors, such as their health status, for example their number of co-
morbidities – may influence their network degree. A diversity score was also 
calculated for each patient’s ego-network through determining the number of 
unique alter types in their networks. This is presented in Table 20, along with 
the size and mean degree for patients by site and gender. There was a 
difference in the overall degree mean and the diversity mean of 0.96 which 
indicates that whilst there is duplication of professional roles in patients’ 
networks which may indicate a gap in continuity of care, that duplication is 
limited.   
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Table 20: Ego-network measures by size and mean degree 
 All Site 1 
male 
Site 2 
male 
Site 1 
female 
Site 2 
female 
Number of patients 61 21 22 9 9 
Number of alters 392 123 134 56 79 
Professional degree range 1-9 1-9 2-8 2-8 3-7 
Lay degree range 0-8 0-6 0-7 0-5 0-8 
Professional degree mean (SD) 4.62 (2.04) 4.38 (2.59) 4.68 (1.78) 4.45 (1.94) 5.22 (1.30) 
Lay degree mean (SD) 1.80 (1.70) 1.43 (1.43) 1.86 (1.61) 1.89 (1.45) 2.44 (2.55) 
Diversity range 1-12 1-12 2-9 3-7 4-9 
Mean diversity 5.40 (2.00) 4.90 (2.32) 5.68 (1.93) 4.89 (1.17) 6.33 (1.80) 
 
Each patient had contact with at least one healthcare professional or healthcare 
support staff member, whilst at both sites some patients reported no friends and 
family in their medicines management networks. There were high levels of 
variation in the degree of patients’ ego-networks presented in composite form in 
Figure 23 and Figure 24, which are sets of sociograms depicting the ego 
networks of patients discharged from Site 1 and Site 2 respectively. They 
visualise the patients and their professional and personal network alters and 
demonstrate the variation in degree and composition within patients’ ego-
networks. Males at Site 1 had the widest range of alters and the widest range of 
networks diversity scores. Overall, patients reported more professional than 
personal alters in their medicines management ego-networks. 
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Figure 23: Composite sociogram of 30 ego-networks of patients discharged from Site 1. Triangles = 
patients; lines = ties; green shapes represent the networks of female patients; four-sided 
shapes=professional contacts; five-sided shapes = lay contacts. 
Green ego-network = a female patient’s ego-network 
Red ego-network = male patient’s ego-network 
 Triangle (red (male) or green (female)) = patient 
 Four sided shape (red or green) = professional contact 
 Five-sided shape (red or green) = lay contact 
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Figure 24: Composite sociogram of 31 ego-networks of patients discharged from Site 2. Triangles = 
patients; lines = ties; green shapes represent the networks of female patients; four-sided 
shapes=professional contacts; five-sided shapes = lay contacts. 
 
 
 
 
 
 
 
5.3 Alter types in patients’ ego-networks 
Alters were classified into one of ten professional (8) or lay (2) groups, as 
described in Chapter 3. The composition of patients’ ego-networks by site and 
gender is presented in Figure 25 and discussed in detail in sections 5.3.1 and   
Green ego-network = a female patient’s ego-net 
Red ego-network = a male patient’s ego-net 
 Triangle (red or green) = patient 
 Four sided shape (red or green) = professional contact 
 Five-sided shape (red or green) = lay contact 
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5.3.2. GPs made up nearly one sixth (14.5%) of patients’ medicines 
management network alters, and 11% were community pharmacists. Specialist 
cardiac rehabilitation or heart failure nurses comprised nearly a tenth (9.4%) of 
all alters. Friends and family other than spouses were the largest single group 
of alters. Spouses of male patients appear more frequently in medicines 
management networks than the spouses of female patients. Females at Site 1 
had contact with a greater proportion of GPs and a smaller proportion of 
community pharmacists than other patients whilst male and female patients at 
Site 2 reported a lower proportion of hospital doctors playing medicines 
management roles. 
 
Figure 25: Ego network alter roles by site and gender. 
Different personal and professional medicines management alters are explored 
in more detail in the following sections, initially with a description of patients’ 
professional network alters.  
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5.3.1 Professional (formal) healthcare alters 
Several different healthcare professions were reported by patients as being part 
of their medicines networks and most of these roles were clinical, including 
GPs, GP practice nurses, hospital nurses, and hospital doctors. Patients also 
had contact about their medicines with community pharmacists and community-
based services, such as community nurses. Many patients had contact with 
specialist nurses, such as cardiac rehabilitation nurses, heart failure nurses, 
COPD nurses, stroke nurses and warfarin nurses. In total 61 patients had 
contact with 282 professional alters.  
Nurses (other than specialist cardiology nurses) were the most commonly 
reported professional alter type. Over half the sample (36) had contact with a 
total of 64 nurses involved in medicines management. These nurses were GP 
practice-based, clinic-based, but also hospital-based. GPs were the next most 
commonly reported HCP network member type: 45 patients recorded direct 
contact with a total of 57 GPs, indicating that a quarter of the sample had no 
direct contact with a GP in the six weeks after they left hospital. Community 
pharmacy was the next most common category of professional alter: again, just 
over half (36) of patients recorded contact with 43 community pharmacists. 
Cardiac rehabilitation nurses, categorised separately to other nurses, were 
present in the networks of 28 patients who had contact with 37 cardiac 
rehabilitation and heart failure nurses concerning their medicines. 
Some patients reported contact with multiple HCPs in the same profession, for 
example they spoke to or saw more than one GP whilst others interacted about 
their medicines with more than one community pharmacist, as indicated in the 
individual sociograms in Figure 26 and Figure 27 visualising the network of 
Patient 1.33, who had contact with four GPs about medicines during the data 
collection period, and Patient 2.21 who had contact with two community 
pharmacists. 
Other patients recalled no direct contact relating to their medicines with primary 
care providers, such as community pharmacists and GPs, in the period 
following their discharge from hospital. In some cases patients used proxy 
contacts, such as a GP receptionist who would relay messages, or pharmacy 
counter assistants. Although the majority of patients had contact with a GP,   
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many patients described their difficulties accessing a GP, even though they 
thought they would benefit from an appointment. 
 
Figure 26: Sociogram of the ego-network for patient number 1-33. 
 
 
Figure 27: Sociogram of the ego-network for patient number 2.21.  
A further type of professional contact described by patients was healthcare 
support staff. These contacts were pharmacy counter assistants, GP 
receptionists, pharmacy delivery drivers delivering medicines to patients’ 
homes, or hospital administration staff.  Forty patients had contact with 57 
healthcare support staff members. Patients often experienced direct contact 
with healthcare support contacts in the course of accessing the instrumental 
[practical aid] functions of other healthcare professionals. For example, they   
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would have contact with GP receptionists, pharmacy counter assistants and 
pharmacy delivery drivers delivering to patients’ homes in order to access 
medicines provided by GPs and pharmacists or to arrange appointments. 
Patients’ professional contacts are shown in the composite sociograms in 
Figures 28–31 for males and female patients at Sites 1 and 2. They 
demonstrate the variation in experience of patients accessing professional 
medicines management services. For example, one male patient at Site 1 in 
Figure 28 used the healthcare services of two cardiac rehabilitation nurses 
(marked in cyan), but had no contact with any other professional alters. In the 
same figure, one patient’s only contact after discharge was with a pharmacy 
assistant. Another male patient, in this case at Site 2, accessed their GP 
(marked in black) and a community pharmacist (marked in grey) whilst a further 
male patient at Site 2 accessed their GP and a cardiac rehabilitation nurse. 
5.3.2  Personal (informal) ego-network alters 
In addition to their professional medicines management alters, patients reported 
the presence of family members and friends in their medicines management 
networks. Forty-nine patients had medicines-related contact with 93 friends and 
family members. Family contacts included spouses, children, parents and 
siblings, whilst friends and neighbours and extended family members were also 
included in patients’ medicines management networks. More distant relatives 
such as in-laws and cousins also featured along with other people patients 
knew but were not close to, for example acquaintances at church. Close 
relatives often lived nearby or with patients, and sometimes patients had moved 
in with relatives during their recovery. Figure 32 shows the sociogram of Patient 
2.20. The parents of the patient were named as medicines management 
contacts and this patient had moved in with her parents after hospital discharge 
for temporary support whilst she waited for further treatment. 
Some patients’ personal alters also had healthcare experience, or were 
perceived by the patient to have such experience. Seventeen patients had 
contact with 17 such alters. Examples included wives who were nurses or 
former nurses, friends or relatives who were GPs, or extended family members 
and neighbours who were perceived to have medicines knowledge because of 
their current or former roles in health or social care.  
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Figure 28: Site 1 male patients’ professional networks. 
 
 
Figure 29: Site 2 male patients' professional networks. 
 
Figure 30: Site 1 female patients' professional networks. 
 
 
Figure 31: Site 2 female patients' professional networks  
 Black = GP 
 Grey = Community 
pharmacist 
 Green = Hospital doctor 
 Cyan = Cardiac rehab / 
heart failure nurse 
Pink = other nurse 
Yellow  = Pharmacy    
staff 
 Red = GP receptionist 
 Blue = Other 
 White = Patient 
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Figure 32: Sociogram of the ego-network for patient number 2.20.  
For example, patients talked about family members who had managed care 
homes who knew about medicines because of their care management 
experience or of neighbours who were nurses. 
Figures 33–36 are composite sociograms of the personal networks of male and 
female patients at different sites. They show personal network members with 
and without healthcare experience and demonstrate how some patients were 
isolated from personal medicines management contacts, whilst others had 
spousal and other friend and family network presence. 
5.3.3 Ego similarity with personal alters 
The concept of homophily in informal networks was explored between egos and 
their personal alters. Of the 43 male patients’ 68 personal alters 70.6% (48) 
were female whilst 29.4% (20) were male. Of the 18 female patients’ 42 
personal alters, 54.8% (23) were female and 45.2% (19) were male. This 
indicates that there is a greater degree of gender homophily in female patients’ 
personal networks than in males’ personal networks.  
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Figure 33: Site 1 male patients’ personal networks. 
 
 
Figure 34: Site 1 female patients’ personal networks. 
 
 
Figure 35: Site 2 male patients’ personal networks. 
 
 
 
Figure 36: Site 2 female patients’ personal networks.  
 Patient 
 Blue = Spouse 
 Other friends and family 
 Patient 
 Four-sided shape = 
Personal contact 
 Five-sided shape = 
personal contact with healthcare 
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To confirm this a gender E-I index was calculated,335 which produced an overall 
index score of 0.42 for males and -0.01 for females. It is calculated by 
comparing the number of similar gender connections to the number of different 
gender connections. The calculation is positive when a group is dissimilar and 
negative when it is similar. The more positive score for males in the sample 
indicates how men reported women more frequently playing a role in medicines 
management than women reported men doing so. 
5.4 Ego-network connectedness 
This section explores patient perceptions of the connections between alters in 
their networks. During interviews, patients were asked if they perceived that 
their network alters were in contact with each other regarding their medicines. 
As data presented in Chapter 6 demonstrates, patients drew a distinction 
between passive receipt of information about their medicines and more active 
communication about them and their treatment. Patients’ responses were 
analysed to give a measure of how connected their medicines management 
networks were and how much they acted themselves to join up their networks. 
The following analysis was conducted on the ego networks of 60 patients who 
were interviewed. One patient was unavailable for interview. 
5.4.1 How connected are patients’ ego networks? 
The number of ties in an ego network is a measure of the number of 
connections among its alters (not including the ego). Because the ties are 
undirected, ties between alters are counted twice, representing two ties per 
connected alter pair. The mean number of ties perceived by patients in their 
networks was 5.28 (SD 9.26). The median and mode number of ties were both 
2, indicating patients’ perceptions of mostly limited contact amongst their 
network members about their medicines. A quarter of the sample (15) perceived 
no ties between their medicines management contacts and more men (11) than 
women (4) reported no ties between their network members. The maximum 
number of network ties reported was 58. These ties were perceived amongst 
the family members of a female patient whose brothers, sisters and mother all 
took similar medicines for their cardiology conditions. Figure 37 is a sociogram 
of this ego network clearly indicating the large number of ties amongst the 
patient’s family members. This patient also perceived ties between two  
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professional members of their networks, in this instance between the cardiac 
rehabilitation nurse and her GP. No connections were perceived between the 
other professional members of her medicines management network, including 
her community pharmacist. 
 
Figure 37: The ego-network of patient number 2.53 with 58 network ties. 
Many patients perceived limited or no connectedness in their ego networks and 
these patients’ networks often contained many alters. To illustrate this, Figure 
38 is a sociogram of the ego network of Patient 1.1. This male patient recorded 
two healthcare professional alters and three personal alters in this network but 
perceived no ties between any of those alters. Patients tended to report limited 
connectedness between professional members of their networks, however 
patients perceived cardiac rehabilitation nurses and heart failure nurses more 
often than others to be in contact with other healthcare professionals 
concerning patients’ medicines (see section 5.3.4). Other nurses and 
community pharmacists and other pharmacy staff were perceived by patients to 
be actively in contact with others less often.  
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5.4.2 Ego network density 
The ‘density’ of a network is a single measure of how connected it is. Density is 
calculated by dividing the number of ties in the network (not including the ego) 
by the possible number of ties, giving a measure of the proportion of potential 
ties that are present. Tables 21–24 show the density of each patient’s ego-
networks along with the number of ties in their networks and the number of 
potential ties. They show that on average women perceive slightly denser (more 
connected) 
 
Figure 38: A sociogram of the ego network of Patient 1.1. 
networks than men, although a series of two-tailed independent sample t-tests 
indicated no significant differences in the perceived density of men’s and 
women’s ego networks (t (58) = -0.979, p = 0.339 (equal variances not 
assumed). There were also no significant differences between the ego networks 
of those discharged from different hospital sites (t (58)= 0.798, p = 0.428). 
Using a Pearson correlation calculation, no significant correlation was found 
between ego network density and patient age (r = -0.203, p = 0.119). 
Patients’ ego-networks were further analysed for the concept of ‘betweenness’. 
An ego is between other alters if they are positioned on the path between them. 
For example, if a patient perceives that they themselves are the conduit 
between their GP and community pharmacist then they are ‘between’ those two 
alters. The calculation of ‘normalised betweenness’ takes into account network   
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size to allow comparisons between networks. A patient who perceived no 
contact at all amongst alters in their network would have a maximum 
normalised betweenness measure. For example, this was the case for Patient 
1-1 represented in Figure 38, in which all connections between alters are 
through the ego. Table 25 presents the betweenness range calculations for 
patients by site and gender and normalized betweenness means. Overall 
patients’ networks were calculated to have high levels of betweenness, 
indicating their perceptions of poor connectedness between those who play a 
role in managing their medicines. Independent samples t-tests indicated no 
significant differences between males and females (t (57) = 0.830 (57), p = 
0.415) and discharge site (t = 0.686 (57), p=0.492). Using a Pearson correlation 
calculation, no significant correlation was found between normalised 
betweenness and patient age (r = 0.128, p = 0.333).  
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Table 21: The density of male patients' ego networks at Site 1. 
Patient Number of ties Number of possible ties Density % 
Patient 1-1 0 20 0.00 
Patient 1-10 6 42 14.29 
Patient 1-11 8 20 40 
Patient 1-12 0 20 0 
Patient 1-18 8 110 7.28 
Patient 1-28 4 20 20.00 
Patient 1-3 4 30 13.33 
Patient 1-34 28 210 13.33 
Patient 1-38 4 20 20.00 
Patient 1-4 7 42 16.67 
Patient 1-41 2 42 4.76 
Patient 1-45 2 20 10.00 
Patient 1-46 0 0 0.00 
Patient 1-47 2 12 16.67 
Patient 1-49 0 6 0.00 
Patient 1-5 0 20 0.00 
Patient 1-51 2 12 16.67 
Mean (SD) 4.35 (6.48) 35.30 (45.89) 11.04 (7.96) 
 
 
 
 
 
 
Table 22: The density of male patients' ego networks at Site 2. 
Patient Number of ties Number of possible ties Density % 
Patient 2-1 4 72 5.56 
Patient 2-10 34 132 25.76 
Patient 2-11 0 6 0.00 
Patient 2-12 8 42 19.05 
Patient 2-13 0 6 0.00 
Patient 2-14 6 42 14.29 
Patient 2-15 0 42 0.00 
Patient 2-16 4 42 9.52 
Patient 2-18 2 30 6.67 
Patient 2-21 2 30 6.67 
Patient 2-23 2 20 10.00 
Patient 2-24 0 12 0.00 
Patient 2-26 4 30 13.33 
Patient 2-33 2 72 2.78 
Patient 2-35 18 90 20.00 
Patient 2-4 2 30 6.67 
Patient 2-5 0 6 0.00 
Patient 2-50 6 56 10.71 
Patient 2-52 2 30 6.67 
Patient 2-6 4 56 7.14 
Patient 2-8 10 90 11.11 
Patient 2-9 0 2 0.00 
Mean (SD 5.00 (7.73) 42.64 (32.72) 8 (7.23) 
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Table 23: The density of female patients' ego networks at Site 1. 
Patient Number of ties Number of possible ties Density % 
Patient 1-7 2 12 16.67 
Patient 1-8 14 56 25 
Patient 1-9 6 90 6.67 
Patient 1-27 2 12 16.67 
Patient 1-33 4 72 5.56 
Patient 1-40 8 20 40 
Patient 1-44 0 30 0 
Patient 1-50 0 12 0 
Patient 1-55 2 42 4.76 
Mean (SD) 3.56 (3.58) 37.56 (33.06) 12.70 (16.33) 
 
 
Table 24: The mean betweenness measures in the ego networks of patients 
by site and gender. 
 Betweenness range Mean normalised 
betweenness (SD) 
All 0 – 79.5 87.28 (12.80) 
Males Site 1 0 – 79.5 86.53 (9.60) 
Females Site 1 5 – 51.0 85.08 (20.56) 
Males Site 2 1 – 39.5 90.01 (10.60) 
Females Site 2 3.5 - 62 84.39 (15.02) 
 
 
 
 
Table 25: The density of female patients' ego networks at Site 2. 
Patient Number of ties Number of possible ties Density % 
Patient 2-17 4 72 5.56 
Patient 2-20 2 56 3.57 
Patient 2-22 8 56 14.29 
Patient 2-25 2 30 6.67 
Patient 2-29 2 56 3.57 
Patient 2-3 4 12 33.33 
Patient 2-30 8 42 19.05 
Patient 2-34 0 20 0.00 
Patient 2-53 58 182 31.87 
Mean (SD) 9.78 (18.29) 58.44 (50.23) 13.10 (12.50) 
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A brokerage measure calculated the extent to which the ego acts as a broker – 
or a go-between – in their network. A brokerage score measures the number of 
pairs in the network that are not connected; the normalised brokerage score 
divides brokerage by the number of pairs in the network. Egos who perceived 
no connectedness in their networks have high normalised brokerage scores 
because all the alters in the network must use the ego as a broker. Figure 38 
depicting the ego network of Patient 1.1 demonstrates this brokerage role, in 
this instance the patient perceives themselves as a broker for all their alters so 
has a normalised brokerage score of 1. Patient 1.40 has the lowest normalised 
brokerage score of 0.60 and their ego network is depicted in the sociogram in 
Figure 39. This patient reported her cardiac rehabilitation nurse to have been in 
contact with her GP about her medicines and her husband, who managed her 
medicines for her, who also had contact with her GP. Her son also kept in 
contact with her husband concerning her medicines. Her community 
pharmacist, for whom the patient acts as a broker, is isolated in this ego 
network.  
 
Figure 39: A sociogram depicting the ego-network of patient number 1.40 with a brokerage score of 
0.60.  
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Data were then analysed for the number of ‘weak components’ present in each 
patient’s ego network. Weak components are a group of actors (or an individual 
actor) who are connected to each other and the ego, but not to others in the 
network. For example, if the patient has a connection to a GP and a cardiac 
rehabilitation nurse who are in turn are connected to each other, but they are 
not connected to any other actors in the network then they form a weak network 
component. This is important because it gives an indication of the number of 
groups of personal and professional contacts patients’ perceived as not being in 
contact and therefore the patient may have needed to take action to join them 
together. Groups of actors in weak components can be referred to as ‘cliques’. 
Patients’ networks had a mean of 4.48 (1.64) weak components and median of 
4 weak components. 
Patient 1.18 reported eight weak components in her network and Figure 40 is a 
sociogram depicting that network. In this instance the clique comprising the 
patient, the cardiac rehabilitation nurse and the hospital doctor, and the clique 
comprising two of the patient’s daughters and her nephew, form two weak 
components. Each of the other isolated alters form six further weak 
components. 
Patient 2.30 reported three weak components in her network which are 
represented in the sociogram in Figure 41. In this case the patient perceived 
connectedness between many members of her network with a large group of 
healthcare professionals and her daughter forming one weak component whilst 
the community pharmacist and the pharmacy assistant form two further weak 
components. 
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Figure 40: A sociogram of the ego-network patient number 1.18 showing eight weak components. 
 
 
 
Figure 41: A sociogram of the ego-network of patient number 2.30 showing three weak components 
and isolated community pharmacy staff.  
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Brokerage and weak component calculations are presented for all patients in 
Tables 27–30. A series of two-tailed independent sample t-tests and Pearson 
correlation tests indicated that there were no significant differences between 
males and females or between patients discharged from different sites. The 
results of these tests are shown in Tables 31–32. The calculations indicate very 
loosely connected networks with patients perceiving themselves in strong 
brokerage roles between their network alters. Patients’ mean brokerage was 
18.25 (SD 16.53) with a mean normalised brokerage calculation of 0.88 (SD 
0.15). On average there were 4.48 (SD 1.64) weak components in each 
patients’ ego network and 74.70% (SD 20.60) of patients’ ego networks 
comprised weak components. Weak components in the networks indicated the 
extent to which patients themselves bridged groups of personal and 
professional alters. 
5.4.5 Density measures of professional alters 
Calculations were made for the density of other HCP and healthcare support 
alters in patients’ ego-networks to offer a comparative measure of how 
integrated patients perceive different types of HCP and healthcare support are 
in their medicines networks. The mean value for each group is presented in 
Table 26. Cardiac rehabilitation nurses were perceived to be the most 
integrated professional network members followed by GPs and hospital doctors. 
It is likely that the density measures for GPs and hospital doctors are increased 
by perceived contact with cardiac rehabilitation nurses because these ego-
networks are undirected. Community pharmacy staff, GP receptionist and other 
nurses are the least connected HCPs, as perceived by patients. These values 
indicate the extent to which patients believe their care to be co-ordinated by the 
professionals involved in it. 
Table 26: Density measure for professional groups 
Role Average density 
Cardiac rehabilitation / Heart failure nurses 0.59 
GPs 0.48 
Hospital doctors 0.42 
Community pharmacists 0.31 
GP practice nurses 0.30 
Community pharmacy drivers 0.27 
GP receptionists 0.25 
Other nurses 0.23 
Community pharmacy staff 0.10 
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Table 27: Brokerage and weak component scores for males at Site 1. 
Patient Brokerage Normalised  
brokerage 
Weak 
components 
Proportion of  
weak 
components 
Patient 1-1 10 1.00 5 100.00 
Patient 1-10 18 0.86 5 71.43 
Patient 1-2 9 0.90 4 80.00 
Patient 1-20 5 0.83 3 75.00 
Patient 1-23 10 1.00 5 100.00 
Patient 1-28 8 0.80 3 60.00 
Patient 1-3 13 0.87 4 66.67 
Patient 1-34 91 0.87 5 33.33 
Patient 1-38 8 0.80 3 60.00 
Patient 1-4 17.5 0.83 3 42.86 
Patient 1-41 20 0.95 6 85.71 
Patient 1-45 9 0.90 3 60.00 
Patient 1-46 0 0.00 1 100.00 
Patient 1-47 5 0.83 3 75.00 
Patient 1-49 3 1.00 3 100.00 
Patient 1-5 10 1.00 5 100.00 
Patient 1-51 5 0.83 3 75.00 
Patient 1-7 5 0.83 3 75.00 
Patient 1-8 21 0.75 4 50.00 
Patient 1-9 42 0.93 7 70.00 
Mean 15.48 0.84 3.9 74 
 
 
 
 
Table 28: Brokerage and weak component scores for males at Site 2. 
Patient Brokerage Normalised 
brokerage 
Weak 
components 
Proportion of 
weak 
components 
Patient 2-1 34 0.94 7 77.78 
Patient 2-10 49 0.74 4 33.33 
Patient 2-11 3 1.00 3 100.00 
Patient 2-12 17 0.81 3 42.86 
Patient 2-13 3 1.00 3 100.00 
Patient 2-14 18 0.86 4 57.14 
Patient 2-15 21 1.00 7 100.00 
Patient 2-16 19 0.90 5 71.43 
Patient 2-18 14 0.93 5 83.33 
Patient 2-21 14 0.93 5 83.33 
Patient 2-23 9 0.90 4  
 
Patient 2-24 6 1.00 4 100.00 
Patient 2-26 13 0.87 4 66.67 
Patient 2-33 35 0.97 8 88.89 
Patient 2-35 36 0.80 4 40.00 
Patient 2-4 14 0.93 5 83.33 
Patient 2-5 3 1.00 3 100.00 
Patient 2-50 25 0.89 5 62.50 
Patient 2-52 14 0.93 5 83.33 
Patient 2-6 26 0.93 6 75.00 
Patient 2-8 40 0.89 6 60.00 
Patient 2-9 1 1.00 2 100.00 
Mean 18.82 0.92 4.64 76.77 
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Table 29: Brokerage and weak component scores for females at Site 1. 
Patient Brokerage Normalised 
brokerage 
Weak 
components 
Proportion of 
weak 
components 
Patient 1-11 6 0.60 2 40.00 
Patient 1-12 10 1.00 5 100.00 
Patient 1-18 51 0.93 8 72.73 
Patient 1-27 5 0.83 3 75.00 
Patient 1-33 34 0.94 7 77.78 
Patient 1-40 6 0.60 2 40.00 
Patient 1-44 15 1.00 6 100.00 
Patient 1-50 6 1.00 4 100.00 
Patient 1-55 20 0.95 6 85.71 
Mean 17 0.87 4.78 76.80 
 
Table 30: Brokerage and weak component scores for females at Site 2.  
Patient Brokerage Normalised 
brokerage 
Weak 
components 
Proportion of 
weak 
components 
Patient 2-17 34 0.94 7 77.78 
Patient 2-20 27 0.96 7 87.50 
Patient 2-22 24 0.86 4 50.00 
Patient 2-25 14 0.93 5 83.33 
Patient 2-29 27 0.96 7 87.50 
Patient 2-3 4 0.67 2 50.00 
Patient 2-30 17 0.81 3 42.86 
Patient 2-34 10 1.00 5 100.00 
Patient 2-53 62 0.68 6 42.86 
Mean 24.33 0.87 5.11 69.09 
 
 
Table 31: t-test results for brokerage and weak component scores by site 
and gender. 
 Brokerage Normalised 
brokerage 
Weak 
components 
Proportion 
of weak 
components 
Site 
 
t(58) = -1.048 
p = 0.299 
t(58) = -0.798 
p = 0.428 
t(58) = -1.432 
p = 0.157 
t(58) = 0.61 
p = 0.952 
Gender 
 
 
t(58) = -0.736 
p = 0.465 
t(58) = 1.228 
p = 0.224 
t(58) = -1.437 
p = 0.156 
t(58) = 0.427 
p = 0.671 
 
 
 
 
Table 32: Pearson's correlations for brokerage and weak component scores 
and patient age. 
 Brokerage Normalised 
brokerage 
Weak 
components 
Proportion 
of weak 
components 
Age 
 
r = -0.051 
p = 0.697 
 
r = 0.203 
p =0.119 
r = -0.053 
p =0.672 
 
r = 0.184 
p =0.159 
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5.5 Medicines management alter value to patients 
During interviews, patients were asked to rate the value of each alter to them in 
managing their medicines. They did so by placing the contact on an egocentric 
mapping tool made up of concentric circles marked with numbers 1–4.  If they 
positioned alters closer to the centre they perceived them to be more valued. 
The concept of value was also explored with patients, who explained why they 
had placed certain alters in higher value positions of their maps. Their decisions 
about high value were made either because the alter was essential to them in 
providing or organising medicines, because they were perceived as efficient, 
because they were at the top of patients’ perceived professional hierarchy, or 
because patients perceived that the alter had time for them. Ego-networks for 
all patients are presented in the sociograms in Appendix 3 in which the lines 
connecting egos to alters are thicker where the tie was reported as more valued 
by each ego. 
Patients valued their friends and family with healthcare experience more highly 
than other alters in their network. Healthcare professionals and patients’ friends 
and family members without healthcare experience were valued similarly highly, 
whilst healthcare support staff were the least valued category of alter. The radar 
plot in Figure 42 shows the comparative mean value of alter types to patients. 
 
Figure 42: A radar plot showing the comparative mean value of alter types to patients.  
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Patients’ ratings of their alters were dichotomised to give a binary indication of 
high and low values. Figure 43 is the proportion of alters by type who were 
highly valued (scores 1 or 2) by patients. In the overall sample nearly three 
quarters of patients’ healthcare network members (72.9%) were valued highly 
by patients and therefore are classified as strong ties, fewer healthcare support 
staff (47.4%) than other alter types were highly valued by patients.  A higher 
proportion of cardiac rehabilitation or heart failure nurses were highly valued 
than any other healthcare professional. More GPs than community pharmacists 
were highly valued, whilst GP receptionists were the least highly valued 
medicines management contact. Over two thirds (68.8%) of network alters who 
were classified as friends and family were highly valued by patient and nearly all 
friends and family with healthcare experience (94.1%) were highly valued by 
patients.  Whilst hospital doctors were present in the networks of females at Site 
2 none were highly valued. 
A Pearson chi-square test with a Fisher’s exact test correction revealed a 
significant association between the type of network member and the strength of 
the tie (X2 (3) = 18.601, p<0.001). Exploration of the standardised residuals 
indicated that significantly fewer healthcare support staff were reported by 
patients to be highly valued than other alter types. Cramer’s V indicated a small 
effect size of 0.22 (values range between 0-1).  
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Figure 43: The proportion of network member types reported as highly valued by patients by site and 
gender. 
5.6 Discussion 
Patients had discharge medicines management networks of different sizes and 
compositions. They comprised healthcare professionals, healthcare support 
staff, and personal network members. The majority of network members were 
those providing formal healthcare services to patients and some patients had 
personal network members who were current or former healthcare 
professionals, who were highly valued by patients. Nurses, GPs and community 
pharmacists were the most commonly reported network alters and 45 patients 
had contact with one or more GPs. Community pharmacists were also present   
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in the networks of 36 patients. Patients perceived limited contact between their 
professional alters, however, cardiac rehabilitation nurses were considered the 
most connected professional group. Community pharmacy staff, GP 
receptionists and other nurses were perceived as the least connected 
professional alters. GPs and cardiac rehabilitation nurses were frequently highly 
valued by patients whilst spouses were more frequently highly valued than other 
personal network members. On average, personal contacts with perceived 
healthcare experience were perceived as the most valuable network types. 
Through the novel application of Social Network Analysis, and specifically an 
ego-network approach, it has been possible to develop an understanding of the 
structure of medicines management viewed from the patient perspective as the 
patient perceived it, rather than as it is designed by policy or perceived to exist 
by healthcare professionals. It has highlighted how patients are at the centre of 
different compositions of professional and personal networks and it has 
demonstrated that those networks are sometimes large and diverse. It has also 
raised questions about the extent to which patients perceive their medicines 
management is currently co-ordinated. The data suggest that there are no 
consistent pathways to help patients with their medicines once they leave 
hospital. Whilst this in part reflects individual variation in patients’ care needs, 
after leaving hospital one in four patients had no contact with a GP who may be 
expected to have an overview of the care patients receive from different 
healthcare professionals and the different treatments prescribed for different 
chronic conditions.336 NICE stresses how medicines optimisation should be 
focussed on the involvement of all HCPs and social care professionals involved 
in the patient’s care and that professional collaboration across healthcare 
settings is required.72 This research shows that patients do not perceive their 
GPs were actively managing polypharmacy and their care co-ordination role 
may well be limited to processing communication from different sources. NICE 
suggests that healthcare providers consider sending discharge medicines 
information to a nominated community pharmacy; however this is not a required 
part of the pathway.72 It is therefore difficult to ascertain what thought is given to 
patients’ hospital discharge and medicines by somebody in primary care looking 
across patients’ co-morbidities and their subsequent appointments with 
specialists. For some patients cardiac rehabilitation nurses to some extent   
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acted in a boundary-spanning role, hence their higher density measures in 
patients’ ego-networks when compared to other HCPs and healthcare support 
staff. 
Personalisation of and participation in healthcare is also a current NHS 
agenda.22 This data demonstrates that care is individualised to each patient, 
however there is no evidence that it is designed around them as individuals, as 
discussed further in Chapter 8. Patients receive care from different 
professionals, but the extent to which their medicines optimisation care is 
planned for them after they leave hospital is unclear. NICE now recommends 
that medicines optimisation services are patient-centred in that they take into 
account individual needs and preferences.72 Implementing a clear pathway for 
accessing professional medicines support following discharge from hospital 
which is common to all patients and communicated clearly to them would help 
orientate patients and would ensure medicines information came from the most 
relevant professional group.  
Contact with community pharmacy 
Many patients in this study had no contact with a community pharmacist 
following their discharge. Several initiatives are underway in the UK to direct 
patients to community pharmacy to provide additional support;111,327,337,338 yet, 
as in previous work, our research indicates more needs to be done to integrate 
community pharmacy into care pathways and consolidate the value of clinical 
community pharmacy services for patients.116 Europe-wide, community 
pharmacy has identified medicines-related problems in nearly two-thirds of 
patients after their discharge from hospital and pharmacists were able to 
intervene through educating patients or communicating with the medicines 
prescriber.125 Formal structured interventions, such as post discharge 
medicines review for patients with heart failure, can contribute to patient safety 
by uncovering post-discharge medicines problems;130 however they are not 
universally implemented. Interventions performed specifically by community 
pharmacists are thought to be beneficial, particularly in identifying medication 
errors;129 however there is a lack of high quality studies to conclusively 
demonstrate this.  
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As described in Chapter 6, few patients in this study underwent an MUR after 
their discharge and this chapter demonstrates the comparative isolation of 
community pharmacists and community pharmacy staff in the eyes of patients. 
If community pharmacy services are to be successfully integrated into the care 
pathway that patients follow once they leave hospital, a consultation should 
occur by default, rather than relying on the community pharmacy to notice that 
the patient has been recently discharged to have the opportunity to conduct a 
review, or on the patient to request help. The purpose of the review needs to be 
made clear to patients, which Chapter 6 will show does not always happen, and 
they should be given guidance about how to prepare for it. Importantly, they 
should be able to find out the outcome of any recommendations the pharmacist 
might make to their GP about their medicines. Community pharmacists also 
need to explore how they can better engage with patients to produce better 
outcomes from treatment. This chapter has shown that patients may engage 
with pharmacy delivery drivers delivering to their homes and community 
pharmacy staff who may act as a proxy for contact with a community 
pharmacist and Chapter 6 will show that community pharmacy may miss 
opportunities to meaningfully engage with patients. Taking steps to facilitate a 
more supportive encounter would reflect more closely the professional vision for 
community pharmacy’s role in optimising patients’ medicines.  
Many patients reported being invited to access cardiac rehabilitation and heart 
failure nurse services, which are services that provide individual care, 
sometimes in the patient’s own home. Eligibility and waiting times for these 
services are increasing nationally and the number of patients with co-
morbidities that access them is also increasing.339 Those that did not have the 
opportunity to access them may not have been given the opportunity to discuss 
their medicines in detail with a healthcare professional after leaving hospital. 
The multi-professional context in which patients experience their care, as 
demonstrated in this chapter, may lead to patients not fully understanding the 
roles that different practitioners may play. Because patients do not automatically 
have contact with a community pharmacist after their discharge and many do 
not see their GP, opportunities to support their medicines use may be missed. 
The findings of this study show how the divide between patient service   
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providers places patients in brokerage roles at a time when they are likely to be 
ill and vulnerable after being in hospital and which they may or may not 
perceive as burdensome. It is accepted that poor coordination of healthcare 
providers can lead to discrepancies between the medicines lists held by 
different care providers and the medicines that the patient actually takes when 
they are leave hospital.72,94,95 At present in the UK community pharmacy does 
not receive patients’ medicines lists by default after leaving hospital, so 
incorrect medicines could be prescribed by GPs and not identified by 
community pharmacists. There are, however moves to allow community 
pharmacy access to patients’ summary care records, which gives concise 
information about current medicines, adverse reactions and known allergies.123 
The role of informal carers 
The role of informal carers and the problems they experience in medicines 
management has long been acknowledged.340–342 It is clear from this research 
that alongside patients and healthcare staff many other personal contacts play 
highly valued roles in medicines management, and so a greater focus on 
supporting and integrating them into the patient pathway may be appropriate. It 
may also be appropriate to ask patients when they are in hospital about who will 
be managing their medicines once they are discharged so that person can be 
appropriately prepared by the hospital to manage the patients’ medicines or 
support the patient in self-managing once they return home. This study has also 
identified a ‘hidden’ network of informal professional support in the form of 
friends and family members who patients reported having some healthcare 
experience and are perceived to have enhanced knowledge because of a 
current or former role. Over a quarter (17) of patients reported having these 
alter types in their networks. Some were qualified HCPs, such as nurses and 
doctors, others had run care homes in the past and patients perceived them to 
know about medicines because of this. Other research has identified the 
presence of such people in patients’ networks but not discussed the risk that 
this might pose to patients.248 If patients are in receipt of information or advice 
about their medicines from a hidden network then their behaviour towards their 
medicines may be modified as a result of this contact that sits outside the formal 
healthcare system. For example, they may not seek advice about a side effect if 
they have been told by someone they perceive to have enhanced healthcare   
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knowledge that that side effect is acceptable or normal, which is evident in the 
results of qualitative semi-structured interviews in the following chapter. Other 
perspectives have viewed access to an expert in an individual’s social network 
as enhanced social capital;343 for the patient this may be a more conveniently 
accessed and more approachable source of perceived expertise. No research 
has been found that looks at this phenomenon in within the context of patient 
safety or medicines safety. 
This chapter has presented the structure of patients’ medicines management 
ego-networks and explored the impact of those structures on the quality and 
safety of care. The following chapter will build on those results by describing the 
content and function of patients’ medicines management networks. 
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Chapter 6 – The content and function of patients’ medicines 
management networks  
6.1 Introduction 
This chapter presents the results of the qualitative thematic analysis of patient 
diary data and the semi-structured interviews that were conducted with patients 
approximately six weeks after their discharge from hospital. It aims to answer 
the following questions: 
• What medicines management content do patients perceive in their ego-
networks? 
• What medicines management functions do patients perceive 
professionals and others to perform? 
It is presented in two main sections: 
• Ego-network content – exploring what flows between actors in the 
network; and 
• Ego-network function – exploring the roles that the network performs. 
The results are presented as a narrative describing the themes and subthemes 
in the data supported by quotes from patients. Quotes are referenced using a 
patient identification number which is prefixed by either the number 1 or 2, 
indicating which site the patient was from (for example 1.33 indicates site 1 
patient 33). 
6.2 Ego-network content 
The content of patients’ ego-networks comprises the substance of the 
interactions between network actors. The content of patients’ ego-networks is 
presented in three main themes and nine subthemes as shown in Figure 44. 
The main thematic areas are: information and advice; attitudes and 
experiences; and requests and offers. 
6.2.1 Information and advice 
The theme of Information and advice is presented in four sub-themes: 
Medicines information; Advice about taking medicines; Patient-provided 
information; and HCP information sharing.   
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6.2.1.1 Medicines information 
Much of the content of interactions between patients and their alters was 
information about medicines. Some patients obtained this actively and some 
passively to augment or fill gaps in the information given to them in hospital. For 
example, one patient described their community pharmacist “putting me right” 
(2.26) about the correct use of a GTN spray a few days after hospital discharge. 
 
Figure 44: Medicines management network content 
Some were able to recall information given to them in hospital, yet many 
described not receiving detailed or adequate medicines information before 
leaving hospital or they had forgotten what they had been told there about their 
medicines. One patient described himself as “in the dark” (1.21) because he 
had not received explanations about his medicines in hospital, which were 
“never discussed or named to me”. Many explained how frustrating they found 
the lack of information given to them and described being treated dismissively. 
 “Well I’d say I don’t think I was really given information [about my 
medicines in hospital], it was just a matter of, “Here’s your tablets, sod off.” (1.1) 
Others explained that the written discharge summaries they were given were 
not designed for their use and were therefore of limited help once they returned 
home. For some patients hospital was not the ideal place to receive medicines 
information because of their poor health or their focus on returning home: one   
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patient described their preference to return to hospital to discuss their health 
and treatment at later date. 
 “Of course, lying in a hospital bed not feeling very well is not always the 
best time to ask questions. So from a personal thing it might have been nice to 
have gone back after a fortnight and just had a chat with somebody on the 
cardiac ward about what was going on.” (1.2) 
Patients received factual information about their medicines from network alters 
after their discharge. Patients reported how GPs, community pharmacists, GP 
practice nurses and specialist nurses – such as cardiac rehabilitation nurses, 
heart failure nurses and warfarin nurses – offered information about the purpose 
of medicines, although they occasionally found this information conflicted. In 
one case the patient had received information from his GP, who was a GP with 
Special Interest (GPSwI) in cardiology, about a safe dose of bisoprolol that was 
different to that given by the hospital. 
 “The GP cardiac specialist [GPwSI] appeared to think actually you know, 
it’s not that big a deal just going over the 10mg, whereas the hospital was a lot 
more careful about it, saying no, we really shouldn’t go over the 10mg unless 
you’re here then we can monitor you.” (1.8) 
Specialist nurses, such as cardiac rehabilitation nurses, were described by 
patients as giving information about new medicines, when to use medicines and 
effects to watch out for “fully and clearly” (1.9). Another patient reported a 
cardiac rehabilitation nurse visit as: 
 “Over an hour of questions and information. Explained how the tablet 
dosages would alter over time and the reason for taking the different drugs.”  
(1-45). 
Other specialist nurses were reported to give information about the impact of 
lifestyle choices on the effects of medicines and future treatment. For example, 
Warfarin nurses gave information about the impact of drinking alcohol on the 
time it took the blood to clot.  
Despite this, patients discussed specific types of information they lacked, 
explaining that they would like more information about the length of time they   
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would be required to take their medicines for, the long-term impact of their 
treatment or the combined effect of their medicines and how they would benefit 
from more information. 
 “Well, short-term, I think they [my medicines] are okay, and… so short 
term, they're working but I’m just wondering long-term, what will happen then.” 
(2.12) 
 “I think, yes, it would be a step forward in giving a bit more…that bit more 
information and that…so you’ve…and then you know that that backing is there 
for you to…” (1.1)  
These gaps were often described in more detail by patients and included the 
purpose of their medicines, how those medicines worked together to help their 
conditions and how long they should take them. Some patients thought 
information was not tailored to them. Others wanted more information 
specifically about the risks their medicines exposed them to.  
 “Well, yeah, I trust them that they do work well with other medicines, I 
trust them that far, but I'd like to know if there's any danger attached to them, 
you know. In a certain way, in a way, I don't, because I don't want to know, 
because I’d start being paranoid about it, and think I can't take that today, you 
know.” (2-12) 
Some used the internet to fill information gaps: in one case a patient described 
trying to match the side effects they perceived with information about side 
effects online. 
 “Well it [getting information] would have been helpful yeah, but I just did 
it myself, I came home and looked on the internet to find out what they were for 
and what they did, yeah. (1-27) 
GP receptionists sometimes acted as conduits of information from GPs to 
patients. For example they would inform patients that GPs required them to 
obtain blood tests or that the GP wanted them to discontinue a medicine. GPs 
themselves, along with GP practice nurses and specialist nurses, would give 
patients information about test results and subsequent changes to their 
medicines.  
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HCPs offered information about side effects or potential adverse effects they 
may experience. These HCPs included GPs and hospital nurses, specialist 
nurses and community pharmacists.  
“Well she [the heart failure nurse]… said about things… you see, what's 
happening with some of my tablets, they're affecting my kidneys…And she 
[said] like Furosemide can affect your kidneys.” (2-25) 
Community pharmacists played a role in providing information about side 
effects to a few patients who described attending medicines use reviews 
(MURs), for example one patient described being given basic information about 
side effects.  
“She [the pharmacist] said you might get side effects and you might get a 
cough.” (1-40) 
HCPs also offered information that helped patients understand the effects they 
had experienced. One patient talked about his chest pains since leaving 
hospital and that a hospital sister explained that his long-term use of aspirin 
may be causing his discomfort and he should see his GP about prescribing a 
proton pump inhibitor. Another patient described being given information by 
their GP explaining how their medicines caused swollen ankles or had the 
potential to cause organ damage.  
 “In fairness to [my GP] he’s explained, it’s like my ankles are atrocious at 
swelling up and again, that’s something new. Now what he said is it’s the 
medication that unfortunately, the job of the medication is to divert the blood 
flow to the heart and keep that pumping and then what happens is, there is, you 
know something suffers and unfortunately it’s my legs. It’s the circulation.” 
(1.44) 
However, some lacked information about medicines side effects because this 
had not been offered to them in hospital or by other professionals they had seen 
since they had been discharged. Occasionally patients were unwilling to seek 
information about side effects because they believed it would have a 
psychological impact on them and their health.  
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 “I don't want to know side effects because I always think, this is just me, I 
think if you see these side effects then it will affect you and if I don't know what 
the side effects are I'm not going to expect them, so I don’t want any side 
effects. And touch wood I haven’t had any that I know of.  So I don't really want 
to know.”  (2.17) 
Patients also obtained information about side effects from their friends and 
family who worked in healthcare. Information included what side effects to 
expect from medicines. 
 “The funny thing that happened is the statin everyone complains that the 
pains the first two weeks, right deep inside my legs, and I thought “crikey” and 
my brother-in-law said, oh that’s normal.” (2.35) 
6.2.1.2 Advice about taking medicines 
Patients received advice from HCPs about adhering to their medicines, 
strategies to help them adhere or strategies to reduce the impact of side effects. 
One patient described how a cardiac rehabilitation nurse advised him to take 
one of his medicines with a glass of orange juice to allay the headaches he 
experienced. Another was advised to take paracetamol to treat headaches 
caused by nicorandil, which is a medicine used to treat angina. A further patient 
reported getting advice from their community pharmacist during a MUR about 
not omitting taking medicines  
 “I gave them the medicine prescription and she told me like the, before 
she handed to me in the medicines and she called me into the small room and 
she explained me do you know what the reason these are medicine for you... 
and she goes you got to take these, you don’t have to miss them.” (1.10) 
Cardiac rehabilitation nurses, community pharmacists and warfarin nurses also 
offered advice about the timing of medicines to help patients get the optimal 
effect or what to do in case a dose was missed by the patient. Some patients 
explained they did not need advice from community pharmacists if they were 
able to ask their GP for advice, indeed some emphasised that it was the GP’s 
and not the community pharmacist’s responsibility to give them medicines 
advice.  
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“If I need to ask some questions [about my medicines]…like I said, I don’t 
discuss with them, pharmacists, it’s mostly doctors.” (1.38) 
 “Well there was various reactions I had with them to start off with, they 
weren’t good and couldn’t sleep at one point with one of the medicines and 
there’s a cardiac nurse that comes round and she explained that if I took it in 
the morning instead of the evening it would probably be better than it was.” 
(1.41) 
Patients’ personal network members with healthcare experience also gave 
advice, for example one patient’s nephew, a GP, advised her to keep track of 
her blood pressure and to review her medicines with her own GP after she 
complained of feeling light-headed. Other personal network members made 
helpful suggestions to patients about the storage and organisation of their 
medicines. 
 “My daughter suggested [getting a compliance aid] because she's 
working as a nurse in the community, so she knows the patients that are on 
them. (2.12) 
6.2.1.3 Patient-provided information 
Patients described proactively giving information to their HCP contacts about 
the medicines they needed. They did this using several channels, including over 
the phone to GP receptionists, and via email.  
 “I just went, because I do it online, so I just emailed the surgery and 
wrote down everything I needed, what they’d [the hospital] said I was on 
permanently and they just did it.” (1.27) 
Others talked about how they were able to tell HCPs about how they were 
feeling about their medicines and offer them information about the side effects 
they perceived. 
“I mean these muscle pains and joint pains I’ve never had before so 
there must be something to do with the drugs. It’s a case of go and discuss it 
with the nurse and try a different dose or something, a different drug. (1.45) 
Patients phoned or spoke face-to-face with GP receptionists in order to obtain 
repeat prescriptions. In some cases patients would communicate important   
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information about new or changed medicines to receptionists, about medicines 
that had been incorrectly supplied, or tell them what medicines supplies or 
devices were needed to ensure they had adequate supplies and to prevent the 
inadvertent continuation of medicines that should have been stopped. 
 “But actually thinking about it, no the next time I rang the receptionist and 
we went through them, she said Candesartan was still on the receptionist’s list 
as an available repeat and I said no you can scrub that, so they ended up 
tidying a couple of..” (1.8) 
Patients would sometimes tell GPs or other clinicians, such as specialist 
doctors, about the medicines they were taking in order to ensure those 
professionals were fully informed about their current treatment regime. Some 
explained that their complicated polypharmacy meant they found organising 
supplies burdensome. 
 “And it’s not easy enough for me to go to say like phone-in and say just a 
repeat prescription, I'm on that many and they change them so frequent that it’s 
easier to go down and do it face to face with the doctor” (1.3) 
 
 
6.2.1.4 Information sharing between HCPs  
Patients discussed their perceptions of HCPs sharing information about them 
and their treatment. Whilst some believed or assumed that HCPs shared 
information about them, many patients perceived very poor levels of 
communication between HCPs in their networks. Some made distinctions 
between sharing information electronically and active communication about 
them and their health and they perceived cardiac rehabilitation nurses to 
actively communicate with others, such as hospital doctors and GPs, to make 
sure they had safe and effective treatment.  
“Yesterday she [the cardiac rehabilitation nurse] said that normally a 
person in my situation would have a particular medication and she mentioned 
the name, provenil… provenol, something like that, and she was a little 
surprised that I weren’t on it and she said she was literally going to contact the 
doctor to ask why not because she said there may be a valid reason but she 
needs to know.” (1.9)  
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Others, however, were frustrated by a perceived lack of active communication 
between members of their healthcare team, for example between their GP and 
their community pharmacist or between their GP and hospital staff. Some 
described their belief that communication sent to GP surgeries was not acted 
upon, rather it was filed and only read when they next visited the surgery. 
 “Well I think the nurses and the specialist, the doctor, it’s just a washout, 
my doctor, because he don’t seem to be reading the emails what the doctors 
have sent from the hospital.  They just don’t communicate, to be honest.” (2.17) 
“It’s all done by letter and I don’t think they [the GPs] look at them, to be 
truthful. I think they get given to the receptionist. She probably puts them on the 
computer and that’s left at that. Because you can go in and they’ll say “Well let 
me have a look. When were that diagnosed? Oh, yes you have.” So they aren’t 
aware of what you’ve got until they actually… I don’t think the GPs look at 
anything that comes through until it’s needed.” (1.27) 
Community pharmacists were judged by some to be isolated from other HCPs 
involved in patient care because of their limited access to information about the 
patient, such as their medical record or discharge summary, or because they 
did not work with other HPCs. 
“I mean the pharmacists are an entity on their own aren’t they? They 
don’t coordinate with anybody.” (1.34) 
“I don’t think I’d be confident enough [to ask a pharmacist a question] 
because they’ve no information have they?” (2-26) 
 
6.2.2 Attitudes and experiences 
This section describes how patients and their network members shared their 
experiences of taking medicines and also how they expressed different attitudes 
about their medicines within their networks. These attitudes were instrumental 
(concerned with the cognitive assessment of the value of their medicines) and 
affective (concerned with how patients feel emotionally about them). Attitudes 
were often exchanged in conversations about medicines with friends and family 
network members.  
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6.2.2.1 Sharing experiences 
Patients described how they shared personal experiences of their medicines 
with friends and family members. They chose to share experiences of 
medicines with contacts, either because they trusted them or because they had 
experience with the same medicines or the same conditions or medicines. 
 “I tell her [my mother] what happened at the hospital and tell her what 
medication I was on. Again, she’s had two or three similar medications so she 
said, “Alright, well, I take this as well.” It was just a general discussion.” (2.50) 
 Patients described discussing the range of medicines they took for similar 
conditions and how effective they perceived those medicines to be. They 
described talking about long-term, new, and changed medicines. Network 
members shared experiences with medicines sometimes led patients’ contacts 
to question the future of their own treatment. 
 “It was the Bisoprolol because me and my dad both have the irregular 
heartbeat and we’ve both been on Atenolol for, well him for about 20 years and 
me for 10 years…So because they changed my medication he wondered why 
and whether they would change his.” (1.2) 
Patients told their friends and family how they were coping with their discharge 
medicines. They shared how they felt about their medicines and sometimes 
expressed the burden of having to take too many medicines. Others talked 
about the different doses they were taking and conversations sometimes led to 
patients wondering why they were taking different doses to their contacts. 
 “Well mainly [we talk about] well I’m taking so what’s such and such a 
dosage, well I wonder why you’re not taking that dosage while you’re taking this 
and (laugh).” (2.29) 
Network members’ second-hand experiences were also shared. In one case, for 
example, the patients’ friend shared her experience of her father’s warfarin use. 
Other patients and their network members shared experiences of side effects, 
sometimes reassuring each other and sometimes intimating that experiencing 
side effects was to be expected.  
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 “It was just that he’d [her father] been on it [warfarin] and he’s fine 
because she was doing that, “I feel compelled to reassure you that you’re going 
to be okay.” (1.2) 
 “I mean the reason why I know about the beta-blockers is because my 
mum and dad have told me that they will tire you.  Because my dad was on 
beta-blockers and he was that lethargic, couldn’t do anything and you know he 
always likes pottering in garden but he couldn’t do anything.” (2.30) 
 “Oh, they [my family members] just said, “How are you going on?” and 
sort of thing like that.” (1.1) 
6.2.2.2 Instrumental attitudes 
Patients described developing instrumental attitudes – for example they 
changed their cognitive assessment of their medicines – as a result of contact 
with network members. HCPs and support staff communicated the importance 
of medicines and in doing so reinforced more positive instrumental attitudes in 
patients. Contact with these network members reinforced how essential it is for 
patients’ to follow their prescribed medicines regimes. For example, a 
conversation with a pacemaker technician emphasised the importance of 
maintaining the correct dose of a beta-blocker. In another case, contact with a 
gym instructor during cardiac rehabilitation led a patient to understand the need 
to keep her GTN spray with her at all times. This enhanced her view of how 
important the GTN spray was to managing her condition.  
 “And then he [the gym instructor] said, ‘Where’s your GTN spray?’ And I 
said, ‘It’s in my handbag in the changing room.’  And he just said, ‘What good is 
it in your handbag!’  And I felt like a little girl….Well I know it sounds so childish, 
I’ve got to have that spray with me, I do take it with me, it’s in my handbag, but 
now… the following day I took it with me and I won’t ever not have it with me in 
the gym again.” (2.27) 
Friends and family contacts also enhanced patients’ positive instrumental 
attitudes. For example, they stressed how important it is for patients’ health to 
adhere to their medicines or emphasised the importance of remembering to 
take medicines through regular reminders.
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 “Yeah, we [me and my daughter] talk about the medicines and 
everything, and she says like if you've got to be on them, you've got to be on 
them Dad, you know, it's simple. You know, if you stop taking them, something 
drastic could happen.” (2.12) 
Indeed, several patients discussed how their personal contacts encouraged 
them to take their medicines seriously, thus influencing their views of how 
important their medicines were. Others discussed how they felt a personal 
responsibility to their family to take their medicines and keep themselves well. 
“She [my wife] makes me take them [my medicines] seriously. My 
problem is if I was more focussed with work, everything else would just get left” 
(2.35) 
“I don’t mind [being reminded by my wife], I don’t mind at all because it 
also gives her peace of mind that I am doing it properly now, and that I am 
following all the stages that I should follow…because you know she cares and 
alright we’ve been married 30 years now, you know and she does care about 
me, and it makes me feel like she still cares and I should take more care of 
myself.” (2.4) 
6.2.2.3 Affective attitudes 
Patients developed affective attitudes – such as their acceptance, anxiety or 
fears – about their medicines from their healthcare network members. In some 
cases they helped patients feel more content about taking their medicines.  
 “Yeah, I feel better [about my medicines], the more that people tell me 
[about them]…” (2.17) 
However, occasionally contact with HCPs would increase patients’ concerns. 
For example, a community pharmacist who telephoned the patient to check 
whether they were experiencing any side effects enhanced the patient’s worry 
about her medicines.  
“Oh it's scary, I think why are they doing this [phoning me], what's going 
to happen?  And sometimes I think well, I might be having… because 
sometimes my head feels like it's going to explode and I think perhaps that's a 
side effect.” (2.22)  
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Friends and family raised concerns about medicines, which led patients to worry 
about those medicines or take action, such as querying their medicines with a 
HCP. One patient reported his wife’s concern about the number of medicines he 
took which amounted to nine tablets a day and seven different medicines. A 
different patient’s daughter highlighted the number of medicines he took with a 
blood-thinning effect and the negative impact this might have. This in turn made 
the patient concerned and he approached his community pharmacist and his 
GP surgery about them. In this case, the community pharmacist advised him to 
stop taking one of his medicines, but staff at the local health centre later 
indicated that the community pharmacist did not have the authority to do this.  
 “Well it was my daughter; she said…my daughter looked at my pills. She 
said, “You’re taking three lots of blood thinning tablets and they’re putting you 
on warfarin”. She said, “What are they trying to do to you?” So I went into the 
health centre and I told her. Before that I went to the chemist and told her. The 
chemist woman said, “Well don’t take your aspirin and don’t take another one”. 
So when I went to the health centre… I must have said to her the chemist said 
I’m to stop taking my aspirin and I have to stop taking this”.  She said, “She’s 
not allowed to do that” (2.15) 
6.2.4 Offers and requests 
This theme describes how patients would make requests for repeat medicines 
and also for medicines that were missing from their prescriptions or delivered 
medicines after their hospital discharge. It also describes how they would 
request and be offered help with their medicines. 
6.2.4.1 Requests for medicines 
Some patients described requesting prescriptions from their GP practice after 
their discharge. They did this via the GP receptionist and saw it as a basic part 
of the receptionist’s role, which some patients valued more than others. 
“I don’t think they [the receptionist] really helped me have they? Just you 
go and ask for your prescription and they give it you.” (2.26) 
“She [the receptionist] was very confident, clearly spoken, asked me 
questions, a lot of the time they just mumble and go ‘what do you want?’. She   
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was very, what was she, she was proactive, she was interested in what, what I 
wanted to know and interested in sorting it out.” (2.35) 
A few patients described how they had needed to request specific medicines 
that they noticed weren’t on their repeat prescriptions after they had checked. 
“No, they [the new medicines] weren’t [on my prescription], I had to ask 
for those; they are on now and they will be next time.” (2.52) 
 
6.2.4.2 Requests and offers of help 
Some patients described how they needed help with their medicines when they 
returned home from hospital. They described how they turned to others in their 
personal networks to provide that help. One patient described how she had felt 
incapable of undertaking the organisation tasks she felt she needed to begin 
taking her discharge medicines so she requested help from her husband. 
“When I first came out I wasn’t feeling very well. My brain to concentrate 
was not, it was fuzzy and normally, I was going to put all the tablets and the 
times I should take them etc. on a spreadsheet and I asked him [my husband] if 
he’d do that for me because I was feeling a bit fuzzy.” (2.34) 
For most patients help seemed to be offered implicitly by their friends and family 
without patients describing needing to ask for it. Some patients described the 
reassurance they got from knowing that they could ask for help from their 
friends and family should they need it. 
“You know it is a fair way [away] but they’re very good [my friends]; if I 
asked them to do anything they would.” (2.1) 
Other patients described how they felt they could ask certain HCPs for help 
should they need to do so, for example they described confidence in how they 
could ask their cardiac rehabilitation nurse for anything at any time. 
“I feel, even when this is all over, well I suppose it is now, I feel that if I 
was apprehensive about anything to do with my tablets I think it would be [the 
cardiac rehabilitation nurse] that I would ring to ask because she’s so easy to 
talk to.” (1.17)  
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Offers of help came from healthcare staff, for example one community 
pharmacy staff member offered to drop medicines off at a patients home after 
she discovered the patient had run out of supplies. Others offered practical 
assistance, for example in writing the names of medicines down for patients or 
in banding medicines boxes together for them.  
“[She] said, “You’ve none?”  I said, “Well I’ve one,” or I'd ran out the 
previous day, and she said, “Well I can’t have you run out, I’ll bring them on my 
way home from work.”  (2.17) 
Whilst help from family was often described by patients as being implicitly 
offered, there were instances where patients described family members 
explicitly offering help, for example with collecting medicines from the 
community pharmacy. 
“He [my brother-in-law] has got all my medicine for me and then when I 
needed to get it he said ‘don’t be doing that, I’ll do that’. (1.47) 
6.3 Ego-network function 
This section explores the functions provided by patients’ medicines 
management ego-networks. It is presented in four thematic areas and in 11 
subthemes, as shown in Figure 45. 
 
Figure 45: Thematic map of the function of patients' medicines management networks  
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Patients’ networks were identified as multiplex because they provided different 
types of function. For example, they offered support as well as supplying 
medicines. The main thematic areas are: health condition management; 
medicines use support; medicines orientation; and patient safety. 
6.3.1 Medicines use support 
The theme of medicines use support is presented in three subthemes: practical 
support work; emotional support; and isolation from support. 
6.3.1.1 Practical support work 
Patients reported personal network members giving them day-to-day practical 
support in managing and organising their discharge medicines. Family 
members set out tablet boxes for them each day or organised each week’s 
supply into multi-compartment boxes. For many this support was invaluable, 
particularly because they felt themselves unable to perform these functions 
because they didn’t have the skills or because they were tired, disorientated or 
unwell. Some patients described working as a team with a close contact, such 
as a spouse, to obtain and organise supplies and to take the correct medicines 
at the recommended time. 
“She [my wife] does my tablets because they’re little, some of them are 
little tablets and that and I find them… so it’s easier if I just stand there and say 
they’re for morning and they’re for evening and she’ll put them in my dosette 
box and that.” (1.3) 
 
Others described needing practical support from close family members 
immediately after discharge from hospital to help establish an in-home 
medicines system. This help comprised making appointments to discuss 
medicines, organising medicines or in buying compliance aids, such as multi-
compartment boxes.  
“So she [the cardiac rehabilitation nurse] took my blood pressure sat 
down, stood up, sat down, stood up… like they do, and she says, ‘are you 
having any problems with your medicine?’  I said ‘no, none at all’, I said 
‘daughter got me one of those things [a dosette box], so it's all laid out, so I do a 
week at a time’. (1.34)  
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 “Well, my husband did it [organised my medicines]. He’d bring me them 
all at first. Yeah, then he had to go back to work after a week. He used to bring 
all the tablets out to me.” (1.27) 
Other patients talked about getting support collecting medicines from the 
community pharmacy or getting lifts to the pharmacy. This was described as 
useful by patients who were either too ill after leaving hospital to collect their 
medicines themselves or were temporarily precluded from driving because of 
their health. Some patients discussed how they relied completely on their 
spouses to manage medicines at home on their behalf. 
 “Well it’s the organising, [my wife] does everything. If she left tomorrow or 
dropped dead tomorrow then that’d be it; I’d go cut my throat then; no seriously 
but I would be totally lost for a while to sort out...” (2.11) 
Some were able to create their own lists in note books or on spread sheets to 
help them keep track of what they had been taking. Others used different tools, 
such as alarms to remind them to take doses they had forgotten, or strategies 
such as placing their medicines in easy view so they would not forget to take 
them. Some described their difficulties keeping track of their doses. Further 
medicines help would have been beneficial for some and they made 
suggestions about the types of help they might have benefitted from, for 
example some described how a checklist or organisation tool might help them 
take their medicines correctly and establish a routine.  
“I think if they sent you out of hospital with some sort of tick box sheet 
you know, I think it would have helped a lot of people, just so that, I mean like, I 
have to keep them there to remind me and my alarm is set on my watch for 
7:00pm every night because the first two are okay with breakfast because it’s 
become a habit, but the evening one, sometimes I forget so I have to set my 
alarm and I mean there was a time in the past where I thought, did I take one, 
and I had to count them all, to see if I'd taken one you know, and I think if there 
was some sort of simple check box or something that you could just keep next 
to you, you know or whatever.” (2.34)  
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6.3.1.2 Emotional support 
Actors in patient’ personal networks offered emotional support enabling them to 
continue their treatment. The fillip provided by people who cared about them 
helped patients recover when they were physically and emotionally depleted, as 
indicated by the exchange below:  
F  “They [my parents] always ask me every day if I’ve took me tablets. But 
always you know I always have. And he’ll come ‘have you took your tablets?’  
Yes.” 
I: And how does that make you feel having that reminder every day from 
your parents? 
F: It’s actually good at the moment because at the moment I can’t think 
straight, I’m a bit, I get very tired. And it’s good to have somebody just 
reminding me that I’ve got to take it even though I am taking it.   (2.20) 
Patients felt cared for by their personal contacts whom they described as being 
available to discuss the emotional impact of taking medicines. They described 
this type of support as valuable, particularly when friends and family lived close 
to them or with them and provided regular or constant support.  
“She [my daughter] is at home and she all the time she takes care of 
me…so it’s the support you need you know, sometimes.” (1.11) 
“Because I see her every day and basically she makes me take my 
medication and says, ‘Are you alright? Are you really alright? If you’re lying to 
me...’ (1-2) 
Emotional support functioned in different ways. Personal contacts provided day-
to-day encouragement, either through nudging patients to take their medicines 
or through listening or discussing concerns about medicines. Some explained 
how close personal contacts would reassure them that they were taking the 
correct medicines. These contacts were usually people who had medical 
training themselves, for example one patient described how his wife who is a 
nurse would reassure him that his treatment was suitable for him. 
“It gives me reassurance if she says oh you’re on right treatment, you’re 
on right drugs then yeah, so that and all that drugs that’s it, you know there’s 
nothing to worry about from that side of it so.” (2.21)  
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Close contacts provided support in making decisions about their medicines, 
such as whether to adjust doses, carry on taking them or to stop taking them 
altogether. For example, one patient in conjunction with his wife decided to stop 
taking ranolazine because of the chest pains he experienced, which were 
eventually attributed to his need for a proton pump inhibitor. 
“The conversation as to whether to take the extra medication was pretty 
much mine, but after I'd talked with [my wife] about it.”  (1.8) 
6.3.1.3 Isolation from support 
Some patients described their isolation from both emotional and practical 
support with their medicines upon leaving hospital. Some patients lived alone 
and perceived that they were managing their medicines single-handedly. Others 
talked about their fears for their health after leaving hospital which were 
exacerbated by their isolation.  
 “It’s difficult really, I think anxiety, see what I fear is that I’m on my own 
and at night time you know they’re not sure whether it’s a phase I went through 
before Christmas when I never slept for four or five days because I was 
frightened of closing my eyes…” (2.1) 
Others felt let down and uncared for by the GP team, disillusioned with the care 
they experienced and some perceived a breakdown in their relationship with 
their GP and consequently had not tried to access their support. Some patients 
described how disorientating it is to leave hospital where they were surrounded 
by members of the medical team and then return home to comparative isolation. 
They explained how this could make them feel insecure and they perceived the 
need for access to support after their discharge from hospital. 
 “Well whilst you’re in hospital you’re very secure, when you leave 
hospital it’s incredible how you feel insecure initially because you’ve got that full 
back up there in hospital. The moment you come out of hospital you’re on your 
own and it is important to have somebody there to...or at the end of a phone 
that you can ring up.” (1.52) 
Some patients perceived a need for a greater role for healthcare professionals 
in providing support after discharge. They were frustrated at the lack of 
continuity in their care team and particularly perceived poor continuity in their   
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contact with a GP. These patients perceived a burden in updating HCP 
members about their health condition or of having to wait to see their GP of 
choice. 
  “I think you should be able to see the same doctor all the time, because 
you keep telling the other doctor, you know, everything, and they don't… you 
can't read it up. (1.25) 
 “I think above anything would be a form of contact with someone that 
knew about it, not possibly personally but about heart attacks, you know, it 
doesn’t happen as much now but in early days there were a lot going on that I 
want answer to and there were nowhere to go for them.” (2.26) 
6.3.2 Medicines orientation 
The theme of medicines orientation describes the process through which 
patients do and do not learn about their medicines and develop different levels 
of confidence in using them. The term was coined as a result of this analysis to 
capture the idea of how patients reach preparedness to manage their medicines 
and it is discussed in depth in section 8.7. It is presented in three sub-themes: 
medicines knowledge; knowledge vacuum; and confidence in medicines. 
6.3.2.1 Medicines knowledge 
Professional network members performed overlapping education functions: 
some patients had contact with several different professionals to find out about 
their medicines, their purpose and how to take them. However, cardiac 
rehabilitation nurses played a valued role for patients in educating them about 
their medicines.  
 “Yeah, well he did say, he told me that is how, this is for your stent, that 
is the one he mentioned. He goes that is for your full year which [you] need your 
body to, you know, recognise in to it.” (1.10) 
They were perceived as being experts and patients described how they would 
fully answer medicines questions. Patients appreciated the easily 
understandable language that cardiac rehabilitation nurses used to teach them 
about their medicines and they were able to recall what they had been taught 
during visits. Cardiac rehabilitation nurses often visited patients at home and   
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patients reported how cardiac rehabilitation nurses appeared to have time for 
them. 
 “Any questions I had to ask her [the cardiac rehabilitation nurse] she 
answered straight away and she knew.  I think she must... she’d been doing it a 
fair while I think so she definitely was on the cardiac wavelength, if you will so 
yeah, she were fine.” (2.10) 
Pharmacists also educated patients about their medicines: a few patients 
described pharmacists conducting medicines use reviews which helped them 
understand more about their medicines. Pharmacists were able to help patients 
allay side effects and optimise their medicines through making 
recommendations about when to take them. Some patients, however, were 
confused about the purpose of their review, thinking it was perhaps for the 
benefit of the pharmacist rather than for their benefit, or they thought that it did 
not give them any additional knowledge, or they were unprepared for their 
review because it was conducted in an ad-hoc way. 
 “But the other thing is that if I’d been prepared to go in and knew that 
she [the pharmacist] was going to talk to me but she literally took me off…” 
(1.40) 
Other patients felt strongly that GPs or other doctors should provide education 
about their medicines, rather than other HCPs, such as pharmacists, because 
they thought the responsibility of educating the patient should sit with the 
prescriber. 
 “In my mind I was going to say they’re the people that put me on it in the 
first instance, they’re the people that said this is the drug you’ve got to take. The 
pharmacist dispenses what the doctor says so he can go through what he 
dispenses but the person who actually puts me on them, he should be telling 
me or she should be telling me the reasons why I’m on it not the other way 
round.” (2.52) 
6.3.2.2 Knowledge vacuum 
At times patients explained how they were frustrated by their lack of knowledge 
of their medicines. They explained that poor provision of patient information 
resulted in poor medicines understanding. Patients talked about how they had   
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left hospital without a good understanding of their medicines and some felt hat 
they had continued to be ill-informed despite contact with others in the six-week 
period following their discharge. 
 “But it’s galling when, you know, like you say, I'm coming out of hospital 
with some new tablets and all I know is to take them twice a day – well what are 
they for?” (1.3) 
 “But I don’t know why I’m on water tablets.  I couldn’t tell you why I’m on 
water tablets. Nobody’s explained that to me. I mean I know what they do, they 
just flush out don’t they but nobody’s actually explained what the water tablets 
do.” (1.20) 
Patients were confused about many aspects of their medicines, including 
changes made in hospital, the explanations they were or were not given in 
hospital, changes to brands of medicines and about side effects they perceived. 
Patients also lacked the ability to tell if their medicines were effective for them 
personally or how they worked together to help their health condition. They 
described making guesses about the effects they should expect. 
 “If I had to make a list of everything that I feel at the moment, yeah I 
would, I would like to go down and say right “is this because of this, is this 
because of the drugs I’m taking, is it part of the symptoms that I’m 
having”?...Because my, thyroid because I’m so high and the beta-blockers are 
slowing me down. So is my thyroid slowing, they did say it would slow me down.  
But is it the thyroid or my heart that I’m having these symptoms for? And if so 
will they change my tablets accordingly or would they you know take me off one 
or reduce the dosage?” 
Other patients admitted that they had limited understanding of their medicines, 
but they were aware that they could find information if they wanted it. 
“The information is there in packets but I couldn’t say I knew what they 
were for now.” (2.26) 
6.3.2.4 Confidence in medicines 
Patients described different levels of confidence in their medicines. Many 
explained that they felt little need to be comprehensively educated about their   
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medicines because they had high levels of trust in the medical team or trust in 
their medicines. They discussed how this confidence had been engendered 
though their contact with others in their network, such as their cardiac 
rehabilitation nurse. Others had confidence in their medicines because of their 
trust in their GP or the hospital doctor who prescribed them.  
 “I trust whatever is given to me. You know if they say it’s going to make 
you better then I just assume that the doctors or nurses or whoever are telling 
me the right thing and I will go with that.  I’ve never felt unsafe taking anything.”  
(1.20) 
Patients’ confidence in their medicines was undermined if they read about or 
experienced side effects that they were not expecting or were more severe than 
they had expected.  
 “I just think you can feel a bit off with that one and I’ve got asthma as well 
and I know when I’ve read the... that one’s really quite bad to give with asthma. 
They say because it’s a beta-blocker and it says warning that it can cause a lot 
more problems with your breathing and everything else but they’ve not 
questioned that, they’ve just given me it, so.” (1.27) 
Some patients considered the impact of stopping their medicines and other 
discontinued medicines they perceived to be making them feel unwell. Others 
experimented with adjusting their doses to allay perceived side effects. Some 
patients described how being in receipt of more information about their 
medicines would help increase their confidence in their medicines.   
 “And it does give you a confidence in taking the tablets they've given 
you, because you know exactly what they are, exactly what they're going to do, 
you know.  So it does give you that bit more confidence, rather than just taking 
them”. (2.12) 
6.3.3 Health condition management 
Patients’ professional contacts optimised their medicines to manage patients’ 
health conditions. They did this through monitoring patients clinically, adjusting 
doses and changing medicines and providing medicines to patients.  
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6.3.3.1 Adjusting medicines 
Warfarin nurses adjusted doses and monitored patients’ INR levels in response 
to the prescribed dose and other lifestyle choices. GPs and hospital doctors 
would increase or decrease doses in response to test results or to instructions 
from other HCPs, such as hospital doctors. A few patients had attended hospital 
again as emergency patients and had their doses re-adjusted by the hospital. 
Patients also reported heart failure nurses adding medicines and adjusting their 
doses of medicines, such as Furosemide, which is used to treat fluid retention in 
heart failure. 
 “Prednisolone yes, that’s because prior to going in hospital the decision 
had been taken by the doctor that gave me that at [the clinic] that we were 
going to gradually reduce it and she said she’d [the GP]  received the letters 
from him and she would take over that, managing that reduction.” (1.9) 
In a few cases, in an MUR community pharmacists would explain how 
medicines could be changed to work more effectively for the patient or how 
patients could modify how they took their medicines to effect more optimal 
outcomes, for example by taking medicines at different times of the day to get 
more effective outcomes. 
“What we were doing, we were taking them at night, weren’t we? She 
[the community pharmacist] said “No”, she said “take them in the morning, 
you’re all right, you can take them any time”. So that’s Ramipril and one of them 
at night, then take some of them in the morning as well.” (1.40) 
 
Others discussed how GPs would amend medicines and doses in the period 
after leaving hospital, sometimes driven by others in the network, such as 
cardiac rehabilitation nurses and sometimes due to the patient’s concerns about 
side effects.  
6.3.3.2 Monitoring 
Patients saw several professionals who monitored their treatment. For example, 
GP practice nurses, specialist nurses and doctors would monitor patients’ 
responses to their medicines by ordering and conducting tests and reviewing 
results. Patients would attend clinic appointments with diabetes specialist, 
COPD nurses and warfarin nurses, whilst cardiac rehabilitation nurses and   
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heart failure nurses would often visit patients and examine them at home. In 
one case a cardiac rehabilitation nurse had asked a patient to keep a diary of 
the pain he was experiencing so she could advise about his use of paracetamol 
and GTN spray. 
Professionals played complementary and overlapping roles, for example GPs 
replaced, adjusted and added new medicines sometimes in response to 
patients’ concerns about side effects or because they identified interactions. 
Cardiac rehabilitation nurses monitored and adjusted medicines, and GP 
practice nurses monitored patients’ medicines. In one case a community 
pharmacist telephoned a patient twice to monitor his response to an increased 
dose of Ramipril. 
Patients described how cardiac rehabilitation nurses were effective in managing 
their medicines to better manage their health condition. They saw these 
specialist nurses as embedded into the healthcare team, working with other 
HCPs to optimise their treatment. They described them actively checking the 
suitability of medicines, substituting medicines that patients were experiencing 
problems with, monitoring and communicating the titration of doses, and 
advising the introduction of medicines that they thought patients should be 
taking.  
 “She [the cardiac rehabilitation nurse] takes my concern and she’s the 
one who has been talking to the doctor. She’s communicating with him and 
getting things done. She came round Tuesday this week and then a couple of 
days later Dr [doctor’s name] rang me up to say “Right. I want to up the dose of 
Bisoprolol to 10.5 mg.” (1.45) 
 “Yes, [the cardiac rehabilitation nurse], she said she’d got some results 
from a blood test that I had at my doctors…and apparently the test is okay but 
this is for the function of the kidneys. So long as it wasn’t affecting the function 
of my kidneys too much I was on two and a half milligrams, now they’ve put me 
up to five. The aim, I believe, is to get up to ten. That would be the ideal dosage 
to work at the best but they’re monitoring and putting it up slowly. At the 
moment I’m taking 5mg as opposed to just 2.5 of Ramipril.” (1.51) 
One patient reported that the cardiac rehabilitation nurse had noticed he should 
be taking isosorbide mononitrate approximately one month after his discharge.   
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The patient subsequently talked about his disappointment that his recovery had 
been hindered because it had not been prescribed to him at discharge.  
 “To be totally honest with you I felt really let down…I should have been 
on these [isosorbide mononitrate tablets]…I thought hang on a minute... Why 
has that happened, you know why, I’ve been suffering for another four weeks, 
because it was every single day I was having an angina attack, every single 
day. I mean within sort of five minutes of meeting the cardiac rehabilitation 
nurse she had it all sorted out.” (2.14) 
GPs also played a role in monitoring medicines, although many patients 
reported problems getting appointments with their GP. However, some patients 
found it difficult to access the monitoring functions of their GP once they left 
hospital, which left them to self-monitor their health.  
 “That was when I left hospital they said they were discharging me into 
the care of my GP, and I had to make an appointment to see him when I got 
out, because they needed him to regular monitor my blood pressure. So the day 
after I got out, I rang them up and the first appointment they could give me was 
three weeks, but fortunately I had a blood pressure monitor in the cupboard, I 
just needed to replace the battery, and for the first few weeks I was taking my 
blood pressure two or three times a day.” (2.34) 
Often patients perceived a lack of co-ordination in the system in optimising their 
medicines. They talked about a lack of communication and co-ordination about 
them and their treatment between HCPs  
 “I mean, like there should be somebody watching each other, you know 
like there is a boss, let’s say my boss is going to be my Mrs, she is going to 
keep an eye on me whether I’m going to be looking after my health or not. So 
she is the one who is giving medicine, tells me what to do, what not to do and 
they should be into doctor wise and even with the pharmacy or doctors, 
anything, they should communicate with each other.” (1.10) 
6.3.3.3 Providing repeat and new medicines 
Patients described how professional network members would co-ordinate 
supplies of their medicines. They described GPs authorising prescriptions, GP 
receptionists acting in an administrative role in taking down notes of patients’   
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medicines and organising repeat medicines, and pharmacists dispensing those 
medicines to patients. 
 “I came out of hospital on the Friday, the Monday I went to see the GP, 
and said look this is what they’ve done, because I took the letter with me, the 
discharge letter…and he said ‘right, so we’ll just order you know these to go 
onto repeat, do you need anything else?’ I said no. I said I’ve got a month’s 
supply, I'd just got a new supply and so I just carried on.  He says you know 
what to do.” (2.4) 
Some patients described community pharmacy playing an important role in 
managing the organisation of their supplies. Pharmacy delivery drivers 
delivering to their homes and pharmacy counter assistants coordinated and 
supplied patients’ repeat medicines and they often precluded the patients’ need 
to have direct contact with a pharmacist in order to obtain their medicines. One 
or two patients reported how their community pharmacists had contacted their 
GP on their behalf to solve problems with the supply of medicines. Others 
patients reported problems with their supply of medicine, for example medicines 
being delivered in stages rather than all at once by their pharmacy. One patient 
reported that the pharmacist supplied 100mcg tablets of Thyroxine on one day 
and 50mcg tablets a few days later to make up her prescribed dose of 150mcg. 
 
6.3.4 Patient safety  
During interviews patients described the safe management of their medicines 
but also medicines related errors that might potentially have caused them harm. 
The theme of patient safety is presented below in two sub-themes: maintaining 
safety; and patient safety incidents. In total 31 incidents described by patients 
were reviewed by two clinicians (See Appendix 6) and 16 were classified as 
being patient safety incidents.  
6.3.4.1 Maintaining safety 
Many patients perceived the system of providing them with medicines as 
working safely and efficiently. Community pharmacists provided a safety-net for 
some patients. For example, in some cases patients described the community 
pharmacist checking with their GP that a medicine was suitable.   
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 “So he took me into his little room at the side of the pharmacy and he 
said well he said I don’t think you should be taking this; he said I’m going to ring 
the doctor.  So he rang the doctor, and checked on it, that I should be taking 
this pill and then he rang back.  He said I’ve had a word with the doctor; yes, he 
said it’s all right.” (1.4) 
Other patients described community pharmacy helping them by providing 
emergency supplies of medicines or taking the time to thoroughly check 
medicines. Some described how they valued the important role the community 
pharmacist plays in providing medicines that are safe. 
 “They are very thorough [the pharmacists], they seem to be… They take 
their time, don’t they, going through it all and checking it all.” (1-27) 
 “Like the chemist for instance I don’t know the chemist…he checks that 
I’ve got the right tablets so he’s very important.” (2-13) 
 
For many patients the systems they accessed to obtain repeat medicines after 
they left hospital worked efficiently. They described how the changes made to 
their medicines in hospital had been maintained when they had been supplied 
new medicines. 
 “No I haven’t had to do anything to anybody [to get my repeats 
medicines], I haven’t had to say anything to anybody, whether they’ve all be on 
you know, they’re on top of their jobs actually.” (2.8) 
One patient also perceived her medicines use review with a pharmacist as a 
valuable safety check ensuring that her medicines would not cause her any 
harm. 
 “Well in effect [the review] made me feel a lot better that you know they 
were checking them and you know if I was...  I wouldn’t be taking an overdose, 
you know that you know they…keeping them in check.” (1-4) 
 
6.3.4.2 Patient safety incidents 
Several patients reported instances in which they were unable to obtain repeat 
medicines after their discharge from hospital. They described trying to order 
their medicines from their GP practice to find that discharge information 
detailing their discharge medicines was not available on the GP practice   
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system. In some cases the paperwork was soon located yet in others the 
patient was asked to list their medicines for the practice or to provide a copy of 
their hospital discharge letter. One patient found that upon asking for a repeat 
prescription, information about his new medicines from the hospital was not 
available. The receptionist at his GP surgery photocopied the discharge 
summary, but only the first page of it so some of his repeat medicines were 
missed. In the process of rectifying this, the GP surgery issued two duplicate 
prescriptions to the pharmacist. Another patient received a set of medicines 
without nicorandil, which had been prescribed by the hospital. This occurred 
one week after his discharge when his wife handed in his repeat medicines 
request slip at the GP surgery.  A further patient received duplicate sets of 
medicines from two different pharmacies, which she described as being 
stressful. Some patients reported repeat medicines supplies being delivered 
without items that were new or had been changed in hospital and patients 
needed to intervene to resolves these errors. 
 “But apparently they couldn’t find that one at the doctors.  So when my 
tablets were due to be renewed, my prescription, they didn’t know anything 
about it.  And I were panicking a bit because I thought I have no more tablets. 
So I went… well I had tablets before I went there, so they were due as well, and 
when they came and they said, you know, they’ll be ready on Wednesday. My 
husband went to pick them up and when he came back, I said ‘Where are my 
new tablets?’ So I rang and she said well, we haven’t been able to find this note 
from the hospital. I said but, when I rang about them, she told me to give her the 
list that was on my list and I did.  I gave her the list and what the tablets were.  
She said, ‘Right, don’t worry, it’ll be ready for you,’ and nothing was.” (2.22) 
One or two patients described receiving incorrect medicines during this post-
discharge period. For example, one 80-year-old patient explained how she was 
supplied uncoated rather than coated aspirin by her GP. She explained that 
uncoated aspirin made her sick and dizzy and she suspected that the GP had 
not read the notes from the hospital. She was frustrated by this, explaining that 
“there's enough wrong me, without being sick on top” (2.25). Others described 
events during the period following their discharge that might have resulted in 
harm which were caused by poor communication between HCPs and patients. 
Patients described being upset and frustrated by what had happened to them   
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and sometimes they experienced adverse effects. One patient, for example, 
had been supplied repeat medicines with different brand names and different 
shaped and sized packaging to his discharge medicines. When he saw the 
boxes he assumed his GP had prescribed these medicines in addition to those 
given to him in hospital. He proceeded to take double the dose of at least three 
cardiology medicines used to treat high blood pressure and angina. He 
described becoming disorientated, nauseous and believes he lost 
consciousness for about ten minutes.  
Another patient was prescribed 50mg of flecainide twice a day by the hospital. 
His GP then prescribed 100mg tablets, however the patient didn’t notice the 
change, which was not actively communicated to him, and he continued taking 
one pill twice a day, effectively taking twice the dose for approximately three 
weeks. He explained that someone should have communicated the change of 
dose to him: 
“If I’d been ill I would have been a bit cross I suppose, probably with 
myself and the pharmacist, which possibly should have said you know these are 
100 just, you’ll need to take half.” (2.33) 
He communicated what had happened to his GP surgery and was surprised 
when he heard nothing in response. 
“It’s sort of, I asked, told the receptionist what had happened…so she 
told the doctor and I went to pick the new prescription up. There was no 
comment from the doctor.  I asked her…so I said, ‘Has he said anything?’ She 
looked on the computer and said, ‘No he just wrote the prescription’, a new 
prescription out, so I went and got those.” (2.33) 
 
6.4 Discussion 
This chapter has provided a rich interpretation of the content and function of 
patients’ medicines management ego-networks in the six weeks following their 
discharge from cardiology wards. The content in patients’ ego-networks 
comprised information and advice about medicines from both professional and 
lay sources. Many patients described leaving hospital with insufficient 
information about their medicines and their networks acted to fill some of those 
gaps. Patients also described instances when they had provided information to   
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HCPs about the medicines they needed and at times their perceptions of the 
effectiveness of information sharing among professionals in their networks was 
poor. Patients’ cognitive and emotional attitudes about their medicines were 
also influenced by their personal and professional contacts, they described 
requesting medicines supplies and asking for and being offered help by their 
network members. Patients’ medicines management networks were multi-
functional: they provided medicines orientation, practical and emotional support 
as well as health condition management through the supply, adjusting and 
monitoring of medicines. It is also clear that patients’ networks pose risks to 
their safety through the failure of systems that support medicines management 
and through failing to ensure patients fully understand the changes that have 
been made to their medicines. 
Patients’ professional network members provided health condition management 
functions, such as providing, amending and monitoring medicines. Medicines 
orientation – the process of developing an understanding of and confidence in 
their medicines – was offered by different HCPs and was duplicated for some 
patients. Some patients had no contact with these functions which resulted in a 
knowledge vacuum: they reported having unanswered questions about their 
medicines and in some cases they considered stopping or actually stopped 
taking them. Despite multiple HCP involvement in their medicines, 
approximately a quarter of patients experienced safety incidents yet the extent 
to which the patient safety incidents identified were officially reported remains 
unclear. In many cases HCPs were made aware of the incidents – for example 
one patient had asked if the GP had commented about his incorrect flecainide 
tablet size and was told that the GP had not left any comments. Patients who 
failed to be prescribed the correct medicines after discharge, or could not obtain 
their prescription because the hospital discharge information had not been 
processed, did not report logging complaints. Patients and practice staff needed 
to take action to ensure the correct medicines were supplied, yet it is likely that 
neither the GP practice nor the patient officially registered these as patient 
safety incidents. The overall level of reporting of safety incidents in primary care 
is thought to be comparatively low.72,76 To counter this in 2015 NRLS launched 
a primary care safety incident e-report form to make it easier for GP practices to 
report incidents for which they can gain continuous professional development   
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credits;344 and the recently launched NICE guidelines on medicines optimisation 
recommends that robust processes to report safety incidents are now 
implemented.72 In secondary care patients have reported, when solicited, safety 
incidents in a range of categories including their medicines.33 As yet, there is no 
evidence about patient reporting of incidents in primary care, although NICE 
now recommends that HCPs tell patients, their families and carers how to 
identify and report medicines-related patient safety incidents.72 Reporting of 
safety incidents is discussed in more detail in the general discussion in section 
8.6. 
As in previous research, for these patients the systems supplying repeat 
medicines after hospital discharge caused problems.150,164,166 This resulted in 
patients intervening to co-ordinate the supply of information to obtain their 
medicines and to avoid taking incorrect medicines. That patients can identify 
and offer information to rectify errors is evidence of increased system resilience 
because patients adapt and take action to enable error recovery; however some 
patients would probably be unaware that their prescriptions were incorrect and 
therefore not able to take action to ensure they received the correct medicines. 
Other patients have experienced problems and discrepancies with their 
medicines after discharge;125,126 yet those studies did not include the problems 
patients had in obtaining their prescriptions before the issues were identified, 
instead focussing on problems identified once prescriptions had been taken to 
the community pharmacy. 
A quarter of the sample had no direct contact with their GP after leaving hospital 
and some patients were disappointed in what they perceived to be their GP’s 
lack of interest in them and their recent health crisis. Fewer had direct contact 
with a community pharmacist. Implementing a pathway for accessing 
professional medicines support following discharge from hospital which is 
personalised to the patient and communicated clearly to them would help 
orientate patients and would ensure medicines information came from the most 
relevant professional group, for example should they be on a cardiac 
rehabilitation programme then medicines orientation is offered by the cardiac 
rehabilitation nurse; should new medicines be supplied to other patients then a 
different pathway should be integrated. NICE recently recommended that 
organisations consider home visits or telephone follow up for some groups of   
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patients after discharge, including those taking multiple medicines and with 
chronic conditions to provide additional support for some groups of people.72 
This research demonstrates how valuable patients perceived the input of 
cardiac rehabilitation nurses and heart failure nurses providing personalised 
support to patients in the home, however not all patients are eligible for that 
level of service. 
The MUR in the UK directs patients to community pharmacy to provide 
additional support with their medicines.345 Although few patients in this study 
had participated in an MUR, our findings suggest that as it is currently designed 
and implemented the MUR may not demonstrate value to patients. This view is 
shared by patients in previous research which found that whilst the MUR 
reassured patients that they were taking their medicines correctly, it could better 
meet patients’ medicines use support needs including discussing any 
complicated concerns patients may have about their medicines.116 Some 
patients did not visit a community pharmacy in person because a relative or 
friend went on their behalf or because they used the delivery service offered by 
a community pharmacy. This limited their opportunity to be approached by a 
community pharmacist to review their medicines. Other patients described 
experiencing an MUR but had not been able to prepare for it because it had 
been conducted straight away, or that they had been unaware of or 
misunderstood the purpose of the MUR. Observation research has found the 
MUR to lack breadth of discussion and that the work environment and workload 
prevented pharmacists from offering a more meaningful service to patients.346 
Patients in this research were not always aware of the purpose of the MUR or 
for whose benefit it was being conducted; in other research MURs were 
presented to patients as a quick medicines check and patients were unable to 
set their own agenda for the consultation.346 Community pharmacists have been 
found to recognise the benefits of the service, although they perceived barriers 
to conducting MURs, including suitable consultation space and resources, and 
they were concerned about how much GPs value MURs.347 During MURs 
community pharmacists have also been found to be reluctant to probe into 
patients’ medical backgrounds or to address sensitive issues.346 
In this research, contact with others provided the multiple functions that both 
facilitated and restricted optimal medicines use and risked the safe   
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management of patients’ medicines. Considering the level of involvement in 
medicines management of other network members, such as spouses, it is clear 
that interventions aimed at optimising patients’ medicines after they leave 
hospital should take into account their social structure. If patients have devolved 
some or all of the responsibility for their medicines to others and are influenced 
by friends and family in how they view their medicines, then interventions aimed 
solely at the patient will fail to have the intended effect. Indeed, other social 
networks health studies have identified the extent to which close family 
members performed illness work and medicines work.247,257 Psychosocial health 
interventions involving family members have reported positive outcomes for 
both patients and families;348,349 and practical support, family cohesiveness and 
not living alone have been found to impact on adherence.256,270 Other patients 
who are socially isolated should follow an alternative pathway that takes into 
account the additional help or guidance they might need to manage effectively.  
This chapter has described the content and function of patients’ medicines 
management ego-networks. The following section will explore patients’ 
responses to a questionnaire about their experiences with their medicines 
administered six weeks after their discharge from hospital and how aspects of 
their ego-networks were associated with their responses. 
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Chapter 7 – Discharged patients’ medicines experiences 
7.1 Introduction 
This chapter explores patients’ responses to the questionnaire administered at 
the end of their qualitative interview, approximately six weeks after they had left 
hospital. The aim of the questionnaire was to measure patients’ experiences 
with their discharge medicines. It explores how well the questionnaire items 
worked to form a reliable scale about patients’ medicines experiences and also 
if there were any robust sub-scales present in the data that could be analysed 
separately. Exploratory data analysis was conducted to synthesise the ego-
network structural data described in Chapter 5 with the questionnaire data. This 
analysis also incorporates the frequency of safety incidents reported by 
patients.   
Patients were asked to answer a series of nine questionnaire items. Each item 
asked about an aspect of their experiences managing their discharge 
medicines, about their understanding of their medicines, their ability to ask 
questions and get information, or about their perceptions of staff working 
together to support them in managing their medicines. All 61 patients answered 
each item. Response options were constructed on a Likert agreement scale and 
participants were able to select one of five response options: Strongly disagree; 
Slightly disagree; Not sure; Slightly agree; and Strongly agree. Participants 
were free to answer in any way they chose. Their responses were given a 
numerical value from 1 (strongly disagree) to 5 (strongly agree). Questionnaire 
items were: 
• When I left the hospital, I clearly understood the purpose for taking each 
of my medicines; 
• I am confident I can take my medicines as instructed; 
• It is easy for me to ask my community pharmacist questions about my 
medicines; 
• When I left the hospital, I clearly understood how to take each of my 
medicines; 
• It is easy for me to understand the instructions I was given for my 
medicines; 
• It is easy for me to ask my GP questions about my medicines;  
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• I currently understand the purpose for taking each of my medicines; 
• The healthcare team work together to support me in managing my 
medicines; 
• It is easy for me to get all the information I need about my medicines. 
7.2 Results 
The frequencies of patients’ responses are shown in Figure 46. In responding to 
questions patients were overall very positive about their experiences. The 
majority of patients strongly agreed that they understood how to take their 
medicines when they left hospital (73.8%) and strongly agreed that they were 
confident in taking their medicines as instructed (78.7%). Fewer patients 
strongly agreed that it was easy for them to ask their GP questions about their 
medicines (45.9%), that it was easy for them to get information about their 
medicines (55.7%) and that the healthcare team worked together to manage 
their medicines (26.1%).  
Mean values for each question were calculated and are presented in Table 33 
by site, gender, deprivation band and for ethnic minority patients, along with 
patients’ overall responses. The lowest mean value overall was for the item 
‘The healthcare team work together to support me in managing my medicines’ 
with a mean of 3.36, and females responded less positively to this item at both 
Site 1 with a mean of 2.44, and Site 2 with a mean 2.78. Comparatively low 
values were reported for the item ‘When I left hospital I clearly understood the 
purpose of taking each of my medicines’ with a mean of 3.72. Males at Site 2 
responded the least positively to this question with a mean 3.55, and females at 
Site 2 the most positively with a mean of 4.33. Patients also gave comparatively 
less positive responses for the item ‘It is easy for me to ask my GP questions 
about my medicines’  with a mean of 3.75. Females at Site 2 were the least 
positively about this item with a mean of 2.89. Patients overall tended to report 
high levels of confidence in their ability to take their medicines as instructed 
(mean 4.51), that they currently understand the purpose for taking each 
medicine (mean 4.4), and that it was easy for them to understand the 
instructions they were given for their medicines (mean 4.31). Patients from 
areas of medium deprivation responded more positively than those from low 
and high deprivation areas. Patients from ethnic minorities were overall less 
positive than others about their confidence to take their medicines as instructed  
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(mean 3.89 vs 4.41) and less positive about the ease of getting the information 
they need about their medicines (mean 3.56 vs 4.15). Women at Site 2 were 
highly positive about their medicines experiences, except for the ease of asking 
their GP questions about their medicines (mean 2.89) and their perceptions of 
the healthcare team working together to support them in managing their 
medicines (mean 2.78). 
7.3 Constructing a medicines experience scale  
Values for all items were summed to form a scale which measured patients’ 
experiences managing their discharge medicines, thereby yielding a scale value 
for each participant. A scale reliability test was subsequently undertaken. In the 
first instance the inter-item correlations were explored to ensure none of the 
scale items were highly correlated. Correlations are reported in Table 34. The 
scale was assessed by determining its Cronbach’s α scale statistic, which was 
α = 0.74.302 A reliability statistic of α > 0.70 is acceptable, thus it was judged the 
items together formed a reliable scale.301 A further investigation into whether the 
scale would be more reliable if any item were deleted was undertaken. The 
results of this analysis are reported in Table 35. 
 
The item-by item analysis indicated that the scale would be improved if the item 
“It is easy for me to ask my community pharmacist questions about my 
medicines” were removed. Without this item removed the scale consisted of 
eight items α = 0.75. This formed a superior scale for analysis following the 
methods of Field (2009). The Medicines Experience Scale (MES) was thus 
formed of eight items. It is possible that this question does not capture a 
meaningful patient perspective on the availability of community pharmacy 
services, for example respondents may have perceived it to be easy to ask their 
pharmacist questions about their medicines, however they may not recognise 
the value in doing so. 
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Figure 46: Patients’ responses to the discharge medicines experience questionnaire (base 61).  
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Table 33: Patients' mean responses to the Medicines Experience Survey by site, gender deprivation and ethnic minority (base = 61) 
Question All (SD) Site 1 male  
(SD) 
Site 1 female 
(SD) 
Site 2 male 
(SD) 
Site 2 female 
(SD) 
Low 
Deprivation 
(SD)  
Medium 
deprivation 
(SD) 
High 
deprivation 
(SD) 
Ethnic 
minority 
(SD) 
When I left the hospital, I 
clearly understood the 
purpose for taking each of my 
medicines 
3.72 (1.44) 3.67(4.53) 3.67 (1.41) 3.55 (1.53) 4.33 (1.00) 3.27 (1.55) 3.94 (1.35) 3.75 (1.46) 4.00 (1.50)  
I am confident I can take my 
medicines as instructed 
4.51 (1. 
13) 
4.43 (1.21) 4.33 (1.32) 4.59 (1.81) 4.67(0.71) 4.36 (1. 
29) 
4.89 (0.32) 4.34 (1.33) 3.89 (1.69) 
It is easy for me to ask my 
community pharmacist questions 
about my medicines 
4.34 (1.06) 4.05 (1.32) 4.56 (0.72) 4.45 (1.01) 4.56 (0.73) 4.27 (1.27) 4.67 (0.69) 4.19 (1.15) 4.11 (1.05) 
When I left the hospital, I 
clearly understood how to take 
each of my medicines 
4.41 (1.17) 4.14 (1.42) 4.22 (1.30) 4.55 (1.06) 4.89 (0.33) 4.55 (1.04) 4.64 (0.97) 4.19 (1.38) 4.11 (1.54) 
It is easy for me to 
understand the instructions I was 
given for my medicines 
4.33 (1.21) 3.90 (1.55) 4.56 (1.01) 4.42 (1.05) 4.89 (0.33) 4.33 (1.21) 4.72 (0.75) 4.22 (1.34) 4.33 (1.32) 
It is easy for me to ask my GP 
questions about my medicines 
3.75 (1.41) 4.05 (1.16) 4.00 (1.58) 3.72 (1.49) 2.89 (1.45) 3.91 (1.70) 3.83 (1.30) 3.66 (1.41) 3.56 (1.42) 
I currently understand the 
purpose for taking each of my 
medicines 
4.21 (1.21) 3.90 (1.30) 3.89 (1.45) 4.32 (1.17) 5.00 (0.00) 4.18 (1.17) 4.56 (0.98) 4.03 (1.33) 4.22 (1.30) 
The healthcare team work 
together to support me in 
managing my medicines 
3.36 (1.53) 3.76 (1.41) 2.44 (1.59) 3.59 (1.65) 2.78 (0.97) 3.18 (1.47) 3.50 (1.72) 3.34 (1.47) 3.22 (1.56) 
It is easy for me to get all the 
information I need about my 
medicines 
4.15 (1.17) 4.24 (1.78) 4.00 (1.58) 4.27 (0.88) 3.78 (1.39) 3.90 (1.17) 4.44 (1.04) 4.06 (1.24) 3.56 (1.42) 
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Table 34: Inter-item correlations for the Medicines Experience Scale (MES) 
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Understood  
the purpose 
on leaving 
hospital 
1.00 0.20 0.20 0.49 0.23 0.12 0.56 0.13 0.23 
Confident I 
can take my 
medicines 
0.20 1.00 0.07 0.57 0.58 0.256 0.24 0.27 0.16 
Easy to ask  
my 
pharmacist 
0.20 0.07 1.00 0.29 0.17 0.08 0.15 -0.19 -0.02 
Clearly 
understood 
how to take 
on leaving 
hospital 
0.48 0.57 0.29 1.00 0.52 0.27 0.56 0.20 0.25 
Easy to 
understand 
instructions 
0.23 0.58 0.17 0.52 1.00 0.14 0.30 0.08 0.08 
Easy to ask 
GP 
questions 
0.12 0.26 0.08 0.27 0.14 1.00 0.01 0.41 0.35 
Currently 
understand 
purpose 
0.56 0.24 0.15 0.56 0.30 0.01 1.00 0.13 0.14 
Healthcare 
team work 
together 
0.13 0.27 -.019 0.20 0.08 0.41 0.13 1.00 0.49 
Easy to get 
information 0.23 0.16 -0.02 0.25 0.08 0.35 0.14 0.49 1.00 
 
Table 35: MES reliability item by item 
Item Scale Mean if Item 
Deleted 
Cronbach's Alpha if Item 
Deleted 
Understood  the purpose on leaving 
hospital 
33.07 0.71 
Confident I can take my medicines 32.28 0.70 
Easy to ask  my pharmacist 32.44 0.75 
Clearly understood how to take on 
leaving hospital 
32.38 0.67 
Easy to understand instructions 32.46 0.71 
Easy to ask GP questions 33.03 0.73 
Currently understand purpose 32.57 0.71 
Healthcare team work together 33.43 0.73 
Easy to get information 32.64 0.72 
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MES means for patients overall and by site, gender, gender, deprivation band 
and for ethnic minority patients are shown in Figure 47. Higher MES values 
were measured for both males (33.00, SD 5.62) and females (33.22, SD 4.09) 
at Site 2. At Site 1 lower MES values were observed for females (31.11, SD 
7.59) and males (32.10, SD 7.25). Mean MES values were also explored for 
those from low, medium and high areas of deprivation. Values for those patients 
from low and high areas of deprivation did not differ greatly (low deprivation = 
31.55, SD 5.99, high deprivation = 31.60, SD 6.81) whilst higher mean values 
were recorded for those from areas of medium deprivation (34.50, SD 5.04). 
Patients from ethnic minorities had less positive MES values than other patients 
(30.89, SD 6.29). 
7.3.1 Constructs within the question scale 
A principal components analysis (PCA) was undertaken to explore any 
underlying constructs within the scale and determine whether the data could be 
formed into valid subscales. 
The PCA was undertaken on the original nine items with an orthogonal 
(varimax) rotation. There is some debate about the sample size necessary to 
perform a PCA: Field described how views on the ratio of participants to 
variable range from 5–15 (in this data there is a ratio of 6.7).301 He goes on to 
describe empirical research that concludes that factors with four or more loads 
of 0.6 are reliable.   
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Figure 47: MES means by gender, site and deprivation  
32.44
32.10
31.11
33.00 33.22
31.55
34.50
31.60
30.89
29.00
30.00
31.00
32.00
33.00
34.00
35.00
Mean
 242 
 
 
A Bartlett’s test of sphericity indicated that overall the inter-item correlations 
were large enough to conduct the analysis (X2 (36) = 148.45, p<0.001) and a 
Kasier-Meyer-Olkin measure of sampling adequacy (0.72) was good overall and 
either adequate or good for each individual variable (values ranged between 
0.610 – 0.778 which are above the minimum accepted value of 0.5). The anti-
image correlation matrix (which presents the amount of variance not explained 
whilst controlling for the effects of the other variables) is presented in Table 36 
with the Kasier-Meyer-Olkin measures of sampling adequacy highlighted. Each 
of the off-diagonal negative correlations was also small, which indicates the 
presence of underlying factors. 
The scree plot in Figure 48 demonstrates several points of inflection indicating 
several components; however as the sample size is small three factors with an 
eigenvalue (the substantive importance of each component) in excess of 1 were 
extracted. Those three components and their loading factors are presented in 
Table 37. In combination they explained 65.3% of the variance. The first 
component comprised of two items about patients’ understanding of the 
purpose of their medicine and one question about the ease of asking 
community pharmacy questions about their medicines, yet this last item fails to 
load strongly onto any of the components and does not logically fit within this 
component. This component explained 34.5% of the variance. 
The second component, explaining 18.2% of the variance, comprised of items 
about patients’ confidence in their ability to take medicines and understanding 
of how to take medicines. The third component, explaining 12.6% of the 
variance, comprised of items about the ease of asking questions and getting 
information from patients’ GPs and an item about the healthcare team working 
together to support them. The three components were named: (1) Medicines 
understanding; (2) Medicines self-efficacy; and (3) Medicines support. 
An analysis of the components as subscales was performed. Subscale 1 
(medicines understanding) had a reliability statistic of α = 0.58, and an improved 
reliability statistic of α = 0.71 if the item ‘It is easy for me to ask my community 
pharmacist questions about my medicines’ were removed, which makes sense 
given that the item does not logically sit well with the two other items in this 
subscale. Subscale 2 (medicines self-efficacy) had a reliability statistic of 0.79.   
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Table 36: The anti-image correlation matrix for PCA. 1 indicates the measure of sample adequacy 
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Understood  the 
purpose on leaving 
hospital 
0.7781 0.039 -0.080 -0.181 0.018 -0.029 -0.396 0.018 -0.134 
Confident I can take my 
medicines 
0.039 0.7061 0.084 -0.372 -0.431 -0.059 0.110 -0.177 0.065 
Easy to ask my 
pharmacist 
-0.080 0.084 0.61011 -0.217 -0.058 -0.113 0.031 0.250 -0.004 
Clearly understood how 
to take 
-0.181 -0.372 -0.217 0.7651 -0.180 -0.156 -0.377 0.011 -0.094 
Easy to understand 
instructions 
0.018 -0.431 -0.058 -0.180 0.7741 0.010 -0.084 0.083 0.008 
Easy to ask GP -0.029 -0.059 -0.113 -0.156 0.010 0.7181 0.186 -0.295 -0.147 
Understand purpose -0.396 0.110 0.031 -0.377 -0.084 0.186 0.6951 -0.097 0.037 
Healthcare team work 
together 
0.018 -0.177 0.250 0.011 0.083 -0.295 -0.097 0.6331 -0.391 
Easy to get information -0.134 0.065 -0.004 -0.094 0.008 -0.147 0.037 -0.391 0.7201 
 
Table 37: PCA component loading values 
Component 1: Medicines Understanding 
 (34.54% of variance) 
Component 1 
loading 
Component 2 
loading 
Component 3 
loading 
When I left the hospital, I clearly understood the 
purpose for taking each of my medicines 
0.84 0.05 0.16 
It is easy for me to ask my community pharmacist 
questions about my medicines 
0.40 0.23 -0.29 
I currently understand the purpose for taking each of 
my medicines 
0.82 0.16 0.06 
Component 2 : Medicines self-efficacy 
(18.19% of variance) 
   
I am confident I can take my medicines as instructed 0.08 0.85 0.22 
When I left the hospital, I clearly understood how to 
take each of my medicines 
0.60 0.61 .019 
It is easy for me to understand the instructions I was 
given for my medicines 
0.19 0.83 -0.01 
Component 3: Medicines support 
 (12.55% of variance) 
   
It is easy for me to ask my GP questions about my 
medicines 
-0.03 0.28 0.65 
The healthcare team work together to support me in 
managing my medicines 
0.01 0.09 0.85 
It is easy for me to get all the information I need about 
my medicines 
0.23 -0.03 0.77 
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Figure 48: A Scree plot mapping the PCA components and their eigenvalues. 
Subscale 3 (medicines support) had a reliability statistic of α = 0.68. As only one 
subscale had a reliability statistic in which was higher than that of the eight-item 
scale (0.75), and that scale only contained two items, it was judged appropriate 
to conduct analysis on the larger, eight-item scale. 
Once the final components of the MES had been established it was decided 
that exploratory modelling using the MES as a dependent variable would offer 
some insight into the impact of patient demographics and their medicines 
management social networks on the scale values, taking into consideration the 
fact that the experience of a patient safety incident would impact on the MES 
value. The results of that analysis are described in the following sections. 
7.4 Patient safety incidents after hospital discharge 
During interviews patients were asked whether anything had happened since 
they left hospital to make them more or less confident in their medicines. Their 
responses were recorded and data were extracted and summarised in table 
format, which is presented in Appendix 6. Data were reviewed by two clinical 
researchers to determine whether patients’ reports indicated that a patient 
safety incident had occurred using the NPSA definition of a patient safety 
incident, quoted below: 
“A patient safety incident is any unintended or unexpected incident which could 
have or did lead to harm for one or more patients receiving NHS care.”14  
In total events relating to 31 patients were extracted and assessed. A Cohen’s 
kappa (κ) agreement statistic was calculated based on the ratings of two   
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assessors on three values: yes; no; and unsure. The results of the ratings are 
shown in Table 38. Assessors agreed that 16 of the 31 extracted events 
(51.6%) were patient safety incidents.  
Table 38: Summary of safety incident assessments by two clinical researchers 
 Assessor 2 
Assessor 1 No Yes Unsure 
No 11 1 1 
Yes 1 16 0 
Unsure 1 0 0 
Total 13 17 1 
 
7.5 Standardising the MES values 
In advance of statistical modelling, MES values were standardised by 
calculating their logarithm base 10 values. Standardisation is important to obtain 
minimum skew in the data so a linear relationship may be measured and to 
minimise the impact of outliers on any statistical models fitted to the data. 
A logarithm base 10 standardisation is suitable for right skewed data with 
positive values. Figure 49 is a histogram of the standardised MES values whilst 
Figure 50 is a boxplot of the values with outliers highlighted. Standardised 
values on the scale ranged from 1.18–1.60 with a mean of 1.50 (SD 0.10). 
Figure 51 is a normal Q-Q plot of the observed versus expected values of the 
standardised scores and Figure 52 is a normal Q-Q plot of scale observed 
versus expected normal values. 
Exploratory MES analysis 
Two-tailed independent samples t-tests indicated a non-significant associations 
between standardised values of the Medicines Experience Scale and gender (t 
(59) = 0.144, p = 0.886) and site (t (59) = -0.959, p = 0.342). A range of other 
categorical variables were also tested and the results of those t-tests are shown 
in Table 39. One test yielded a significant result: unsurprisingly those patients 
who had reported a safety incident (n = 16) reported less positive experiences 
with their medicines (m = 1.46, SE = 0.01) than those who did not   
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(n= 44; m = 1.52, SE 0.02) (t (58) = 2.189, p<0.05, r = 0.28). A subsequent 
series of correlations were explored between interval variables and values on 
the standardised MES. They are presented in Table 40. Only one variable was 
significantly correlated: the number of weak components in patients’ networks 
was significantly negatively correlated with values on the standardised MES (r = 
0.285, p<0.05), indicating a linear relationship between higher numbers of weak 
network components and less positive experiences. Lower degree scores 
values also negatively correlated, indicating that patients with more network 
members have less positive experiences, although this failed to reach statistical 
significance. 
7.6 Modelling patients’ post-discharge medicines experience 
Using the results of the exploratory data analysis, a multiple linear regression 
model using the standardised MES as a dependent variable was constructed. A 
hierarchical blockwise approach was used to ascertain the change in squared 
residual values as each variable was added to assess how effective each model 
was in explaining MES variation and the impact of additional variables of the 
significance of the model. The binary variable recording whether patients had 
reported a safety incident was included as a control variable. Some variables 
were excluded to avoid multicollinearity, which occurs when there are strong 
positive or negative correlations between independent variables. For example, 
the number of weak components was significantly correlated with network 
density and network degree. 
In total eight multiple linear regression models were fitted and each was 
statistically significant in explaining a proportion of the variation in the 
standardised MES. Each of these statistical models is presented in Table 41 
with overall F statistic for the analysis of variance, the value of the squared 
residuals and the parameter estimates. The final model was selected as it 
explains the most variation in the MES (29%), whilst controlling for the most 
demographic variables. The addition of further predictors produced a non-
significant model.  
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Table 39: Two-tailed independent sample t-tests on the standardised MES –  significant tests 
highlighted * 
Variable t (df =59) p 
Gender 0.144 0.886 
Site -0.959 0.342 
Ethnic minority 1.217 0.228 
Deprivation (low vs medium) -1.365 0.184 
Deprivation (low vs high) 0.106 0.916 
Deprivation (medium versus high) 1.529 0.133 
Spouse present in the network (equal 
variances not assumed) 
-1.348 0.184 
Highly valued spouse -0.994 0.324 
GP present in the network 0.901 0.371 
Highly valued GP -1.228 0.224 
Community pharmacist present in the 
network 
-0.117 0.908 
Highly valued CP 0.716 0.447 
Cardiac rehab / HF nurse present in the 
network 
0.533 0.596 
Highly valued CR / HF 0.595 0.554 
Safety incident 2.189 (df=58) 0.039 * 
 
 
 
 
Table 40: Correlations with the standardised MES – significant correlations highlighted * 
Variable Pearson correlation (r) p 
Age 0.134 0.302 
Number of weak components -0.285 0.028 * 
Proportion of weak components 0.007 0.960 
Density - 0.015 0.908 
Degree -0.201 0.121 
Lay degree -0.096 0.461 
Prof degree -0.125 0.339 
Diversity -0.033 0.803 
Broker -0.114 0.387 
Normalised Broker 0.123 0.348 
Ego between -0.128 0.331 
Normalised ego betweenness 0.029 0.947 
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Figure 49: A histogram of the log10 MES values 
 
Figure 50: A boxplot of the log10 MES values 
  
Figure 51: A Normal QQ plot of observed log10 MES values 
 
Figure 52: A normal Q-Q plot of the observed vs expected log10 MES values 
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The regression model equation therefore is:  
y (MES) = 1.497 – 0.073 (safety incident) – 0.020 (weak network components) 
+ 0.019 (spouse in network) – 0.065 (ethnic minority) + 0.038 (deprivation 
medium) + 0.05 (deprivation high) + 0.017 female + 0.001 (age) + 0.30 (Site2). 
The model overall is statistically significant (p<0.0005), and two predictor 
variables within it have statistically significant parameter estimates. Patients 
who were assessed to have experienced a patient safety incident had 
significantly lower MES values than other patients (-0.073 (CI -0.128, -0.017)) 
(p<0.05), whilst controlling for gender, age, site, ethnicity and deprivation. 
Those with greater numbers of weak components in their networks also had 
significantly lower values on the scale (-0.020 (CI -0.035,-0.004)) (p<0.05), 
again controlling for the same demographic variables. 
Two cases had standardised residuals greater than two and none had greater 
than three, and as this figure is less than 5% of the sample size it can be 
concluded that there are no outliers with a significant influence on the 
regression model. Cook’s distance measures the overall influence of a case on 
the regression model. For the selected model, no values of Cook’s distance 
were greater than 1 (range 0.00-0.311), which indicates that no individual case 
has an overly large influence. A case-by-case analysis of standardised DFBeta 
values – which calculate the differences in parameter estimates should cases 
be removed – were not greater than +/- 1; and only one case had a 
Mahalanobis’ distance value greater than 15 (15.033) (which was case 2-3). 
This statistic indicates whether cases are outliers. The average leverage for the 
model is 0.167 and no cases had a leverage value greater than twice the 
average leverage, again indicating that no case is overly influential in fitting the 
model. Together the results of these tests suggest a high degree of confidence 
that no one case exerted too great an influence of the model parameter 
predictions. 
Model assumptions were tested by examining the residuals for 
heteroscedasticity and non-linearity. Figure 53 is a scatterplot of the 
standardised predicted values of the regression model versus the standardised 
residuals showing a relatively random array of values with no curves, which 
indicates limited heteroscedasticity and non-linearity Figure 54 is the normal   
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probability plot of the regression model residuals, showing relatively normally 
distributed residuals, and Figure 55 is a histogram of the residuals with a normal 
curve indicating their normal distribution. It was judged that these assumptions 
had not been violated.
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Table 41: Multiple linear regression models explaining MES variation 
Model F (df) p R2 Change 
(p) 
Constant (SE) 
(95% CI) 
Constant 
(p) 
Coefficients (SE) 95% CI Coefficients (p) 
1 4.437 (59) 0.039 * 0.07  1.519 (0.015) 
(1.490–1.548) 
<0.0005 
*** 
Safety incident -0.059 (-0.028) -0.116 – -0.003 0.039 * 
2 
 
4.469 (59) 0.016 * 0.135 0.044* 1.586 (0.036) 
(1.515–1.658) 
<0.0005 
*** 
Safety incident  -0.052 (0.028) 
Weak components -0.015 (0.007) 
-0.108– -0.003 
-0.030–0.000 
0.063 
0.044 * 
3 
 
 
3.762 (59) 0.016 * 0.168 0.147 1.567 (0.038) 
(1.491–1.642) 
<0.0005 
*** 
Safety incident -0.059 (-0.028) 
Weak components -0.015 (0.007) 
Spouse present in the network 0.036 
(0.024) 
-0.114– -0.003 
-0.030–0.000 
-0.013–0.084 
0.038 * 
0.053 
0.147 
4 4.437 (59) 0.005** 0.232 0.037 1.559 (0.040) 
(1.520–1.679) 
<0.0005 
*** 
Safety incident -0.071 (-0.027) 
Weak components -0.017 (0.007) 
Spouse present in the network 0.024 
(0.024) 
Ethnic minority -0.075 (0.035) 
-0.126– -0.016 
-0.032– -0.003 
-0.024–0.073 
 
-0.145-0.005 
0.012 * 
0.021 * 
0.124 
 
0.037 * 
5 2.997 (59) 0.014 * 0.252 0.472 
 
 
1.592 (0.49) 
(1.493–1.690) 
<0.0005 
*** 
Safety incident -0.069 (-0.028) 
Weak components -0.018 (0.007) 
Spouse present in the network 0.019 
(0.025) 
Ethnic minority -0.070 (0.036) 
Deprivation medium vs low 0.034 (0.036) 
Deprivation high vs low 0.002 (0.035) 
-0.125– -0.014 
-0.033– -0.003 
-0.032–0.070 
 
-0.142–0.003 
-0.038–0.108 
-0.068–0.071 
0.015 * 
0.019 * 
0.461 
 
0.059 
0.351 
0.965 
6  0.023 * 0.258 0.585 1.587 (0.050) 
(1.487 –
1.688) 
 
<0.0005 
*** 
Safety incident -0.069 (-0.028) 
Weak components -0.019 (0.008) 
Spouse present in the network 0.022 
(0.026) 
-0.125– -0.013 
-0.034– -0.003 
-0.031–0.074 
 
0.015 * 
0.019 * 
0.461 
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Ethnic minority -0.073 (0.037) 
Deprivation medium vs low 0.036 (0.036) 
Deprivation high vs low 0.005 (0.036) 
Gender 0.015 (0.036) 
-0.147–0.001 
-0.037–0.108 
-0.066–0.076 
-0.040–0.070 
0.059 
0.351 
0.965 
0.585 
7  0.030 * 0.270 0.351 1.518 (0.089) 
(1.339 –
1.697) 
 
<0.0005 
*** 
Safety incident -0.071 (-0.028) 
Weak components -0.018 (0.008) 
Spouse present in the network 0.022 
(0.026) 
Ethnic minority -0.067 (0.037) 
Deprivation medium vs low 0.034 (0.036) 
Deprivation high vs low 0.004 (0.036) 
Gender 0.016 (0.027) 
Age 0.001 (0.001) 
-0.127– -0.015 
-0.033– -0.003 
-0.031–0.074 
 
-0.142–0.008 
-0.038–0.107 
-0.067–0.075 
-0.039–0.071 
-0.001–0.003 
0.014  * 
0.021  * 
0.408 
 
0.077 
0.345 
0.911 
0.554 
0.351 
8  0.031 0.291 0.233 1.497 (0.090) 
(1.315 –
1.678) 
 
<0.0005 
*** 
Safety incident -0.073 (-0.028) 
Weak components -0.020 (0.008) 
Spouse present in the network 0.019 
(0.026) 
Ethnic minority -0.065 (0.037) 
Deprivation medium vs low 0.038 (0.036) 
Deprivation high vs low 0.05 (0.035) 
Gender 0.017 (0.027) 
Age 0.001 (0.001) 
Site 2 0.30 (0.25) 
-0.129– -0.017 
-0.035– -0.004 
-0.033–0.072 
 
-0.140–0.010 
-0.035–0.110 
-0.066–0.076 
-0.038–0.072 
-0.002–0.003 
-0.020–0.079 
0.011  * 
0.013  * 
0.461 
 
0.087 
0.345 
0.911 
0.554 
0.351 
0.233 
  
  
 
 
253 
 
 
Figure 53: A scatterplot of the standardised predicted values of the 
regression model versus the standardised residuals. 
 
 
Figure 54: A normal probability plot of the regression model residuals. 
 
 
 
 
 
 
Figure 55: A histogram of the regression model residuals.  
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7.7 Discussion 
In this chapter a reliable medicines experience scale was created and explored 
from a series of questions put to patients six weeks after their hospital 
discharge. The question set explored patients’ understanding of their medicines, 
their access to HCPs, their confidence to take their medicines, and their 
perceptions of the multi-disciplinary nature of their care. In answering these 
questions patients reported on the whole positive experiences with their 
medicines, which were not reflected in their qualitative accounts. Patients were 
less positive about their views of the healthcare team working together to 
support them in managing their medicines. There were no convincing subscales 
in the data, but this may be a reflection of the relatively small number of 
questions in the scale. Exploratory data modelling indicated that the number of 
weak components in patients’ networks – which are the number of individuals or 
groups of individuals in the ego-network connected only to the patient – 
impacted on their experiences with their medicines, whilst controlling for socio-
demographic factors and whether the patient had disclosed a patient safety 
incident during their interview. This indicated that a lack of connectivity in 
patients’ ego-networks negatively impacted on their experiences with their 
medicines. 
7.8.1 Creating the scale 
It was necessary to create a new question set to attempt to capture patients’ 
experiences specifically with their discharge medicines as no suitable measure 
existed. A review of measures showed that instruments recorded: medicines 
use self–efficacy; 290 adherence;182,183,350 beliefs about medicines;351 
satisfaction with information about medicines;236 general transitions and 
continuity;58 and medicines discrepancies.291 Yet no measure was identified that 
recorded patients’ experiences of leaving hospital, although there is evidence 
that the patient experience can be linked to patient safety and clinical 
effectiveness for many different health conditions.352 Doyle et al. argue, based 
on their literature review, that a focus on improving the patient experience will 
also impact on the safety and effectiveness of the care patients receive;352 
however no studies were identified that linked patients’ experiences with their 
medicines to patient safety. This measure has gone some way to developing 
such a tool, however more work needs to be done to refine and validate it.   
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It was noticeable that in interviews patients recounted experiences that were 
less positive than their responses to the questionnaire and they had less 
positive assessments of their own understanding of their medicines than they 
were willing to admit when they were asked to definitively assess their abilities 
by selecting an answer option on a questionnaire. Including no reverse 
response options may also have constituted a weakness. Reversing 
questionnaire items (for example through negatively wording some questions) is 
a widely used approach to preventing acquiescent or inattention response bias 
in surveys,  although there is now some debate over the reliability of such 
methods.353 
The question set together formed a reliable scale, although the Cronbach’s 
alpha statistic was towards the lower end of what is generally thought to be 
acceptable.301 Removing the community pharmacy question improved the alpha 
statistic slightly, and as this question had low correlations with other questions, 
it is possible that it measured something that it did not set out to measure. For 
instance, the question ‘It is easy for me to ask my community pharmacist 
questions about my medicines’ intended to measure self-efficacy to access the 
clinical services of a community pharmacist. It may, however, actually have 
measured whether patients found their community pharmacist accessible, 
rather than whether they would find it appropriate to or have the confidence to 
ask their pharmacist questions about their discharge medicines, or indeed 
whether they would wish to. Qualitatively in Chapter 5, patients reported 
preferring to ask their GP if they had questions about their medicines or 
perceiving the GP or hospital doctor to be the superior source of information or 
decision-making, which is also a finding in other studies.116,354–356 
7.8.2 Exploratory modelling of the data  
Exploratory modelling of the Medicines Experience Scale attempted to unite the 
datasets collected from patients: aspects of their ego-networks structure, their 
experiences of patient safety incidents, along with demographic data were used 
as independent variables in a multiple linear regression. When controlling for 
other variables, including whether a patient experienced a safety incident, the 
perceived number of weak components in their network was found to have a 
significant impact on the scale value. The analysis indicates that for this group 
of cardiology patients, the lack of connectivity in their networks has an impact   
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on their medicines experiences. However, the findings should be treated with 
some caution: it is possible that this result is influenced by responses to one 
item in the MES exploring patient views of the healthcare team working together 
to support them in managing their medicines. However, the scale alpha statistic 
indicated that it was a robust measure, i.e. the questions adequately measured 
a single construct. A larger sample and further refinement of the scale is now 
needed to explore these potential weaknesses and generate further evidence to 
confirm or refute the findings of this study. 
7.8.3 Further development of the Medicines Experience Scale 
Whilst the questionnaire used in this research formed a reliable scale, several 
problems were noted during the qualitative semi-structured interviews with 
patients. For example, in one or two instances patients explained that they did 
not understand their medicines, yet when completing the questionnaire they still 
responded positively to the items exploring their understanding, possibly 
displaying a social desirability bias that did not come into play during 
interviews.357 This finding also indicates how qualitative work can often draw out 
perceptions and experiences from patients more effectively than quantitative 
instruments and use that data to develop survey instruments.358 The 
questionnaire would benefit from revision; the qualitative interview data 
described in Chapter 6 indicate how important the practical and emotional 
support of friends and family are in enhancing patients’ abilities to self-manage 
their medicines. Therefore, a question about having or needing help with 
medicines may enhance the survey as tool to measure experience. The 
questionnaire may also usefully explore the interventions that patients are 
required to make to ensure they get the correct medicines when they need them 
after they have left the hospital to further explore the patient role in system 
resilience.67,359 This could be done through asking a question about their 
experiences providing medicines information to HCPs, as described                 
in Chapter 6.  
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Chapter 8 – General discussion 
8.1 Introduction 
This thesis has explored cardiology patients’ experiences of and roles in 
medicines management from the point of discharge in two hospitals, until 
approximately six weeks after they arrived home. In the first instance, an 
observational study described what patients were told about their medicines 
when they left hospital and identified the contributory and protective factors that 
might impact on medicines safety at discharge. Secondly, a social network 
analysis of the medicines management system as perceived by patients 
identified the range of HCPs and personal contacts who operate within that 
system.  
The research described has employed a range of methods: structured and 
unstructured observation; semi-structured interviews; social network analysis; 
and survey. Analysis methods included descriptive statistics, the application of 
the YCFF, social network structural analysis, thematic analysis, principal 
components analysis, and linear regression. One of the strengths of this 
research is how data triangulated to generate a clear picture of patients’ 
experiences of medicines management when their care was transferred after a 
period in hospital. Complementary qualitative and quantitative methods were 
able to measure and describe aspects of patients’ discharge medicines 
management ego-networks. Triangulation of data collected through mixed 
methods made it possible to verify the results of different stages of the 
research.221 Evidence collected at different stages of the study converged: for 
example, the results of observations made on wards and the identification of 
individual and patient factors as contributory factors to potential medicines-
related safety incidents were validated by patients’ retrospective accounts of 
their experiences of being discharged from hospital. Further triangulation was 
achieved through different means. Firstly, collecting both observation and 
interview data over an eight month period meant that data collected at different 
times contributed to the same results; secondly, data were collected in two 
distinct healthcare economies, which meant that data from different places 
triangulated; and finally data were collected from different groups – staff and 
patients – which provided complementary findings.  
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The aim of this chapter is to discuss the studies’ findings and their implications 
for patients, and for policy and practice. Firstly, it will summarise the key 
findings from each chapter, then it will discuss those findings, relating them to 
other research and policy. 
8.2 Summary of chapter findings 
Chapter 4 described the results of an observational study of hospital 
discharges. It identified a lack of consistency in the way patients were informed 
about their medicines during and after their hospital discharge. At discharge, 
nurses most commonly told patients about the timing of their medicines but 
rarely told them about how to take them or the side effects they might 
experience. Nurses in the discharge lounge told patients less about their 
medicines than nurses on the ward and the discharge discussion was of a 
shorter duration in the discharge lounge. There was also variation in patients 
being told about whether and how the hospital would communicate with the 
patients’ primary care team, and how patients should get repeat medicines. 
Most patients were not told this and staff also usually did not highlight the 
written discharge summary or other written medicines information to patients. 
Furthermore, the findings showed how hospital policy impacts on the quality 
and safety of the care that patients experience. Using the YCFF,30 this study 
also suggested there was a range of factors that could contribute to an unsafe 
medicines management process at discharge as well as various defences 
against medicines safety incidents. Active failures included errors of execution, 
for example lapses, skill-based mistakes, and violations. Individual factors 
included the staff approach to discharging patients with medicines; and patient 
factors were also evident. Local working conditions gave rise to delays and 
interruptions; and problematic task characteristics, such as the complex nature 
of discharging patients with medicines, and internal patient transfer were also 
identified as contributory factors. Defences included individual staff and patient 
factors, such as note taking, and staff training and education where staff had 
specialist cardiology knowledge and experience. 
Chapter 5 was an analysis of the structure of patients’ medicines management 
ego-networks. Using SNA, it described how patients had developed networks of 
different sizes and compositions and how some had personal network members 
who they perceived to be current or former healthcare professionals. One in   
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four patients had no contact with their GP in the period after their discharge 
from hospital and almost half had no direct contact with a community 
pharmacist. The structure of medicines management was complex and 
individual to each patient; some patients managed the involvement of many 
healthcare professionals and healthcare support staff providing medicines-
related care or services in the post-discharge period. Patients perceived low 
levels of connectivity between alters in their networks. The most connected 
professional network members were perceived to be cardiac rehabilitation and 
heart failure nurses, followed by GPs. Community pharmacists were perceived 
to be less connected than GPs, specialist nurses and hospital doctors, 
demonstrated by their comparative isolation in those networks where they did 
feature. 
Chapter 6 presented a thematic analysis of semi-structured interviews with 
patients using a social network analysis framework to identify the content and 
function of patients’ medicines management ego-networks. Content comprised 
information and advice about medicines from both professional and personal 
network members. Many patients described leaving hospital with insufficient 
information about their medicines, however, their networks were proactive and 
reactive in filling some of those gaps. Additionally, patients’ cognitive and 
emotional attitudes about their medicines were influenced by their personal and 
professional contacts. Patients’ medicines management networks were multi-
functional: they provided medicines orientation, practical and emotional support 
as well as health condition management. Networks also risked patient safety 
though the failure of medicines management systems which meant that some 
patients did not fully understand changes made to their medicines and some 
patients were not able to access repeat medicines when they needed to. 
Chapter 7 presented the results of the Medicines Experience Survey. It found 
that patients were on the whole positive about their medicines experiences, 
even though the experiences described during interviews were not positive. 
Patients were less positive in their evaluation of the extent of the healthcare 
team working together to support them in managing their medicines. The 
questions formed a reliable scale which was improved after removing one item, 
which was about the ease of being able to ask questions of a community 
pharmacist. A principal components analysis did not identify any convincing   
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subscales in the data. A multiple linear regression was used to perform 
exploratory analysis of the scale data. A model was fitted using the 
standardised MES as the dependent variable which explained nearly a third of 
the MES variation. Whilst the model overall was significant, only two individual 
independent variables were significant, they were the number of weak 
components patients’ ego-networks (the number of unconnected people or 
groups of people) and whether patients had experienced a safety incident 
related to their medicines since their hospital discharge.  
The following sections will discuss these findings in synthesis with reference to 
theory, current policy, practice and models in healthcare. I will begin with 
management of medicines at hospital discharge, the patient-centredness of 
medicines management and with systems, patient safety and patient resilience.  
8.3 Medicines management at hospital discharge 
Keeping patients safe from preventable harm from their medicines continues to 
be a worldwide and UK priority. Since this research was started, UK policy has 
recognised the risks faced by patients when they leave hospital (or transition) 
and issued guidelines to help make their care safer.72,90,327  
Transitional care is a set of actions that co-ordinate continuity of care;54 and 
patients in this study shared many of the experiences of those who participated 
in other research exploring medicines management experiences after discharge 
from hospital. For example, many experienced unsafe care, which has been 
previously measured in the form of ADEs,47,48,50,51,166 although unsafe care may 
not have been the direct cause of an ADE. Others felt that they lacked 
information and understanding concerning their medicines;137,143–145,147,148,164 
and some perceived a lack of co-ordination of care.144,150,166,167 
Transitional care is the responsibility of the person or organisation transferring 
care and the person or organisation receiving care. All the patients in this study 
experienced a care transfer, even though the extent to which they recognised 
their hospital discharge as a ‘care transition’ is debatable. It is likely that many 
patients viewed their return home as the end of an episode of care or the 
recovery from the health crisis that found them admitted into acute care. During   
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this period, patients themselves spanned the divide between hospital and 
primary care. They had a view of the care they received from different staff in 
different organisations that is not afforded to those staff. It is patients’ “unique 
observational position”305(p4) which has been described in this research and 
which has laid bare some of the gaps in medicines management during their 
care transfer as well as illustrating where medicines management can work 
well.  
By employing a systems-based analysis, the data yielded new insight into the 
extent of risk in the current system of discharge medicines management in two 
hospitals, along with the defences therein. Systems approaches have long been 
recommended as a way of reducing risk to patients.13,360 Specifically, use of 
systems-based models has afforded a view about how poorly designed systems 
can negatively impact on the safety of medicines use.63,79,98 However, the care 
components that potentially delivered safer care, synthesised from all the data 
presented in chapters 4–7, are detailed below: 
1 Ward discharge rather than pre-transfer before discharge, in this case 
to a discharge lounge. 
2 Accurate and timely reconciliation of patients’ medicines in primary 
care. 
3 Adequacy of individual preparation to use medicines after discharge. 
4 Adequacy of explanation of changes made to medicines after 
discharge. 
5 Consistency of follow-up in primary care to support medicines use. 
In the UK in general, guidelines about what patients should be told about their 
medicines at discharge are vague, especially about how to prepare patients to 
self-manage their medicines.72,91,92 In contrast, more in-depth information is 
offered in Australia by the Australian Pharmaceutical Advisory Council’s Guiding 
Principles to Achieve Continuity in Medicines Management.361 It specifies that 
patients need to be given sufficient information in a usable and understandable 
format to “enable safe and effective use”,361(p39)  listing the information patients 
should receive in verbal and written formats: 
• Stopped and started medicines; 
• Active ingredients and brand names; 
• Medicines purpose and actions;  
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• Medicines dose, route and administration schedule; 
• Special directions and precautions; 
• Side effects, interactions and how to manage them; 
• How to store medicines; 
• Safe disposal of medicines; 
• Contact details for HCPs for follow-up information. 
The way discharge is currently managed in UK hospitals may mean that 
providing this depth of information verbally is beyond hospital resource. In 
addition, evidence from ward observations and patient interviews in this 
research indicates that hospital may not be the best place to give detailed, 
verbal medicines information – the patients are still unwell and they are anxious 
to get home. 
Both hospital sites had policies about discharging patients with medicines; 
however, neither gave adequate detail about how patients should be counselled 
about their medicines. This reflects current national guidelines that focus more 
on what healthcare organisations tell each other about patients’ discharge 
medicines than what they should tell the patient.  
Once home, many patients themselves co-ordinated the system that supplies 
their medicines, which is discussed in more detail in section 8.5.1, yet it was 
also clear that some patients were managing a system that lacked co-ordination 
and personalisation. Overall, observation, interview, ego-networks, and survey 
data together demonstrated how patients are at the centre of a complex and 
sometimes incomplete medicines management system involving multiple 
healthcare professionals and multiple medicines for various co-morbidities, 
which they must navigate and co-ordinate often without tailored support from 
HCPs. The system experienced by some patients in this research had 
insufficient barriers to prevent hazards becoming losses:32,63 as many as a sixth 
of patients experienced patient safety incidents. 
Whilst many patients in this study had contact with community pharmacy staff to 
obtain repeat medicines, interview data suggested that most of the patients did 
not access NMS or MUR services, even though they were all in the target group 
for MUR and they reported that it was easy to ask community pharmacists 
questions about their medicines. Social network data demonstrated how many   
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patients had no direct contact with a community pharmacist. Even the few 
patients who had an MUR did not fully benefit from it, either because they had 
not been given time to prepare or they did not understand the purpose of the 
consultation. Some patients also indicated that they perceived other HCPs, 
such as cardiac rehabilitation nurses and GPs, to have the necessary authority 
and expertise to discuss their medicines. Other patients did not themselves 
attend their community pharmacy to obtain their repeat medicines, sometimes 
because they felt too ill and a relative collected their medicines, or because they 
used community pharmacy delivery services. Community pharmacy could play 
a positive role in supporting discharged patients and recent work has found 
benefits to the formal integration of community pharmacy into the post-
discharge pathway;117 and community pharmacists themselves are positive 
about medicines review services.347 There needs to be further work exploring 
how patients can benefit more fully from these services, which may involve a 
more formal referral from the hospital or from the GP, or home-based 
consultations, taking into account local cardiac specialist nurse contacts. There 
is some evidence that changing services or products so that they are the default 
option is a successful approach to behaviour change because it guards against 
inertia and the target audience perceives the default option to be the advised 
option.362,363 The behavioural insights framework EAST – easy, attractive, social 
and timely – suggests services should be designed in a way that reduces the 
very barriers that prevent people from using them.364 The framework sets out 
how services should be designed so they are: 
• Easy to access and the default option. They should also be simple to 
understand;  
• Attractive, so that they are incentivised or personalised; 
• Social, so that people understand that others also access the service, 
and so that they also encourage their peers to do so;  
• Timely, so that people are offered the service when they need it most 
and are receptive to it, and that the immediate perceived cost (or 
‘hassle’) to people in using the service does not outweigh the perceived 
long-term benefit. 
Redesigning the MUR using this framework may be a successful approach to 
increase the number of discharged patients who access the service. It would   
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become a default, personalised appointment made for patients with a 
community pharmacist at an easy-to-access location, which happens soon after 
they have left hospital. It needs clear, simple messages about its purpose and 
the immediate and long-term benefits, and an unequivocal message that all 
patients using certain groups of medicines will be asked to attend MURs. 
8.4 Patient-centred medicines management 
An important measure of the quality of healthcare is whether it provides care 
designed to meet individual patient’s needs.365 The literature review in Chapter 
2 identified how patients’ experiences did not reflect the person-centred care 
specified by current healthcare policy.72,87,106 This research has demonstrated 
that every person’s experience of medicines management is, in a sense, 
individual: each sociogram in Chapter 5 and Appendix 3 showed the different 
structures of care perceived by patients. However, the extent to which the care 
that patients experience is individualised or tailored to their needs and values is 
questionable. Yet there is a current drive to position patients as fully integrated 
into the healthcare systems and in receipt of patient-centred, individualised 
care. For instance, the Health Foundation offers a framework for person-centred 
care with four key principles: 
• Care is co-ordinated; 
• Care is personalised; 
• Care supports people to recognise their own strengths; 
• Care affords people dignity and respect.366 
The NHS vision for individual participation is: 
“Patients and carers are involved in managing their own health, care and 
treatment. This means being involved in decisions about their care and having 
choice and control over the NHS services they receive.”367(p13)  
Based on the qualitative interview data in Chapter 6, many of the patients who 
took part in this research would probably not recognise the care they 
experienced in these descriptions. Some could not easily access their GP and 
felt confused and isolated from support. NICE guidelines on medicines 
optimisation reinforces that the care patients receive should be patient-centred, 
although health professionals should understand the extent to which patients 
wish to be involved in decisions about their treatment.72 The parental model of   
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healthcare (one where the clinician would interpret the optimal treatment for a 
patient based on its clinical relevance) was probably highly familiar (and 
acceptable) to many of the patients in this study. Indeed, some patients talked 
about the trust that they had in the prescribers of their medicines to give them 
safe and effective care, which negated their need to understand more about 
their treatment. Many were indeed grateful for the good care they perceived. 
However, some patients in this study described situations where access to 
services and management of their treatment was out of their control, their ego-
networks highlighted the perceived lack of communication between their 
healthcare providers, and many described how the care they received regarding 
their medicines fell short of their expectations. To begin with, both observation 
and interview data indicated that their experiences of being discharged from 
hospital were highly varied. They were not involved in decisions about the 
timing and location of their discharge and it was not apparent that their 
individual needs or preferences were taken into account when deciding the level 
of medicines information to give them. The experiences of these patients reflect 
findings elsewhere: readmitted patients have described how their capabilities 
and resources and knowledge of their condition and medicines history was 
ignored by HCPs during discharge.368 The patient-centredness of discharge in 
nine hospitals in five countries has been specifically examined with little 
evidence of a patient-centred approach.369 The study found that there was a 
lack of care provider prioritisation of discharge consultations and that discharge 
information was given too quickly, used jargon, and was unclear, with little time 
for patients’ questions. It also described how patients’ abilities to self-manage 
their care after discharge were often not critically assessed by hospital staff.  
In this research, it was clear that many factors combined to inhibit patient-
centred encounters, many of which align with the conceptual framework 
proposed by Mead and Bower for doctors (see Figure 56).370 These were: 
• Consultation-level influences: work pressures faced by staff, interruptions 
whilst discharging patients, the presence of third parties (other than 
those the patient wished to be there) and time limitations. 
• Clinician factors: the nurse’s knowledge of the patient; attitudes towards 
the importance of discharge discussions; and knowledge of the condition 
and medicines.  
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• Patient factors: attitudes and expectations. 
Mead and Bower’s model maps other dimensions influencing patient-
centredness, such as remote ‘shapers’, which include cultural norms and formal 
and informal learning, professional context; and additional clinician and patient 
factors such as age and personality. These were not looked for in this research, 
however it may be the case that alternative research methods, such as 
qualitative interviews with staff members, would uncover these additional 
influencers in the hospital discharge context. 
 
Figure 56: A model of a patient-centred relationship, from Mead and Bower.370 Reproduced with kind 
permission. 
An important limitation of the Mead and Bowers model it that it deals only with 
single clinician-patient relationships, which is also reflected in other studies of 
patient-centredness which focus on preferences, therapeutic alliances, and the 
balance of power within single patient-practitioner relationships.371–374 
Observations, interviews and ego-networks highlighted the multi-professional, 
multi-organisational context in which patients experience healthcare across 
transitions – and even in single settings – with different clinicians in different 
roles performing specialist functions at different times and different locations. 
Instead of a one-to-one patient-clinician relationship, patients in this research 
mostly experienced one-to-many relationships. Even if patients experienced 
individual, patient-centred encounters with a clinician, such as a cardiac 
rehabilitation nurse, the overall system itself may not have been calibrated to   
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deliver patient-centred medicines management at all its touch points. This is 
reflected in patients’ ambivalent responses to the item on the medicines 
experience survey (see Chapter 7) that probed their opinion of whether the 
healthcare team works together to support them in managing their medicines, 
and the significant impact that disconnectedness in patients’ networks had on 
their MES value. The ego-networks developed for each patient were mostly 
very loosely connected, which also demonstrated patients’ views of the lack of 
co-ordination between their care providers. 
Questions must be raised, therefore, about how an integrated patient-centred 
medicines management process could be designed and embedded into policy 
to make it an actionable goal for all care providers within healthcare economies. 
Interventions have attempted to enhance the person-centredness of medicines 
management, although few have been delivered by multidisciplinary teams.375 
Previous work has to some extent explored this issue and proposed allocating 
specific care providers in primary care who would help patients through the 
transfer, acting as a bridge, being an advocate and communication and 
information manager, helping patients “navigate” the healthcare 
system.376(p2850),377 An Organisation for Economic Co-operation and 
Development (OECD) report in 2007 identified that primary care systems would 
need to adapt to meet the increasing demands of those living with chronic 
conditions, and recommended the introduction of non-medical care co-
ordinators to better co-ordinate care.377 Obviously this role would come with a 
significant resource implication, however for some patients here their cardiac 
rehabilitation nurse or heart failure nurse already performed some aspects of 
this function. These clinicians bridged the gaps in care continuity through 
proactive communication between clinicians in different healthcare 
organisations. It has been proposed that safety incidents may occur because 
conditions outstrip the ability of staff to bridge gaps in care;41 this was indeed 
true for some patients in this study, for example those who did not receive the 
correct set of repeat medicines. Some patients here compensated by bridging 
the gaps themselves, demonstrating enhanced resilience in the medicines 
management system, which is discussed in more detail in section 8.5.1. The 
high betweenness measures of patients in their ego-networks – often viewed as 
an indicator of ‘control’ in a network –296 indicated the high levels of ‘control’ 
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they needed to have to manage their medicines effectively. In this context, it is 
likely that patient ‘control’ compensates for poor system co-ordination, which is 
discussed in more detailed in section 8.5. It should be considered, however, 
that as people age and their conditions deteriorate, they may increasingly lack 
the ability to both identify and bridge gaps in their care. 
Recent USA work developed ten patient-centred priority areas for medicines 
management, including patients using peers, families and social networks to 
improve medicines management (patients themselves identified this as a higher 
priority than researchers and other stakeholders). Other priorities included those 
relating to prescribing education, enhanced patient knowledge, and the 
development of tools and systems to evaluate patient-centred medicines 
plans.375,378 It is apparent, though, that medicines management outcome 
measures need to reflect patients’ views and values. Adherence is the measure 
often used to measure the success of medicines management interventions, 
and more patient-centred outcomes are less commonly measured.375 
Adherence is not a patient-centred outcome because patients’ values and 
preferences may not be aligned with adhering to their medicines instructions. 
Patient involvement and satisfaction measures, it could be argued, are 
measures of experience rather than of outcome, yet these are amongst many 
methods of measuring aspects of patient-centred care.375,379 
Collins expertly demonstrates the dissonance between how the system records 
outcomes and how the patient experiences their own health condition.380 In 
doing so, he highlights the difficulty in recording patient-centred outcomes: 
currently the healthcare system values person-centred care for its impact on 
pre-defined outcomes such as biomedical measures or system measures, i.e., 
readmissions or appointment keeping, but has no effective way of linking 
person-centredness to person-centred outcomes. What is required, according to 
Collins, are Person-Centred-Process-Measures linked to Person-Centred-
Outcome-Measures; and measures that take into account the episodic nature of 
healthcare encounters which deliver outcomes for patients over time. For 
patients in this study, a person-centred outcome measure might have been their 
level of orientation about their medicines. Many patients managed multiple 
medicines for co-morbidities and saw both multiple healthcare professionals 
and support staff to manage their treatment; their level of confidence and   
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understanding of their complete medicines set might be a useful indication of 
the person-centredness of medicines management. Medicines orientation is 
discussed in more depth in section 8.7. 
The next section will discuss the results of this research in the context of 
systems, patient safety and patient resilience. 
8.5 Systems, resilience and patient safety 
The work in this thesis has been informed by human factors theory, a systems 
approach that is capable of effecting safer patient outcomes and understanding 
where weaknesses in systems create risks for patients. Human factors has 
been used extensively as a basis to study and improve healthcare 
systems;9,25,32,360,381–384 and policy specifically has attempted to make 
healthcare safer during care transfers with a growing focus on the safety of 
medicines due to poor co-ordination at handovers of care.92,385 
Medicines management is a large, important and expensive system within UK 
healthcare;74 this research demonstrates, through a wide range of patient-
derived data, that this system spans multiple organisations and many HCPs and 
healthcare support staff but with patients themselves playing a central role in 
the system. This research also demonstrates that there are multiple contributory 
factors and defences that respectively pose both risks and protect patients. In 
doing so, it reflects the premise of Carayon’s work looking at a systems 
engineering model for patient safety that sees the patient as an integral part of 
the whole system.383 Carayon et al. developed a model that places the ‘person’ 
in the medicines work system who performs tasks and who must interact with 
others, the physical environment, and organisations to take their medicines at 
home.383 ‘Task factors’ include the number of medicines and doses; ‘tools and 
technologies’ are, for example, medicines boxes; ‘organisation factors’ can be 
access to medicines. Patients in this study were subject to those contributory 
factors in self-managing their medicines. The safety incidents in Appendix 6 
demonstrate that tools and technologies, such as medicines boxes, confused 
patients, and organisational factors such as poor management of 
communication, adversely impacted on patients’ access to medicines. 
Reactive and proactive approaches to safety management are conceptualised 
by Hollnagel as Safety 1 and Safety 2.386 Safety 1, the traditional approach of   
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learning from failure, is driven by what goes wrong in healthcare to minimise the 
risk of failures reoccurring. The hypothesis of Safety 1 is that adverse events 
and events that succeed have different causes. Hollnagel describes this as 
reactive safety management, because it reacts when things go wrong and takes 
steps to remedy the system. Alternatively, Safety 2 has a focus on ‘what goes 
right’ and how systems can be resilient to variations in practice. For example, 
how people in systems adapt depending on the working conditions, embracing 
how people are variable and capable of adapting processes in order to fulfil a 
task safely. Safety 2 is a proactive practice that attempts to ensure safety 
through a thorough understanding of systems and people, anticipating where 
the system has weaknesses and adapting before something goes wrong, rather 
than afterwards.  
For many of the patients in this study the system appeared to work well enough 
to prevent harm, although not necessarily to proactively optimise benefit from 
medicines. A focus on what worked well could proactively add to the resilience 
of the current medicines management system through identifying where 
systems and the people therein need additional resources to achieve similarly 
safe outcomes. For example, the following synthesis of the data indicates that: 
• Many patients were able to safely self-manage their medicines at home 
and qualitative semi-structured interviews demonstrated how some 
developed routines and their own checklists or spreadsheets to help 
them organise and keep track of their medicines routines. Patient 
resilience is discussed in more depth in section 8.5.1. 
• Interviews also demonstrated that many patients received emotional and 
practical support after hospital discharge from friends and family, 
including those people who patients perceived to have heightened 
knowledge of their medicines.  
• Observation data described how some patients benefitted from more 
patient-centred medicines management at discharge – nursing staff 
helped them to develop a good understanding of their medicines. 
• Ego-network value measures and qualitative interview data showed that 
some patients obviously valued contact with cardiac rehabilitation or 
heart failure nurses after their discharge; these staff offered in-depth   
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• tailored support with patients’ treatment and on-going condition 
management. 
• Healthcare professionals often fulfilled medicines management tasks in a 
way that resulted in safe care, for example there is evidence from 
interviews that for many patients, discharge medicines information was 
communicated and acted upon in a timely way, repeat prescriptions were 
issued and medicines were dispensed. Some patients’ denser ego-
networks also indicated that some HCPs worked to ensure system gaps 
did not have too great an impact on patients. 
According to Hollnagel, the consequence of the traditional focus of safety on 
things that go wrong, is a “creeping lack of attention to things that go right.”387(p4) 
Referred to as habituation, characterised as disregarding things that regularly 
happen, it is possible that because patients often do receive their repeat 
medicines once back in primary care, there has been little proactive attention on 
understanding where systems have worked so that good practice can be 
developed where it is lacking. Indeed, there are positive findings in this thesis. 
For example, there are robust defences in the system when patients are 
discharged, including nursing staff using the discharge summary as a checklist 
when telling patients about their medicines, and the structured processes in 
place for discharging patients. In short, many aspects of the system function 
well much of the time. Nevertheless, a substantial minority of patients reported 
experiencing safety incidents and there are clear opportunities for improvement 
based on resilience. Although it is an approach that, according to Vincent and 
Wears clashes with traditional healthcare models that seek to make 
management decisions through measuring performance;388 however they also 
point out that systems can over rely or mistakenly rely on resilience, for 
example where resources are stretched, where system issues do not represent 
real challenges, and where system changes actually should be made. 
In summary, when considering the medicines management system a balance 
should be achieved between understanding the causes of safety incidents when 
they occur and in understanding where systems operate well in order to 
understand and develop good practice. The following section discusses how 
patients themselves were able to build resilience into the medicines 
management system.  
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8.5.1 Patient resilience  
Vincent et al. argue that resilient safety management “depends on the ability of 
managers and operators to detect and anticipate dynamic vulnerabilities within 
the system”.389(p27) Patients can also do this – and it is also important to take 
into account the potential role of patients’ friends and family – in identifying, 
avoiding and reporting system vulnerabilities and enhancing their strategies to 
add resilience. Resilience in a system is its ability to continue operating safely in 
spite of circumstance that may potentially contribute to error, such as 
unexpected spike in demand, or interruptions during the delivery of care. The 
data here suggest that patients and their personal contacts play an important 
role in creating a resilient system, and a deeper understanding of this may 
contribute towards Safety 2-informed system management. The literature 
review in Chapter 2 highlighted how research has characterised the patient role 
in discharge medicines management as one that passively receives care. 
Research has seldom focussed on patients’ own strengths and their often 
successful self-management of their medicines when they leave hospital and 
are away from the protective environment of 24-hour hospital care. Furniss et 
al. outlined seven categories of ‘cognitive resilience’ – “the ability to identify and 
implement strategies that minimise the likelihood or consequences of cognitive 
slips.”35(p96) This framework was later applied to understand how patients 
developed resilience strategies to minimise the risk of unintentional non-
adherence to medicines.67 The categories are listed in Table 42 below and used 
to highlight how, as demonstrated in observation and interview data, patients 
and their personal contacts enhanced discharge medicines management 
system resilience to avoid patient safety incidents. The patients in this research 
described or were observed in six of the seven resilience domains, indicating 
that they and their personal contacts had wide-ranging roles in creating a 
resilient system that exceeded avoiding unintentional non-adherence, which 
was the focus of the previous medicines-related application of the framework.67 
This framework does not account for emotional resilience, which patients in this 
study described developing through accessing the support of their family and 
friends. Emotional resilience helped them come to terms with their health 
condition and enhanced their abilities to continue with their medicines regimens 
once they had left hospital; in essence providing a protective effect.         
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Research has explored different impacts of social support on responses and 
resistance to stress and other physical health outcomes;390,391 and it has been 
argued that developing more positive emotions can positively impact on illness 
recovery.392 Further work could usefully explore how emotional resilience 
amongst patients may enhance medicines management systems. 
Table 42: Resilience strategies, definitions and examples from this research, from Furniss et al. and 
Furniss et al.35,67 
Resilience strategy Definition 
 
Patient and family examples from this study 
Cue creation to 
support prospective 
memory 
A cue is created as a 
reminder about something in 
the future. 
Leaving medicines out in a visible place to 
remember to take them. 
 
Setting alarms to remember to take medicines. 
Premature 
completion 
awareness 
Action is taken as a reminder 
about ‘X’ after the main goal 
has been achieved 
None discussed or observed 
Pre-emptive 
separation and 
disambiguation 
Things are separated or 
differentiated so they are not 
mixed up 
Grouping medicines together into the time of 
day they should be taken. 
 
Separating medicines into multi-compartment 
boxes with differentiating daily medicines doses. 
Pre-commitment 
check 
Things are checked before 
committing to a course of 
action 
Checking the medicines on their repeat 
prescription after discharge are correct before 
ordering them. 
 
Checking the medicines given to them by 
community pharmacy before taking them. 
 
Keeping hospital packaging and checking new 
medicines against it. 
 
Asking friends and family members and HCPs 
about possible side effects they perceive. 
Managing resource 
availability 
Resources are managed so 
they are available. 
Patients and family members contacting GP 
surgeries to arrange repeat prescriptions. 
 
Carrying around GTN sprays. 
 
Patients and family members taking in or 
telephoning surgeries with information about 
new and changed medicines. 
 
Accessing help to collect medicines from the 
community pharmacy. 
Routine adjustment Routine is adjusted in 
response to a threat or an 
opportunity. 
Patients and family members buying 
compliance aids to help establish a routine with 
new and changed medicines. 
 
Patients and family members creating 
spreadsheets and checklists to keep track of 
medicines taken. 
 
A family member taking control of supply 
management and organisation. 
Safety reinforcement Where some safety barrier, 
procedure or practice is 
reinforced. 
Organising face-to-face contact with an HCP to 
re-order complicated medicines sets. 
 
Patient involvement in reconciliation through 
giving information about discontinued 
medicines. 
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Whilst some patients and their networks worked hard to make medicines 
management safer, for example in their management of their medicines at 
home, it remains evident that others are compensating for poorly performing 
systems that, for example, may fail to accurately perform reconciliation in 
primary care in a timely way. A recent doctoral study has identified that primary 
care medicines reconciliation post-hospital is often performed by untrained 
staff;393 which falls short of recent medicines optimisation guidelines (NICE 
2015).72 In the context of increasing medicines use in primary care,74 it is vital 
that adequate attention is paid to improving the quality and safety of care that 
patients receive. 
8.6 Learning from patient-reported incidents and concerns 
Chapter 5 described how many patients in this research alerted their GP 
practice or pharmacy when there was been a failure in the system that supplied 
their medicines. As discussed in that chapter, it is probable that most or all of 
those events went officially unreported. There has been a recent, growing 
interest in the roles that patients can play in managing their own safety and the 
tools that may be needed to help them do so. Lawton and Armitage argue that 
patient reports of patient safety incidents offer new insight into the type and 
frequency of patient safety incidents over and above those generated through 
staff reports.34 For example, open questions, rather than closed, have been 
assessed as more effective in eliciting patient experiences, such as adverse 
events;394 and patients are willing to report events when asked.33 There is 
debate, however, about whether patient reports of unsafe care are accurate. 
For example, a USA study highlighted the differences between the events 
patients reported as unsafe and the classification of the study’s investigators;395 
yet further work demonstrated that patient accounts uncovered more adverse 
events than medical record review.66,396 Such data, however, can be hard to 
collect, for example because patients may feel uncomfortable reporting or 
challenging the care they have received.34  
As in previous research, patients in this study were able to recount care 
experiences that may have caused them harm.66,395–397 They described them 
during the interviews focussing on their experiences of managing their 
medicines and the involvement of other people in doing so. However, it is 
debatable whether the patients themselves or the staff they interacted with   
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would have characterised some of their experiences as unsafe and reported 
them as such. In several instances patients described their experiences as 
inconvenient or as evidence of poorly organised care, for instance if their GP 
practice had not updated their medicines list with changes made in hospital. In 
this study, patients responded to a question asking whether anything had 
happened that made them more or less confident in their medicines. As 
previous work has found, the use of this non-technical language (i.e. avoiding 
terms such as adverse events and medication error) may have been key in 
helping elicit patient accounts of unsafe care.394 One question in the semi-
structured interview schedule asked patients about the safety of their 
medicines, and this mostly elicited views of the safety of the medicines products 
themselves, which they felt were heavily regulated and therefore unlikely to 
cause them harm. Instead, patient accounts of unsafe care were volunteered in 
response to a more general, experience-based question. Given the ability of 
patients here to recount unsafe care when asked about their experiences 
qualitatively, there may be opportunities to review the way that reporting 
systems collect information about patient safety incidents using language 
patients can understand and that can capture their concerns more effectively. 
8.7 Medicines orientation  
The literature review in Chapter 2 found that studies aiming to understand how 
staff educate patients about their medicines and how much patients understand 
their medicines did not take into account the many strategies that may be 
employed to support desired health behaviours.152,398 Instead, they focussed on 
patients’ recall of receiving information and their knowledge of their medicines. 
The thematic analysis of interview data revealed a process that for some 
patients was different to solely receiving information or developing knowledge. I 
have used the term Medicines Orientation to describe this process and its 
components are displayed in Figure 57. It was a joint process of the patient 
developing knowledge about and building confidence in medicines, along with 
developing particular cognitive and emotional attitudes to their medicines 
management. Knowledge was developed through receiving or seeking 
information about medicines, through advice and shared experiences. 
Confidence was developed through cognitive and emotional attitudes, advice 
and shared experiences and through receiving information about medicines.   
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Functionally, medicines orientation led to effective management of medicines in 
the home. 
It is conceptually different from health orientation, which is described as a 
person’s individual motivation to be healthy.399 Health orientation is based on 
four indicators: health consciousness; health information orientation; health 
oriented beliefs; and healthy activities – currently medicines orientation is based 
on two indicators – knowledge and confidence – and describes how these are 
built through people’s interaction with healthcare professionals and their 
personal contacts. After leaving hospital, some patients became competent and 
confident medicines managers and their orientation included adjusting to the 
new activity involved in medicines taking or their re-adjusting to a changed 
medicines routine. The different data sources here revealed that medicines 
orientation was a process that began in hospital and continued through their 
interactions not only with HCPs – cardiac rehabilitation nurses, community 
pharmacists, GPs and nurses – but also with their friends and family members 
who offered advice, shared their experiences and communicated their own 
attitudes about medicines. This research indicated that HCP involvement in 
medicines orientation was more effective when a more person-centred 
approach was adopted, for example the approach used by cardiac rehabilitation 
nurses. Other research exploring patient-centred medicines activities in a 
hospital setting found nurses to adopt varying ways of interacting with patients 
about their medicines and cited time constraints as a barrier to patient-centred 
medicines activities;400 interestingly, patients in this study often indicated that 
whilst some HCPs appeared not to have much time for them, cardiac 
rehabilitation nurses seemed to dedicate as much time as required to 
discussing their health and their medicines and ensuring that medicines 
orientation was as complete as possible. As discussed in section 8.11, there is 
an opportunity to further explore and refine medicines orientation as a concept 
through additional research. 
Finally, Bodenheimer proposed a self-management education model, drawing 
comparisons with traditional methods of educating patients, as shown in Figure 
58.401 Traditionally, education is imparted by health professionals through giving 
disease specific information with the goal of compliance with treatment. Self-
management education aims to enhance the patient’s confidence to improve   
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their clinical outcomes through offering problem-solving skills. Education can be 
provided by those other than a clinician, although the education is still 
embedded in formal settings. 
 
Figure 57: A medicines orientation map, based on qualitative thematic analysis. 
Table 43: A comparison of traditional patient education and self-management education, from 
Bodenheimer.401 
 Traditional patient education Self-management education 
What is taught? Information and technical skills 
about the disease 
Skills on how to act on problems 
How are problems formulated? Problems reflect inadequate 
control of the disease 
The patient identifies problems 
he/she experiences that may or 
may not be related to the disease 
Relation of education to the 
disease 
Education is disease-specific and 
teaches information and technical 
skills related to the disease 
Education provides problem-
solving skills that are relevant to 
the consequences of  chronic 
conditions in general 
What is the theory underlying 
the education? 
Disease-specific knowledge 
creates behaviour change, which 
in turn produces better clinical 
outcomes 
Greater patient confidence in 
his/her capacity to make life-
improving changes (self-efficacy) 
yields better clinical outcomes 
What is the goal? Compliance with the behaviour 
changes taught to the patient to 
improve clinical outcomes 
Increased self-efficacy to improve 
clinical outcomes 
Who is the educator? A health professional A health professional, peer 
leader, or other patients, often in 
group settings. 
  
Medicines 
orientation
Knowledge
Information
Advice
Shared 
experiences
Confidence
Instrumental 
attitudes
Affective 
attitudes
Advice
Shared 
experiences
Information
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This research has demonstrated that patients orientate themselves towards 
their medicines in a much more dynamic and fluid way through multiple 
interactions. In this sense it is more aligned to Pescosolido’s Network Episode 
Model,245,402 which comprises two internal and three external ‘systems’ that 
impact on someone’s illness career. This is discussed in more detail in the 
following section which explores this research in the context of Social Network 
Analysis. 
8.8 Social Network Analysis 
Exploring patients’ social contexts has provided new insights into the quality of 
the care patients perceive and the range of professional and personal contacts 
involved in providing that care. Whilst recent work undertaken at the University 
of Manchester has used SNA to describe the ‘medicines work’ undertaken by 
the patient and others in their social network,247 this is the first study that has 
mapped the structures of those networks informed by human factors theory to 
view a ‘system’ of medicines management. Using SNA, and specifically an ego-
network approach, has facilitated an understanding of the real structure of 
medicines management viewed from the patient perspective as they 
experienced it, rather than as it was designed or delivered by HCPs. The 
research has given novel insight into the degree of patient-centredness in an 
established system in two distinct geographical areas, which was discussed 
earlier in section 8.4. Using diaries, interviews and a hierarchical network 
mapping tool (Figure 14) it has highlighted how patients are at the centre of 
different compositions of professional and personal contacts and it has allowed 
an understanding of the types of post-discharge medicines management 
support some patients benefit from, and of the lack of support and system-
access problems experienced by others. The study findings have also given 
insight into how health policies, such as the move to encourage patients to 
access the clinical care offered by community pharmacy, are experienced by 
patients. It has allowed insight into the role patients played in managing those 
networks of HCPs involved in medicines, affording an understanding of the 
perceived lack of connectivity amongst HCPs. Finally, the research has aided 
an understanding that informal communities of personal contacts were 
leveraged by many patients to gain support in medicines management.  
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It is universally accepted that people’s social networks impact on their health 
and wellbeing.250,255 Effects on health arise from perceived and actual social 
support, social influence, social engagement, social contact and resource 
access.250 However, people’s use of their social networks in managing their 
medicines has been less commonly explored or understood. This study has 
shown the often extensive networks surrounding patients and explored the 
multiple functions of those networks in providing medicines orientation, health 
condition management, and medicines support. Importantly, it has shown that 
patients’ medicines management networks have both facilitated and threatened 
patient safety. Further work might explore in more detail the functional aspects 
of social networks in patient safety. As a method, SNA has yet to demonstrate 
its potential value to patient safety research, although there is a small body of 
work that explores professional networks and the quality and safety of 
healthcare.254  
Pescosolido’s Network Episode Model describes the impact of social 
environments on people’s illness careers.245,402 She has explained that SNA 
“puts human face on issues of access, barriers, intervention, by conceptualizing 
these as actions of individuals”,403 and it also gives context to the human 
interactions that comprise the care patients receive. She criticises traditional 
models that have been used to explain health behaviour, such as the Health 
Belief Model404 and the Theory of Planned Behaviour,405 for their inability to 
explain phenomena such as delay in seeking help, or compliance with 
treatment. Instead, it is people’s networks that connect them to help, care and 
resources. In most recent version of the Network Episode Model, health choices 
and illness careers are affected by internal and external systems. Internal 
systems are genetics and biology; and the external systems are personal 
connections, health organisations and community. In more recent work 
Pescosolido argued that a SNA approach offers an ideal mechanism for 
intervention through understanding the social environments that, for example, 
create a supportive home, a helpful community or a caring or effective 
organisation.402 Healthcare policies, for example, may be well intentioned, but 
the HCP interpretation and resultant practice in a real-world setting may not 
reflect the spirit or the content of the policy. Conversely policies may be 
ineffective and it is crucial to understand these differences. The Network   
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Episode Model presents the treatment system as a changing network of 
healthcare providers and different organisations that people interact with, which 
change according to people’s health changes and resource availability. 
Importantly, a network approach and specifically the Network Episode Model, 
“allows us to unpack what happens to people when they go for treatment, and 
to think about how their experiences effect whether they stay in treatment, take 
their medications, get better.”406(p437) This research has demonstrated that 
people’s health and treatment is experienced through social ties, either through 
personal ties that support and facilitate recovery and access to treatment, or 
through the social, episodic context in which people experience healthcare 
systems. 
Finally, there is a clear opportunity for SNA to explore and understand more 
about people’s behaviours around their medicines. Other research into health 
behaviours have studied peer-effects on dieting behaviour;407 weight-loss 
interventions targeting peer groups;408,409 smoking behaviours;410 substance 
use;411 and the spread of obesity.412 The obesity study described how obesity 
spread within populations – the chances of someone becoming obese were 
influenced by whether their social contacts also became obese. The study 
explained that people did not become obese because their friends and family 
were obese, rather friends and family members became obese concurrently. 
Given these applications of SNA, it would be both interesting and plausible to 
design research to understand if peer-group interventions would yield positive 
effects, for example on attending a medicines use review, or perhaps on 
reporting a patient safety concern. There is evidence that network-based 
interventions have been effective in changing behaviour;413,414 and Smith and 
Christakis  assert that “the cumulative impact of a therapeutic or preventative 
intervention is thus the sum of the direct health outcome in the focal individual 
plus the collateral health outcomes in those to whom he/she is socially 
connected”.250(p419) 
8.9 Critique of the study 
Many of the limitations of the research outlined in this thesis were discussed in 
Chapter 3 and throughout the results Chapters 4–7. Here, an overview of the 
most important limitations will afford some broader context for readers to 
consider when evaluating the various approaches as a whole.   
 281 
 
 
The necessity to conduct a relatively small sample study to determine the extent 
of patients’ ego-networks through qualitative methods meant that, whilst 
saturation occurred, the quantitative aspects of the mixed methods research 
cannot in any statistical sense be generalised. Indeed, this is why the statistical 
modelling undertaken in Chapter 7 was designed to be exploratory and to aid 
interpretation, rather than to be statistically inferential. Despite this, the 
quantitative aspects of the research gave a strong indication of the types of 
experiences patients had and the range of different demographics achieved in 
the sample also adds to confidence that the findings are not limited to a narrow 
group of patients.  
This work focussed on only one category of health condition. As discussed in 
Chapter 3, cardiology was chosen because of its growing prevalence in the 
population and the impact it has on both patients and the UK healthcare 
system. Cardiology patients will almost inevitably have changes made to their 
medicines after a hospital admission. A focus on just one health condition 
means the work cannot fully represent the patient population and the myriad 
health conditions people live with, however the research literature reviewed in 
Chapter 2 indicated that patients with a range of different health conditions 
share some of the same experiences of the medicines management system. It 
is therefore likely that conducting the same research with patients with other 
chronic conditions may uncover similar experiences. Further research across a 
spectrum of conditions, however, would provide a stronger evidence base. 
This study focussed on all patients who left hospital with medicines, rather than 
those who left hospital with just new or changed medicines, although within the 
sample very few patients had not had their medicines amended during their 
inpatient stay. Targeting the sample to only those patients with changed 
medicines might have given clearer insight into the experiences of those people 
who may benefit from targeted support with medicines changes or completely 
new sets of medicines following their discharge. However, the wider focus 
meant that the study included those patients who may have been struggling to 
manage their medicines before their hospital admission, which indeed may 
have precipitated or contributed to their need for acute care. It also afforded an 
insight into people’s established medicines routines in the home and the pattern 
of interactions about their medicines with HCPs and informal contacts.  
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8.10 Conclusions 
This research has explored the structure, content and function of patients’ 
discharge medicines management ego-networks in two healthcare economies 
in England. A structured narrative literature review highlighted how studies of 
patients’ experiences of discharge medicines management had not used 
systems frameworks, despite a quarter of a century of international and UK 
policy advocating systems approaches in healthcare.   
In applying a combined human factors framework and SNA this research has 
generated novel insights into the composition of the discharge medicines 
management system. Clearly triangulated data offered evidence about the 
preparation patients received to use their medicines, related during interviews 
and complemented by the analysis of the observations made during hospital 
discharge. Together the data also highlighted the wide variation in post-hospital 
experiences; uncovered previously ‘hidden’ parts of the system; found ways that 
patients and their personal network members bridge gaps in their care through 
developing resilience strategies; and highlighted how the formal system places 
patients at risk and in some instances failed to enhance patient resilience 
through a lack of preparation to enable patients to effectively self-manage 
medicines. It has described the healthcare professionals and healthcare support 
staff who, along with patients and their informal networks, comprise the 
discharge medicines management system and it has demonstrated 
considerable variation in the structure of medicines management experienced 
by patients. This research has highlighted how patients experience a loosely 
connected network of professionals performing medicines management 
functions. Patients perceived little contact between professionals engaged in 
managing their medicines and the study showed that patients experienced 
significant gaps in the continuity of their care. 
8.11 Recommendations for future research 
The results of this research have raised several issues that merit further 
exploration. The optimum time for providing medicines support after hospital 
discharge would benefit from further exploration. The observation study showed 
that for some patients the focus of their last day in hospital was about getting 
home, rather than absorbing new information. This study found wide variation in 
what patients were told about their medicines when they left hospital and each   
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individual had different needs associated with developing their capabilities 
around their medicines. Further research should explore patients’ medicines 
support needs in more depth to build a personalised framework that considers 
the optimal time for provision of medicines orientation. This should be 
undertaken in a way that fully involves patients, for example through 
experience-based co-design.415 
This research constructed a measure of patients’ discharge medicines 
management experiences. Future research could refine that measure with the 
input or co-design of patients to explore how it could be further developed as a 
specific, patient-centred outcome measure. This work should begin qualitatively 
to explore patients’ views of the importance of the questionnaire items and how 
well they are able to capture their experiences of the complex medicines 
management system.  
In addition, the study found that patients with multiple morbidities had many 
different healthcare professionals involved in prescribing, monitoring and 
adjusting their medicines. Currently, information from different HCPs about 
patients’ medicines are fed through to GP practices. As the number of people 
living with multiple chronic conditions who require multiple specialist inputs 
increases, it will be crucial to pay attention to the role of GP practices in 
proactively managing this network. Further research should explore the barriers 
and facilitators to GP practices’ safe and proactive management of patients’ 
medicines information. This research should be informed by human factors and 
should also take into account the patient’s role in managing information about 
their medicines. 
As described in section 8.7, the process of medicines orientation would benefit 
from further research to develop a deeper understanding of how patients 
develop knowledge of and confidence in their medicines. This should be done 
qualitatively in the first instance, following patients with newly prescribed 
medicines over a period of time, collecting data regularly, to understand the 
drivers of developing understanding, shifting attitudes and growing confidence.  
Section 8.8 described how network-based peer interventions can positively 
impact of health behaviours. Further research to develop a peer-group 
medicines management intervention using a social network analysis framework   
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could explore whether peer-group interventions might yield positive effects on 
patient safety, medicines management and on patient-centred outcomes. Areas 
for research might include medicines orientation, attending a MUR, or reporting 
a patient safety concern. 
Finally, research exploring possible links between patient-centredness and 
patient safety would usefully contribute towards understanding how these two 
important aspects of healthcare can be further and more effectively integrated. 
8.12 Recommendations for policy 
There are clear implications for policymakers arising from the results of this 
research. In the first instance, and perhaps most importantly, there should be an 
increased drive to encourage patient reporting of medicines-related patient 
safety incidents following hospital discharge. Before this happens, patients need 
to know what a patient safety incident is, and why reporting is important, so as 
to help patients recognise situations where they have been at risk of 
preventable harm. It is crucial, however, that patients do not perceive that the 
quality of their care will be adversely impacted. Secondly, the NHS should act 
on information from this and other research and develop the role of a transfer 
manager to work with patients, their families and clinicians and to support 
patients in their post-discharge condition management. This should be a 
patient-centred role and policy-makers could usefully explore the transferability 
of the cardiac rehabilitation model. There might also be a review of the way GP 
practices manage the polypharmacy of patients with multiple morbidities and 
whether they take a proactive role in coordinating and overseeing the input of 
specialist clinicians from other organisations. 
Policy should draw attention to how medicines management systems that 
perform well achieve good quality and safe care for their patients. Further 
exploration of patients’ medicines management resilience strategies might 
enable HCPs to share those strategies in other patients. Patients could also be 
encouraged to share their strategies within peer networks. 
Changes need to be made to how patients are introduced to the MUR; for 
example, by referral from the hospital or by their GP which would aid patient 
understanding of its importance and its purpose, enhance patient confidence in 
it and give them the time to prepare for what is potentially a key aspect of their   
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care. Moving the review from the high street into a more clinical environment, 
such as a GP practice, may also enhance patient perceptions of its value. The 
content of the MUR consultation should also be re-visited so that patients 
receive tailored, practical help in organising medicines or creating checklists. 
Some patients in this research had devolved responsibility for their medicines to 
a family member, so therefore including a family member who manages the 
patient’s medicines may also enhance the MUR’s outcomes. Redesigning the 
service and how it is communicated based on a behavioural insights framework, 
such as EAST,364 might positively impact on its uptake.  
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4 Sample size considered in terms of analysis  12 Justification for analysis 
5 Representative sample     13 Assessment of reliability of process 
6 Description of data collection procedure   14 User involvement in design 
7 Rationale for data collection tools   15 Strengths and limitations discussed 
8 Detailed recruitment data 
 
Author / year 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Adeponle et al. 2009 0 3 2 0 2 3 2 3 0 2 1 1 0 0 1 
Ahmad et al. 2012 0 2 1 0 2 1 2 1 1 2 2 1 / 0 2 
Ahmad et al. 2014 0 3 2 0 2 2 2 3 1 2 1 2 / 0 2 
Ali et al. 2009 0 2 3 0 3 3 1 3 0 2 2 1 / 0 3 
Arnetz et al. 2010 0 2 2 0 2 3 3 3 2 0 2 2 / 0 3 
Attebring et al. 2005 0 2 3 0 3 2 2 2 / 3 3 3 3 0 1 
Bagge et al. 2014 0 3 3 0 3 2 2 3 / 1 3 3 3 0 1 
Beers et al. 1992 0 2 3 0 1 3 0 1 1 0 1 0 / 1 1 
Bennett et al. 2014 0 3 3 0 3 1 2 1 2 2 2 1 / 0 2 
Blennerhasset and 
Hilbers, 2011 
0 2 1 0 2 2 1 0 / 2 1 0 0 0 0 
Borgsteede et al. 2011 0 2 2 3 2 1 0 2 / 0 2 0 1 0 2 
Bremner et al. 2012 0 0 2 2 1 2 0 1 / 2 3 2 2 0 2 
Brown, 1995 0 1 2 0 2 2 0 2 0 0 0 0 / 0 0 
Burns et al. 1992 0 0 2 0 2 1 0 2 0 0 1 0 0 0 0 
Bushnell et al. 2010 0 3 3 0 3 3 3 3 0 3 3 2 / 0 2 
Calkins et al. 1997 0 3 2 0 2 3 1 3 0 0 1 1 / 
 
0 3 
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Author / year 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Chau et al. 2011 0 2 3 2 2 3 1 2 0 0 3 3 / 0 3 
Cochrane et al. 1992 0 2 3 0 2 3 0 1 0 0 2 0 / 0 0 
Coleman et a. 2005 0 3 3 0 2 1 3 1 2 0 2 1 / 0 1 
Conn et al. 1991 0 2 3 0 2 3 3 3 0 3 3 1 / 0 1 
Conn et al. 1992 0 2 3 0 2 2 1 0 0 3 1 0 / 0 0 
Decker et al. 2008 2 2 3 0 2 2 3 2 / 2 3 2 3 0 2 
Ehrenreich et al. 2012 1 3 3 0 1 3 2 3 0 1 2 2 / 0 3 
Eijsbroek et al. 2013 0 3 3 0 2 3 3 1 / 2 3 2 1 0 2 
Enguidanos and 
Brumley, 2005 
0 2 3 1 3 1 0 2 0 0 2 0 / 0 0 
Forster et al. 2005 0 2 3 0 3 3 2 2 2 0 2 3 / 0 2 
Forster et al. 2004 0 2 3 0 3 3 1 3 2 0 2 1 / 0 1 
Forster et al. 2003 0 2 3 0 3 2 2 2 0 0 2 1 / 0 3 
Garavalia et al. 2011 0 2 3 3 2 2 1 2 / 2 2 1 3 0 2 
Gray et al. 1999 0 3 3 2 2 3 1 3 2 0 2 1 / 0 3 
Gray et al. 2001 0 2 3 2 2 3 1 3 2 0 3 1 / 0 3 
Glintborg et al. 2007 0 2 3 0 2 3 2 3 1 1 0 2 / 0 2 
Graham and Kunkle, 
1996 
0 3 3 0 2 2 1 2 0 3 2 0 / 0 2 
Hain et al, 2012 0 1 2 0 2 3 3 1 2 1 1 1 / 0 1 
Johnson et al. 2010 0 2 2 0 1 3 1 3 0 1 0 1 / 0 3 
Kerzman et al. 2004 0 3 3 2 2 2 1 2 0 0 2 0 / 0 3 
Kimmel et al. 2010 0 1 3 0 2 3 2 3 0 0 2 0 / 0 2 
King et al. 1998. 0 3 3 0 2 2 3 1 1 3 2 2 0 1 3 
Knight et al. 2011 0 3 3 0 2 3 1 3 / 2 3 0 0 0 1 
Kripalani et al. 2008a 0 2 2 0 2 3 3 3 3 0 2 2 / 0 3 
Kripalani et al., 2008b 0 2 3 0 5 1 1 3 0 1 3 1 / 0 3 
Krishnan et al. 2004 0 2 3 0 1 2 1 3 0 1 2 1 / 0 2 
Leegaard And 
Fagermoen, 2007 
0 2 3 0 1 2 3 2 / 2 2 2 2 0 3 
Lindquist et al. 2011 0 2 2 0 2 3 1 3 0 2 2 2 / 0 2 
Maniaci et al. 2008 0 2 2 0 2 3 1 3 0 0 1 1 / 0 2 
Makaryus and 
Friedman,  2005 
0 1 2 0 1 1 0 1 0 0 1 0 / 0 0 
Manuel et al. 2011 0 0 3 0 2 2 0 1 / 0 2 1 2 0 1 
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Author / year 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Mansur et al. 2008  0 3 2 0 2 2 0 2 1 0 3 2 / 0 2 
Mansur et al. 2009 0 3 2 0 2 3 3 3 0 3 2 1 / 0 2 
Martens 1998 0 2 3 0 3 3 2 2 / 0 0 0 0 0 0 
Marusic et al. 2014 0 2 3 0 2 3 0 2 0 2 2 2 0 0 3 
Melloni et al. 2009 0 2 3 0 3 3 2 3 0 3 2 2 / 0 2 
Micheli et al. 2007 0 3 3 0 3 3 1 2 0 0 2 3 / 1 2 
Mistiaen et al. 1997 0 0 3 0 2 3 3 3 3 3 2 0 / 1 0 
Mulhem et al. 2013 0 1 1 1 1 2 0 3 0 0 1 1 / 0 1 
Nikolaus et al. 1996 0 3 3 0 2 3 3 2 0 0 1 0 / 0 1 
Olfson et al. 2000 0 1 3 0 3 3 2 3 0 3 1 1 / 0 0 
Pasina et al. 2014 0 1 3 0 2 2 2 3 0 3 2 2 / 0 3 
Paulino et al. 2004 0 3 3 0 2 3 0 3 0 3 3 1 / 0 3 
Rushworth et al. 2012 0 2 2 2 2 2 3 2 / 2 3 2 2 1 3 
Sexton and Brown, 
1999 
0 3 3 0 1 2 2 1 0 1 1 0 / 0 0 
Souter et al. 2014 0 3 3 3 3 3 3 3 / 3 2 0 2 0 3 
Stafford et al. 2012 0 3 3 0 1 2 2 2 / 0 3 2 2 0 3 
Stange et al. 2012 0 1 2 0 2 3 2 2 1 2 3 2 / 0 1 
Stewart and Pearson, 
1999 
0 3 2 0 2 3 1 1 0 0 2 0 / 0 3 
Tarantino et al. 2010 1 3 2 0 2 3 2 2 0 2 2 1 / 0 0 
Toren et al. 2006 0 3 2 0 2 3 3 3 0 2 3 0 / 0 3 
Ulfvarson et al. 2005 0 2 3 0 3 3 2 2 0 2 2 1 / 0 2 
Ulfvarson et al. 2006 0 2 3 0 2 3 3 1 0 2 2 2 / 2 0 
West et al. 2010 1 2 2 0 1 3 2 3 0 0 0 2 / 0 1 
White et al. 2010 0 3 3 3 2 2 2 2 / 0 2 0 3 0 2 
Ziaeian, B et al. 2012 0 1 3 0 3 3 1 3 0 0 2 2 / 0 3 
Total 5 153 188 26 152 177 115 158 29 87 137 83 29 7 127 
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Appendix 2 – Data collection tools 
A Patient information leaflet 
 
 
You are being invited to take part in a research study. 
Before you decide whether to take part, it is important for you to understand 
why the research is being done and what is involved. Please take time to read 
the following information carefully and discuss it with friends or relatives if you 
wish. You are entirely free to decide whether or not to take part in this study.  
Your decision about taking part will not affect the standard of care you receive. 
 
If there is anything that is not clear, or if you would like more information, 
please speak to Beth Fylan – the study co-ordinator – who will be 
available on the ward to answer your questions. 
 
The study will involve you keeping a record of who you contact and who 
contacts you about your medicines from the time you are discharged from 
hospital until just after you receive your first repeat prescription from your GP 
surgery. We also would like you take part in a 30-45 minute interview either at 
the hospital, at your home or in a place of your choice that is convenient to you.  
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PATIENT INFORMATION LEAFLET 
• We would like to invite you to take part in our research study.  
 
• Before you decide we would like you to understand why the research is being 
done and what it would involve for you. One of our team will go through the 
information sheet with you and answer any questions you have. We‘d 
suggest this should take about 15 minutes.  
 
• Talk to others about the study if you wish.  
 
• Ask us if there is anything that is not clear. 
 
About the study 
The main purpose of this study is to find out who you contact and who contacts 
you about your medicines once you are discharged from hospital. We want to 
find out more about how well the healthcare team tells you about your 
medicines, who, if anyone, helps you understand how to take your medicines 
and whether you are given enough help and information to take your medicines 
as they should be taken. We also want to know which healthcare professionals 
– for example GPs, nurses, pharmacists – you have contact with about your 
medicines as well as any other people you talk to about your medicines.  
 
Why have I been chosen? 
You have been in hospital being treated for a heart condition for which a 
combination of medicines is known to benefit your heart and improve your 
health and wellbeing. It is important that you receive good information about 
your medicines, that you understand them, and that others involved in your care 
– your consultant, your nurse, your GP and your community pharmacist – 
communicate well with each other and with you about them. 
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Do I have to take part? 
No, it is up to you to decide to join the study. We will explain the study and go 
through this information sheet with you. If you agree to take part, we will then 
ask you to sign a consent form. You are free to change your mind at any time, 
without giving a reason. This would not affect the standard of care you receive 
and you will not be treated any differently whether you decide to take part or 
not. 
 
How do I take part? 
If you might like to take part in this study you should complete the Study Sign-
up form accompanying this leaflet, sign the Agreement to Participate form and 
return them in the envelope provided to the ward reception area or to Beth 
Fylan, the study co-ordinator, who will be available on the ward. We will use 
your answers on the questionnaire to check that you are suitable for the study. 
If you are suitable, we will give you a short contact sheet to complete from the 
day of your discharge from hospital for approximately six weeks. We will also 
phone you within a week of your discharge to see how you are getting on filling 
in your contact sheet and to see if you have any questions about it. 
 
There is an example of the type of information we want you to record attached 
to this leaflet. 
 
What am I being asked to do? 
We want you to keep a record of who you have contact with about your 
medicines from the time you are discharged from hospital and receive your 
discharge medication until just after your receive your first repeat prescription 
from your GP. On this sheet we want you to make a note of when you contact 
other people about your medicines and when they contact you. This contact 
might be a letter from the hospital, a conversation with a pharmacist, or a 
conversation with your GP or nurse. We also want you to note down any times 
you ask friends or family for information or help with your medicines or if anyone 
offers you advice or asks you questions about your medicines. We hope that 
you will fill in the contact sheet every evening.
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After six weeks we will ask you to take part in an interview with one researcher 
that will last around 30-45 minutes, during which we will ask you about your 
diary and about your views about the different roles people and professionals 
play in helping you with your medicines. We will also ask you to answer 
questions about what you think about your medicines. The interview will be with 
one person and it will be audio recorded with your permission. 
The interview may be held at the Cardiac Rehab Clinic, in your own home, or in 
another place of your choice – whichever you prefer. There are no right or 
wrong answers – we are just interested in your experiences and what you think. 
 
Will the information I give be kept confidential? 
Nobody – including your healthcare team – will be able to find out what 
individual people have written down or said. All information which you give us 
will be kept strictly confidential, and any information will have your name 
removed before it is stored electronically. With your permission, we will audio 
record interviews but your name will not kept with the transcript or the recording 
of your interview. Data you give us will be stored securely at the University of 
Bradford and only members of the research team will have access to it. All the 
data you give us will be stored for three years and then destroyed. 
 
The things that people talk about during interviews and write in their contact 
sheets will be summarised and included in a report, but no information will be 
included that would allow anyone to find out what individual people have said.  
 
What are the benefits of taking part? 
The information we get from this study may help the way that other patients are 
told about their medicines and it may prevent them from experiencing problems 
in the future. It may prevent people from experiencing problems with medicines 
or from not understanding their medicines well enough. 
 
What are the drawbacks of taking part? 
You will need to regularly fill in your contact sheet for approximately six weeks 
and also spare the time to be interviewed about your experiences. 
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What happens at the end of the study? 
Your part in the study will end with the interview approximately six weeks after 
you leave hospital. We will then take the information you and others have given 
us and use it to see if improvements can be made to the way people 
communicate with patients. The information will be used to write a report and 
we will also publish the study results in a professional journal, but you will not 
be identified in any published report or journal article. 
 
What if I decide during the research that I don’t want to take part any 
more? 
That’s ok – just tell me that you don’t want to talk any more. You don’t have to 
give a reason.  
 
What if I have worries about my medicines? 
If you have worries about your medicines whilst you are taking part in the study 
you should talk to your doctor, nurse or pharmacist. As researchers we cannot 
give you medical advice, but it is important that you speak to a qualified person 
if you are worried about your medicines for any reason. 
 
Study organisation 
This study has been designed coordinated and funded by researchers at the 
University of Bradford. The study design has been reviewed and agreed by 
independent Research Ethics Committees. 
 
What if I have questions about the study? 
If there’s anything you’re not sure about, or if you have any questions, you can 
ask Beth Fylan who will be available on the ward or by telephone on 07866 
678764 or email e.m.m.fylan@bradford.ac.uk   
 
What if I have a complaint about the study? 
If you want to make a complaint at any point about any aspect of the study you 
can contact Professor Alison Blenkinsopp (01274 234290) or Professor Gerry 
Armitage (01274 236474) at the University of Bradford.  
 
Thank you for considering taking part.  
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B Patient consent form 
 
 
Do you consent to take part in the study?  
 
A study of communication about medicines after 
discharge from hospital 
 
Please read each of the following points and tick the box if you agree. 
Just ask if there is anything you don’t understand or you are unsure 
about. 
1. I confirm that I have had the opportunity to ask questions about the study  
and, if I asked, my questions were answered fully………………………… 
2. I have read and understand the information sheet version [….] date 
[………….] …………………………………………………………………….. 
 
3. I understand that participation is voluntary and I am free to withdraw at any 
time without giving and reason, and without my medical care being 
affected………………………………………………………………………… 
 
4. I understand that any data about me will be anonymised, confidential, and  
kept securely. I give permission for members of the research team to 
have access to my anonymised responses……………………………….. 
 
5.   I agree to take part in the above study…………………………….............. 
 
Your name 
(print)………………………………….......................................................... 
Your signature …………………………………...................          
Date ……………... 
Researcher’s signature …………………………………….            
 Date ……………… 
Office use: Patient ID number for study: ____________ 
One copy to researcher and one copy to the patient  
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C  Staff information leaflet  
 
 
Observation of communication about medicines at discharge –  
Information for staff  
You are being invited to take part in a research study. Before you decide whether or 
not you would like to participate it is important that you understand why the research is 
being carried out and what will be involved if you decide to participate. The following 
information explains the purpose of the study and other relevant information. Please 
take time to read it carefully and discuss it with others if you wish.  If there is anything 
that is not clear, or if you would like more information, please do not hesitate to ask.  
Who is conducting the research?  
The research is being conducted by Beth Fylan Gwynn from the University of Bradford. 
Telephone Number 07866 678764 or e-mail e.m.m.fylan@bradford.ac.uk 
What is the purpose of the study?  
The aim of the study is to gain understanding of the ways in which information about 
medicines is communicated to patients.   
Who is being invited to take part in the study?  
You have been invited to take part in this study as you carry out one or more aspects of 
medicines management as part of your everyday role and you are caring for a patient 
who has agreed to participate in the study. 
What will be involved if I take part?  
The study will be explained and you will have the opportunity to ask any questions. You 
will then be asked to sign a consent form to show you have agreed to take part. You 
will be able to keep a copy of this sheet and the consent form.  If you consent to take 
part, you will be observed whilst you are communicating with patients about their 
discharge ‘take-home’ medicines. The researcher will take notes during the 
observation. The researcher will ensure that the shadowing does not interrupt patient 
care.  
Do I have to take part?  
No.  You can decide whether or not you want to take part.  If, however, you do decide 
to take part, but then decide that you no longer want to be part of the study, you are 
free to withdraw at any time, without giving a reason.   
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What happens to the information collected during the study?  
Your identity and any personal information that may be required to communicate with 
you will be completely confidential and known only to the researcher. No record will be 
kept of actual names and locations.  The information obtained will remain confidential 
and stored within a locked filing cabinet. Data will be kept safely and you will not be 
identified in any report or publication.  
What are the benefits of taking part?  
By taking part in this research, you will be providing valuable information regarding 
medicines management. It is hoped that this information can be used to improve the 
process of medicines management, reduce medication errors, and improve patient 
safety. 
Who has reviewed the study?  
This study has been reviewed and approved by a team of research supervisors at the 
University of Bradford, and the Yorkshire and the Humber (Bradford) Research Ethics 
Committee. 
 If you have any further questions?  
If you would like more information about the study you can contact Beth Fylan Gwynn, 
School of Pharmacy, University of Bradford, Bradford, BD7 1DP. Telephone Number 
07866 678764 or e-mail e.m.m.fylan@bradford.ac.uk. 
What will happen to the research when it is finished? 
The research will be written up for publication in academic journals so that others can 
learn from the findings.  The data will also be submitted as part of a doctoral thesis 
(PhD) in Pharmacy.  If you would like a copy of the findings you can contact Beth Fylan 
Gwynn using the contact details above. 
What should I do if I would like to complain about the study?  
If you are unhappy about any aspect of the study, please contact myself in the first 
instance.  Alternatively you can contact Professor Alison Blenkinsopp at the University 
of Bradford on 01274 234698 or professor Gerry Armitage at the University of Bradford 
on 01274 236474.  
Thank you for taking time to read the above information.  
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D Staff consent form  
 
 
 
Observation of communication about medicines at discharge 
 
Please tick 
the box  
I have read and understand the information sheet  
dated.................... (version........) for the above study. I have  
had the opportunity to consider the information, ask questions and  
have had these answered fully.  
 
I understand that my participation is voluntary and that I am free  
to withdraw at any time, without giving any reason. 
 
I understand that my data will be anonymised, confidential, and  
kept securely. I give permission for members of the research team  
to have access to my anonymised responses 
 
 
 
Your name   ____________________________________________ 
   
Date    ____________________________________________ 
  
 
Signature   ____________________________________________ 
 
 
Name of Researcher  ____________________________________________ 
 
Date    ____________________________________________ 
 
Signature   ____________________________________________ 
 
1 copy to the participant 1 copy to the researcher  
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E Discharge observation contact sheet  
  
Patient ID:_________ Site:_____________ Date:_____________Time: _____________ 
 
 
 
  
                                                          
1 Staff types: HCA1 (Health care assistant 1); CD1 (Consultant 1); D1 (Doctor 1); S1 (Sister 1); 
N1 (Nurse1); P1 (Pharmacist 1); PT1 (Pharmacy Technician 1); O1 (Other 1)  
2 Purposes: P (purpose of the medicines; N (new medicines); Dis (Discontinued medicines) S 
(Side effects); D (dose information); T (timing information); HC (hospital communication with 
primary care); R (obtaining repeat medicines in primary care); U (using pre-admission supplies 
of medicines); W (giving written take-home information); OTC (over-the-counter drugs to avoid); 
F (foods / drinks to avoid). 
 
 
Observation 
number 
Staff 
type1 
Purposes2 Understanding 
check? (Y/N) 
Question? 
(Y/N) 
Researcher 
notes 
1 N1 P; W; D; 
Dis; N 
N Y  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
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F Medicines contact diary sheet 
Please keep a brief record in the table below of the contacts you make or receive 
concerning your medicines. Please give as much detail as possible and try to 
differentiate between people – for example you may over the course of the next six 
weeks speak to more than one pharmacist or GP so try to capture at least their initials 
or first name if possible. 
Date People I 
contacted 
People 
who 
contacted 
me 
Role / 
relationship 
to me 
Contact 
type 
What happened 
15/09/13 Dave  Son Face-to-
face 
Asked me if I 
needed help 
organising my 
medicines 
packages 
16/09/13 No contact  No contact    
17/09/13 Sainsbury’s 
pharmacy 
– 
Pharmacist 
 Pharmacist I visited in 
person 
I asked for 
indigestion tablets. 
Advised to take 
brand X 
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G Patient interview schedule 
Briefing. Permission to record.  
Thank you for completing your contact diary sheet. I have a few questions I’d like to ask you 
about what you have written down. First though, I’d like to ask you some questions about your 
experiences with your medicines since leaving hospital. There are no right or wrong answers – I 
am interested in your opinions and experiences. 
1. Tell me about your experiences with your medicines since leaving hospital.  
When you left hospital were you given a supply of medicines to take home with you? (Probe – 
who, when, where, number of days’ supply of meds)  
Did someone at the hospital give you a list of your medicines?  Who? 
Did someone at the hospital speak to you about your medicines before you went home? (Probe 
– who? Nurse / doctor /pharmacy technician, when and where did this happen? What was said? 
Were you given any written information? Did you ask any questions? Why / why not?) How 
much information were you given about the possible side effects from your medicines?  
How easy or difficult was it to understand the information you were given?  
How different were the medicines you left hospital with to those you took before you were 
admitted? Were any of them new? Did anyone explain the changes to you? Did you know if you 
needed to use any of the supply of medicines you had before you went into hospital? 
How many different medicines do you now take? What are they for? At what times of day do 
you take them? 
How easy or difficult has it been to take your medicines as instructed? Why is this the case? 
When you left hospital was there anything you were unsure about or any questions you had 
about your medicines? 
When you left hospital were you able to get out and about easily or was this difficult for you? 
2. How confident are you in your medicines?  
Are you taking them? To what extent do you feel they are effective? Do you feel safe taking 
them? Why / why not? Do you feel like they help your condition(s)? 
Has anything happened since you left hospital to make you more or less confident in your 
medicines?  
How much do you understand how to take your medicines? And why you are taking them? 
3. Now I’d like to discuss your diary sheet. 
Could you tell me about how you think each person in your diary helped you manage your 
medicines after you left hospital? (take each person in turn) 
How positive or negative is their input? How does the contact you have with them make you 
feel? Confident? Confused? Reassured? Cared for? Something else? 
What input does your GP have? How about the community pharmacy? Other healthcare 
professionals? 
What input do your friends and family have? 
How about other sources of information – the internet, leaflets? Anything else? How useful are   
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they to you? 
How have each of these contacts influenced how you take your medicines? And how you feel 
about your medicines? 
Why did you choose to discuss your medicines with this person?  
How easy or difficult are they to contact? How helpful or unhelpful do you find them? How useful 
do you find the information, help or advice you get from them? How much time do you think they 
have for you? 
4. Now I’d like you to look at this personal network diagram 
How would you rate the contacts involved in your medicines? (There will be a diagram with 
concentric circles and patients will indicate where this person sits – the closer to the centre the 
more they value them). 
Why do these people play a bigger role than others in your medicines? And why are these 
people not so important? 
How much do you feel each of these people listen to you? And understand you? 
Have your medicines needs been met? How could the care you receive from professionals 
relating to your medicines be improved? 
How much do you think each of the contacts in your diary communicate with each other about 
your medicines? 
How much do you have to co-ordinate the input of healthcare professionals into your 
medicines? 
How joined up do you think the professional medicines care you get is? Do you think 
professionals work together to make sure your medicines are right for you? 
Thank you. Debrief. Do you have any questions?  
If you have any questions or concerns about your medicines you should contact a healthcare 
professional to discuss them. This could be your GP, your community pharmacist, or a 
community nurse. Contact details.  
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H Medicines experience survey 
Many thanks for agreeing to complete this short survey. Your answers to these 
questions will be kept confidential. There are no right or wrong answers – we are only 
interested in what you think. 
How much to you agree or disagree with the following ten statements? Tick one box for 
each question to tell us what you think. 
 Strongly 
disagree 
Slightly 
disagree 
Not sure Slightly 
agree 
Strongly 
agree 
When I left the hospital, I 
clearly understood the 
purpose for taking each of 
my medicines 
     
I am confident I can take my 
medicines as instructed 
     
It is easy for me to ask my 
community pharmacist 
questions about my 
medicines  
     
When I left the hospital, I 
clearly understood how to 
take each of my medicines 
     
It is easy for me to 
understand the  instructions 
I was given for my 
medicines 
     
It is easy for me to ask my 
GP questions about my 
medicines 
     
I currently understand the 
purpose for taking each of 
my medicines 
     
The healthcare team work 
together to support me in 
managing my medicines 
     
It is easy for me to get all 
the information I need about 
my medicines 
     
 
Many thanks! 
Patient ID: _____________ 
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I  About you survey 
About you 
 
Age  (in years): _________ 
Gender:        Male           Female 
Home address:  
___________________________________________________________________ 
___________________________________________________________________ 
 
Postcode:  _________________ 
 
Contact email address (if you have one): ______________________ _______ 
 
Home phone number: _____________________________ 
 
Mobile number (if you have one): __________________________________ 
 
GP name: __________________________________ 
 
GP surgery: __________________________________ 
 
Which community pharmacy do you usually use? 
 
____________________________________________________________________ 
 
 
 
Thank you! 
 
[Patient ID number [for office use only]_____________________]  
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J Network grid 
Patient ID__________ 
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Appendix 3 – Ego-networks for all patients 
Thicker lines between ego and alters indicate more valued ties. 
 
Figure 58: Sociogram of ego-network of Patient 1.1 
 
Figure 59: Sociogram of the ego-network of Patient 1.2 
 
 
 
 
Figure 60: Sociogram of ego-network of Patient 1.3 
 
 
Figure 61: Sociogram of the ego-network of Patient 1.4  
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Figure 62: Sociogram of the ego-network of Patient 1.5 
 
 
Figure 63: Sociogram of the ego-network of Patient 1.7 
 
Figure 64: Sociogram of ego-network of Patient 1.8 
 
Figure 65: Sociogram of the ego-network of Patient 1.9  
  
 
 
343 
 
Figure 66: Sociogram of the ego-network of Patient 1.10 
 
Figure 67: Sociogram of the ego-network of Patient 1.11 
 
Figure 68: Sociogram of the ego-network of Patient 1.12 
 
 
Figure 69: Sociogram of the ego-network of Patient 1.18  
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Figure 70: Sociogram of the ego-network of Patient 1.20 
 
 
Figure 71: Sociogram of the ego-network of Patient 1.21 
 
 
Figure 72: Sociogram of the ego-network of Patient 1.23 
 
 
 
 
Figure 73: Sociogram of the ego-network of Patient 1.27  
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Figure 74: Sociogram of the ego-network of Patient 1.28 
 
 
Figure 75: Sociogram of the ego-network of Patient 1.33 
 
 
 
Figure 76: Sociogram of the ego-network of Patient 1.34  
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Figure 77: Sociogram of the ego-network of Patient 1.38 
 
Figure 78: Sociogram of the ego-network of Patient 1.40 
 
 
Figure 79: Sociogram of the ego-network of Patient 1.41 
 
 
 
Figure 80: Sociogram of the ego-network of Patient 1.44  
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Figure 81: Sociogram of the ego-network of Patient 1.45 
 
 
 
Figure 82: Sociogram of the ego-network of Patient 1.46 
 
Figure 83: Sociogram of the ego-network of Patient 1.47 
 
 
 
Figure 84: Sociogram of the ego-network of Patient 1.49  
  
 
 
348 
 
Figure 85: Sociogram of the ego-network of Patient 1.50 
 
Figure 86: Sociogram of the ego-network of Patient 1.51 
 
Figure 87: Sociogram of the ego-network of Patient 1.55 
 
Figure 88: Sociogram of the ego-network of Patient 2.1  
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Figure 89: Sociogram of the ego-network of Patient 2.3 
 
Figure 90: Sociogram of the ego-network of Patient 2.4 
    
 
Figure 91: Sociogram of the ego-network of Patient 2.5 
 
 
 
Figure 92: Sociogram of the ego-network of Patient 2.6  
  
 
 
350  
Figure 93: Sociogram of the ego-network of Patient 2.8 
 
Figure 94: Sociogram of the ego-network of Patient 2.9 
 
Figure 95: Sociogram of the ego-network of Patient 2.10 
 
 
Figure 96: Sociogram of the ego-network of Patient 2.11  
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Figure 97: Sociogram of the ego-network of Patient 2.12 
 
 
 
Figure 98: Sociogram of the ego-network of Patient 2.13 
 
Figure 99: Sociogram of the ego-network of Patient 2.14 
 
Figure 100: Sociogram of the ego-network of Patient 2.15  
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Figure 101: Sociogram of the ego-network of Patient 2.16 
 
Figure 102: Sociogram of the ego-network of Patient 2.17 
 
Figure 103: Sociogram of the ego-network of Patient 2.18 
 
Figure 104: Sociogram of the ego-network of Patient 2.20  
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Figure 105: Sociogram of the ego-network of Patient 2.21 
 
Figure 106: Sociogram of the ego-network of Patient 2.22 
 
Figure 107: Sociogram of the ego-network of Patient 2.23 
 
Figure 108: Sociogram of the ego-network of Patient 2.24  
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Figure 109: Sociogram of the ego-network of Patient 2.25 
 
Figure 110: Sociogram of the ego-network of Patient 2.26 
 
 
Figure 111: Sociogram of the ego-network of Patient 2.29 
 
Figure 112: Sociogram of the ego-network of Patient 2.30  
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Figure 113: Sociogram of the ego-network of Patient 2.33 
 
Figure 114: Sociogram of the ego-network of Patient 2.34 
 
 
Figure 115: Sociogram of the ego-network of Patient 2.35 
 
Figure 116: Sociogram of the ego-network of Patient 2.50  
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Figure 117: Sociogram of the ego-network of Patient 2.52 
 
 
Figure 118: Sociogram of the ego-network of Patient 2.53 
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Appendix 5 – Chi square test results 
This appendix presents the detail of the chi square tests performed on 
observation data. The tests are referred to in Section 4.3 
 
A series of chi square tests explored the association between the type of 
medicine given to patients and the information they were given about them. 
 
Medicines purpose 
Achi-square test revealed a non-significant association between the category of 
medicine and whether they were told about the medicines purpose (X2 (5)= 
9.694, p=0.084). Staff told patients about their medicines purpose similar 
numbers of times regardless of the medicines type. 
 
Medicines Dose 
The chi-square test revealed a significant association between the category of 
medicine and whether staff told patients the dose of that medicine (X2 (5)= 
16.891, p<0.005). Exploration of the standardised residuals indicated that 
significantly more staff told patients about the dose of their beta-blocker than 
expected and fewer than expected told patients the dose of their GTN spray. 
Cramer’s V indicated an effect size of 0.31 (values range between 0-1). 
 
How to take medicines 
The chi-square test with a Fisher’s exact test correction revealed a significant 
association between the category of medicine and whether staff told patients 
how to take that medicine (X2 (5)= 98.885, p<0.001). Exploration of the adjusted 
standardised residuals indicates that fewer people than expected were told how 
to take their beta-blocker, their statin, their Anti-platelet and their ACE inhibitor 
/ARB. Significantly more staff told patients how to use their GTN spray. 
Cramer’s V indicated an effect size of 0.75. 
 
Medicines frequency 
The chi-square test revealed a non-significant association between the category 
of medicine and whether they were told about the medicines frequency (X2 (5)= 
0.717, p=0.984). Staff told patients how often they should take their medicines 
similar numbers of times regardless of the medicines type. 
 
Medicines timing 
The chi-square test revealed a significant association between the category of 
medicine and whether staff told patients when they should take them (X2 (5)= 
14.336, p<0.05). Staff told patients a when to use their GTN spray significantly 
more often than they did other medicines.  Cramer’s V indicated an effect size 
of 0.28. 
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Side effects 
The chi-square test with a Fisher’s exact test correction revealed a non-
significant association between the category of medicine and whether patients 
were told about the side effects of that medicine (X2 (5)= 3.073, p=0.677). Staff 
told patients about their medicines side effects similar numbers of times 
regardless of the medicine type. 
 
Tests 
The chi-square test with a Fisher’s exact test correction revealed a non-
significant association between the category of medicine and whether patients 
were told about tests they would need because of that medicine (X2 (5)= 5.468, 
p=0.306). Staff told patients about tests similar numbers of times regardless of 
the medicines type. 
 
Understanding checks 
The chi-square test with a Fisher’s exact test correction revealed a significant 
association between the category of medicine and whether staff checked that 
patients understood what they had been told about that medicine  (X2 (5)= 
20.033, p<0.01). Exploration of the adjusted standardised residuals indicates 
that staff checked patients’ understanding of what they were told about their 
GTN spray more frequently than for other medicines. Cramer’s V indicated an 
effect size of 0.34. 
 
Asking questions  
The chi-square test with a Fisher’s exact test correction revealed a non-
significant association between the category of medicine and whether patients 
were told about tests they would need because of that medicine (X2 (5)= 2.866, 
p=0.735). Patients asked questions about specific medicines similar numbers of 
times regardless of the medicines type. 
 
What are patients told about their medicines at different sites? 
Tables 3, 4 and 5 show the frequency (%) of the categories of information staff 
gave patients about their discharge medicines by site and by medicines 
category. A further series of chi-square tests explored the association between 
what patients were told about their medicines and the hospital site. 
 
Medicines purpose 
The chi-square test revealed a significant association between the discharge 
site and whether staff told patients the purpose of medicines whilst discharging 
them (X2 (2)= 42.185, p<0.001). Exploration of the adjusted standardised 
residuals indicates that staff on the ward in Site 1 and Site 2 told patients the 
purpose of their medicines significantly more frequently, whilst staff told people 
were the purpose of their medicines less frequently in the discharge lounge at 
Site 1. Cramer’s V indicated an effect size of 0.49. 
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Medicines dose 
The chi-square test revealed a non-significant association between the 
discharge site and whether staff told patients the dose of their medicines whilst 
discharging them (X2 (2)= 1.159, p<0.57). Staff at each discharge site told 
patients about their medicines dose similar numbers of times. 
 
How to take medicines 
The chi-square test revealed a significant association between the discharge 
site and whether staff told patients how to take their medicines whilst 
discharging them (X2 (2)= 8.317, p<0.05). Exploration of the adjusted 
standardised residuals indicates that staff on the ward in Site 1 told patients 
how to take medicines significantly more frequently. Staff in the Discharge 
Lounge at Site 1 told patients how to take their medicines significantly less 
frequently. Cramer’s V indicated an effect size of 0.22). 
 
Medicines frequency 
The chi-square test revealed a non-significant association between the 
discharge site and whether staff told patients how often to take their medicines 
whilst discharging them (X2 (2)= 4.049, p=0.133). Staff told patients about the 
frequency of their medicines a similar number of times at all sites. 
 
Medicines timing 
The chi-square test revealed a significant association between the discharge 
site and whether staff told patients when to take their medicines whilst 
discharging them (X2 (2)= 7.870, p<0.05). Exploration of the adjusted 
standardised residuals indicated that staff on the ward and discharge lounge in 
Site 1 told patients how to take medicines significantly more frequently. 
Cramer’s V indicated an effect size of 0.210. 
 
Medicines side effects 
The chi-square test with a Fisher’s exact test correction revealed a significant 
association between the discharge site and whether staff told patients about 
side effects whilst discharging them (X2 (2)= 21.003, p<0.001). Exploration of 
the adjusted standardised residuals indicated that staff on the ward in Site 1 told 
patients about side effects significantly more frequently. Staff in the discharge 
lounge in Site 1 told patients significantly less frequently. Cramer’s V indicated 
an effect size of 0.344. 
 
Tests 
The chi-square test revealed a non-significant association between discharge 
site and whether staff told patients about required tests (X2 (2)= 3.708, 
p=0.174). Staff  told patients about required tests similar numbers of times 
regardless site. 
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Understanding checks 
The chi-square test with a Fisher’s exact test correction revealed a significant 
association between the discharge site and whether staff checked that patients 
understood what they had been told about medicines (X2 (2)= 12.795, p<0.005). 
Exploration of the adjusted standardised residuals indicates that staff on the 
ward at Site 2 checked patients’ understanding significantly more frequently and 
staff in the Discharge Lounge at Site 1 significantly less frequently. Cramer’s V 
indicated an effect size of 0.27. 
 
Asking questions  
The chi-square test with a Fisher’s exact test correction revealed a non-
significant association between site and whether patients asked questions 
about their medicines (X2 (2)= 4.171, p=0.128). Patients asked questions about 
specific medicines similar numbers of times regardless of the site. 
 
Additional information 
Using a Fisher’s Exact test correction, a significant association was indicated 
between the discharge site and whether patients were told how to get repeat 
medicines (X2(2)=6.337, p<0.05). Cramer’s V indicated an effect size of 0.37. 
Exploration of the adjusted standardised residuals indicated that staff at Site 2 
gave this information significantly more frequently. 
 
A non-significant association was indicated between the discharge site and 
whether staff highlighted written take home medicines information to patients 
(X2(2)=5.139, p=0.081). Staff gave this information a similar number of times 
regardless of the site. 
 
A significant association was indicated between the discharge site and whether 
staff explained how the hospital would communicate with the patient’s primary 
care teams (X2(2)=10.130, p<0.01).  Cramer’s V indicated an effect size of 0.43. 
Staff give this information significantly more frequently on the ward in Site 2 and 
significantly less frequently in the discharge lounge at Site 1. 
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Appendix 6 – Assessment of the safety incidents reported by 
patients 
ID 1.1 
Patient age 72 
Safety incident 
description 
Uses a knife to get into medicines packaging because he finds the 
metal push out packs difficult to get into. 
 
Two sets of Warfarin tablets were missing from his repeat medicines. 
“Well, it’s supposed to have been done by computer from the surgery 
to the thing and they’ve been put in…oh, they forgot…two lots were 
missing, not this last time, the time before where it was supposed to 
have gone computerised and they’d put Warfarin tablets in, just one 
packet of pink ones, I think that’s 5mg and I don’t take them ‘cause it 
can vary from every…like, at the moment I’m on thee and a half, one 
blue and one white, whereas just over two month ago I was on one 
blue, one brown, one white.” 
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 1.8 
Patient age 79 
Patient gender 
Safety incident 
description 
Information about increased dose of Bisoprolol not on GP system 
after a week. Patient was unable to get a repeat prescription for this 
higher dose when he needed to. The GP phoned him the next day 
and said that the paperwork had just arrived. Patient: “I suspect it 
had been there, but they were playing catch up with the paperwork to 
actually enter it onto the system.”  
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 2.35 
Patient gender 59 
Safety incident 
description 
One week after discharge his right foot swelled up from gout. He has 
been taking Allopurinol daily and hasn’t had a gout attack for years. 
He decided to take Coltrazine. He told his GP he had done this and 
the GP ‘went into a flat panic’. The patient explained there may be an 
interaction with his statin (simvastatin). The patient recalled being 
told in hospital he could take Coltrazine so he rang the ward and was 
put through to the hospital pharmacy. The pharmacy then rang the 
GP and explained why he could use the Coltrazine. The patient 
explained ‘it all got sorted out, but that was panic stations at one 
point’. 
Assessor 1 No 
Assessor 2 No  
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ID 2.10 
Patient gender 66 
Safety incident 
description 
This patient was mistakenly prescribed a statin in the hospital to 
which he is allergic. The hospital later apologised to him. 
 
Patient was getting what he thought was severe chest pains which 
he thought may be due to his Ramipril dose. The patient nearly 
stopped taking Rampril because he thought the chest pains were a 
side effect. He saw his GP, who advised him to continue with his 
hospital medicines as prescribed. The hospital sister later suggested 
he should have been on a PPI because he had been taking aspirin 
for so long and this may be causing his pain. He saw his GP the 
following day who agreed that he should have been prescribed a PPI 
earlier.  
 
Assessor 1 Yes 
Assessor 2 2 incidents, allergy to statin = Yes 
Aspirin and PPI, would depend whether the patient was a known risk 
for GI bleed. I don’t think that it is routine to prescribe a PPI with low 
dose aspirin unless the patient is a known risk. If he were a risk and 
the hospital and the GP didn’t pick up on this risk, then YES. 
 
ID 1.41 
Patient age 65 
Safety incident 
description 
Went for repeat prescription to the GP and the information about his 
new medicines from the hospital was not on the GP system. The 
receptionist at his GP surgery photocopied the discharge summary, 
but only the first page of it so he only got some of his repeat 
medicines. In the process of rectifying this, the GP surgery issued 
two prescriptions and he received two sets of medicines 
simultaneously. 
 
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 1.44 
Patient age 52 
Site BRI 
Safety incident 
description 
Patient was sent the wrong information by the hospital before a 
stress test. She was told to stop taking Bisoprolol before the test in a 
letter but the consultant had wanted her to take the test whilst taking 
a betablocker. She stopped taking her betablocker as instructed. 
This was attributed to a clerical error. 
Assessor 1 Yes 
Assessment 
DN 
Yes 
 
ID 1.47 
Patient age 72 
Safety incident 
description 
The GP practice didn’t have this patient’s medicines list when he 
tried to order his repeat medicines. 
 
Assessor 1 Yes 
Assessor 2 Yes 
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ID 1.49 
Patient age 79 
Safety incident 
description 
The repeat medicines supplied by the GP team had different brand 
names and very different packaging to his discharge medicines. As a 
result, the patient believed the GP had prescribed even more 
medicines in addition to those given to him in hospital and he 
proceeded to take double the dose of at least three cardiology 
medicines used to treat high blood pressure and angina. He 
described becoming disorientated, nauseous and believes he lost 
consciousness for about ten minutes. His wife insisted he contact the 
local pharmacist, who asked him to come into the pharmacy. The 
pharmacist subsequently banded the medicines boxes together to 
help him understand which brands were the same medicines. 
 
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 2.15 
Patient age 75 
Safety incident 
description 
This patient is unable to read and suffers from memory loss due to a 
stroke. He was unable to read the instructions on his blister pack 
properly and he mixed up his doses in the blister pack, taking the 
wrong doses at the wrong times and double dosing. He also 
described mixing up his warfarin doses. 
 
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 2.22 
Patient age 62 
Safety incident 
description 
The patient was supplied a repeat set of medicines without the new 
post-hospital medicines. She rang the surgery and they told her they 
couldn’t find the note from the hospital. Her pharmacist then phoned 
the surgery, which had found the discharge summary, and issued an 
emergency supply. The next day but a different pharmacy (which 
was not the pharmacy she had dealt with) delivered her another 
repeat set. 
 
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 1.29 
Patient age 66 
Safety incident 
description 
This patient had an MUR and the pharmacist told her she shouldn’t 
be on omeprozole with clopidogrel and said she would contact the 
patient’s GP to see if they could be changed. The patient didn’t hear 
anything from the pharmacy or the GP but put her repeat prescription 
in ordering omeprozole but when she received the medicines they’d 
written lansoprazole for the following repeat, but given her 
omeprozole. She was left confused by the process. 
Assessor 1 Yes  - written prescription and medicines did not match which 
impacted on the patient 
Assessor 2 No  (think this was very badly handled, interaction is documented but 
not dangerous, antiplatelet effect is reduced. Risk would depend on 
indication for omeprazole/lansoprazole. Risk of GI bleed if stopped 
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taking. 
 
ID 2.25 
Patient age 80 
Safety incident 
description 
Patient was supplied the incorrect form of aspirin by her GP – she is 
unwell if she takes uncoated aspirin (described feeling sick and 
dizzy): “So there's enough wrong me, without being sick on top”.  
She suspects the surgery may not have read the hospital notes.   
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 2.30 
Patient age 62 
Safety incident 
description 
Patient began to feel unwell when her dose of betablocker was 
increased following her pacemaker check, which revealed she had 
experienced palpitations. Managed to She had trouble speaking to a 
GP about it – her daughter had to intervene and speak to the 
receptionist – but subsequently she spoke to a GP on the telephone 
who reduced the dose to its previous level. 
Assessor 1 No 
Assessor 2 No 
 
ID 2.52 
Patient age 67 
Safety incident 
description 
His new medicines including a betablocker were not supplied with his 
repeat medicines. He noticed when he checked the medicines he 
received in the pharmacy. The pharmacy offered to contact the GP 
surgery for him.  
 
He halved his dose of Bisoprolol without consulting an HCP because 
he was feeling flutter. During a pacemaker check he told the 
technician what he’d done and they advised him to resume his 
normal dose. The flutters were eventually attributed to a faulty 
pacemaker connection  
 
Assessor 1 Yes (two PSIs here – drug omission and faulty connection?) 
Assessor 2 Yes (for failure to supply beta blocker) 
 
ID 1.27 
Patient age 52 
Safety incident 
description 
Hospital gave her soluble Aspirin and her doctor gave her ‘crunchy’ 
Aspirin.  Her husband checked with the pharmacist who reassured 
him that it was alright to have the different type of aspirin. 
Assessor 1 No 
Assessor 2 No 
 
ID 1.34 
Patient age 70 
Safety incident 
description 
Couldn’t order some of his repeat medicines using the online system 
as some are marked for review. He needed to see his GP. 
Assessor 1 No 
Assessor 2 No 
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ID 2.33 
Patient age 65 
Safety incident 
description 
The patient described being prescribed 50mgs of flecainide twice a 
day by the hospital. The GP then prescribed 100mg tablets the 
patient didn’t notice the change and continued taking one pill twice a 
day which meant he was having twice the dose for about three 
weeks. 
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 1.46 
Patient age 50 
Safety incident 
description 
The patient described suffering from bad skin irritation. The GP 
stopped his clopidogrel and the itching became less severe. 
Assessor 1 No 
Assessor 2 No 
 
ID 2.24 
Patient age 64 
Safety incident 
description 
Patient has stopped taking all his cardiology medicines because he 
doesn’t think they are working for him. “What’s the point taking 
something which it doesn’t relieve any symptoms?” 
Assessor 1 No 
Assessor 2 No (for action/inaction of HCP, but Yes for risk to patient) 
 
ID 2.26 
Patient age 71 
Safety incident 
description 
The patient was given a GTN spray which he was confident about 
using. The first repeat prescription issued by his GP after leaving 
hospital replaced the spray with GTN tablets. He had less confidence 
in the GTN tablets and when he raised concerns with the GP 
practice the receptionist relayed a message that the practice did not 
issue sprays, only pills: 
“I weren’t actually happy because I’ve been given all this information 
on spray and written information but just on spray not anything else, 
just on this spray and then to get another and you can’t have one, 
you’ve to have pills with no information.” 
A GTN spray was later issued. 
Assessor 1 Yes (communication failure) 
Assessor 2 Yes 
 
ID 2.17 
Patient age 67 
Safety incident 
description 
Pharmacy supplied simvastatin instead of atorvastatin after the 
patient mentioned that she wanted smaller tablets to swallow – the 
pharmacy had consulted her GP. She was worried that she should 
be taking atorvastatin because the hospital doctor told her he wanted 
her to be on atorvastatin. Her cardiac rehab nurse also told her she 
should really be on Atorvastatin. She is now confused about the 
dose she should be taking – her Atorvastatin was 80mg and the 
simvastatin is 40mg. She asked the pharmacy if she should take two 
of the Simvastatin but was told to just take one, which doesn’t make 
sense to her.  
Assessor 1 No 
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Assessor 2 No (assuming decision of GP is correct, although this could be a Yes 
if the relative potencies of simvastatin 40mg compared with 
atorvastatin 80mg are taken into account and patient has very high 
cholesterol) 
 
ID 2.14 
Patient age 67 
Safety incident 
description 
Patient continued having bad angina attacks after leaving hospital. 
He had spoken to the cardiac rehab nurse twice, and the pharmacist 
on the telephone before  the cardiac rehab sister identified four 
weeks after discharge that he should have been prescribed 
isosorbide mononitrate as one of his TTOs. “She asked me was I not 
taking this certain tablet, I said no, and she told me I should have 
been on it when I left hospital, and since I’ve subsequently started 
taking that tablet everything’s started to settle down.” 
Assessor 1 Yes 
Assessor 2 Yes 
 
ID 1.18 
Patient age 58 
Safety incident 
description 
Patient gets confused by the staged supply of her medicines by the 
pharmacist:  
“As I told you I was eating only thyroid medicine, so this is 150mg, 
they give me 
150mg on separate… so first 100mg and then after a few days the 
50mg.  So I'm really confused with these, you know, with this 
situation.   
Assessor 1 Unclear – if the patient is on 150mgs and the staged supply means 
she will sometimes only have 100mgs tablets (and I would have 
thought that splitting tabs should ideally be carried out by a 
pharmacist) – while waiting for the 50mgs tablets, this could be 
construed as a PSI as she cannot receive the correct dose on a 
continuing basis 
Assessor 2 No, but this is not good service 
 
ID 1.33 
Patient age 39 
Safety incident 
description 
Patient became ill after leaving hospital got a sore mouth and thrush 
and the GP said it was a side effect of one of her medicines (an 
antibiotic) and once she stopped taking them she’d feel fine. She 
became very confused and lost the feeling on one side of her face. 
Her friend contacted the GP and it took three hours for them to ring 
back and they requested she visit the surgery and suggested that 
she get a taxi when she said she was too unwell to attend. The GP 
then suggested she was anxious and told her again to come to the 
surgery and ended the call. He phoned back five minutes later and 
suggested she wasn’t getting enough oxygen to your brain. Three 
hours later a different doctor visited her at home.  
 
Assessor 1 Not enough clarity to decide – I would exclude  
Assessor 2 I would think initial GP reaction was correct but that there was no 
connection between the thrush and loss of sensation to the face and 
this should be investigated, which it was, problematic communication 
rather than safety risk 
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ID 2.6 
Patient age 70 
Safety incident 
description 
The patient explained that he has been receiving different brand 
medicines from the pharmacy.  
“Well I was taking what the doctor had said, that’s all you can do, I 
know the boxes keep changing… The chemist keeps changing them 
and you’re not getting the same.” 
Assessor 1 No 
Assessor 2 No 
 
ID 2.8 
Patient age 75 
Safety incident 
description 
Patient explained that isosorbide mononitrate was making him dizzy. 
A nurse on the phone suggested he take it with orange juice and this 
has helped alleviate the side effect 
Assessor 1 No 
Assessor 2 No 
 
ID 2.20 
Patient age 62 
Patient gender Female 
Site RBH 
Safety incident 
description 
Patient is sometimes dizzy, has achy legs black spots in front of her 
eyes. She suspects that side effects may be due to her medication. 
Assessor 1 No (but minimal knowledge on the case) 
Assessor 2 No 
 
ID 2.53 
Patient age 50 
Safety incident 
description 
Patient was getting mixed up with her medicines because there were 
so many of them and reported that sometimes she would double 
dose. She now has a blister pack. 
 
Her repeat prescription after discharge included aspirin when she 
reported the hospital had written to the GP to instruct them not to 
prescribe aspirin. 
Assessor 1 Yes (part 2 only) 
Assessor 2 Yes 
 
ID 2.9 
Patient age 73 
Safety incident 
description 
Patient reported only taking half his dose of Zicron as he thought it 
was making him feel nauseous. He has not discussed this with a 
HCP. 
 
Assessor 1 No 
Assessor 2 No 
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ID 2.11 
Patient age 68 
Safety incident 
description 
Nicorandil was missing from the repeat prescription when his wife 
put in the repeat request. This was about 1 week after he left 
hospital and his wife handed in the repeat slip issued with his 
previous medicines 
 
The patient decided to stop taking nicorandil soon after leaving 
hospital because of the severe headaches he was experiencing. He 
was his GP soon after to discuss this. 
Assessor 1 Yes  (part 1 only) 
Assessor 2 Yes 
 
ID 1.55 
Patient age 61 
Safety incident 
description 
Patient reported feeling breathless and wondered if it was caused by 
her medicines. She was too scared to stop taking them. 
Assessor 1 No 
Assessor 2 No, (assuming not known asthmatic who could have been prescribed 
a beta blocker). 
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Appendix 7 – Conference abstracts 
The following pages contain the published abstracts from conference 
presentations of the work in this thesis. All abstracts are reproduced with kind 
permission. 
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